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Abstract 
Ovarian cancer survival varies widely worldwide. This variation may be explained by 
several factors, including international variation in the histological subtypes of ovarian 
cancer, stage at diagnosis and race/ethnicity.  
Data used for this thesis were extracted from the CONCORD-2 study. The CONCORD-2 
study collected data for 793,098 adult women (aged 15-99 years) in 61 countries who 
were diagnosed during the 15-year period 1995-2009 with a cancer of the ovary. Ovarian 
cancer was defined broadly to include tumours of the fallopian tube, uterine ligaments 
and adnexa, other specified and unspecified female genital organs, peritoneum or 
retroperitoneum. Age-standardised net survival was the main outcome for each analysis.  
The worldwide distribution of and international variation in histological groups of ovarian 
cancer was examined, as an approach to understanding international differences in 
overall ovarian cancer survival. International comparisons of ovarian cancer survival have 
traditionally analysed ovarian cancer as a single homogenous group. However, ovarian 
cancer comprises several histologically distinct subtypes, which have very different 
survival outcomes. Survival from the most common histology, type II epithelial, was much 
lower than that for other histological groups in most countries.  
International differences in stage-specific net survival were also explored, where 
adequate data were available, in order to understand the impact of stage at diagnosis on 
survival. Survival from localised tumours was much higher overall, and for each 
histological group, than for advanced-stage disease in all countries. 
Net survival by race was estimated for Israel, New Zealand and the United States. Survival 
was consistently higher for the majority racial group than for the minority group. 
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The results presented in this thesis provide a valuable contribution to the understanding 
of variations in ovarian cancer survival, which may thus be used to inform health care 
policies and plans to reduce disparities in survival. 
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Chapter 1: Introduction 
Ovarian cancer ranks 7th in both incidence and mortality among women worldwide. In 
2012, an estimated 238,000 women were diagnosed with and 151,000 women died from 
ovarian cancer, representing 4% of all new cancer diagnoses and 4% of cancer deaths 
among women1. Early symptoms, such as persistent abdominal pain, bloating or 
decreased appetite, are vague2, and most women present with disease at an advanced 
stage3.  
1.1 Anatomy and biology of the ovary and fallopian tubes 
1.1.1 Ovaries  
The ovary is the primary endocrine gland of the female reproductive system. It has two 
main functions: to produce the eggs and to secrete the female sex hormones, oestrogen 
and progesterone4,5. Suspended within the peritoneal cavity by the broad ligament, the 
ovaries are paired organs that are attached to either side of the body of uterus by the 
ovarian ligaments [Figure 1.1]. The ovarian ligaments extend from the posterior side of 
the uterus as the round ligament. The tubal extremity of the ovary is attached to the broad 
ligament by the suspensory ligament of the ovary. The tubal extremity is the area of the 
ovary closest to the fimbriated end of the fallopian tube5. Recent evidence suggests that 
the fimbriated end of the fallopian tube may be the primary site of origin for most pelvic 
high-grade serous tumours among women6.   
The ovary has three main components: surface, cortex and medulla. The surface is made 
up of epithelial cells, one of the three main types of cell found in the ovaries. The cortex 
is located just below the ovarian surface epithelium and contains the outer supporting 
stroma and the follicles, which produce the eggs. Stromal cells form the supporting 
structural tissue of the cortex and produce oestrogen and progesterone, and germ cells 
are found in the follicles. The medulla is the central part of the ovary: it contains the inner 
15 
 
 
Figure 1.1 The female reproductive system 
Source: Editors of Encyclopædia Britannica. Fallopian tube: anatomy - uterus 
[illustration]. 2012. [cited 12 September 2016]. Available from: 
https://www.britannica.com/science/fallopian-tube/images-videos/uterus/138859. 
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supporting stroma and a rich neurovascular network providing blood to the ovary from 
the ovarian arteries7. 
1.1.2 Fallopian tubes 
The fallopian tubes comprise the fimbriae, infundibulum, ampulla and isthmus [Figure 
1.1]. The infundibulum is the end of the tube closest to the ovary into which the finger-
like fimbriae help gather the ovulated egg(s) into the fallopian tube. The ampulla is the 
longest part of the tube and the most common site of fertilisation of the egg by a sperm. 
The fallopian tube narrows at the uterine end to form the isthmus which enters into the 
body of the uterus5. 
1.1.3 The menstrual cycle 
The ovaries are involved in the regulation of the menstrual cycle as part of the endocrine 
system, through a complex feedback loop [Figure 1.2]. The cycle begins with the follicular 
phase when the hypothalamus recognises low levels of oestrogen and progesterone in 
the bloodstream and secretes gonadotropin-releasing hormone (GnRH). The pituitary 
gland responds to the release of GnRH by producing and releasing luteinising hormone 
(LH) and follicle-stimulating hormone (FSH). LH and FSH signal the ovaries to produce 
oestrogen and progesterone, which stimulate growth of the follicles and prepare the 
uterus for pregnancy. During the follicular phase, one dominant egg-producing follicle 
develops from a primordial follicle to a matured egg. Once the follicle has completely 
matured, ovulation occurs. During ovulation, the ovarian surface epithelium ruptures to 
release the egg into the fimbriated end of the fallopian tube where it then travels to the 
uterus4. 
The second half of the menstrual cycle is called the luteal phase and occurs immediately 
after ovulation. During the luteal phase, the lining of the dominant follicle grows to form 
a corpus luteum [Figure 1.2]. The corpus luteum temporarily secretes oestrogen and  
17 
 
 
Figure 1.2 The menstrual cycle 
Source: Editors of Encyclopædia Britannica. Fallopian tube: anatomy - pituitary gland: 
secretion and function of gonadotropins [illustration]. 2013. [cited 12 September 2016]. 
Available from: https://www.britannica.com/science/fallopian-tube/images-videos/The-
hypothalamus-and-pituitary-gland-control-the-secretion-of-gonadotropins/102076. 
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progesterone to thicken the lining of the uterus for pregnancy and prevent further 
ovulation. If pregnancy does not occur, the corpus luteum stops producing hormones and 
degenerates. This reduction in oestrogen and progesterone will be recognised by the 
hypothalamus and a new cycle will begin4. 
1.2 Ovarian cancer 
Since the early part of the 20th century, it has been recognised that ovarian cancer is not 
a single disease, but comprised of various histologically different tumour types8. Ovarian 
cancers have generally been divided into epithelial and non-epithelial groups for many 
years. Epithelial, germ cell and sex cord-stromal tumours are the commonest types of 
ovarian cancer. They can be further subdivided into distinct histological subtypes [Figure 
1.3]. The developmental pathway and clinical prognosis for a particular ovarian tumour 
depends upon the histological subtype2.  
1.2.1 Epithelial ovarian, fallopian tube and primary peritoneal cancer 
Epithelial ovarian cancer is the most common type of ovarian tumour, making up 90% of 
all primary malignant ovarian cancers9. Histological subtypes of epithelial tumours 
primarily include: clear cell, endometrioid, mucinous, serous, squamous, transitional cell 
(Brenner) and undifferentiated carcinoma2,10. Recent work has enabled finer subdivision 
of epithelial ovarian cancers into different groups according to a combination of 
morphological, molecular and clinical characteristics10-14. Each histological subtype has 
distinct molecular pathways that influence chemosensitivity, the pattern of metastasis 
and the probability of survival11,15. 
Under one proposed classification scheme, “type I” epithelial tumours include low-grade 
serous, endometrioid, clear cell, mucinous, squamous and transitional cell (Brenner) 
carcinomas. They often present at an early stage, may arise from borderline ovarian 
tumours or endometriosis, and typically have a good prognosis10-12,16.  
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Figure 1.3 The histological subtypes of ovarian cancer, including fallopian tube and primary peritoneal tumours 
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Using the same classification scheme, “type II” epithelial tumours comprise high-grade 
serous carcinoma, undifferentiated carcinomas and malignant mixed mesodermal 
tumours (carcinosarcoma). They account for around 75% of epithelial ovarian cancers, 
typically present at an advanced stage and have a poor prognosis10-12,16.  
Fallopian tube and primary peritoneal carcinoma arise outside the anatomical ovary, but 
most tumours at these sites are now considered to be part of the spectrum of ovarian 
malignancies.  
Primary fallopian tube carcinoma is a rare cancer that presents clinically in a similar 
manner to epithelial ovarian cancer and is treated clinically in the same way17. Malignant 
subtypes of fallopian tube carcinoma include clear cell, endometrioid, mucinous, serous, 
transitional cell and undifferentiated epithelial carcinomas2. Non-epithelial fallopian tube 
tumours are extremely rare, accounting for only around 7% of malignant fallopian tube 
cancers, and can include leiomyosarcoma and germ cell tumours2,18.  
Primary peritoneal carcinoma in women is also extremely rare. Macroscopically, primary 
peritoneal carcinoma may look like an epithelial ovarian carcinoma that has spread to the 
abdomen, and microscopically, the cells often resemble those of epithelial ovarian 
carcinoma19. Primary peritoneal carcinomas are also managed in the same way as 
advanced-stage epithelial ovarian cancer10,17. Non-epithelial types of primary peritoneal 
cancer do occur, such as malignant mesothelioma, desmoplastic small round cell tumours 
and solitary fibrous tumours, but these types account for only one-third of primary 
peritoneal cancers2,18.  
Due to the anatomical location of the three sites, primary fallopian tube and peritoneal 
carcinomas may be diagnosed as primary epithelial ovarian cancer12,17. Around 15% of 
tumours diagnosed as primary ovarian have been found to actually be primary peritoneal 
tumours2. During 1995-2004, age-adjusted annual incidence of primary ovarian 
21 
 
carcinoma in the US was much higher (119.9 per million) than for primary peritoneal (6.78 
per million) or fallopian tube (3.72 per million) carcinomas18. The incidence of ovarian 
carcinoma fell over the 33-year period from 1973 to 2005, and the incidence of peritoneal 
and fallopian tube carcinomas increased. The decrease in incidence in ovarian cancer over 
time may be partially artificial and attributable to the establishment of guidelines in 1993 
to define primary peritoneal carcinoma18,20.  
The guidelines for diagnosis of primary fallopian tube cancer are more restrictive than 
those for primary ovarian cancer. In order for a tumour to be considered a primary 
fallopian tube carcinoma, the majority of the tumour has to be within the fallopian tube 
rather than the ovary, and there must be evidence of an intraepithelial tubal carcinoma. 
Additionally, there must be a clear transition from benign to malignant epithelium21.  
A diagnosis of primary peritoneal cancer is rare because the guidelines for diagnosis are 
also very restrictive. Regardless of whether there is extensive tumour involvement of the 
peritoneum or other abdominal organs, if the tumour within the ovary is greater than 
5mm, the cancer is, nevertheless, considered to be primary ovarian rather than primary 
peritoneal carcinoma12,20. 
Subtypes of epithelial ovarian, fallopian tube and primary peritoneal cancer 
Serous 
Serous carcinoma is the most common histological subtype at all three primary sites2,18. 
Around 40-50% of ovarian cancers and around 66-90% of fallopian tube carcinomas are 
serous tumours2,22. Non-serous peritoneal carcinoma is extremely uncommon2. 
Serous tumours of ovarian, tubal and peritoneal origin are divided into low-grade and 
high-grade serous carcinoma depending upon the degree of differentiation2. Low-grade 
serous carcinoma (LGSC) is distinct from high-grade serous carcinoma (HGSC); progression 
from low-grade to high-grade only occurs rarely10. Low-grade serous ovarian carcinomas 
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are relatively rare, accounting for only 5% of serous ovarian carcinomas. Low-grade serous 
fallopian tube carcinoma is also very rare2. 
High-grade serous ovarian carcinoma is the most common subtype of epithelial ovarian 
cancer, and women with high-grade serous ovarian tumours typically present at older 
ages than women with low-grade tumours. Most serous peritoneal tumours are high-
grade and resemble high-grade serous ovarian tumours2.  
Endometrioid carcinoma 
Endometrioid tumours are the second most common type of ovarian and fallopian tube 
carcinoma18. Around 20-33% of women diagnosed with endometrioid tumours also have 
primary endometrial cancer or hyperplasia9. Most endometrioid tumours are early-stage 
and are confined to the ovary at diagnosis, with only 17% of women diagnosed with 
bilateral tumours. Endometrioid tumours are generally well-differentiated and low-grade, 
and women with low-grade tumours have higher survival than women diagnosed with 
high-grade tumours2.  
Clear cell carcinoma 
Clear cell tumours are generally large (around 15 cm in diameter), but unilateral2. Around 
85% of clear cell tumours are stage I or II at diagnosis9. Survival from early-stage disease 
is high, but advanced-stage disease does not respond well to chemotherapy and thus, 
survival is lower2.  
Mucinous carcinoma 
Mucinous tumours account for around 3-4% of all ovarian tumours2. Mucinous ovarian 
tumours are usually stage I at diagnosis and are well-differentiated or moderately-
differentiated. Survival from early-stage mucinous tumours is generally high, but 
advanced-stage disease, though rare, is often aggressive and does not respond well to 
chemotherapy. Metastatic tumours from other sites, such as the gastrointestinal tract, 
often mimic a primary ovarian mucinous tumour. Thus, identifying a mucinous tumour as 
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a primary ovarian tumour is often difficult. Primary ovarian tumours are more frequently 
unilateral and larger than mucinous tumours at other primary sites23.  
Transitional cell (Brenner) carcinoma 
Transitional cell tumours are large (16-20 cm in diameter) and usually confined to the 
ovary at diagnosis. Around 80% of these tumours are stage I at diagnosis and only 12% 
are bilateral. Women diagnosed with stage I disease have high 5-year survival, while 
women diagnosed with tumours that have spread outside the ovaries have similar survival 
to other advanced epithelial tumours2. 
Squamous carcinoma 
Squamous carcinomas are an extremely rare form of malignant epithelial ovarian tumour 
comprised of squamous cells that do not originate from germ cells. Squamous tumours 
are primarily high-grade and survival from these tumours is poor19. Around 34% of women 
diagnosed with squamous carcinoma have stage I disease, while 21% and 25% have stage 
III and stage IV, respectively. Survival varies by stage and can be as high as 86% for early 
stage tumours, but as low as 3% for stage IV tumours24.   
Carcinosarcoma 
Carcinosarcomas can also be referred to as malignant mixed mesodermal or malignant 
mixed Müllerian tumours. These tumours are rare, accounting for only 2% of ovarian 
tumours. Most women are diagnosed at advanced stages with high-grade large tumours 
(14 cm)2.  
Undifferentiated carcinoma 
An undifferentiated carcinoma is an epithelial tumour without differentiation, thus 
identifying a specific cell type is impossible. Most women diagnosed with undifferentiated 
carcinoma have advanced-stage disease and poor survival2.  
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Epidemiology of epithelial tumours 
A strong family history of either breast or ovarian cancer in a first degree relative at an 
early age is a primary risk factor for epithelial ovarian cancer17. Older age of the woman is 
another important risk factor, and the median age at diagnosis for epithelial ovarian 
cancer is 60 years25. In a recent study from the US, peritoneal carcinomas were generally 
diagnosed at older ages (mean age at diagnosis of 67 years) than fallopian tube (mean age 
at diagnosis of 64 years) and ovarian (mean age at diagnosis of 63 years) carcinomas18. 
While only 10% of epithelial ovarian cancers are due to genetic abnormalities, women 
with BRCA1 mutations have a 35-50% increased risk of disease, and women with BRCA2 
mutations have a 10-30% increased risk26. Lynch syndrome can also increase a woman’s 
risk of ovarian cancer by 3-33%27. Women with BRCA mutations are more likely to develop 
type II tumours12. BRCA mutations are also more common in women with fallopian tube 
and peritoneal cancer than women in the general population2. Additional risk factors 
include endometriosis, nulliparity, early menarche, late menopause and lack of oral 
contraceptive use9,26. 
Biological mechanisms of epithelial tumours 
The pathogenesis of ovarian cancer is not fully understood. There are two conventional 
theories regarding the development of epithelial ovarian cancer. The first theory refers to 
incessant ovulation, or the repeated wounding and repair of the surface epithelium of the 
ovary during ovulation28. This repetition increases epithelial proliferation for repair and, 
therefore, the frequency of DNA mutations and the formation of ovarian cortical inclusion 
cysts25. Ovarian inclusion cysts form through invagination of the ovarian surface 
epithelium into the surrounding ovarian stroma12. The second theory involves the 
increase of gonadotropic hormones (LH and FSH) during ovulation, which also increase 
proliferation, potentially leading to malignant transformation of the epithelium of ovarian 
inclusion cysts25,26,29. Most risk factors traditionally associated with epithelial ovarian 
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cancer, such as older age, nulliparity, early menarche, late menopause and lack of oral 
contraceptive use, can be used to support both theories of the development of ovarian 
cancer because they are all associated with an increased lifetime number of ovulations. 
Additionally, BRCA mutations result in a decreased ability to repair genetic damage, which 
increases risk of disease. 
The primary critique of the theory of incessant ovulation is that the ovarian surface 
epithelium does not resemble the main histologic types of epithelial ovarian tumours 
(serous, endometrioid, mucinous, clear cell or transitional cell). The second theory, 
involving gonadotropic hormones, attempts to mitigate this weakness by assuming that, 
prior to malignant transformation, ovarian inclusion cysts undergo metaplastic change. 
The cysts, which comprise the mesothelium (the cell type of the ovarian surface 
epithelium), undergo metaplasia and are converted to cell types representing the primary 
histological subtypes of epithelial ovarian cancer12,25. 
Epithelial ovarian cancer has conventionally been defined as cancer that begins in the 
ovaries and this idea is central to both traditional theories of epithelial ovarian cancer 
development. However, while some epithelial ovarian tumours may start in the ovaries, 
given the lack of evidence of a precursor lesion arising from or in the ovary, it is possible 
that some epithelial ovarian tumours may originate outside the ovaries and only involve 
the ovaries secondarily12. 
LGSC is thought to develop in a step-wise manner from a serous cystadenoma or 
adenofibroma to an atypical proliferative serous tumour (APST). APSTs are serous 
borderline tumours which then progress to non-invasive micropapillary serous borderline 
tumours (MPSC). Once an MPSC becomes invasive, it is considered an LGSC30.  
The pathogenesis of HGSC is less clear than that of LGSC30. Most high-grade serous ovarian 
tumours are now thought to originate in the fallopian tubes rather than the ovary31-33. 
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Recent studies examining the fallopian tubes of high-risk women with BRCA mutations 
have found that early-stage invasive tubal carcinomas are present in up to 70% of women 
with high-grade serous ovarian carcinoma, and serous tubal intraepithelial carcinoma 
(STIC) is now considered to be a precursor lesion for this particular histological subtype of 
epithelial ovarian cancer. Malignant cells from a STIC may shed and implant on the ovarian 
surface during ovulation when the fimbriated end of the fallopian tube is in close contact 
with the ovary. Additionally, normal, non-malignant tubal epithelial cells may shed from 
the fimbria and implant on the ovary to form an inclusion cyst. Once implanted, the cyst 
may then undergo malignant transformation12. 
The aetiology of fallopian tube cancer is unknown, but some studies show a protective 
effect of oral contraceptive use and parity, similar to the pattern observed for serous 
ovarian carcinoma22. Similarly, the aetiology for primary peritoneal carcinoma is unknown 
and difficult to establish because this type of cancer is so rare. There is some evidence 
that primary peritoneal carcinomas develop along the same pathway as ovarian 
carcinoma, particularly high-grade serous ovarian carcinoma18. However, while 
contraceptive use may decrease the risk of primary peritoneal carcinoma, increasing 
parity may not be as protective as for ovarian cancer22.  
Endometrioid and clear cell tumours are known to develop from endometriotic cysts, 
which are said to be the result of endometrial tissue implanted on the ovary26 or passing 
through the fallopian tube12 due to endometriosis. Endometriosis is a disease that 
primarily affects women of reproductive age, and around 10% of women of reproductive 
age have endometriosis. Endometriosis is when cells similar to the ones lining the uterus 
are found outside the womb; these cells are linked to the menstrual cycle, growing and 
bleeding along with the cells lining the uterus. However, unlike the cells lining the uterus, 
the cells are not shed from the body during menstruation. This can cause inflammation, 
27 
 
pain and the formation of scar tissue34. Endometriosis is an established risk factor for 
ovarian cancer26.  
The molecular development of transitional cell and mucinous tumours is not well 
established, but these tumours may develop from transitional cell nests at the tubal-
mesothelial junction. Transitional cell nests are clusters of benign epithelial cells, usually 
located in the connective tissue of the fallopian tubes. Transitional cell and mucinous 
tumours may develop from these cell nests located in the transitional epithelium between 
the fallopian tubes and peritoneum. Further, it is believed that mucinous and transitional 
cell tumours develop along the same molecular pathway and may develop 
simultaneously, although transitional cell tumours tend to be small and slow-growing, 
while mucinous tumours tend to be large and fast-growing12. 
Treatment guidelines for epithelial tumours 
Staging of ovarian cancer requires a surgical procedure to examine the spread of disease. 
During an exploratory laparotomy, samples of tissue from the ovary, fallopian tube, pelvic 
lymph nodes, omentum and diaphragm are biopsied and examined microscopically for 
malignant cells. The stage of disease is then based on the size, extent and location of the 
tumour (see section 1.4). Treatment for ovarian cancer depends on the stage of disease, 
therefore accurate staging of disease is critical for receipt appropriate treatment17.  
Standard treatment for early-stage epithelial ovarian cancer includes surgery, usually 
consisting of hysterectomy, bilateral salpingo-oophorectomy and omentectomy, and 
platinum-based chemotherapy. Early-stage tumours are generally confined to the ovary 
and are well-differentiated. For those tumours, salpingo-oophorectomy (unilateral or 
bilateral) may be adequate on its own. Women with early-stage and well-differentiated 
tumours may receive unilateral salpingo-oophorectomy to preserve fertility. Adjuvant 
28 
 
chemotherapy with cisplatin, carboplatin and paclitaxel is recommended for all early-
stage patients, except those with stage IA well-differentiated tumours17.  
Treatment for advanced-stage tumours includes total abdominal hysterectomy, bilateral 
salpingo-oophorectomy, omentectomy, and other procedures to remove the tumour, 
such as debulking, followed by combination chemotherapy17. Optimal cytoreduction – 
where the residual tumour is less than 1cm – has been shown to improve survival 
significantly.  Systemic chemotherapy is recommended for women who have residual 
disease of 1cm or more after surgery.  Around 80% of advanced-stage tumours will relapse 
and should then be treated with either platinum-based treatment if the tumour was 
platinum-sensitive (i.e. the disease relapsed six months or more after cessation of initial 
treatment), or alternative options for platinum-resistant disease  (i.e. the disease recurred 
within six months of stopping initial treatment or progressed during induction therapy)17.  
Advanced-stage epithelial tumours may also be treated with intraperitoneal (IP) 
chemotherapy after surgery. Clinical trials have shown favourable outcomes for IP 
chemotherapy for women with platinum-sensitive, small residual tumours. Hyperthermic 
peritoneal chemotherapy (HIPEC) is another treatment option that has been only recently 
used to treat ovarian cancer. Exploratory trials are in progress to examine the most 
effective drug combination and time at target temperatures for drug delivery, in addition 
to defining which women will benefit the most from HIPEC17.  
Treatment for fallopian tube and peritoneal carcinomas is the same as for epithelial 
ovarian tumours17,18.  
1.2.2 Germ cell 
Germ cell tumours are responsible for 3% of invasive ovarian tumours worldwide, though 
they can account for up to 20% of ovarian tumours in some East Asian countries19. Germ 
cell tumours include several histologically distinct tumour subtypes2. The majority (95%) 
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of germ cell tumours are benign mature cystic teratomas19,35. Dysgerminomas are the 
most frequent subtype of malignant germ cell tumour, but only make up 1-2% of all 
malignant ovarian tumours. Immature teratomas are the second most common subtype 
of malignant germ cell tumours. Mixed germ cell tumours represent about 8% of 
malignant germ cell tumours and are a mixture of two or more malignant germ cell 
tumours. The most common mixed germ cell tumour is a mixed dysgerminoma and yolk 
sac tumour. Pure yolk sac tumours, non-gestational choriocarcinomas and embryonal 
carcinomas are extremely rare subtypes of malignant germ cell tumours2.  
Epidemiology of germ cell tumours 
Germ cell tumours represent 60% of all malignant ovarian tumours among women aged 
21 years or younger19. The average age at diagnosis for dysgerminoma is 22 years, 
immature teratomas are most common among women aged 30 or younger and the mean 
age at diagnosis is 16 years for mixed germ cell tumours2. While most risk factors for germ 
cell tumours are unknown, congenital malformations of the genital tract, Turner’s 
syndrome and gonadoblastomas are possible risk factors for dysgerminoma9. 
The majority (60-70%) of malignant germ cell tumours are stage I or II at diagnosis, while 
only 20-30% are stage III. Stage IV tumours are extremely rare36.  
Biological mechanisms of germ cell tumours 
Germ cell tumours develop from benign germ cells, which are the egg-producing cells 
within the ovary. However, the pathway to malignant transformation of these cells is not 
clearly understood19,37. The duration of symptoms prior to diagnosis is generally only two 
to four weeks; therefore, germ cell tumours are thought to develop rapidly36.  
Treatment guidelines for germ cell tumours 
As germ cell tumours are primarily unilateral, standard surgery may be more conservative 
than for epithelial tumours38. Standard treatment typically involves unilateral salpingo-
oophorectomy or total abdominal hysterectomy and bilateral salpingo-oophorectomy, 
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plus platinum-based adjuvant combination chemotherapy. If the cancer is early-stage, 
unilateral salpingo-oophorectomy may be performed to preserve fertility in young 
women, and chemotherapy may not be required. For advanced-stage disease, unilateral 
salpingo-oophorectomy if followed by chemotherapy may be performed instead of 
bilateral salpingo-oophorectomy and hysterectomy, in order to preserve fertility39. Germ 
cell tumours generally respond well to chemotherapy38. 
1.2.3 Sex cord-stromal 
Sex cord-stromal tumours are a diverse group of rare ovarian tumours that can involve a 
variety of different cell types40. Subtypes of malignant sex cord-stromal tumours primarily 
include fibrosarcoma, steroid cell, adult granulosa cell and Sertoli-Leydig cell tumours2,19. 
The diversity of cell types and the fact that the tumours may be composed of one or more 
cell type leads to difficulty in correctly identifying the tumour subtype40. Adult granulosa 
cell tumours, the most common subtype, only comprise 1% of all malignant ovarian 
tumours and steroid cell tumours only account for 0.1% of ovarian tumours2.  
Adult granulosa cell tumours are generally low-grade, unilateral and confined to the ovary 
at diagnosis2. Though adult granulosa cell tumours are slow-growing, these tumours have 
been known to recur up to 20 years after the initial diagnosis2. Sertoli-Leydig cell tumours 
are usually confined to the ovaries at diagnosis, and are well-differentiated40. A recent 
study found that 86% of Sertoli-Leydig cell tumours were stage I at diagnosis41. 
Epidemiology of sex cord-stromal tumours 
While the incidence of sex cord-stromal tumours is highest among women in their fifties26, 
these tumours can occur throughout the reproductive years and after menopause19,42.  
The average age of adult granulosa cell patients is 53 years, but the mean age for Sertoli-
Leydig cell tumours is 25 years2. Risk factors for sex cord-stromal tumours are not well 
known, but may include race/ethnicity, obesity, family history of breast or ovarian cancer, 
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lack of oral contraceptive use and nulliparity, particularly for granulosa cell tumours43. 
BRCA mutations do not increase the risk of granulosa cell tumours44.  
Biological mechanisms of sex cord-stromal tumours 
The aetiology of sex cord-stromal tumours is unknown; however, the development of 
granulosa cell tumours may be associated with infertility and the use of ovulation-
stimulating drugs19,44,45. There are two proposed pathways for development of granulosa 
cell tumours due to ovulation-stimulating drugs: the granulosa cell tumour may already 
exist within the ovary and the hormonal drugs trigger growth, or increased amounts of 
follicle-stimulating hormone may be carcinogenic to granulosa cells44,45. Granulosa cell 
tumours may also be associated with endometrial hyperplasia due to stimulation of the 
endometrium in response to the increase in oestrogen, which is secreted by granulosa cell 
tumours. Around 13% of women diagnosed with granulosa cell tumours also develop well-
differentiated endometrial adenocarcinoma44.   
Treatment guidelines for sex cord stromal tumours  
The treatment for sex cord-stromal tumours is similar to that for epithelial ovarian 
tumours. Early-stage disease may be treated with conservative surgery, consisting of only 
unilateral salpingo-oophorectomy44. Adjuvant chemotherapy may be used to treat early-
stage disease, but the benefits of such treatment are not yet confirmed42,46,47. For 
advanced disease, total abdominal hysterectomy, bilateral salpingo-oophorectomy and 
debulking surgery may be performed along with administration of platinum-based 
combination chemotherapy42,44,47. Accurate staging of the tumour is of particular 
importance because of the higher tendency for advanced-stage disease to relapse many 
years later. All patients should be observed indefinitely after initial treatment42.   
1.3 Definition of ovarian cancer  
Given the newly proposed theories of development for serous ovarian carcinoma 
involving the fallopian tubes, and the extra-ovarian nature of the development of 
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endometrioid, clear cell, mucinous and transitional cell tumours, it seems likely that the 
majority of epithelial ovarian tumours may actually originate outside the ovary10,12. 
Additionally, the restrictive guidelines for primary fallopian tube and peritoneal 
carcinoma lead to a bias in diagnosing pelvic tumours as “ovarian” carcinoma. Since 2000, 
fallopian tube and primary peritoneal carcinomas have been included in ovarian cancer 
trials17. Therefore, for the purposes of this thesis, the definition of ovarian cancer will 
include primary fallopian tube and peritoneal cancer as well as tumours of the uterine 
ligaments and adnexa, and other specified and unspecified female genital organs 
(International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) topography 
codes C48.0-C48.2, C56.9, C57.0-C57.4 and C57.7-C57.9)48.  
1.4 Classification systems for stage of disease at diagnosis 
The stage of disease is important for accurate treatment of ovarian, tubal and peritoneal 
cancer. When examining cancer survival, stage at diagnosis is key, and the staging system 
should not allow for changes in stage after biopsy or initial treatment. The stage of the 
disease describes the extent of the spread of disease and is based on location of the 
primary tumour, tumour size, lymph node involvement and metastasis at diagnosis. 
Unless the disease is advanced at diagnosis, ovarian cancer is generally staged through 
surgery and pathological analysis of tissue samples of the tumour49. Three main staging 
systems for ovarian cancer are used: the Fédération Internationale de Gynécologie et 
d'Obstétrique (FIGO) system, the Union for International Cancer Control’s (UICC) Tumour 
Node Metastasis (TNM) system and the Surveillance, Epidemiology and End Results (SEER) 
programme’s Summary Stage 2000. Agreement between FIGO, UICC and the American 
Joint Committee for Cancer ensures that the different staging systems for ovarian cancer 
are compatible and comparable between countries.   
33 
 
1.4.1 Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) 
The FIGO staging classification system for is unique to gynaecological tumours [Table 
1.1]49. The staging guidelines are applicable to all histological subtypes of ovarian cancer, 
as well as primary fallopian tube and primary peritoneal carcinoma. 
1.4.2 Tumour node metastasis (TNM) 
Ovarian cancer can also be staged using the TNM system50. Tumours are classified on the 
basis of the size and extent of the primary tumour (T), involvement of regional lymph 
nodes (N) and the presence or absence of metastasis (M). Individual TNM values can be 
combined to create a grouped variable representing stages I-IV, which are compatible 
with FIGO stages I-IV. T, N and M may be determined through pathological or clinical 
examination, or both. Clinical examination for staging can include physical examination or 
imaging, while pathological examination involves microscopic examination of the tumour. 
1.4.3  Surveillance, Epidemiology, and End Results (SEER) Summary 
Stage 2000 
SEER Summary Stage 2000 is primarily used by the North American Association of Central 
Cancer Registries51. It was developed by the US National Cancer Institute’s SEER 
programme. SEER Summary Stage 2000 is compatible with TNM and the stages and 
definitions of each stage are listed in Table 1.2. Previous work has shown that for ovarian  
cancer there is very little misclassification when converting SEER Summary Stage 2000 to 
TNM52. 
1.5 Screening for ovarian cancer 
Successful screening techniques for ovarian cancer have been difficult to develop. 
Screening tests should follow the classic guidelines proposed by Wilson and Jungner in 
1968 [Figure 1.4]53. These guidelines have been updated over the past few decades, and 
new criteria build upon the guidelines originally proposed by Wilson and Jungner        
Continued on page 37 
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Table 1.1 Compatibility of FIGO and TNM staging systems 
FIGO T Na Mb Definition 
I T1 N0 M0 Tumour limited to the ovaries or fallopian tubes 
IA T1a N0 M0 
Tumour limited to one ovary, capsule intact, or 
fallopian tube, no tumour on surface, no malignant 
cells in ascites or peritoneal washings 
IB T1b N0 M0 
Tumour limited to both ovaries, capsules intact, or 
fallopian tubes, no tumour on surface, no malignant 
cells in ascites or peritoneal washings 
IC T1c1-3 N0 M0 
Tumour limited to one or both ovaries or fallopian 
tubes with any of the following: surgical spill, capsule 
ruptured, tumour on ovarian surface, malignant cells 
in ascites or peritoneal washings 
II T2 N0 M0 
Tumour involves one or both ovaries or fallopian 
tubes with pelvic extension or primary peritoneal 
cancer 
IIA T2a N0 M0 Extension and/or implants on the uterus and/or 
tubes and/or ovaries 
IIB T2b N0 M0 Extension to other pelvic tissues 
III T1/T2 N1 M0 
Tumour involves one or both ovaries or fallopian 
tubes, or primary peritoneal cancer, with 
microscopically confirmed peritoneal spread outside 
the pelvis and/or metastasis to the retroperitoneal 
lymph nodes 
IIIA T3a2 N0/N1 M0 
Positive retroperitoneal lymph nodes only or 
microscopic peritoneal metastasis beyond the pelvis  
IIIB T3b N0/N1 M0 Macroscopic peritoneal metastasis beyond the pelvis 
< 2cm  
IIIC Any T N0/N1 M0 
Macroscopic peritoneal metastasis beyond the pelvis 
> 2cm  
IV Any T Any N M1 Distant metastasis excluding peritoneal metastases 
IVA Any T Any N M1 Pleural effusion with positive cytology 
IVB Any T Any N M1 Parenchymal metastases and metastases to extra-
abdominal organs 
a N0 indicates no regional lymph node involvement and N1 indicates regional lymph node 
involvement. b M0 indicates no metastasis and MI indicates metastasis.  
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Table 1.2 SEER Summary Stage 2000 Classification 
Stage Definition 
0 In situ 
1 Localised only 
2 Regional spread by direct extension only 
3 Regional lymph nodes involved only 
4 Regional spread by both direct extension and lymph node involvement 
5 Regional, NOS (not otherwise specified) 
7 Distant site(s) or lymph node(s) are involved 
9 Unknown if there is extension or metastasis 
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Wilson and Jungner classic criteria for screening 
1. The condition sought should be an important health problem. 
2. There should be an accepted treatment for patients with recognised 
disease. 
3. Facilities for diagnosis and treatment should be available. 
4. There should be a recognisable latent or early symptomatic stage. 
5. There should be a suitable test or examination. 
6. The test should be acceptable to the population. 
7. The natural history of the condition, including development from latent to 
declared disease, should be adequately understood. 
8. There should be an agreed policy on whom to treat as patients. 
9. The cost of case-finding (including diagnosis and treatment of patients 
diagnosed) should be economically balanced in relation to possible 
expenditure on medical care as a whole. 
10. Case-finding should be a continuing process and not a “once and for all” 
project. 
Figure 1.4 Wilson and Jungner classic screening criteria 
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[Figure 1.5]54. As ovarian cancer is a leading cause of death from gynaecological 
malignancy worldwide, it meets the first criterion for screening. Standard treatment 
guidelines for most types of ovarian cancer exist and access to treatment is generally 
available, which satisfy the second and third criteria. 
Screening tests will only be useful in reducing mortality if a precursor lesion can be 
detected and the rate of tumour growth is slow enough to allow for early disease 
detection. Mathematical modelling using data from risk-reducing salpingo-
oophorectomies among women with BRCA1 mutations suggests that serous tumours may 
be in situ, stage I or stage II for more than four years, and stage III or stage IV for an 
additional year, before they present clinically55. While it appears there may be a lengthy 
latent period for serous ovarian cancer, the latent period is not easily recognisable and 
there is no early symptomatic stage for most ovarian tumours, which is required for the 
fourth criterion. 
Serous tumours tend to be small and slow-growing during this occult phase of 
development, remaining only 1 cm in diameter for the majority of the time before 
increasing to only 3 cm as the tumour progresses to stage III or IV55. Once the disease is 
stage III or IV, tumours grow rapidly, doubling in size every 2-3 months56. This evidence 
suggests that in order for a screening test to achieve 50% sensitivity, an annual screening 
test would need to be able to detect tumours as small as 1.3 cm in diameter. For 80% 
sensitivity, the screening test would need to detect tumours less than 0.4 cm in diameter, 
and for a 50% reduction in mortality from serous tumours, the annual screening test 
would need to detect tumours 0.5 cm in diameter55. Previous work has shown that in 
order to achieve a positive predictive value of 10% for a screening test for epithelial 
ovarian cancer (meaning that 10% of women who screen positive for epithelial ovarian  
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Updates to the classic screening criteria 
1. The screening programme should respond to a recognised need. 
2. The objectives of screening should be defined at the outset. 
3. There should be a defined target population. 
4. There should be scientific evidence of screening programme effectiveness. 
5. The programme should integrate education, testing, clinical services and 
programme management. 
6. There should be quality assurance, with mechanisms to minimize potential 
risks of screening. 
7. The programme should ensure informed choice, confidentiality and 
respect for autonomy. 
8. The programme should promote equity and access to screening for the 
entire target population. 
9. Programme evaluation should be planned from the outset. 
10. The overall benefits of screening should outweigh the harm. 
Figure 1.5 Updates to the classic screening criteria 
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cancer actually have the disease), the screening test should have a sensitivity of greater 
than 75% and a specificity of at least 99.6%25.  
Screening methods previously assessed in trials may not be able to detect such small 
tumours required to achieve a mortality benefit from annual screening. Lead-time bias 
will occur if a screening test detects disease earlier than it would have been if it had been 
diagnosed without screening, but does not result in a delay of death. With lead-time bias, 
the perceived survival time is longer with screening but this “improvement” in survival is 
due only to the earlier detection of disease through screening rather than an impact of 
the screening test on mortality. Screening techniques for ovarian cancer include pelvic 
examination, measurement of serum cancer antigen 125 (CA125) and transvaginal 
sonography, and used separately these tests have not been successful in reducing ovarian 
cancer mortality57. However, there is some evidence that when used in combination, 
ovarian cancer may be detected at an earlier stage. Recent results from the UK 
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) show that multimodal 
screening consisting of transvaginal ultrasound and CA125 assessment using the risk of 
ovarian cancer algorithm is more likely to lead to earlier diagnosis of ovarian or primary 
peritoneal cancer than no screening. The UKCTOCS also showed that multimodal 
screening could prevent up to 20% of ovarian cancer deaths. Women eligible for the trial 
were post-menopausal and did not have an increased risk of ovarian cancer57. Results 
from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial in the US 
showed no evidence of a mortality benefit from screening58 and more research is needed 
to confirm the results from the UKCTOCS.  
Further, given the histologically distinct subtypes of ovarian cancer, one screening test is 
unlikely to be sufficient for detecting all ovarian tumours. Therefore, screening techniques 
such as the multimodal screening method used in UKCTOCS would be difficult to 
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implement at the population level25. For type I tumours that grow slowly and tend to reach 
a large size while still confined to the ovary, pelvic examination and transvaginal 
ultrasound may be effective tools for early diagnosis. However, type I tumours are much 
less common and less aggressive than type II tumours, thus a mass screening programme 
for these tumours may not be appropriate. Requiring that screening tests for ovarian 
cancer focus on detecting tumours while still confined to the ovary is unlikely to be 
effective for type II tumours, which appear to develop outside the ovary. Effective 
screening tools for type II tumours might focus on detection while the tumour is small, 
rather than early stage, and would need to include examination of the fallopian tubes and 
transvaginal ultrasound12.  
The target population for ovarian cancer screening tests may change based on the specific 
subtype of ovarian tumour for which the test is aiming to detect. Additionally, screening 
techniques may need to be tailored further for different risk groups because the effect of 
annual screening on ovarian cancer mortality may vary between low-risk women and 
high-risk women. High-risk women, particularly those with Lynch syndrome or BRCA 
mutations, may benefit from more frequent screening, such as 4-monthly CA125 
assessment as implemented in Phase II of the UK Familial Ovarian Cancer Screening 
Study27,56.  While risk stratification for screening for ovarian cancer may be necessary, it 
must also be cost-effective.  
While there is some evidence of a mortality benefit from screening as shown in the 
UKCTOCS, more research is needed to confirm this result in the general population, and 
to achieve similar results in high-risk groups. Additionally, screening tests for other 
ovarian cancer subtypes need to be explored. Thus, the majority of the Wilson and 
Jungner screening criteria have yet to be satisfied for ovarian cancer.  
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1.6 Aims and objectives 
The aim of this thesis is to examine various factors that may help to explain how and why 
ovarian cancer survival differs between and within countries. 
 Objective 1: Does the distribution of histology vary by country or geographic 
region, or over time? 
 Objective 2: Does survival vary between histological groups? 
 Objective 3: Does survival vary by stage at diagnosis?  
 Objective 4: Does survival vary by race/ethnicity?  
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Chapter 2: Literature review 
2.1 Methods 
The aim of this literature review is to synthesise current knowledge on the factors that 
influence ovarian cancer survival. These factors include histology, stage at diagnosis, place 
of residence, race/ethnicity, treatment, socioeconomic status and health insurance 
status.  
The Medline, EMBASE and Global Health databases were searched using the keywords 
detailed in Table 2.1 for articles published between January 1970 and August 2016. The 
review was limited to articles in English.  
Additional articles for the literature review were found by hand-searching the references 
of articles included in the review.  
2.2 Survival and histology 
The different histological subtypes of ovarian cancer differ in aetiology and 
developmental pathways, risk factors, prognosis and survival outcome10,12. The majority 
of women are diagnosed with epithelial ovarian cancer, which confers the lowest survival 
of the three main types of ovarian cancer. In particular, survival for women with high-
grade serous carcinoma is much lower than for other types of ovarian cancer. For women 
diagnosed between 1988 and 2001 with epithelial ovarian cancer in the US, 5-year 
disease-specific survival was highest for those with endometrioid tumours (71.5%) and 
lowest for those with serous tumours (38.6%). Women with mucinous (67.1%) and clear 
cell (64.6%) carcinoma also had relatively high survival compared to those with serous 
tumours59.  
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Table 2.1 Key topics and search terms for literature review 
Key topics Search terms 
Disease of interest (ovar* OR gynecol* or gynaecol*) AND (neoplasm* OR 
oncol* OR cancer* OR tumour* OR tumor*) 
Factor of interest  
  histology morphology OR histology OR type* OR subtype*  
  stage at diagnosis  stage at diagnosis OR (cancer staging AND diagnosis) 
  race/ethnicity rac* OR ethnicit* 
  place of residence geography OR region* OR residence 
  socioeconomic status   socioeconomic status OR SES OR social class OR 
socioeconomic factor* OR socioeconomic difference* 
OR socioeconomic inequal* OR socioeconomic inequit* 
OR disparit* OR income OR education OR employment 
OR occupation* OR poverty OR deprivation 
  treatment  treatment OR surgery OR chemotherapy  
  insurance status  insurance OR insurance coverage OR insurance status  
Outcome survival analysis OR survival  
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There is some evidence, however, that histology may not impact risk of death from 
ovarian cancer. Among women receiving treatment for ovarian cancer, particularly 
primary debulking surgery, at a tertiary care centre in Germany from 2000 to 2010, 
histological subtype did not influence mortality for women diagnosed with advanced-
stage disease60. The results from this analysis suggest that differences in survival between 
histological subtypes may be due to differences in the distribution of stage at diagnosis 
within each subtype. 
Survival from borderline ovarian tumours is extremely high. In a study of long-term 
survival from borderline tumours among women diagnosed from 2000 to 2007 in Sweden, 
5-year relative survival from borderline tumours was 97%. Survival for women diagnosed 
from 1980 to 1989 was as high as 94% 10 years after diagnosis and 91% 15 years after 
diagnosis61.  
The incidence of the various ovarian cancer histological subtypes varies with age62, and 
they may respond differently to standard treatment. In a prospective study conducted in 
India, younger women were more likely to be diagnosed with germ cell tumours while sex 
cord-stromal tumours were more common among older women, and epithelial tumours 
were diagnosed in women of all ages. The peak age of incidence ranged from 21 to 30 
years for germ cell tumours, 51 to 60 years for sex cord-stromal tumours and 21 to 50 
years for epithelial tumours63. A study in Iran in 2004 found that young women aged 20-
29 and older women aged 70-79 had higher incidence of germ cell tumours than women 
of other ages. The median age of diagnosis overall was 49 years. While this age at 
diagnosis is much younger than in more developed countries, the age structure of cancer 
patient populations in less developed regions is generally younger64.  
Some studies have examined the differences of the histological subtypes of ovarian 
cancer, but the literature focuses primarily on incidence rather than survival. Articles are 
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limited by small numbers of patients and restricted to only a few countries. The majority 
of the literature focuses on epithelial ovarian cancer; very few studies include or focus on 
women with germ cell or sex cord-stromal tumours.  
Survival from a specific histological subtype may vary by topographical sub-site. Women 
diagnosed with primary peritoneal serous tumours have been shown to have poorer 
survival than women diagnosed with serous tumours of the ovary or fallopian tube. No 
differences in survival from serous tumours were seen between women diagnosed with 
fallopian tube or ovarian topography65,66.  
2.3 Survival and stage at diagnosis 
For most cancers, patients with the most advanced-stage have the lowest survival and 
this is also true for women with ovarian cancer. Though there is no traditional stepwise 
prognosis from the earliest stage to the most advanced stage with ovarian cancer, women 
diagnosed at an earlier stage do tend to survive much longer than women diagnosed at a 
later stage of disease67. Differences in survival between groups defined by stage at 
diagnosis may be partly explained by the differences in the histological subtypes of 
ovarian cancer, or the socioeconomic status, race/ethnicity, residence, treatment or 
insurance status of the patient3,68.  
Women with unstaged disease are of particular interest, since understanding why these 
women are unstaged should inform and help improve efforts to diagnose ovarian cancer 
earlier. In the US, women diagnosed from 2000-2007 with unstaged disease were 
identified from the SEER database. Unstaged disease was higher among older women, 
black women, unmarried women and those living in rural Appalachia in the south-eastern 
part of the US. Over time, however, the overall percentage of patients with unstaged 
disease has fallen69, signifying that efforts to adequately stage all patients have been 
successful.   
46 
 
International differences in survival have also been observed at each stage of disease. 
Using population-based cancer registry data from Australia, Canada, Denmark, Norway, 
and the UK, 20,073 women diagnosed with ovarian cancer from 2004-2007 were 
analysed. Overall 1-year survival was the lowest for the UK (69% vs. 72-75% elsewhere) 
and women with advanced disease also had lower survival in the UK than in four of the 
other countries. Survival differences within each stage suggest that distribution of stage 
at diagnosis does not fully explain the international differences in overall survival, and 
that other factors such as tumour biology, diagnostic delay, staging procedures or 
treatment are likely to be relevant3. In order to compare stage-specific survival in different 
countries, staging guidelines must be specific and used accurately in all regions52.  
The symptoms of ovarian cancer vary for each stage, with early-stage cancer having little 
or no obvious symptoms. Therefore, early-stage ovarian cancer may be diagnosed more 
by accident than through early presentation with symptoms. Women (n=2,371) diagnosed 
with one of 15 different cancers, including ovarian cancer, were interviewed as part of a 
study on the duration of symptoms before diagnosis. Symptoms that are typically 
associated with ovarian cancer, such as urinary problems, changes in bowel habits and 
difficulty in eating were all associated with delay in presentation70. Health insurance 
claims data may be used to indicate whether a woman has ovarian cancer, and therefore, 
diagnose women earlier than relying upon self-presentation71,72. Non-recognition of the 
seriousness of symptoms has been shown to be the main cause of patient-mediated delay 
in presentation73,74 and evidence shows that women are less aware of either the 
symptoms of ovarian cancer symptoms or the lethality75,76 especially when compared to 
that with breast cancer77.   
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2.4 Survival and race/ethnicity 
2.4.1 United States 
Research in the US focuses primarily on the disparities in survival between white and black 
women. While white women may have a higher incidence of ovarian cancer, black women 
have higher mortality78. Additionally, 5-year survival has increased from 1974 to 2001 
from 37% to 44% for white women, but has decreased from 41% to 38% for black 
women79. Evidence from previous studies suggests that racial disparities first appeared in 
the 1980s with the emergence of debulking surgery, thus implying a lack of access to 
optimal treatment for black women. In a recent study of women diagnosed from 1973-
2007 with follow-up until 2008, black women were more likely to die from ovarian cancer 
than white women, even when controlling for age, stage, marital status, year of diagnosis 
and surgery. The study, however, did not control for any socioeconomic factors80. In a 
similar study of women in the US diagnosed during 1994-1998, black women were more 
likely to die from ovarian cancer than white women, even after controlling for age, stage 
at diagnosis, tumour grade, family history of ovarian cancer and parity, as well as 
socioeconomic factors such as the percentage of households below the federal poverty 
line, the percentage of households enrolled in Medicaid, and years of education81.  The 
results from this study suggest that access to treatment and differences in quality of 
treatment may explain much of the variation in survival between white and black women.  
Socioeconomic status (SES) and race/ethnicity have been shown to be interconnected, 
and race/ethnicity has been used as a proxy measure for SES for studies based in the 
United States. However, studies have shown inconsistent results regarding the impact of 
SES on racial disparities in cancer survival and mortality. Though ovarian cancer survival 
tends to be lower for black women than white women (e.g., for women diagnosed 
between 1988 to 2001, 5-year disease-specific survival was 40.1% for black women 
compared to 44.1% for white women59), this differential is not always evident after 
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adjustment for factors that are usually correlated with SES, such as education, income and 
insurance status82-84. Additionally, while there is some evidence that racial disparities in 
survival may persist after controlling for SES, these differences may be minimised if white 
and black women have equal access to standard care and treatment85,86.  
Among women enrolled in Medicare in the US and diagnosed with advanced-stage 
epithelial ovarian cancer during 1995-2007, black women were less likely to receive 
guideline-adherent care than white women (54% vs. 68%) and differences in rates of 
treatment were associated with differences in survival87. However, clinical trial results85 
and data on women treated in the same hospital88 show that when black and white 
women diagnosed with advanced-stage epithelial ovarian cancer received similar 
treatment, there were no survival differences. Furthermore, when the likelihood of 
receiving treatment is controlled for, differences in survival across racial groups are 
eliminated89.  
Providing equal access to optimal treatment may not be all that is required to eliminate 
racial disparities, however, because some studies have shown that some racial disparities 
in outcome persist even with equal access to treatment90,91. Evidence from the Southwest 
Gynaecologic Oncology Group phase III clinical trials showed that the risk of mortality was 
48% higher for black women than for white women. However, this analysis did not control 
for the likely differences in background mortality between black and white women, and 
the higher risk of death could be explained by differences in the risk of dying from causes 
other than ovarian cancer.  
Black women may also be more likely to be diagnosed with advanced-stage cancer than 
white women92,93, even after adjustment for socioeconomic factors94, suggesting that 
stage at diagnosis may partly explain racial differences in overall survival. In a study of 
women diagnosed with advanced-stage disease, race was not associated with mortality 
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when controlling for age and tumour characteristics. Women included in the analysis were 
treated at the same tertiary care centre, thus, the results suggest that differences in 
survival between white and black women at each stage at diagnosis may be due to 
differences in treatment83.   
In addition to differential access to treatment95-97, lower socioeconomic status and 
differences in histological subtype, racial differences in survival may be explained by 
differences in comorbidities and other modifiable risk factors between white and black 
women in the US98.  
American Indian and Alaskan Native (AI/AN) populations in the United States have the 
lowest 5-year survival of all ethnic groups for several cancers, including ovarian cancer. 
The primary explanation for this difference is sub-optimal treatment. AI/AN women are 
less likely to receive surgery and standard care than all other racial and ethnic groups99. 
AI/AN women may be less likely to receive optimal care because they are not accessing 
available treatment through Medicaid. Women with ovarian cancer did not enrol in 
Medicaid any sooner than women without ovarian cancer, signalling that there may be 
other barriers to access to optimal care than insurance status for AI/AN women100.  
Histological subtype is an important predictor of survival, thus, if there are racial 
differences in the incidence of specific subtypes of ovarian cancer, this could contribute 
to the differentials seen between ethnic groups in survival from all ovarian cancers 
combined. In the US, white women are more likely to present with low-risk histological 
subtypes than black women101, and in one study, after adjustment for histology, survival 
differences between black and white women were eliminated102, suggesting that 
histology may partly explain racial differences in survival. Thus, the higher survival seen 
for white women may be partly explained by a higher proportion of white women 
diagnosed with tumours with favourable outcomes. This study, however, was limited to 
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germ cell tumours of the ovary, for which survival is generally high for both white and 
black women, and a more recent study showed contrasting results. For white and black 
women diagnosed with germ cell tumours from 2003 to 2011, black women had lower 
survival than white women, even after controlling for stage and treatment103.  
Asian Americans have higher survival from ovarian cancer than white women. Data from 
the SEER programme for women diagnosed during 1988 to 2009 showed that Asian 
women were younger at diagnosis (56 vs 64 years), more likely to undergo primary 
surgery, have earlier stage disease, have non-serous histology and have lower tumour 
grade. The 5-year disease-specific survival was 59.1% for Asian Americans compared to 
47.3% for white women. Better survival for this population may be explained by the higher 
proportion of women diagnosed with non-aggressive tumour histology104.  
2.4.2 New Zealand 
Studies from New Zealand have explored survival differences between racial and ethnic 
groups. Ovarian cancer incidence is higher for Pacific (17.6 per 100,000) and Māori (13.8 
per 100,000) women in New Zealand than non-Māori, non-Pacific women (12.3 per 
100,000)105. When comparing 5-year age-adjusted relative survival, Māori women had 
higher survival than Pacific Islander women and non-Māori/non-Pacific women. When the 
results were adjusted for stage at diagnosis, the survival differences were eliminated106. 
While Māori people are generally more deprived and utilise health services less frequently 
than non-Māori/non-Pacific women, they tend to present at earlier stages and have more 
well-differentiated tumours than non-Māori/non-Pacific women. This evidence may 
suggest that Māori women are more likely to be diagnosed with histological subtypes that 
are less aggressive106,107.  
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2.5 Survival and place of residence 
2.5.1 National-level differences 
Access to high-quality care is key to ensuring optimal survival, and access may be 
influenced by where a woman lives. Women in living rural areas of a given country are 
less likely to access optimal and timely care, and may therefore have a disadvantage 
compared to women living in more urban areas108-113. In a recent study of epithelial 
ovarian cancer survival in Australia, mortality was higher for women living in rural areas 
than women living in urban areas. Higher mortality persisted even after adjustment for 
FIGO stage, treatment, socioeconomic status, histology and age114.  
The influence of residence on stage at diagnosis is varies by population. There were no 
differences in stage at diagnosis for women diagnosed with ovarian cancer between 2004 
and 2011 and living in large cities, small towns or rural areas of Poland. Tumour grade and 
morphology also did not differ between the three groups. However, this study only 
included women who were treated at a large urban medical centre, and thus all women 
had access to the same quality of care115. In northern England, distance to hospital was 
found to predict diagnosis of ovarian cancer at death, suggesting that distance to care 
may be an important barrier to receiving optimal care116. However, earlier studies found 
that time to hospital or care did not impact stage at diagnosis, receipt of treatment or 
survival117,118, and in the US the variation in treatment is primarily explained by age, stage 
at diagnosis and comorbidities rather than area of residence119.     
2.5.2 International differences 
International differences in cancer survival are also of particular interest to gauge how 
well a country is faring in its cancer control programmes. Data from the EUROCARE-4 
database on over 97,000 women with ovarian cancer diagnosed between 1995 and 2002 
with follow-up until 2003 were used to measure differences in ovarian cancer survival 
between European countries. Overall survival increased moderately from 32.4% in 1991-
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1993 to 36.3% in 2000-2003, but there were still marked differences between countries. 
One-year survival for women in 2000-2003 was highest for Sweden (79.3%) and lowest 
for Slovakia (56.1%). There were also wide differences in five-year survival. Five-year 
survival was highest in Austria (45.1%) and lowest in Slovakia (25.3%). Differences in the 
distribution of histological subtypes may account for some of the variation in survival 
between countries, because Sweden and Austria have a lower percentage of serous 
tumours, which are thought to be more aggressive than other histological subtypes, than 
Slovakia. Differences in stage at diagnosis and treatment may also contribute120,121. 
EUROCARE-5 provided updated results to the EUROCARE-4 study, though the patterns for 
ovarian cancer are similar. The study included women diagnosed with ovarian cancer 
between 1995 and 2007 with follow-up until 2008. For Europe as a whole, 5-year relative 
survival was 38.2% in 2005-2007 and there was no significant change in relative survival 
over time from 1999 to 2007. Regionally, the UK and Ireland had the lowest 5-year relative 
survival of 31.0% and northern Europe had the highest (41.1%). The greatest 
improvements in survival were seen in eastern Europe122.    
2.6 Survival and socioeconomic status 
Since the 1950s, studies have shown that socioeconomic status (SES) is an important 
factor in cancer survival for various populations. SES differences in cancer survival have 
been observed for many different types of cancer. The differences tend to be wider for 
cancers that are generally diagnosed at a localised stage (breast, uterine, bladder, colon 
cancers) than for those more often diagnosed at an advanced stage. Conceptually, 
socioeconomic differences in cancer survival could be explained by factors related either 
to the tumour (e.g., stage at diagnosis and biological characteristics), or to the patient 
(host factors, susceptibility to treatment, psychosocial factors) or to the health care 
system (treatment received, medical expertise and screening)3,123,124.  
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Socioeconomic differentials in stage at diagnosis may be an important contributing factor 
to socioeconomic inequalities in overall cancer survival. Given the potential for higher 
survival with earlier diagnosis, if affluent patients are more likely to be diagnosed at a 
localised stage than deprived patients, then they will experience higher survival than 
deprived patients. When differences in stage at diagnosis do not contribute meaningfully 
to inequalities in survival, residual confounding by stage may still occur if deprived 
patients are more likely than affluent patients to be misclassified as having localised 
disease rather than advanced disease due to inadequate diagnostic investigation.  
Stage migration bias occurs when one group of patients “migrates” from one stage to 
another solely due to differences in diagnostic techniques. With the development of 
improved diagnostic techniques, some patients who would previously have been 
incorrectly staged with localised disease will now be correctly staged with advanced 
disease. This “migration” from localised to more advanced disease will result in higher 
stage-specific survival for both localised-stage patients and advanced-stage patients. The 
newly diagnosed advanced-stage patients have higher survival than the original 
advanced-stage patients because their disease is not as advanced as the original group of 
advanced-stage patients, thus, the stage-specific survival for the group will increase. 
Further, the stage-specific survival for localised-stage patients will also increase because 
the patients incorrectly staged as localised-stage had lower survival than the true 
localised-stage patients, and moving the misclassified patients to the advanced-stage 
group will improve the stage-specific survival of the localised-stage group. Because 
affluent patients tend to have access to better quality care, they may be more likely to be 
accurately stages with improved techniques than deprived patients. Therefore, the lower 
stage-specific survival for deprived patients than affluent patients may be a consequence 
of inadequate staging of deprived patients resulting in inaccurate staging123,125.  
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Studies of the impact of SES on ovarian cancer survival have shown that inequalities in 
survival between SES groups remain after controlling for age and stage, and are evident 
regardless of which socioeconomic indicator is used, suggesting that there are other 
underlying causes than stage for differences in survival between socioeconomic groups123.  
Women living with epithelial ovarian cancer in economically deprived areas of New South 
Wales (Australia) had higher excess mortality than women living in affluent areas. Women 
living in poorer areas had a 21% higher risk of death from ovarian cancer than affluent 
women, and poorer survival persisted even after adjustment for FIGO stage and age114. 
Stage, however, may not completely explain socioeconomic differences in survival. For 
women living in England and diagnosed between 2006 and 2010, SES was not associated 
with stage at diagnosis126. 
Socioeconomic status is intricately linked with occupation. In a review of 48 studies on 
environmental and occupational risk factors for ovarian cancer published from 1970 to 
1997, there was evidence that women working as hairdressers or beauticians or working 
in the printing industry may be at an increased risk of disease. However, these studies did 
not assess whether the increased risk of disease was confounded by income127. A study in 
Sweden found contrasting results, showing that incidence of ovarian cancer from 1961 to 
1979 did not differ between blue collar workers, white collar workers and self-employed 
non-agricultural workers128. Occupational data on middle-aged women living in France in 
1975 was used to classify women with ovarian cancer into seven occupational classes: 
professional and managerial, routine non-manual workers, self-employed, farmers, 
skilled manual workers, unskilled manual workers and agricultural workers. Occupational 
class was not found to be associated with ovarian cancer mortality129.  
Socioeconomic status may indirectly influence awareness of ovarian cancer symptoms, 
thus resulting in a delay of diagnosis70,130,131. Women living in Wales who were included in 
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the International Cancer Benchmarking Partnership were interviewed regarding their 
awareness of ovarian cancer symptoms and how long they would wait to see their doctor 
if they experienced certain symptoms. Women were asked about key ovarian cancer 
symptoms, including post-menopausal bleeding, pelvic and abdominal pain, eating 
difficulties and changes in bladder and/or bowel movements. Lower symptom awareness 
was more common in women who were less educated, single or older, or who did not 
have a family history of ovarian cancer. A long delay in presentation (longer than 3 weeks 
after symptom onset) was more common among women who reported more practical 
and emotional barriers to seeing their doctor. While presentation delay was not more 
common in those with lower symptom awareness, women who are less educated may 
also face more practical barriers to seeing their doctor within three weeks. Increasing 
awareness of symptoms may lead to a shortening of the delay in presentation to the 
health care system and, thus, may lead to better survival130. 
Biological characteristics of the tumour, such as histology, may also vary by socioeconomic 
group or may be influenced by lifestyle factors that are impacted by SES. However, further 
research is needed to quantify the impact of socioeconomic differentials in tumour 
biology on cancer survival123.  
Early studies of data from the 1960s and 1970s show that ovarian cancer incidence and 
mortality were highest for the most affluent women in some countries in Europe and 
South America, though this gradient was not evident in North America or other European 
countries132. A more recent study from Iran shows similar results, with higher incidence 
of ovarian cancer in the most affluent provinces than in deprived areas133. In more 
developed countries, recent studies show that while incidence of ovarian cancer is still 
highest for the most affluent women, mortality from ovarian cancer is lowest134,135.  
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The relationship between SES and ovarian cancer survival varies by country and 
population. A study of 635 Swedish women diagnosed with epithelial ovarian cancer 
between 1993 and 1995 and followed until December 2007 found no association between 
SES and survival after adjustment for tumour stage and grade136. A similar study in Norway 
found that differences in survival between highly educated women and those with only 
7-9 years of education were eliminated after controlling for age, stage at diagnosis and 
smoking status137. Results from the ELDCARE project showed that for European women 
who were older (aged 65-84), affluence was not correlated with relative survival from 
ovarian cancer138. In a Canadian study of the effect of macro-level SES indicators, 
community income was found to have no impact on the risk of dying from ovarian 
cancer139. For women diagnosed with ovarian cancer from 1980-1989 in England, 
deprivation did not influence relative survival140. 
2.7 Survival and treatment 
Differences in access to or the quality of treatment are likely to be a primary reason for 
differences in ovarian cancer survival. Treatment differentials may explain some of the 
survival inequalities between SES groups, and in the US may even explain much of the 
variation in survival for different racial and ethnic groups. Differences in the expertise of 
the physician or type of treatment centre may contribute to treatment differentials123. 
Factors associated with the quality of treatment a woman receives include hospital 
characteristics (public vs. private, low- vs. high-case load or non-teaching vs. teaching) and 
physician characteristics (low- vs. high-case load or subspecialty). Women treated at 
private, high-case load or teaching hospitals are more likely to receive standard and 
complete treatment97,141-149. Additionally, women who are attended by a gynaecological 
oncologist or high-case load surgeons tend to receive better care than those attended by 
general physicians or low case load surgeons97,141,143,145,147,150-154. The impact of receiving 
specialised, guideline-adherent care may not be equal for women diagnosed at different 
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stages. Women with advanced-stage disease may be less likely to have better survival 
after receiving specialised treatment than women with early-stage disease148,155. 
Additionally, when the likelihood of receiving treatment is controlled for, there were no 
differences in survival between women treated by specialists and those treated by non-
specialists156,157.  
Differences in treatment guidelines may lead to inaccurate staging. In the UK, systematic 
lymphadenectomy is not required as part of the standard surgical treatment for women 
who are thought to have stage I disease, and this may lead to some women with 
advanced-stage disease being incorrectly diagnosed with early-stage disease. Thus, if 
stage-specific survival is lower in the UK, this may be explained, at least partially, by 
inaccurate staging of tumours in women with advanced-stage disease158. 
Disparities in surgical treatment may also impact survival. Optimal cytoreduction, where 
residual disease is less than 1cm, has been shown to improve survival significantly for 
women with advanced-stage epithelial ovarian cancer. Differences between countries in 
the proportion of women whose tumours are optimally debulked may therefore partly 
explain variation in stage-specific survival. Fewer women in the UK have their tumours 
optimally surgically debulked than women in the US and other European countries. This 
lower rate of optimal cytoreduction could explain lower 1-year survival estimates seen in 
the UK for advanced-stage women compared to women in other European countries3,158.  
Disparities in surgical treatment may also partially explain differences in survival between 
white and black women in the US. Data from the National Cancer Data Base in the US for 
47,160 women diagnosed from 1998 to 2002 showed that black women were less likely 
than white women to receive surgical treatment than white women. For black women 
who did receive treatment, they were less likely than white women to receive guideline-
adherent care as recommended by the National Comprehensive Cancer Network159. Thus, 
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variation in stage-specific survival between racial groups may be partially explained by 
disparities and differences in treatment. 
Receipt of standard and complete treatment is a key factor in improving survival160. 
Studies in the US have shown that women who are non-white, publicly insured or 
uninsured, older, have comorbidities or lower income are less likely to receive standard 
treatment141,142,159,161-167 and may be more likely to be treated by physicians who do not 
follow standard treatment guidelines141,145,146,164,168. These women are obviously at a 
disadvantage compared to their white, privately insured, younger or more affluent 
counterparts. Women who are enrolled in Medicare may also receive sub-optimal 
treatment169. Improvements in survival over time are similar across age groups for ovarian 
cancer. For women diagnosed with ovarian cancer from 1988 to 1999 in England there 
was not much improvement in survival over time for both middle-aged (55-69 years) 
women and older (70-84 years) women, suggesting that while age may impact receipt of 
treatment, the overall survival benefit for new treatments is equal for all age groups170.  
Access to treatment may be influenced by SES and access to optimal care important in 
survival. Even with a national healthcare programme and cancer plan, disparities in 
treatment persist171,172. Women diagnosed from 1995-2006 in England deprived patients 
were less likely to receive full hysterectomies including omentectomies compared to 
more affluent patients. Therefore, there may be other factors beyond insurance status 
that influence access to treatment, particularly for women with lower SES171. 
Socioeconomic status was also shown to be a significant factor in ovarian cancer survival 
in Japan, where there is also a universal health care system, for women diagnosed during 
1993 to 2004. Deprivation gaps in 1-year survival were narrower than for 5-year and 
conditional 5-year survival173.  
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In two clinical trials, survival differences between socioeconomic groups in England and 
Wales were eliminated when women received high-quality treatment and standard care 
for ovarian cancer. The International Collaborative Ovarian Neoplasm (ICON2 and ICON3) 
trials included 1,408 women diagnosed with ovarian cancer from 1991-1998. Women 
diagnosed during 1991-1996 were included in the ICON2 trial and received either 
cyclophosphamide, doxorubicin and cisplatin combination chemotherapy or single-agent 
carboplatin. Women diagnosed from 1995-1998 received either of the two treatments 
from the ICON2 trial, or paclitaxel plus carboplatin. The results from the clinical trial 
showed that all treatments had a similar impact on survival, therefore further analysis 
could be done using the entire trial group. After adjusting for age, calendar period of 
diagnosis, duration of follow-up and stage, deprived women did not have higher excess 
mortality from ovarian cancer than affluent women. The results from these trials suggest 
that the socioeconomic differences in ovarian cancer survival in England and Wales may 
be due to barriers to receiving high-quality treatment and standard care174. 
Insurance status may also be a significant predictor of ovarian cancer survival. Evidence 
from both the USA and Switzerland suggests that women with private insurance are more 
likely to receive better treatment and to have higher survival than underinsured or 
uninsured women175,176, and when results from the US were stratified by insurance status, 
racial disparities in survival between white and black women were eliminated177.   
2.8 Other influences on ovarian cancer survival 
Social support may positively influence survival, particularly for younger women and 
those diagnosed with early-stage disease. Deprived patients are less likely to have access 
to social support, and this differential may also contribute to survival inequalities. Other 
patient characteristics such as nutrition, health-seeking behaviours and comorbidities 
may also influence SES differences in survival, but further research is needed to quantify 
the impact of these factors123,178,179.  
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Marital status can be an indicator of social support. Though marital status may be related 
to SES, there is evidence that married women are more likely to be diagnosed at an earlier 
stage, to receive standard treatment, and to be less likely to die from their cancer, even 
after controlling for age, histology, treatment, race/ethnicity, education and median 
household income180-182. The impact of marriage may not be the same worldwide or for 
widows. In India, single women had higher survival from ovarian cancer than married 
women183, which contrasts with previous results from the US and Norway180-182. In 
Norway, while married women had better survival than single and divorced women, they 
had similar survival outcomes as widows184.  
Comorbidities may influence stage of disease, treatment and survival, and may also be 
associated with older age, which is also associated with lower survival. Women with lower 
SES tend to have more comorbidities than women with a higher SES185. Women with 
comorbidities had a significantly higher 30-day mortality than women without any 
comorbidities186. Women in the US diagnosed with ovarian cancer from 1998 to 2000 
were less likely to receive aggressive treatment if they had comorbidities, and women 
with comorbidities had lower survival than women without comorbidities across all 
stages187.  
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Chapter 3: Material and methods 
3.1 Methods to achieve the aim and objectives of the PhD 
The aim of this thesis is to examine differences in ovarian cancer survival between 
countries and over time, with the ultimate purpose of explaining variations in survival to 
stimulate and guide the development of cancer control policies.  
In order to compare accurately survival estimates from different regions or populations, 
the data used for analysis must be population-based and adhere to a strict, centralised 
protocol. Standardised quality control indicators should be used to evaluate the quality 
and completeness of the data. Population-based cancer survival is usually estimated as 
net survival in a relative survival framework, where the cause of death is either unknown 
or cannot be used because it is unavailable or unreliable. Net survival is the survival of 
cancer patients up to a specified time after diagnosis of cancer after controlling for other 
causes of death. To account for differences in competing risks of death – background 
mortality – between countries or over time within a specific country, life tables that 
accurately represent the mortality experience of the populations from which the cancer 
patients come are required to estimate net survival in a relative survival framework. To 
ensure that any survival differences seen are not due to differences in the age structure 
of the cancer populations, survival estimates that will be compared between countries or 
over time should also be age-standardised, to minimise any remaining effect age may 
have on survival.  
3.2 The CONCORD programme 
The CONCORD programme for the global surveillance of cancer survival, led by the Cancer 
Survival Group at the London School of Hygiene & Tropical Medicine, currently includes 
data from 279 population-based cancer registries in 67 countries, 38 of which have 100% 
national coverage for adult cancers. Patients diagnosed with a cancer of the breast 
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(women), cervix, colon, liver, lung, ovary, prostate, rectum or stomach, or leukaemia 
(adults and children) during the 15-year period from 1995 to 2009 were included in the 
second cycle of the CONCORD programme, which included data for over 25 million cancer 
patients worldwide188.  
3.2.1 Population-based cancer registry data 
Population-based cancer registries aim to collect systematically a limited set of data on 
every cancer patient resident within a defined geographic area. Population-based 
registries can be general, collecting data on all cancer types, or specific, focusing on one 
type of cancer. Sources of data for population-based cancer registries include medical 
records from hospitals, oncology clinics, screening programmes, radiology and pathology 
laboratories, and clinical trials, as well as death registries.  
By contrast, hospital-based registries collect information from patients seen at or 
receiving treatment at a specific hospital. The catchment area for a hospital is often hard 
to define. Hospitals may receive patients living nearby or far away; thus, it is difficult to 
define the geographic area from which the patients visiting the hospital come. While the 
data collected by a hospital-based registry can be used to monitor clinical performance of 
a particular hospital, these data cannot be used to understand the burden of cancer in a 
defined population.  
The primary responsibility of a population-based cancer registry is to measure and 
monitor the burden of cancer within a specific region. The data collected by population-
based registries may be used to measure the incidence, prevalence or survival for a 
particular malignancy. Incidence rates and trends are used to plan and monitor strategies 
for prevention, while prevalence data may be used to establish priorities for cancer care. 
Survival data are used to measure the effectiveness of health systems in dealing with 
cancer in order to guide cancer control policies. Since population-based registries collect 
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data on all cancer patients within a defined population, and the survival estimates 
obtained using data from population-based cancer registries account for the fact that 
cancer patients may die from other causes than their cancer, survival patterns and trends 
derived from population-based cancer registry data can be used for regional and 
international comparisons.  
The data collected by registries include information on the patient (date of birth, sex, 
address or postcode), the tumour (date of diagnosis, topography, histology, behaviour), 
the treatment (chemotherapy, radiation, surgery) and the outcome (vital status, date of 
vital status).  
Specific rules for defining the date of diagnosis for a tumour are recommended by the 
International Agency for Research on Cancer (IARC), the European Network of Cancer 
Registries (ENCR) and the US National Cancer Institute’s SEER programme189-191. Generally, 
the date of diagnosis will be the date of first histological or cytological confirmation of 
malignancy. If that date is unknown, then the date of first hospital admission where the 
patient is treated for the malignancy of interest may be used. Finally, the date of first 
outpatient consultation may be used if the first two dates are not available.  
In order to be able to use cancer registry data for survival analysis, the vital status of the 
patient (alive, dead, emigrated, lost to follow-up) and the date of the last known vital 
status are required. Cancer registries may follow up their registered patients for vital 
status either actively or passively.  
Passive follow-up is the term used when cancer registries routinely receive notification of 
deaths from a vital statistics office, or they link cancer patient registrations to vital 
statistics records at routine intervals. Deaths are usually registered in the jurisdiction 
where the patient died and then forwarded, if necessary, to the vital statistics office in 
the region where the patient lived. Deaths among patients who are diagnosed when living 
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in a different location than the location at the time of their death will be missed by 
registries with linkages to only local vital statistics records. Linkages with a national death 
database can capture deaths among cancer patients who have moved within the country 
between the time of diagnosis and death, but will not capture deaths among patients who 
have moved to another country192. Computerised linkages with other databases, such as 
social security systems, health insurance, driver’s licence records or electoral registers, 
may also be used to obtain the date on which a patient was last known to have been alive, 
to have moved within a country, or to have emigrated. Patients are matched to vital 
statistics records with their national identification number and/or demographic variables, 
such as name, sex and date of birth. Patients whose cancer registration record does not 
match with a death record are then considered as alive at the date of the linkage. Thus, 
patients who are lost to follow-up are presumed to be still alive at the date of the linkage 
or the end of study, because it is impossible to distinguish them from patients whose 
registration record cannot be matched to a death record because they are in fact still 
alive. There is an assumption, therefore, that patients who are lost to follow-up are 
similar, with respect to their survival, to patients who are alive at the date of linkage or 
end of the study period. If patients who are lost to follow-up are different from those who 
are alive, however, the survival estimates may be biased, particularly if the reason for the 
patient being lost to follow-up is associated with a patient’s risk of dying193. 
 Due to the reliance on vital statistics, passive follow-up requires high-quality death 
registration within the region covered by the population-based cancer registry. Problems 
with the record linkage between the registry data and the vital statistics data may lead to 
“immortals”, or cancer patients who are assumed to be alive but who have actually died.  
Active follow-up is the term used when the registry actively and routinely obtains the vital 
status of each patient by contacting hospitals, clinics or patients’ families. Active follow-
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up is more expensive and time-consuming than passive follow-up, but may result in fewer 
patients being lost to follow-up than passive follow-up. With passive follow-up, patients 
who are lost are assumed to be alive, and thus, identical to patients who are still in the 
population and actually alive. Therefore, it is impossible to quantify the number of 
patients lost to follow-up when using passive follow-up. However, given the direct contact 
active follow-up requires, it can be assumed that this may lead to fewer patients being 
lost to follow-up. Active follow-up is often used when vital registration systems are not 
reliable, but it may also be used to complement passive follow-up. 
Of the 279 registries included in the CONCORD-2 study, 60% followed-up their registered 
patients passively, 2% actively and 38% used both active and passive follow-up188. Survival 
estimates derived from data collected by population-based cancer registries using 
different methods of follow-up are comparable if death ascertainment is complete, 
because missing deaths can inflate survival estimates192,193, and all patients whose records 
were not matched to death records are presumed to be alive at the end of the study192,193.     
Protocol for inclusion  
In order for their data to be included in the CONCORD programme, population-based 
cancer registries must have recorded incident cancers at some point during 1995-2009, 
and have follow-up data on the vital status of all those patients until at least 31 December 
2009. Cancer registries were required to code their data on topography, histology and 
behaviour according to the ICD-O-3 classification48. Women aged 15-99 years diagnosed 
with a malignant primary neoplasm of the ovary (ICD-O-3 topography code C56.9) were 
included in the analyses reported here. Tumours of the peritoneum and retroperitoneum 
(C48.0-C48.2), fallopian tube, uterine ligaments and adnexa (C57.0-C57.4), other specified 
and unspecified female genital organs (C57.7-C57.9) were also included, because these 
tumours are treated clinically in the same manner as ovarian neoplasms, and high-grade 
serous carcinomas (the most common subtype of tumours of the ovary) are often found 
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at these sites. Tumours of in situ, benign or uncertain behaviour, or metastatic from 
another primary site, were excluded from survival analyses. Records that were incomplete 
or contained invalid data were also excluded.  
Death-certificate and autopsy-only registrations 
Women whose cancer was detected only at autopsy or registered only through a death 
certificate were not included in the analyses. Survival time is calculated from the date of 
diagnosis until the date of death, date of last known vital status or last date of the study; 
therefore, cancers detected at autopsy or registered only through a death certificate 
would appear to have zero survival time. In reality, the survival time of autopsy only and 
death-certificate-only (DCO) patients is not zero, but unknown. Therefore, in order to 
avoid biasing the results, women registered through DCO or autopsy only were excluded 
from the analysis.  
Attempts are made by each registry to trace back death-certificate-initiated (DCI) 
registrations, to see if the date of diagnosis can be obtained. If the registry is successful in 
obtaining the date of diagnosis for a DCI registration, then the actual survival time for that 
patient can be calculated and they are included in survival analyses with patients 
registered while alive [Figure 3.1]. Patients with DCI records that can be traced back by 
the registry tend to have lower survival than patients registered while alive194. Thus, it is 
important for registries to attempt to trace back all DCI registrations, or the survival 
estimates for that population may be overestimated. If the date of diagnosis for a DCI 
registration remains unknown after efforts to trace back the record, then the date of 
diagnosis is set as the date of registration, and these DCO patients are not included in 
analysis.  
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Figure 3.1 Methods of cancer patient registration and criteria for inclusion in survival analyses 
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Second or higher-order tumours 
Second or higher-order tumours are primary tumours diagnosed in the same person. A 
woman with a second or higher-order primary ovarian tumour may have lower survival 
than a woman who has been diagnosed with a first primary ovarian cancer, because the 
prior cancer may inhibit adequate treatment of the ovarian tumour195,196. The detection 
of second or higher-order primary by a cancer registry depends on how long the cancer 
registry has been active. Longer-established cancer registries are more likely to identify 
subsequent tumours as second or higher-order cancers because they have had more time 
to collect data on first primaries than newly-established cancer registries. Newer registries 
may not have any data on a first primary tumour that was diagnosed prior to the operation 
of the registry and may thus wrongly assume that the second or higher-order cancer is in 
fact a first primary tumour. If survival analysis were restricted to patients with first 
primary tumours, then the proportion of patients excluded for analysis with second or 
higher order cancers will depend on how long a registry has been active and will result in 
cancer patient populations from longer-established and newly-established registries that 
will not be directly comparable. Data from the longer-established cancer registry will 
comprise a group of patients who are more likely to have true first primary tumours and 
consequently higher survival than patients with subsequent tumours, while data from the 
newly-established cancer registry will include not only patients with true first primaries, 
but also patients with second or higher-order primaries and will, consequently, have 
lower survival195,197,198. 
Differences in the implementation of screening programmes may also influence the 
proportion of cancer patients diagnosed with a second or higher-order cancer. Patients 
who are diagnosed with their first primary cancer through screening tests that detect 
slow-growing tumours that may not result in death from that cancer, such as the prostate 
specific antigen (PSA) test for prostate cancer or liquid based cytology for cervical cancer, 
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and who are then later diagnosed with a second primary cancer, would be excluded from 
analyses for the second primary if survival analyses were restricted to first primaries. 
Differences in the intensity of screening programmes between countries and within 
countries may thus lead to differences in the prevalence of patients with multiple 
primaries and the proportion of patients excluded from analyses.  
Improvements in diagnostic tests and treatment for some malignancies will lead to 
increases in survival. Thus, the number of cancer survivors remaining at risk of being 
diagnosed with a second primary cancer will also increase. As the prevalence of patients 
with multiple primaries increases, the proportion of patients excluded from analyses 
restricted to first primaries would also increase.   
Inclusion of second or higher-order tumours may impact survival estimates only slightly, 
particularly for cancers with poor prognosis195,196. However, these tumours should still be 
included in analysis, to ensure comparison of the same groups of patients in different 
countries or regions, which may follow different rules to define multiple primary 
tumours196.  
Women diagnosed with an ovarian cancer that was their second or higher-order primary 
tumour were included in the analysis, using the rules to define multiple primary tumours 
proposed by the International Association of Cancer Registries (IACR) and ENCR199. 
Different coding rules, which are less restrictive, are used by the US National Cancer 
Institute’s SEER programme200; however, data collected by registries using the SEER 
guidelines were recoded according to the IACR rules before extraction of datasets. If a 
woman was diagnosed with two or more ovarian cancers, only the first tumour was 
included in the analysis. 
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Quality control 
The CONCORD Analytic Team assessed the quality and completeness of the cancer 
registry data. The CONCORD programme quality control procedures are performed in 
three phases, designated as protocol adherence, exclusions and editorial checks.  
In “protocol adherence”, each variable is checked to ensure that it is correctly coded 
according to the CONCORD protocol [appendix A]. The CONCORD protocol specified a 
range of valid values for each variable. Any value outside the range of valid values is 
considered non-compliant. A detailed protocol adherence report is then created sent to 
each registry, and the registry is given the opportunity to correct any mistakes.  
In the “exclusions” phase, the logical coherence between variables in each record is 
assessed, and incomplete or inaccurate records are assigned to one or more error 
categories. These include errors such as inconsistency in date sequences, and 
inconsistencies between sex and site, site and morphology, and age and site. Records with 
incomplete or inaccurate data are excluded during this phase. Duplicate registrations – 
records with the same site, person identifier and tumour identifier – are excluded, with 
the most complete record being retained. Synchronous tumours are designated as 
tumours diagnosed in the same person, at the same site and with the same date of 
diagnosis: only the most complete record for these tumours is retained. For multiple 
tumours diagnosed in the same person at the same topographic site but with different 
dates of diagnosis, the record with the earliest date of diagnosis is retained. A detailed 
report on all exclusions is sent to each registry. The report includes exclusion tables for 
each cancer that show the number and proportion of patients excluded in each error 
category for 1995-1999, 2000-2004 and 2005-2009.  
During the “editorial” phase, the plausibility of the distributions of the main quality 
indicators is assessed. A detailed report is sent to each registry, including editorial tables 
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that show the distribution of histologically verified tumours, tumours of non-specific 
morphology, the proportion of patients lost to follow-up, the proportion of patients 
censored within five years of diagnosis and the proportion of deaths occurring within 30 
days of diagnosis, for each cancer. The distributions of the day and the month of the date 
of birth, the date of diagnosis and the date of last known vital status should be constant 
across all months and days, since one would expect an even distribution of diagnoses 
across all months and days of the year, except for days 28-31. Spikes in the distributions 
indicate where registries may have imputed data when these dates were missing.  
Variables 
A cleaned dataset containing only registrations of women diagnosed with tumours of the 
ovary, fallopian tube, peritoneum, uterine ligaments and adnexa was provided by the 
CONCORD Central Analytic Team [Table 3.1]. Age at diagnosis, date of diagnosis, vital 
status and date of vital status are required variables for calculating the time survived since 
diagnosis for each woman. The variables for continent, country, registry and region were 
used to identify the place of residence for each woman for international comparisons of 
survival. The basis of diagnosis, ICD-O-3 topography and ICD-O-3 morphology were used 
in analyses examining the distribution of and survival from different histological subtypes 
of ovarian cancer. The CONCORD protocol offered several options to submit information 
on stage: T, N and M (pathological and clinical), condensed TNM, SEER Summary Stage 
2000 and FIGO were the most relevant stage classification systems for ovarian cancer. A 
complex algorithm was developed to optimise the availability of the stage information 
(i.e., to reduce the proportion of missing information). Several grouped variables were 
created in order to obtain a broader (localised vs. advanced) and, when possible, a more 
detailed stage distribution (TNM stage, SEER Summary Stage 2000). Survival by stage at 
diagnosis was examined using the grouped (localised vs. advanced) stage variable.  
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Table 3.1 Main variables for analysis 
Variable Description 
Continent Continent 
Country Country of residence of the patient 
Registry Cancer registry in which the patient is registered 
Person code Unique patient identifier 
Tumour code Assigned to each tumour to identify first, second or higher-
order tumours 
Sex Sex of cancer patient 
Region Smaller geographic regions (province, state, county, etc.) 
within each registry coverage area 
Race/ethnicity Race/ethnicity of patient 
Date of diagnosis Date of cancer diagnosis  
Age Age at diagnosis 
Vital status  Alive, dead, lost to follow-up, not known 
Date of vital status Date of last known vital status  
Basis of diagnosis Indicates method of the cancer diagnosis (clinical, 
microscopically verified, death certificate only, autopsy 
only) 
ICD-O-3 topography Four-character ICD-O-3 code indicating anatomic site of 
tumour 
ICD-O-3 morphology Four-digit ICD-O-3 code indicating morphology of tumour 
Behaviour Indicates whether the tumour is benign, in situ, invasive or 
uncertain whether benign or malignant 
SEER Summary stage 
2000 
Stage of disease (in situ, localised, regional, distant, 
unknown) based on the North American Association of 
Central Cancer Registries' guidelines 
Pathological T First component of the TNM classification of stage 
indicating tumour size based on pathological examination 
Pathological N Second component of the TNM classification of stage 
indicating extent of regional lymph node involvement based 
on pathological examination 
Pathological M Third component of the TNM classification of stage 
indicating presence or absence of distant metastases based 
on pathological examination 
Clinical T First component of the TNM classification of stage 
indicating tumour size based on clinical examination 
Clinical N Second component of the TNM classification of stage 
indicating extent of regional lymph node involvement based 
on clinical examination 
Clinical M Third component of the TNM classification of stage 
indicating presence or absence of distant metastases based 
on clinical examination 
Condensed T Indicates localised or advanced disease based on European 
Network of Cancer Registries' guidelines 
Condensed N Indicator of regional lymph node involvement 
Condensed M Indicator of metastasis 
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Variable Description 
FIGO stage Specialised classification of tumour stage for gynaecological 
cancers 
Tumour size Maximum tumour diameter in millimetres 
Number of lymph nodes 
examined 
Exact number of lymph nodes examined 
Number of lymph nodes 
involved 
Exact number of lymph nodes containing tumour cells 
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Ethical approval 
Ethical approval for the CONCORD programme was obtained from the London School of 
Hygiene and Tropical Medicine’s Observational/Interventions Research Ethics Committee 
(LSHTM Ethics Reference No. 6396) [appendix B]. Ethical approval was also obtained from 
the Ethics and Confidentiality Committee of the UK’s National Information Governance 
Board (now the Health Research Authority; ECC 3-04(i)/2011) and the National Health 
Service’s Research Ethics Service (Southeast; 11/LO/0331). Separate statutory or ethical 
approval was obtained in more than 40 other jurisdictions before data were released. 
3.3 Incidence, prevalence and mortality 
Cancer incidence, prevalence and mortality are important population-based measures of 
the cancer burden. Incidence can be used to understand better the causes of cancer and 
to plan prevention programmes. The prevalence of a cancer is useful for planning the 
allocation of cancer services, and mortality may be used to assess the effectiveness of 
cancer care.   
3.3.1 Incidence  
The cancer incidence rate refers to the number of new cancer patients per unit of 
population over a defined period of time, typically, per year. It is defined as the number 
of new cancers per 100,000 (or 10,000 or 1,000,000) person-years at risk over a specified 
time period – usually one year. The incidence rate is an important measure to identify 
populations at higher risk for a particular cancer, for cancer prevention and control. The 
number of new cases in a defined population, the numerator of the incidence rate, can 
be obtained from cancer registry data. The denominator is the person-years at risk, and 
is usually defined as the total person-time at risk during a given time period201. The mid-
year population can be used to approximate the number of person-years lived by persons 
in the defined population during the year of interest. 
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𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑟𝑎𝑡𝑒 =  
𝑁𝑜. 𝑜𝑓 𝑛𝑒𝑤 𝑐𝑎𝑛𝑐𝑒𝑟 𝑐𝑎𝑠𝑒𝑠 𝑖𝑛 1 𝑦𝑒𝑎𝑟
𝑁𝑜. 𝑜𝑓 𝑝𝑒𝑟𝑠𝑜𝑛𝑠 𝑐𝑜𝑚𝑝𝑟𝑖𝑠𝑖𝑛𝑔 𝑚𝑖𝑑-𝑦𝑒𝑎𝑟 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
  𝑥 105 
= 𝑟𝑎𝑡𝑒 𝑝𝑒𝑟 105 𝑝𝑒𝑟𝑠𝑜𝑛-𝑦𝑒𝑎𝑟𝑠 
The incidence rate of a particular cancer will influence the mortality rate from that 
malignancy, but is not influenced by events after diagnosis, such as treatment or survival. 
Incidence is, however, influenced by events that occur before diagnosis, such as 
screening, as well as changed in the definition and coding of malignancies. International 
differences in incidence rates may be partly due to varying levels of ascertainment of 
cases as well as actual differences in the incidence. Trends in incidence over time may be 
useful, but these can be affected by changes in the definition of the cancer, improved 
diagnostic techniques, screening programmes and the completeness of registration201. 
3.3.2 Prevalence 
Total, or complete, point prevalence is defined as the current number of people alive with 
a particular disease in a given population at a specified point in time. Partial prevalence 
limit total prevalence to patients diagnosed during a certain time period. Prevalence can 
be used by health care providers to allocate resources for cancer treatment and care 
within a population.  
Unlike incidence, prevalence is affected by survival, because the pattern of survival 
determines the number of people alive with a particular cancer at a given time, which is 
the numerator of the prevalence. 
𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 =  
𝑁𝑜. 𝑜𝑓 𝑐𝑎𝑛𝑐𝑒𝑟 𝑠𝑢𝑟𝑣𝑖𝑣𝑜𝑟𝑠 𝑖𝑛 𝑑𝑒𝑓𝑖𝑛𝑒𝑑 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
𝑁𝑜. 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑖𝑛 𝑑𝑒𝑓𝑖𝑛𝑒𝑑 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
 𝑥 105 
= 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 𝑝𝑒𝑟 105 𝑝𝑒𝑟𝑠𝑜𝑛s 
3.3.3 Mortality 
A cancer mortality rate is the number of deaths attributed to that specific cancer per unit 
of population in a defined period of time, typically a year, usually expressed per 100,000 
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person-years. It is defined as the number of deaths, the numerator, available from 
national statistics agencies, divided by the denominator, the person-years at risk,  
approximated by the mid-year general population estimate201.  
𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑟𝑎𝑡𝑒 =  
𝑁𝑜. 𝑜𝑓 𝑑𝑒𝑎𝑡ℎ𝑠 𝑖𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 1 𝑦𝑒𝑎𝑟
𝑁𝑜. 𝑜𝑓 𝑝𝑒𝑟𝑠𝑜𝑛𝑠 𝑐𝑜𝑚𝑝𝑟𝑖𝑠𝑖𝑛𝑔 𝑚𝑖𝑑-𝑦𝑒𝑎𝑟 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
 𝑥 105 
= 𝑟𝑎𝑡𝑒 𝑝𝑒𝑟105 𝑝𝑒𝑟𝑠𝑜𝑛-𝑦𝑒𝑎𝑟𝑠 
Mortality is affected by both incidence and survival. In order to die from a certain cancer, 
a patient must first be diagnosed with and then fail to survive from that cancer, and the 
patient’s death must be accurately recorded as due to that cancer. In order for the death 
to be attributable to that cancer, the death must be medically certified and the underlying 
cause of death on the death certificate must be recorded as that cancer. The mortality 
rate can be affected by changes in coding of death and differing practices in selecting the 
underlying cause of death. The mortality rate for a particular time period is thus a 
combination of the incidence and survival from earlier years for cancers with good 
prognosis and the incidence and survival for cancers with poorer prognosis for the recent 
time period201. The mortality rate, therefore, is a delayed evaluation of progress, or lack 
thereof, in the effectiveness of cancer care. Mortality may not be the best evaluative 
measure of changes in diagnosis or treatment, because the mortality rate is derived from 
deaths of patients diagnosed in several different years, particularly for cancers with good 
prognosis, who may not have had the same treatment.  
3.4 Net survival  
Population-based cancer survival (net survival) can be used as a measure of the overall 
effectiveness of cancer care and management in a given health system for earlier periods 
of diagnosis. It can evaluate the utilisation of and access to cancer care and stimulate and 
guide the development of cancer control policies. Survival can be affected by changes in 
diagnostic techniques, and the intensity of screening or early diagnostic activity, as well 
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as the efficacy of treatment. Screening programmes may result in an increase in survival 
that is not necessarily due to improvements in treatment or care. This increase may occur 
if smaller, slower-growing tumours are detected by a new screening programme, resulting 
in a group of longer-surviving patients who previously would have not been diagnosed. 
An increase in survival may also occur if tumours are detected during the pre-clinical 
asymptomatic phase, but there is no delay in death for the cancer patients – the increase 
in survival in this case is solely due to the earlier detection of the tumour201.  
Monitoring survival over time is important for helping guide health policy and cancer 
control plans. Improvements in survival can reflect progress in diagnosing patients earlier 
or the efficacy of treatment. Survival data can be more accurate than mortality data for 
evaluating progress in diagnosis and cancer care, because survival data from population-
based registries undergo several quality control checks while mortality data comes from 
a single source – the death certificate. Death certificates are very rarely validated with 
clinical or pathological information.  
Unlike incidence, prevalence and mortality, survival is not a simple ratio calculation. The 
outcome of survival analysis is the time to a particular event; therefore, some element of 
time must be included in the calculation of survival. For cancer survival analysis, survival 
time is usually measured from the date of diagnosis until the date of death, date of last 
known vital status or the end of the study. Full dates, including the day, month and year 
of the patient’s birth, diagnosis and death should be used in cancer survival analysis to 
obtain the most precise estimates202. Using partial dates with just the month and year, 
can create bias in the estimation of survival. If a patient is diagnosed and dies in the same 
month, the survival time for that patient will be zero while the true survival time can be 
up to 31 days. Using partial dates may also make it impossible to distinguish DCO 
registrations from patients where the survival is known but appears to be zero because 
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the patient was diagnosed and died within the same month. Given that the first few 
months after diagnosis is when the probability of death changes the most rapidly and the 
widest differences in survival are most often seen during this time period, using partial 
dates makes it impossible to determine the precise differences in survival between 
countries. 
The outcome of survival analysis – the distribution of the time to an event – can be 
expressed as the survival function S(t) or the hazard function h(t). The survival function 
gives the probability that a person survives longer than some specified time t since 
diagnosis. The hazard function is defined as the rate at which the event of interest, usually 
death from any cause, occurs at a specified time since diagnosis. The hazard function is 
also known as the force of mortality. The hazard will usually change over time, often 
substantially. While the population at risk was the general population for incidence and 
mortality, the population at risk for survival analyses is the cancer patient population.  
The objective of population-based cancer survival analyses is to obtain an estimate for net 
survival. Net survival is formally defined as the survival of cancer patients in the 
hypothetical world where the only cause of death is cancer. It more readily interpretable 
to describe it as estimating the survival of cancer patients up to a specified time after 
diagnosis after controlling for competing risks of death. 
Net survival can be estimated in two general contexts: cause-specific, where the exact 
cause of death is known, or relative survival where the exact cause of death is unknown, 
unreliable or inaccessible. Population-based cancer survival is usually estimated in a 
relative survival framework because the cause of death available from cancer registries 
may not be reliable, particularly when comparing survival from different countries. 
Estimating cancer survival within a relative survival framework also eliminates any issues 
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with differences or inaccuracies in cause of death coding, because the cause of death is 
not required for analysis.  
Cancer patients may die from causes other than their cancer, and because of the lack of 
cause of death data in the relative survival setting, it is impossible to identify which cancer 
patients have died from their cancer and which have died from other causes. Therefore, 
the relative survival setting requires that the background mortality, or mortality in the 
general population, is accounted for to ensure that excess deaths in the cancer patient 
population are due to cancer and not other causes. Deaths from causes other than cancer 
are assumed to be conditionally independent of deaths due to cancer and deaths due to 
cancer are assumed to be small. Life tables are used to account for the background 
mortality in a population when estimating survival, assuming that the mortality from 
other causes within the cancer patient population is similar to the mortality of the general 
population. Life tables are required when comparing population-based cancer survival in 
populations with differing levels of background mortality, because the net survival 
estimates then provide a true representation of differences in cancer survival after 
adjusting for differences in background mortality. Life tables should be specific to a given 
sex, country or region of residence, race and level of deprivation, to control for differing 
levels of background mortality between these groups.  
Pohar Perme recently proposed a non-parametric method to estimate net survival that 
takes into account competing risks of death and the fact that competing risks are higher 
in the oldest age groups203. This method is considered as an unbiased estimator of net 
survival.  
3.5 Cohort, period and complete approaches 
In survival analysis, patients are generally followed for a specified amount of time to 
observe whether the event of interest, usually death, occurs. If all patients can be 
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followed for a specified time (e.g., 5 years), then survival can be estimated using the 
cohort approach. For cancer survival analysis, a cohort of patients will usually be a group 
of patients diagnosed within the same year or calendar period. All patients who are 
included in the analysis have had the potential to be followed-up for the specified amount 
of time. The cohort approach to survival estimation is the gold standard, because all 
patients are diagnosed within the same period, are likely to have receive the similar 
treatment, and are observed and followed through time for at least the specified amount 
of time [Figure 3.2]. Five-year survival can be estimated using the cohort approach for 
patients diagnosed between 1995 and 2004, because at least five years of follow-up are 
available for patients diagnosed in each of those years. However, 5-year survival cannot 
be estimated using the cohort approach for patients diagnosed between 2005 and 2009 
because five years of follow-up are not available for all patients. 
The period approach can be used to estimate five-year survival for patients diagnosed 
between 2005 and 2009 with follow-up until 31 December 2009. The period approach 
enables prediction of 5-year survival for patients diagnosed in 2005-2009 by using the 
survival experience of patients who were diagnosed in earlier years and who were alive 
at some point during 2005-2009.  It is assumed when using the period approach that the 
survival probabilities for the patients diagnosed in each year of the analysis will remain 
identical to the actual survival experience of the patients diagnosed in the year for which 
survival is being estimated. Thus, in Figure 3.1 it is assumed that the survival probabilities 
seen in 2009 will remain the same as the probabilities that will be seen in later years. This 
assumption is likely true for estimates of short-term survival, but may be problematic 
when estimating long-term survival. In the period approach, different parts of the survival 
function are contributed by patients diagnosed during different years, and period survival 
can then be interpreted as the predicted short-term survival for a specified number of 
years after diagnosis for patients diagnosed in a recent year or period for which complete  
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    Calendar year of follow-up 
   1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
C
al
en
d
ar
 y
e
ar
 o
f 
d
ia
gn
o
si
s 
1995 0 1 2 3 4 5 6 8 8 9 10 11 12 13 14 
1996  0 1 2 3 4 5 6 7 8 9 10 11 12 13 
1997   0 1 2 3 4 5 6 7 8 9 10 11 12 
1998    0 1 2 3 4 5 6 7 8 9 10 11 
1999     0 1 2 3 4 5 6 7 8 9 10 
2000      0 1 2 3 4 5 6 7 8 9 
2001       0 1 2 3 4 5 6 7 8 
2002        0 1 2 3 4 5 6 7 
2003         0 1 2 3 4 5 6 
2004          0 1 2 3 4 5 
2005           0 1 2 3 4 
2006            0 1 2 3 
2007             0 1 2 
2008              0 1 
2009               0 
 
Numbers indicate the minimum number of years of follow-up available for a particular year of diagnosis. 
  
    Cohort                
    Period                
  
 
Complete               
Figure 3.2 Cohort, period and complete approaches to survival estimation
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follow-up of all patients is not yet available204. The period approach allows for survival to 
be estimated for more recent years of diagnosis, rather than having to wait for the full 
follow-up time to pass (for example, five years) as with the cohort approach.  
The complete approach can also be used. The complete approach uses all relevant data 
available, i.e., for patients diagnosed more recently than those available for the cohort 
approach, but without requiring full follow-up data for all patients diagnosed during the 
years of interest. If there is at least one diagnosis year with full follow-up time available, 
then the complete approach can be used. For example, for estimating survival for five 
years after diagnosis for patients diagnosed between 2004 and 2009, a complete 
approach can be used because there is five years of follow-up available for the patients 
who were diagnosed during 2004. Patients who do not have full five-years of follow up 
are then censored at the end of the study (31 December 2009) if they have not died or 
been lost to follow-up205.  
3.6 Age-standardisation 
Age-standardisation is important for appropriate comparison of cancer survival estimates 
for all ages combined. The excess risk of death from cancer increases with age; therefore, 
differences in the age distribution of cancer patients can confound comparisons of 
survival for all ages combined between countries or within the same country over time. 
While using life tables and net survival to control for the fact that competing risks increase 
with age, a residual effect of age on survival estimates for all ages combined may still 
occur. Age-standardisation removes most or all of the remaining effect of age on survival 
estimates. In order to produce an age-standardised survival estimate, age-specific survival 
estimates for each age group must first be calculated. The age-specific survival estimates 
are multiplied by the corresponding age-specific weights, which represent the proportion 
of cancer patients in each specific age group. The recommended set of age-specific 
weights for cancer survival is the International Cancer Survival Standard (ICSS)206. ICSS 
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weights for cancers for which incidence increased with age, were used in this thesis when 
age standardisation was possible. Using the same age-specific weights for all groups being 
compared will ensure that the differences in the age distributions of the cancer patients, 
by country and over time, will not affect the comparison of the survival estimates. A 
summation of the weighted age-specific survival estimates provides the age-standardised 
survival estimate for all age groups combined, which is a weighted average of the age-
specific estimates.  
3.7 Statistical analyses  
All statistical analyses were conducted using Stata version 14207. Net survival was 
estimated up to five years after diagnosis using the Pohar Perme estimator implemented 
in Stata using stns208. Survival was analysed by calendar period of diagnosis (1995-1999, 
2000-2004 and 2005-2009), histological group, stage at diagnosis and race/ethnicity. 
Cumulative probabilities of survival are reported as percentages, truncated to 0-100%. 
Standard errors were derived using the Greenwood209 method and 95% confidence 
intervals are reported. Life tables for single year of age (0-99 years), calendar year, sex, 
country and, where possible, race were used to account for the background mortality of 
the populations. Age-standardisation was attempted using ICSS weights. Age at diagnosis 
was categorised into five age groups: 15-44, 45-54, 55-64, 65-74 and 75-99 years. If an 
age-specific estimate could not be produced, or fewer than 10 women were available for 
analysis in an age group, data for adjacent age groups were pooled and the re-estimated 
survival used for both of the original age groups. If two or more age-specific estimates 
could not be produced, or fewer than 10 women were available for analysis in two or 
more age groups, then only the unstandardised estimate is reported. Survival was 
estimated using the cohort approach for women diagnosed during 1995-1999 and 2000-
2004 and the period approach for women diagnosed during 2005-2009 for the analysis by 
histological group and race/ethnicity. The periods of diagnosis were slightly different for 
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the analysis by stage at diagnosis: 2001-2003 and 2004-2009. The cohort approach was 
used to estimate survival for the first calendar period, while the complete approach was 
used to estimate survival for the later calendar period. More detailed descriptions of the 
methods used for each analysis are provided in each chapter.   
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Chapter 4: Histological groups of ovarian cancer: 
worldwide distribution 
4.1 Introduction 
International comparisons of cancer incidence, mortality and survival are crucial to inform 
and plan health policy and cancer control programmes. Low survival has been a stimulus 
for cancer plans and strategies in many countries, such as the United Kingdom and 
Denmark3. Comparisons of lung cancer survival have routinely been divided into small-cell 
and non-small cell subtypes due to their different prognosis, clinical behaviour and 
treatment.  
Ovarian cancer is arguably an even more heterogeneous group of diseases than lung 
cancer, and histology should thus be considered in the interpretation of international 
variation in ovarian cancer survival, particularly the distribution of type I and type II 
epithelial tumours. This is because type I epithelial tumours are generally associated with 
higher survival than type II tumours, so the proportion of type I epithelial tumours may 
influence survival estimates for all ovarian cancers combined. Differences in the 
distribution of histology may thus contribute to international variations in survival from 
all ovarian cancers combined, in addition to international differences in stage at diagnosis 
and treatment. 
The CONCORD-2 study on the global surveillance of cancer survival has shown the extent 
to which ovarian cancer survival varies worldwide when comparing estimates for ovarian 
cancer with all histological types combined188. It remains unclear how much of the 
variation in ovarian cancer survival could be attributed to international variation in the 
distribution of histological groups in each country. The international distribution of 
ovarian cancer histology was examined using population-based data from the CONCORD-
2 study. The aim was to describe the worldwide variation of ovarian cancer histological 
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groups, and then to examine whether this variation may influence international 
comparisons of population-based cancer survival. 
4.2 Material and methods 
The CONCORD-2 study188 collected data for 779,302 adult women (aged 15-99 years) in 
61 countries who were diagnosed during the 15-year period 1995-2009 with a cancer of 
the ovary. Ovarian cancer was defined broadly to include tumours of the fallopian tube, 
uterine ligaments and adnexa, other specified and unspecified female genital organs, 
peritoneum or retroperitoneum (International Classification of Diseases for Oncology, 3rd 
edition (ICD-O-3) topography codes C56.9, C57.0-C57.4, C57.7-C57.9, C48.0-C48.2)48. The 
CONCORD-2 protocol, the ethical approvals and the quality control procedures have been 
described elsewhere188 and in Chapter 3a. 
Six “histological groups” were defined based on ICD-O-3 morphology codes, the 
literature210 and clinical advice [Table 4.1]. Based on the categorisation proposed by 
Kurman and Shih in 200416, recently updated in 201610, type I epithelial tumours included 
clear cell, endometrioid, mucinous, squamous and transitional cell carcinomas, and type 
II epithelial tumours included serous carcinoma, mixed epithelial and stromal carcinoma 
and undifferentiated and other epithelial carcinoma. Throughout this chapter, 
“histological group” refers to the broader categories of tumours, each comprising one or 
more of the “histological subtypes”.   
Individual patient data were available for 793,098 women diagnosed with ovarian cancer 
from 1995 to 2009 [Figure 4.1]. This number is slightly larger than the number of women 
included in the analysis for the main CONCORD-2 article, because of a data submission  
                                                             
a The material in Chapters 4-7 is based on examination of the distribution of and survival from 
ovarian cancer histology, stage at diagnosis and race/ethnicity. A few paragraphs of material and 
methods are repeated in each of these chapters for ease of reference and to ensure consistency 
of the descriptions. A detailed definition and description of the data and methods can be found in 
Chapter 3.  
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Table 4.1 Ovarian cancer histological groups and subtypes 
Histological groupa Histological subtype ICD-O-3 morphology code 
Type I epithelial Clear cell carcinoma 8005, 8310, 8443, 9110 
Endometrioid 
carcinomab 
8380, 8382-8383, 8560, 8570 
Mucinous carcinoma 8470-8471, 8480-8482, 8490 
Squamous carcinoma 8051-8084 
Transitional cell or 
Brenner carcinoma 
8120-8131, 9000 
Type II epithelial Serous carcinomac 8050, 8441, 8450, 8460-8461 
Mixed epithelial-stromal 
carcinoma 
8313, 8323, 8381, 8930-8991, 
9010-9030 
Undifferentiated or 
other epithelial 
8010-8015, 8020-8046, 8090-
8110, 8140-8231, 8246-8300, 
8311-8312, 8314-8322, 8324-
8325, 8336-8337, 8341-8375, 
8384-8440, 8452-8454, 8500-
8551, 8561-8562, 8571-8589 
Germ cell Germ cell  8240-8245, 8330-8335, 8340, 
9060-9105, 9380-9523 
Sex cord-stromal Sex cord-stromal 8590-8671, 8810  
Other specific non-
epithelial 
Other specific non-
epithelial 
8680-8806, 8811-8921, 9040-
9055, 9120-9373, 9530-9589 
Non-specific Non-specific 8000-8004 
a Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and 
those with missing morphology codes were excluded from the analysis of distribution 
of histological groups and topographical sub-sites (see text). b No information on grade 
was available; therefore, all endometrioid tumours were classified as type I epithelial. c 
No information on grade was available; therefore, all serous tumours were classified as 
type II epithelial. 
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Figure 4.1 Data exclusion flow chart for the worldwide distribution of ovarian cancer histology, 
1995-2009 
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error that was corrected after the analysis for the main article had been completed. Data 
submitted by Ontario for women diagnosed from 1995 to 2007 did not initially include 
tumours of the ovary, but included only tumours of the fallopian tube and peritoneum. 
The registry resubmitted data including all sub-sites for the entire 15-year period, 
resulting in an increase of 13,796 women. 
Recent evidence suggests that high-grade serous carcinoma, the most common type of 
ovarian cancer, originates in the fallopian tube. Therefore, cancers of the fallopian tube 
and other specified and unspecified female genital organs were included in a broader 
definition of ovarian cancer. Similarly, primary peritoneal and retroperitoneal carcinomas 
are managed in the same way as advanced-stage epithelial ovarian cancer, and they are 
also included12. The term “ovarian” in this chapter refers to tumours at all sub-sites, unless 
the context makes clear that it refers to tumours of the anatomic ovary. 
Ovarian cystadenomas were reclassified from invasive (behaviour code 3) in ICD-O-2 to 
borderline (uncertain whether benign or malignant with a behaviour code 0 or 1) in ICD-
O-3, which was introduced in 2000. Due to this change in coding, some women diagnosed 
with borderline tumours were included in the data submissions to the CONCORD-2 study. 
Women diagnosed with borderline tumours or haematological malignancies were 
excluded (n=13,072). Of the remaining 780,026 women, 90.6% (706,808) had tumours 
that were coded by the registry as having been morphologically verified, while 7.5% 
(58,682) were not coded as morphologically verified and 1.9% (14,536) were coded as 
unknown whether morphologically verified or not. For tumours coded as morphologically 
verified, 705,997 (99.9%) had a valid ICD-O-3 morphology code, but no morphology code 
or only an invalid code (codes not included in either ICD-O-2 or ICD-O-3) was available for 
811 (0.1%), and these tumours were excluded. Tumours coded as not morphologically 
verified were primarily those with morphology coded as missing (CONCORD-2 assigned 
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code of 9999; 30,287, 51.6% of non-morphologically verified tumours); these tumours 
were excluded. A further 18,200 non-morphologically verified tumours with non-specific 
morphology were excluded.  
The remaining 10,195 tumours that had been coded as not having been morphologically 
verified were included, because a specific ICD-O-3 morphology code was nevertheless 
available, implying that morphological verification had in fact been performed. Tumours 
for which it was unknown whether morphological verification had been performed or not 
were evenly distributed across specific (n=5,017), non-specific (n=4,798) and missing 
morphology (n=4,721). Of these tumours, those with non-specific morphology and 
missing morphology were excluded. The remaining 5,017 tumours coded as unknown 
whether morphologically verified were included, because a specific morphology was also 
recorded, again implying that morphological verification had been completed.  
In total, 721,209 women (98.3% with specific ICD-O-3 morphology codes and a further 
1.7% with non-specific morphology codes 8000-8004) were available for analysis after the 
first round of exclusions.  
The distribution of ovarian cancer histology was examined for all countries in each 
calendar period (1995-1999, 2000-2004 and 2005-2009) for which data were available for 
at least 100 women. Records from registries from which the survival estimates in the main 
CONCORD-2188 analysis were considered less reliable were also excluded, because the 
results from this analysis will be used to inform the results of survival analyses of ovarian 
cancer. Survival estimates were flagged as less reliable if a higher than usual proportion 
of patients was excluded from analyses because the cancer was registered only through 
a death certificate, or the date of last vital status was not known. The focus of this analysis 
was the distribution of specific histological groups, so women diagnosed in Sweden had 
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to be excluded, because 97.5% of tumours were coded by the registry as undifferentiated 
or other epithelial carcinoma, or as non-specific morphology (ICD-O-3 codes 8000-8004).  
The distribution of the three main topographical sites (fallopian tube, peritoneum and 
ovary) was also examined for all continents for each calendar period. The distribution of 
topography was also examined within histological groups for each continent.  Tumours 
grouped as “fallopian tube” (ICD-O-3 codes C57.0-C57.4, C57.7-C57.9) include those 
coded to the uterine ligaments and adnexa and other specified and unspecified female 
genital organs, as well as fallopian tube neoplasms. Tumours grouped as “peritoneal” 
(ICD-O-3 codes C48.0-C48.2) include tumours of the peritoneum and retroperitoneum. 
Tumours grouped as “ovarian” include only tumours coded as ovarian (ICD-O-3 code 
C56.9). 
After all exclusions, 681,759 women (86.0% of the 793,098 women for whom data were 
available for analysis) were included in the analysis of the histological and topographical 
distributions (192,080 in 1995-1999; 240,397 in 2000-2004; 249,282 in 2005-2009) [Table 
4.2]. 
4.3 Results 
4.3.1 Topographical sub-site 
Of the 681,759 women whose data were available for analysis, 615,681 (90.3%) were 
diagnosed with a tumour of the ovary, 40,905 (6.0%) were diagnosed with peritoneal 
cancer and 25,713 (3.7%) with fallopian tube cancer [Table 4.2]. From 1995 to 2009, the 
proportion of tumours assigned to the ovary decreased from 91.9% to 88.9% for all 
countries combined, while the proportion of peritoneal and fallopian tube tumours 
increased from 4.6% to 7.0% and 3.5% to 4.1%, respectively.  
The distribution of sub-sites varied somewhat by continent, though tumours of the ovary 
was by far the most common sub-site in all continents [Table 4.2]. During 1995-1999, the  
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Table 4.2 Distribution (%) of topography (sub-site) by continent and calendar period of 
diagnosis, 1995-2009, 51 countries 
 
Fallopian 
tubea Peritonealb Ovarianc Total 
  N % N % N % N 
ALL COUNTRIESd 
Total 25,173 3.7 40,905 6.0 615,681 90.3 681,759 
1995-99 6,635 3.5 8,926 4.6 176,519 91.9 192,080 
2000-04 8,280 3.4 14,448 6.0 217,669 90.5 240,397 
2005-09 10,258 4.1 17,531 7.0 221,493 88.9 249,282 
AMERICA (CENTRAL AND SOUTH) 
Total 143 2.0 554 7.8 6,393 90.2 7,090 
1995-99 21 1.9 102 9.2 990 88.9 1,113 
2000-04 65 2.0 300 9.2 2,913 88.9 3,278 
2005-09 57 2.1 152 5.6 2,490 92.3 2,699 
AMERICA (NORTH) 
Total 11,500 3.9 23,504 7.9 261,127 88.2 296,131 
1995-99 2,950 3.4 5,117 5.9 79,392 90.8 87,459 
2000-04 3,638 3.6 8,277 8.1 89,859 88.3 101,774 
2005-09 4,912 4.6 10,110 9.5 91,876 85.9 106,898 
ASIA 
Total 1,785 3.1 1,959 3.5 53,021 93.4 56,765 
1995-99 381 2.9 397 3.1 12,142 94.0 12,920 
2000-04 566 2.9 734 3.8 18,012 93.3 19,312 
2005-09 838 3.4 828 3.4 22,867 93.2 24,533 
EUROPE 
Total 10,934 3.6 13,347 4.4 277,432 92.0 301,713 
1995-99 3,062 3.6 2,899 3.4 78,095 92.9 84,056 
2000-04 3,723 3.4 4,559 4.2 100,609 92.4 108,891 
2005-09 4,149 3.8 5,889 5.4 98,728 90.8 108,766 
OCEANIA 
Total 811 4.0 1,541 7.7 17,708 88.3 20,060 
1995-99 221 3.4 411 6.3 5,900 90.3 6,532 
2000-04 288 4.0 578 8.1 6,276 87.9 7,142 
2005-09 302 4.7 552 8.6 5,532 86.6 6,386 
Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those 
with missing morphology codes were excluded from the analysis of distribution of 
topographical sub-site (see text). Only microscopically verified tumours or those with a 
clinical diagnosis but specific morphology code were included. a Tumours grouped as 
“fallopian tube” (ICD-O-3 codes C57.0-C57.4, C57.7-C57.9) include those coded to the 
uterine ligaments and adnexa and other specified and unspecified female genital organs, as 
well as fallopian tube neoplasms. b Tumours grouped as “peritoneal” (ICD-O-3 codes C48.0-
C48.2) include tumours of the peritoneum and retroperitoneum. c Tumours grouped as 
“ovarian” include only tumours coded as ovarian (ICD-O-3 code C56.9). d African countries 
were not included because fewer than 100 women were available for each calendar period. 
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proportion of primary peritoneal cancer was highest in Central and South America (9.2%) 
and lowest in Asia (3.1%). Correspondingly, the lowest proportion of ovarian cancer was 
in Central and South America (88.9%) while the highest proportion was in Asia (94.0%). A 
similar distribution was seen for women diagnosed between 2000 and 2004, but for 
women diagnosed between 2005 and 2009, the highest proportion of peritoneal cancer 
(9.5%) and the lowest proportion of ovarian cancer (85.9%) were seen in North America.  
Tumours assigned to the ovary were the most common sub-site within each histological 
group except for other specific non-epithelial tumours [Figure 4.2]. The majority (84.8%) 
of other specific non-epithelial tumours were coded as primary peritoneal cancers, while 
only 11.5% of ovarian tumours and 3.7% of fallopian tube cancers were other specific non-
epithelial tumours [Table 4.3]. The distribution of topography by histological group was 
generally constant over time and similar for each continent. 
Given the similarities in biological origin and development of tumours of the fallopian 
tube, peritoneum and ovary, as well as their treatment and survival10,12,17, the remainder 
of the analysis focuses on the distribution of histological groups for all sub-sites combined. 
4.3.2 Ovarian cancer histology 
Type II epithelial tumours were the most common histological group worldwide (476,461; 
69.9%), followed by type I epithelial (152,874; 22.4%) [Table 4.4]. Germ cell, sex cord-
stromal, other specific non-epithelial and non-specific tumours were all rare: they only 
comprised 8% of tumours worldwide; the distribution of these groups remained relatively 
stable over the 15-year period 1995 to 2009 [Figure 4.3]. The proportion of type II 
epithelial tumours increased slightly from 68.6% to 71.1% from 1995 to 2009, and there 
was a corresponding decrease in type I epithelial tumours (from 23.8% to 21.2%: Table 
4.4).  
Continued on page 102 
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Figure 4.2 Anatomic sub-site distribution within histological group by continent, 1995-2009
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GC = Germ cell; SCS = Sex cord-stromal;      
NS = Non-specific 
Type I Type II GC SCS Other NS Type I Type II GC SCS Other NS 
Type I Type II GC SCS Other NS Type I Type II GC SCS Other NS 
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Table 4.3 Distribution (%) of topography (sub-site) by ovarian cancer histological 
group, calendar period and continent, 1995-2009, 51 countries 
  Fallopian tubea Peritonealb Ovarianc Total 
  N % N % N % N 
TOTAL 
Type I 4,566 3.0 1,124 0.7 147,184 96.3 152,874 
1995-99 1,248 2.7 288 0.6 44,234 96.6 45,770 
2000-04 1,582 2.9 355 0.7 52,336 96.4 54,273 
2005-09 1,736 3.3 481 0.9 50,614 95.8 52,831 
Type II 19,121 4.0 23,286 4.9 434,054 91.1 476,461 
1995-99 4,928 3.7 4,071 3.1 122,704 93.2 131,703 
2000-04 6,207 3.7 8,205 4.9 153,096 91.4 167,508 
2005-09 7,986 4.5 11,010 6.2 158,254 89.3 177,250 
Germ cell 291 2.2 456 3.4 12,562 94.4 13,309 
1995-99 80 2.2 122 3.3 3,491 94.5 3,693 
2000-04 107 2.3 169 3.6 4,412 94.1 4,688 
2005-09 104 2.1 165 3.3 4,659 94.5 4,928 
Sex cord-stromal 54 0.5 207 1.8 11,183 97.7 11,444 
1995-99 21 0.6 79 2.3 3,280 97.0 3,380 
2000-04 17 0.4 74 1.9 3,906 97.7 3,997 
2005-09 16 0.4 54 1.3 3,997 98.3 4,067 
Other non-epithelial 654 3.7 14,896 84.8 2,019 11.5 17,569 
1995-99 201 4.1 4,141 84.7 546 11.2 4,888 
2000-04 212 3.4 5,250 84.9 720 11.6 6,182 
2005-09 241 3.7 5,505 84.7 753 11.6 6,499 
Non-specific 487 4.8 936 9.3 8,679 85.9 10,102 
1995-99 157 5.9 225 8.5 2,264 85.6 2,646 
2000-04 155 4.1 395 10.5 3,199 85.3 3,749 
2005-09 175 4.7 316 8.5 3,216 86.8 3,707 
AMERICA (CENTRAL AND SOUTH) 
Type I 28 2.0 14 1.0 1,335 96.9 1,377 
1995-99 4 1.8 3 1.4 213 96.8 220 
2000-04 15 2.6 8 1.4 564 96.1 587 
2005-09 9 1.6 3 0.5 558 97.9 570 
Type II 91 1.9 265 5.6 4,345 92.4 4,701 
1995-99 14 1.9 45 6.3 661 91.8 720 
2000-04 39 1.8 160 7.2 2,010 91.0 2,209 
2005-09 38 2.1 60 3.4 1,674 94.5 1,772 
Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with 
missing morphology codes were excluded from the analysis of distribution of topographical sub-
site and histological group (see text). Only microscopically verified tumours or those with a 
clinical diagnosis but specific morphology code were included. a Tumours grouped as “fallopian 
tube” (ICD-O-3 codes C57.0-C57.4, C57.7-C57.9) include those coded to the uterine ligaments 
and adnexa and other specified and unspecified female genital organs, as well as fallopian tube 
neoplasms. b Tumours grouped as “peritoneal” (ICD-O-3 codes C48.0-C48.2) include tumours of 
the peritoneum and retroperitoneum. c Tumours grouped as “ovarian” include only tumours 
coded as ovarian (ICD-O-3 code C56.9). d African countries were not included because fewer 
than 100 women were available for each calendar period. 
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  Fallopian tubea Peritonealb Ovarianc Total 
  N % N % N % N 
Germ cell 10 3.6 7 2.5 263 93.9 280 
1995-99 2 4.0 1 2.0 47 94.0 50 
2000-04 6 4.8 4 3.2 114 91.9 124 
2005-09 2 1.9 2 1.9 102 96.2 106 
Sex cord-stromal 0 0.0 6 3.1 188 96.9 194 
1995-99 0 0.0 1 3.3 29 96.7 30 
2000-04 0 0.0 3 3.3 87 96.7 90 
2005-09 0 0.0 2 2.7 72 97.3 74 
Other non-epithelial 8 2.8 226 79.6 50 17.6 284 
1995-99 0 0.0 51 83.6 10 16.4 61 
2000-04 1 0.8 104 79.4 26 19.8 131 
2005-09 7 7.6 71 77.2 14 15.2 92 
Non-specific 6 2.4 36 14.2 212 83.5 254 
1995-99 1 3.1 1 3.1 30 93.8 32 
2000-04 4 2.9 21 15.3 112 81.8 137 
2005-09 1 1.2 14 16.5 70 82.4 85 
AMERICA (NORTH) 
Type I 2,195 3.5 706 1.1 60,599 95.4 63,500 
1995-99 563 2.7 178 0.9 20,042 96.4 20,783 
2000-04 759 3.4 233 1.1 21,015 95.5 22,007 
2005-09 873 4.2 295 1.4 19,542 94.4 20,710 
Type II 8,758 4.2 15,000 7.1 187,230 88.7 210,988 
1995-99 2,232 3.7 2,676 4.4 55,525 91.9 60,433 
2000-04 2,704 3.7 5,431 7.5 64,345 88.8 72,480 
2005-09 3,822 4.9 6,893 8.8 67,360 86.3 78,075 
Germ cell 79 1.4 244 4.3 5,342 94.3 5,665 
1995-99 20 1.3 59 3.7 1,512 95.0 1,591 
2000-04 26 1.4 82 4.3 1,799 94.3 1,907 
2005-09 33 1.5 103 4.8 2,031 93.7 2,167 
Sex cord-stromal 18 0.4 63 1.4 4,389 98.2 4,470 
1995-99 7 0.5 29 2.1 1,324 97.4 1,360 
2000-04 7 0.5 20 1.4 1,427 98.1 1,454 
2005-09 4 0.2 14 0.8 1,638 98.9 1,656 
Other non-epithelial 308 3.7 7,187 87.4 731 8.9 8,226 
1995-99 88 3.6 2,086 86.4 239 9.9 2,413 
2000-04 96 3.5 2,393 87.5 245 9.0 2,734 
2005-09 124 4.0 2,708 88.0 247 8.0 3,079 
Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with 
missing morphology codes were excluded from the analysis of distribution of topographical sub-
site and histological group (see text). Only microscopically verified tumours or those with a 
clinical diagnosis but specific morphology code were included. a Tumours grouped as “fallopian 
tube” (ICD-O-3 codes C57.0-C57.4, C57.7-C57.9) include those coded to the uterine ligaments 
and adnexa and other specified and unspecified female genital organs, as well as fallopian tube 
neoplasms. b Tumours grouped as “peritoneal” (ICD-O-3 codes C48.0-C48.2) include tumours of 
the peritoneum and retroperitoneum. c Tumours grouped as “ovarian” include only tumours 
coded as ovarian (ICD-O-3 code C56.9). d African countries were not included because fewer 
than 100 women were available for each calendar period. 
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  Fallopian tubea Peritonealb Ovarianc Total 
  N % N % N % N 
Non-specific 142 4.3 304 9.3 2,836 86.4 3,282 
1995-99 40 4.6 89 10.1 750 85.3 879 
2000-04 46 3.9 118 9.9 1,028 86.2 1,192 
2005-09 56 4.6 97 8.0 1,058 87.4 1,211 
ASIA 
Type I 303 1.6 28 0.1 18,560 98.2 18,891 
1995-99 71 1.6 2 0.0 4,251 98.3 4,324 
2000-04 96 1.5 8 0.1 6,484 98.4 6,588 
2005-09 136 1.7 18 0.2 7,825 98.1 7,979 
Type II 1,263 4.1 562 1.8 28,967 94.1 30,792 
1995-99 249 3.7 73 1.1 6,453 95.2 6,775 
2000-04 396 3.9 194 1.9 9,652 94.2 10,242 
2005-09 618 4.5 295 2.1 12,862 93.4 13,775 
Germ cell 122 4.4 41 1.5 2,589 94.1 2,752 
1995-99 34 4.4 13 1.7 723 93.9 770 
2000-04 37 3.9 15 1.6 888 94.5 940 
2005-09 51 4.9 13 1.2 978 93.9 1,042 
Sex cord-stromal 5 0.4 14 1.2 1,168 98.4 1,187 
1995-99 1 0.4 4 1.5 263 98.1 268 
2000-04 1 0.2 6 1.4 415 98.3 422 
2005-09 3 0.6 4 0.8 490 98.6 497 
Other non-epithelial 57 3.5 1,226 74.9 354 21.6 1,637 
1995-99 19 5.3 289 80.1 53 14.7 361 
2000-04 21 3.4 471 77.3 117 19.2 609 
2005-09 17 2.5 466 69.9 184 27.6 667 
Non-specific 35 2.3 88 5.8 1,383 91.8 1,506 
1995-99 7 1.7 16 3.8 399 94.5 422 
2000-04 15 2.9 40 7.8 456 89.2 511 
2005-09 13 2.3 32 5.6 528 92.1 573 
EUROPE 
Type I 1,914 3.0 329 0.5 62,582 96.5 64,825 
1995-99 570 3.0 86 0.5 18,231 96.5 18,887 
2000-04 670 2.8 90 0.4 22,865 96.8 23,625 
2005-09 674 3.0 153 0.7 21,486 96.3 22,313 
Type II 8,361 3.9 6,440 3.0 200,761 93.1 215,562 
1995-99 2,263 3.8 1,036 1.7 55,930 94.4 59,229 
2000-04 2,836 3.7 2,032 2.6 72,508 93.7 77,376 
2005-09 3,262 4.1 3,372 4.3 72,323 91.6 78,957 
Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with 
missing morphology codes were excluded from the analysis of distribution of topographical sub-
site and histological group (see text). Only microscopically verified tumours or those with a 
clinical diagnosis but specific morphology code were included. a Tumours grouped as “fallopian 
tube” (ICD-O-3 codes C57.0-C57.4, C57.7-C57.9) include those coded to the uterine ligaments 
and adnexa and other specified and unspecified female genital organs, as well as fallopian tube 
neoplasms. b Tumours grouped as “peritoneal” (ICD-O-3 codes C48.0-C48.2) include tumours of 
the peritoneum and retroperitoneum. c Tumours grouped as “ovarian” include only tumours 
coded as ovarian (ICD-O-3 code C56.9). d African countries were not included because fewer 
than 100 women were available for each calendar period. 
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  Fallopian tubea Peritonealb Ovarianc Total 
  N % N % N % N 
Germ cell 70 1.7 147 3.6 3,922 94.8 4,139 
1995-99 23 2.0 45 3.9 1,081 94.1 1,149 
2000-04 30 2.0 62 4.0 1,445 94.0 1,537 
2005-09 17 1.2 40 2.8 1,396 96.1 1,453 
Sex cord-stromal 31 0.6 119 2.2 5,232 97.2 5,382 
1995-99 13 0.8 40 2.4 1,580 96.8 1,633 
2000-04 9 0.5 45 2.3 1,911 97.3 1,965 
2005-09 9 0.5 34 1.9 1,741 97.6 1,784 
Other non-epithelial 260 3.8 5,817 84.1 837 12.1 6,914 
1995-99 87 4.6 1,580 83.3 230 12.1 1,897 
2000-04 88 3.5 2,119 83.9 319 12.6 2,526 
2005-09 85 3.4 2,118 85.0 288 11.6 2,491 
Non-specific 298 6.1 495 10.1 4,098 83.8 4,891 
1995-99 106 8.4 112 8.9 1,043 82.7 1,261 
2000-04 90 4.8 211 11.3 1,561 83.8 1,862 
2005-09 102 5.8 172 9.7 1,494 84.5 1,768 
OCEANIA 
Type I 126 2.9 47 1.1 4,108 96.0 4,281 
1995-99 40 2.6 19 1.2 1,497 96.2 1,556 
2000-04 42 2.9 16 1.1 1,408 96.0 1,466 
2005-09 44 3.5 12 1.0 1,203 95.6 1,259 
Type II 648 4.5 1,019 7.1 12,751 88.4 14,418 
1995-99 170 3.7 241 5.3 4,135 91.0 4,546 
2000-04 232 4.5 388 7.5 4,581 88.1 5,201 
2005-09 246 5.3 390 8.3 4,035 86.4 4,671 
Germ cell 10 2.1 17 3.6 446 94.3 473 
1995-99 1 0.8 4 3.0 128 96.2 133 
2000-04 8 4.4 6 3.3 166 92.2 180 
2005-09 1 0.6 7 4.4 152 95.0 160 
Sex cord-stromal 0 0.0 5 5.6 206 231.5 89 
1995-99 0 0.0 5 5.6 84 94.4 89 
2000-04 0 0.0 0 0.0 66 100.0 0 
2005-09 0 0.0 0 0.0 56 100.0 0 
Other non-epithelial 21 4.1 440 86.6 47 9.3 508 
1995-99 7 4.5 135 86.5 14 9.0 156 
2000-04 6 3.3 163 89.6 13 7.1 182 
2005-09 8 4.7 142 83.5 20 11.8 170 
Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with 
missing morphology codes were excluded from the analysis of distribution of topographical sub-
site and histological group (see text). Only microscopically verified tumours or those with a 
clinical diagnosis but specific morphology code were included. a Tumours grouped as “fallopian 
tube” (ICD-O-3 codes C57.0-C57.4, C57.7-C57.9) include those coded to the uterine ligaments 
and adnexa and other specified and unspecified female genital organs, as well as fallopian tube 
neoplasms. b Tumours grouped as “peritoneal” (ICD-O-3 codes C48.0-C48.2) include tumours of 
the peritoneum and retroperitoneum. c Tumours grouped as “ovarian” include only tumours 
coded as ovarian (ICD-O-3 code C56.9). d African countries were not included because fewer 
than 100 women were available for each calendar period. 
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  Fallopian tubea Peritonealb Ovarianc Total 
  N % N % N % N 
Non-specific 6 3.6 13 7.7 150 88.8 169 
1995-99 3 5.8 7 13.5 42 80.8 52 
2000-04 0 0.0 5 10.6 42 89.4 47 
2005-09 3 4.3 1 1.4 66 94.3 70 
Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with 
missing morphology codes were excluded from the analysis of distribution of topographical sub-
site and histological group (see text). Only microscopically verified tumours or those with a 
clinical diagnosis but specific morphology code were included. a Tumours grouped as “fallopian 
tube” (ICD-O-3 codes C57.0-C57.4, C57.7-C57.9) include those coded to the uterine ligaments 
and adnexa and other specified and unspecified female genital organs, as well as fallopian tube 
neoplasms. b Tumours grouped as “peritoneal” (ICD-O-3 codes C48.0-C48.2) include tumours of 
the peritoneum and retroperitoneum. c Tumours grouped as “ovarian” include only tumours 
coded as ovarian (ICD-O-3 code C56.9). d African countries were not included because fewer 
than 100 women were available for each calendar period. 
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Table 4.4 Worldwide distribution (%) of ovarian cancer by histological group and calendar period, 1995-2009, 51 countries 
Period of diagnosis  Totala   Type I epithelialb Type II epithelialc Germ cell 
Sex cord-
stromal 
Other specific 
non-epithelial Non-specificd 
  N   N  %   N  %   N  %   N  %   N  %   N  %  
1995-99 192,080 45,770 23.8 131,703 68.6 3,693 1.9 3,380 1.8 4,888 2.5 2,646 1.4 
2000-04 240,397 54,273 22.6 167,508 69.7 4,688 2.0 3,997 1.7 6,182 2.6 3,749 1.6 
2005-09 249,282 52,831 21.2 177,250 71.1 4,928 2.0 4,067 1.6 6,499 2.6 3,707 1.5 
Total 681,759 152,874 22.4 476,461 69.9 13,309 2.0 11,444 1.7 17,569 2.6 10,102 1.5 
a Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from the 
analysis of the distribution of histological groups (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology 
code were included. b No information on grade was available; therefore, all endometrioid tumours were classified as type I epithelial.  c No information on 
grade was available; therefore, all serous tumours were classified as type II epithelial.  d Morphologically verified tumours with ICD-O-3 morphology codes 
8000-8004.  
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Figure 4.3 Worldwide distribution (%) of ovarian cancer histology: 51 countries, 1995-2009 
Type II Type I
Germ cell
Sex cord-stromal
Other specific
Non-specific
0 10 20 30 40 50 60 70 80 90 100
1995-99
(n=192,080)
2000-04
(n=240,397)
2005-09
(n=249,282)
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During 2005-2009, type II ovarian cancer was the most common group in all continents, 
although the proportion was much higher in Oceania (73.1%), North America (73.0%) and 
Europe (72.6%) than in Central and South America (65.7%) and Asia (56.1%) [Figure 4.4, 
Table 4.5]. The range at the national level, however, was much wider. The highest 
proportion of type II tumours was in Latvia (78.9%), with the lowest proportion in Thailand 
(40.4%) [Table 4.6]. There was little between-country variation in the proportion of type 
II tumours in Central and South America, North America and Oceania [Figures 4.5-4.6]. 
However, the proportion varied widely between countries in Asia, where the proportion 
of type II tumours was lower than that of type I epithelial tumours in Hong Kong and 
Thailand [Figure 4.6]. There was also variation in the proportion of type II tumours in 
Europe [Figure 4.7], where type II tumours accounted for over 70% of tumours in 15 
countries, 60% in 11 countries and only 50.2% in Russia [Table 4.6].  
For type II epithelial tumours, the largest increase was seen in North America (from 69.1% 
in 1995-1999 to 73.0% in 2005-2009). Increases in the proportion of type II epithelial 
tumours were seen in most countries, though there were decreases in a few countries in 
Central and South America (Cuba and Ecuador), Asia (Japan) and Europe (Bulgaria, 
Croatia, Italy, Latvia, Lithuania and Russia). In a few countries, the proportion remained 
stable over time (Thailand, Austria, Iceland, Ireland, Poland and Slovenia) [Table 4.6]. 
Type I epithelial tumours were the second most common group for all continents during 
2005-2009. The highest proportion was seen in Asia (32.5%), while North America showed 
the lowest proportion (19.4%) [Table 4.5]. The proportion was similar in all countries in 
Central and South America, North America and Oceania [Table 4.6]. In Europe, however, 
there was wider variation, the proportion ranging from 11.3% in Latvia to 28.7% in Finland 
[Table 4.6]. The variation was even wider for countries in Asia, with the lowest proportion 
in Israel (12.8%) and the highest in Hong Kong (51.7%) [Figure 4.6]. 
Continued on page 119 
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Figure 4.4 Distribution (%) of ovarian cancer histological groups by continent, 2005-2009
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Sex cord-stromal
Other specific Non-specific
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ASIA (n=24,533)
AMERICA (CENTRAL AND SOUTH)
(n=2,699)
EUROPE (n=108,766)
AMERICA (NORTH) (n=106,898)
OCEANIA (n=6,836)
Continents are ranked by the proportion of type II epithelial tumours from highest to lowest.
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Table 4.5 Distribution (%) of histological groups by continent and calendar period of diagnosis, 1995-2009 
  Totala Type I epithelialb Type II epithelialc Germ cell Sex cord-stromal Other specificd Non-specifice 
 N N % N % N % N % N % N % 
AMERICA (CENTRAL AND SOUTH) 
1995-99 1,113 220 19.8 720 64.7 50 4.5 30 2.7 61 5.5 32 2.9 
2000-04 3,278 587 17.9 2,209 67.4 124 3.8 90 2.7 131 4.0 137 4.2 
2005-09 2,699 570 21.1 1,772 65.7 106 3.9 74 2.7 92 3.4 85 3.1 
AMERICA (NORTH)                     
1995-99 87,459 20,783 23.8 60,433 69.1 1,591 1.8 1,360 1.6 2,413 2.8 879 1.0 
2000-04 101,774 22,007 21.6 72,480 71.2 1,907 1.9 1,454 1.4 2,734 2.7 1,192 1.2 
2005-09 106,898 20,710 19.4 78,075 73.0 2,167 2.0 1,656 1.5 3,079 2.9 1,211 1.1 
ASIA                     
1995-99 12,920 4,324 33.5 6,775 52.4 770 6.0 268 2.1 361 2.8 422 3.3 
2000-04 19,312 6,588 34.1 10,242 53.0 940 4.9 422 2.2 609 3.2 511 2.6 
2005-09 24,533 7,979 32.5 13,775 56.1 1,042 4.2 497 2.0 667 2.7 573 2.3 
EUROPE                     
1995-99 84,056 18,887 22.5 59,229 70.5 1,149 1.4 1,633 1.9 1,897 2.3 1,261 1.5 
2000-04 108,891 23,625 21.7 77,376 71.1 1,537 1.4 1,965 1.8 2,526 2.3 1,862 1.7 
2005-09 108,766 22,313 20.5 78,957 72.6 1,453 1.3 1,784 1.6 2,491 2.3 1,768 1.6 
OCEANIA                     
1995-99 6,532 1,556 23.8 4,546 69.6 133 2.0 89 1.4 156 2.4 52 0.8 
2000-04 7,142 1,466 20.5 5,201 72.8 180 2.5 66 0.9 182 2.5 47 0.7 
2005-09 6,386 1,259 19.7 4,671 73.1 160 2.5 56 0.9 170 2.7 70 1.1 
a Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from the analysis of the 
distribution of histological groups (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid 
tumours were classified as type I epithelial.  c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Morphologically 
verified tumours with ICD-O-3 morphology codes 8000-8004.  
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Table 4.6 Distribution (%) of histological groups by country and calendar period of diagnosis, 1995-2009 
 Total
a  Type I epithelialb Type II epithelialc Germ cell Sex cord-stromal Other specificd  Non-specifice 
 N N %  N %  N %  N %  N %  N %  
AMERICA (CENTRAL AND SOUTH)                     
Argentinian registries                       
1995-99 - - . - . - . - . - . - . 
2000-04 182 39 21.4 117 64.3 6 3.3 5 2.7 5 2.7 10 5.5 
2005-09 598 112 18.7 403 67.4 28 4.7 14 2.3 9 1.5 32 5.4 
Brazilian registries                         
1995-99 168 49 29.2 92 54.8 3 1.8 3 1.8 20 11.9 1 0.6 
2000-04 434 96 22.1 281 64.7 15 3.5 6 1.4 27 6.2 9 2.1 
2005-09 252 60 23.8 160 63.5 13 5.2 4 1.6 8 3.2 7 2.8 
Colombia (Cali)                         
1995-99 302 78 25.8 181 59.9 12 4.0 8 2.6 12 4.0 11 3.6 
2000-04 337 86 25.5 204 60.5 19 5.6 7 2.1 10 3.0 11 3.3 
2005-09 335 81 24.2 216 64.5 13 3.9 13 3.9 4 1.2 8 2.4 
Cuba*                           
1995-99 455 71 15.6 320 70.3 22 4.8 10 2.2 19 4.2 13 2.9 
2000-04 1,464 187 12.8 1,060 72.4 42 2.9 50 3.4 55 3.8 70 4.8 
2005-09 560 130 23.2 371 66.3 9 1.6 25 4.5 19 3.4 6 1.1 
a Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from the analysis of the 
distribution of histological groups (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid 
tumours were classified as type I epithelial.  c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Morphologically 
verified tumours with ICD-O-3 morphology codes 8000-8004. *100% coverage of the national population. 
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 Total
a  Type I epithelialb Type II epithelialc Germ cell Sex cord-stromal Other specificd  Non-specifice 
 N N %  N %  N %  N %  N %  N %  
Ecuador (Quito)                         
1995-99 188 22 11.7 127 67.6 13 6.9 9 4.8 10 5.3 7 3.7 
2000-04 209 32 15.3 133 63.6 15 7.2 9 4.3 13 6.2 7 3.3 
2005-09 270 43 15.9 173 64.1 21 7.8 7 2.6 16 5.9 10 3.7 
Puerto Rico*                         
1995-99 - - . - . - . - . - . - . 
2000-04 652 147 22.5 414 63.5 27 4.1 13 2.0 21 3.2 30 4.6 
2005-09 684 144 21.1 449 65.6 22 3.2 11 1.6 36 5.3 22 3.2 
AMERICA (NORTH)                         
Canada*                           
1995-99 10,366 2,828 27.3 6,859 66.2 226 2.2 128 1.2 251 2.4 74 0.7 
2000-04 11,347 2,787 24.6 7,906 69.7 209 1.8 114 1.0 247 2.2 84 0.7 
2005-09 12,196 2,676 21.9 8,762 71.8 258 2.1 133 1.1 276 2.3 91 0.7 
US registries                         
1995-99 77,093 17,955 23.3 53,574 69.5 1,365 1.8 1,232 1.6 2,162 2.8 805 1.0 
2000-04 90,427 19,220 21.3 64,574 71.4 1,698 1.9 1,340 1.5 2,487 2.8 1,108 1.2 
2005-09 94,702 18,034 19.0 69,313 73.2 1,909 2.0 1,523 1.6 2,803 3.0 1,120 1.2 
a Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from the analysis of the 
distribution of histological groups (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid 
tumours were classified as type I epithelial.  c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Morphologically 
verified tumours with ICD-O-3 morphology codes 8000-8004. *100% coverage of the national population. 
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 Total
a  Type I epithelialb Type II epithelialc Germ cell Sex cord-stromal Other specificd  Non-specifice 
 N N %  N %  N %  N %  N %  N %  
ASIA                           
Chinese registries                         
1995-99 131 31 23.7 76 58.0 4 3.1 2 1.5 2 1.5 16 12.2 
2000-04 1,139 246 21.6 669 58.7 49 4.3 27 2.4 33 2.9 115 10.1 
2005-09 3,150 687 21.8 2,031 64.5 116 3.7 64 2.0 93 3.0 159 5.0 
Cyprus*                           
1995-99 - - . - . - . - . - . - . 
2000-04 - - . - . - . - . - . - . 
2005-09 225 42 18.7 163 72.4 2 0.9 3 1.3 13 5.8 2 0.9 
Hong Kong*                         
1995-99 527 280 53.1 247 46.9 - . - . - . - . 
2000-04 1,012 522 51.6 490 48.4 - . - . - . - . 
2005-09 437 226 51.7 211 48.3 - . - . - . - . 
Indian registries                         
1995-99 391 46 11.8 252 64.5 27 6.9 13 3.3 1 0.3 52 13.3 
2000-04 - - . - . - . - . - . - . 
2005-09 - - . - . - . - . - . - . 
Indonesia (Jakarta)                         
1995-99 - - . - . - . - . - . - . 
2000-04 - - . - . - . - . - . - . 
2005-09 182 73 40.1 86 47.3 14 7.7 7 3.8 1 0.5 1 0.5 
a Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from the analysis of the 
distribution of histological groups (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid 
tumours were classified as type I epithelial.  c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Morphologically 
verified tumours with ICD-O-3 morphology codes 8000-8004. *100% coverage of the national population. 
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 Total
a  Type I epithelialb Type II epithelialc Germ cell Sex cord-stromal Other specificd  Non-specifice 
 N N %  N %  N %  N %  N %  N %  
Israel*                           
1995-99 1,690 336 19.9 1,195 70.7 34 2.0 15 0.9 53 3.1 57 3.4 
2000-04 1,921 309 16.1 1,407 73.2 57 3.0 9 0.5 78 4.1 61 3.2 
2005-09 1,957 251 12.8 1,522 77.8 40 2.0 11 0.6 71 3.6 62 3.2 
Japanese registries                         
1995-99 1,790 537 30.0 958 53.5 58 3.2 16 0.9 72 4.0 149 8.3 
2000-04 3,124 1,176 37.6 1,573 50.4 93 3.0 21 0.7 126 4.0 135 4.3 
2005-09 3,647 1,508 41.3 1,732 47.5 129 3.5 26 0.7 119 3.3 133 3.6 
Jordan*              
1995-99 - - . - . - . - . - . - . 
2000-04 305 61 20.0 196 64.3 22 7.2 11 3.6 8 2.6 7 2.3 
2005-09 382 58 15.2 246 64.4 31 8.1 18 4.7 19 5.0 10 2.6 
Korea*                           
1995-99 4,526 1,648 36.4 2,274 50.2 356 7.9 123 2.7 29 0.6 96 2.1 
2000-04 6,036 2,132 35.3 3,162 52.4 382 6.3 215 3.6 42 0.7 103 1.7 
2005-09 7,859 2,512 32.0 4,550 57.9 392 5.0 207 2.6 64 0.8 134 1.7 
Malaysia (Penang)                         
1995-99 144 52 36.1 75 52.1 11 7.6 4 2.8 - . 2 1.4 
2000-04 220 93 42.3 104 47.3 11 5.0 8 3.6 2 0.9 2 0.9 
2005-09 281 93 33.1 164 58.4 14 5.0 7 2.5 2 0.7 1 0.4 
a Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from the analysis of the 
distribution of histological groups (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid 
tumours were classified as type I epithelial.  c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Morphologically 
verified tumours with ICD-O-3 morphology codes 8000-8004. *100% coverage of the national population. 
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 Total
a  Type I epithelialb Type II epithelialc Germ cell Sex cord-stromal Other specificd  Non-specifice 
 N N %  N %  N %  N %  N %  N %  
Saudi Arabia*                         
1995-99 392 95 24.2 234 59.7 36 9.2 14 3.6 5 1.3 8 2.0 
2000-04 552 118 21.4 335 60.7 54 9.8 19 3.4 19 3.4 7 1.3 
2005-09 - - . - . - . - . - . - . 
Taiwan*                           
1995-99 2,768 1,098 39.7 1,177 42.5 215 7.8 65 2.3 183 6.6 30 1.1 
2000-04 3,998 1,568 39.2 1,783 44.6 226 5.7 93 2.3 277 6.9 51 1.3 
2005-09 5,165 2,112 40.9 2,400 46.5 248 4.8 126 2.4 252 4.9 27 0.5 
Thai registries                         
1995-99 171 76 44.4 70 40.9 16 9.4 6 3.5 2 1.2 1 0.6 
2000-04 478 218 45.6 200 41.8 30 6.3 9 1.9 10 2.1 11 2.3 
2005-09 549 252 45.9 222 40.4 30 5.5 23 4.2 10 1.8 12 2.2 
Turkey (Izmir)                         
1995-99 390 125 32.1 217 55.6 13 3.3 10 2.6 14 3.6 11 2.8 
2000-04 527 145 27.5 323 61.3 16 3.0 10 1.9 14 2.7 19 3.6 
2005-09 699 165 23.6 448 64.1 26 3.7 5 0.7 23 3.3 32 4.6 
EUROPE                           
Austria*                           
1995-99 4,331 674 15.6 3,287 75.9 95 2.2 63 1.5 83 1.9 129 3.0 
2000-04 4,180 603 14.4 3,168 75.8 45 1.1 67 1.6 86 2.1 211 5.0 
2005-09 3,653 552 15.1 2,744 75.1 47 1.3 64 1.8 93 2.5 153 4.2 
a Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from the analysis of the 
distribution of histological groups (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid 
tumours were classified as type I epithelial.  c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Morphologically 
verified tumours with ICD-O-3 morphology codes 8000-8004. *100% coverage of the national population. 
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 Total
a  Type I epithelialb Type II epithelialc Germ cell Sex cord-stromal Other specificd  Non-specifice 
 N N %  N %  N %  N %  N %  N %  
Belgium*                           
1995-99 - - . - . - . - . - . - . 
2000-04 948 228 24.1 653 68.9 16 1.7 14 1.5 25 2.6 12 1.3 
2005-09 4,720 980 20.8 3,444 73.0 60 1.3 39 0.8 153 3.2 44 0.9 
Bulgaria*                           
1995-99 2,792 448 16.0 2,045 73.2 34 1.2 155 5.6 73 2.6 37 1.3 
2000-04 3,368 691 20.5 2,323 69.0 45 1.3 142 4.2 104 3.1 63 1.9 
2005-09 3,933 785 20.0 2,750 69.9 44 1.1 166 4.2 133 3.4 55 1.4 
Croatia*                           
1995-99 771 138 17.9 597 77.4 12 1.6 5 0.6 12 1.6 7 0.9 
2000-04 1,998 428 21.4 1,491 74.6 20 1.0 31 1.6 20 1.0 8 0.4 
2005-09 1,930 428 22.2 1,422 73.7 29 1.5 28 1.5 12 0.6 11 0.6 
Czech Republic*                         
1995-99 5,223 1,339 25.6 3,330 63.8 76 1.5 209 4.0 131 2.5 138 2.6 
2000-04 5,502 1,366 24.8 3,565 64.8 81 1.5 172 3.1 160 2.9 158 2.9 
2005-09 5,220 1,090 20.9 3,632 69.6 55 1.1 140 2.7 143 2.7 160 3.1 
Denmark*                           
1995-99 3,068 796 25.9 2,080 67.8 44 1.4 47 1.5 78 2.5 23 0.7 
2000-04 2,991 750 25.1 2,050 68.5 54 1.8 41 1.4 58 1.9 38 1.3 
2005-09 2,997 633 21.1 2,161 72.1 27 0.9 8 0.3 74 2.5 94 3.1 
a Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from the analysis of the 
distribution of histological groups (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid 
tumours were classified as type I epithelial.  c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Morphologically 
verified tumours with ICD-O-3 morphology codes 8000-8004. *100% coverage of the national population. 
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 Total
a  Type I epithelialb Type II epithelialc Germ cell Sex cord-stromal Other specificd  Non-specifice 
 N N %  N %  N %  N %  N %  N %  
Estonia*                           
1995-99 792 133 16.8 511 64.5 5 0.6 47 5.9 16 2.0 80 10.1 
2000-04 710 116 16.3 495 69.7 10 1.4 19 2.7 18 2.5 52 7.3 
2005-09 613 95 15.5 432 70.5 10 1.6 21 3.4 23 3.8 32 5.2 
Finland*                           
1995-99 2,325 901 38.8 1,266 54.5 21 0.9 26 1.1 28 1.2 83 3.6 
2000-04 2,512 895 35.6 1,431 57.0 41 1.6 21 0.8 20 0.8 104 4.1 
2005-09 2,485 712 28.7 1,561 62.8 30 1.2 11 0.4 53 2.1 118 4.7 
French registries                         
1995-99 2,495 580 23.2 1,724 69.1 51 2.0 28 1.1 87 3.5 25 1.0 
2000-04 2,870 621 21.6 2,035 70.9 56 2.0 27 0.9 98 3.4 33 1.1 
2005-09 242 62 25.6 163 67.4 7 2.9 - . 9 3.7 1 0.4 
German registries                         
1995-99 5,295 912 17.2 4,003 75.6 50 0.9 118 2.2 110 2.1 102 1.9 
2000-04 9,047 1,574 17.4 6,921 76.5 95 1.1 160 1.8 172 1.9 125 1.4 
2005-09 10,566 1,809 17.1 8,223 77.8 110 1.0 114 1.1 207 2.0 103 1.0 
Iceland*                           
1995-99 113 21 18.6 86 76.1 3 2.7 2 1.8 1 0.9 - . 
2000-04 127 24 18.9 94 74.0 2 1.6 1 0.8 6 4.7 - . 
2005-09 118 20 16.9 90 76.3 1 0.8 - . 7 5.9 - . 
a Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from the analysis of the 
distribution of histological groups (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid 
tumours were classified as type I epithelial.  c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Morphologically 
verified tumours with ICD-O-3 morphology codes 8000-8004. *100% coverage of the national population. 
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 Total
a  Type I epithelialb Type II epithelialc Germ cell Sex cord-stromal Other specificd  Non-specifice 
 N N %  N %  N %  N %  N %  N %  
Ireland*                           
1995-99 1,332 323 24.2 948 71.2 21 1.6 10 0.8 15 1.1 15 1.1 
2000-04 1,477 375 25.4 1,043 70.6 19 1.3 9 0.6 15 1.0 16 1.1 
2005-09 1,607 382 23.8 1,146 71.3 23 1.4 20 1.2 24 1.5 12 0.7 
Italian registries                         
1995-99 6,772 1,384 20.4 4,711 69.6 85 1.3 83 1.2 298 4.4 211 3.1 
2000-04 8,394 1,724 20.5 5,811 69.2 89 1.1 78 0.9 383 4.6 309 3.7 
2005-09 5,087 1,104 21.7 3,448 67.8 60 1.2 47 0.9 234 4.6 194 3.8 
Latvia*                           
1995-99 1,219 71 5.8 1,064 87.3 23 1.9 33 2.7 28 2.3 - . 
2000-04 1,205 104 8.6 1,013 84.1 13 1.1 46 3.8 20 1.7 9 0.7 
2005-09 1,233 139 11.3 973 78.9 9 0.7 75 6.1 27 2.2 10 0.8 
Lithuania*                           
1995-99 1,630 116 7.1 1,367 83.9 21 1.3 58 3.6 31 1.9 37 2.3 
2000-04 1,781 203 11.4 1,428 80.2 17 1.0 44 2.5 63 3.5 26 1.5 
2005-09 1,780 295 16.6 1,346 75.6 23 1.3 47 2.6 53 3.0 16 0.9 
Malta*                           
1995-99 149 50 33.6 85 57.0 5 3.4 3 2.0 5 3.4 1 0.7 
2000-04 197 60 30.5 113 57.4 4 2.0 3 1.5 3 1.5 14 7.1 
2005-09 191 47 24.6 120 62.8 4 2.1 1 0.5 7 3.7 12 6.3 
a Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from the analysis of the 
distribution of histological groups (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid 
tumours were classified as type I epithelial.  c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Morphologically 
verified tumours with ICD-O-3 morphology codes 8000-8004. *100% coverage of the national population. 
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 Total
a  Type I epithelialb Type II epithelialc Germ cell Sex cord-stromal Other specificd  Non-specifice 
 N N %  N %  N %  N %  N %  N %  
Netherlands*                         
1995-99 6,624 1,714 25.9 4,484 67.7 88 1.3 173 2.6 157 2.4 8 0.1 
2000-04 6,289 1,508 24.0 4,385 69.7 109 1.7 101 1.6 177 2.8 9 0.1 
2005-09 6,403 1,437 22.4 4,631 72.3 95 1.5 82 1.3 150 2.3 8 0.1 
Norway*                           
1995-99 2,358 534 22.6 1,639 69.5 37 1.6 61 2.6 69 2.9 18 0.8 
2000-04 2,506 534 21.3 1,783 71.1 52 2.1 26 1.0 82 3.3 29 1.2 
2005-09 2,416 385 15.9 1,848 76.5 44 1.8 29 1.2 73 3.0 37 1.5 
Poland*                           
1995-99 3,158 683 21.6 2,177 68.9 64 2.0 136 4.3 34 1.1 64 2.0 
2000-04 13,114 3,017 23.0 8,945 68.2 237 1.8 474 3.6 188 1.4 253 1.9 
2005-09 14,837 3,455 23.3 10,206 68.8 251 1.7 463 3.1 191 1.3 271 1.8 
Portugal*                           
1995-99 574 120 20.9 392 68.3 23 4.0 11 1.9 28 4.9 - . 
2000-04 2,153 454 21.1 1,497 69.5 46 2.1 32 1.5 99 4.6 25 1.2 
2005-09 1,978 419 21.2 1,388 70.2 33 1.7 21 1.1 97 4.9 20 1.0 
Romania (Cluj)                         
1995-99 - - . - . - . - . - . - . 
2000-04 - - . - . - . - . - . - . 
2005-09 196 47 24.0 129 65.8 2 1.0 4 2.0 6 3.1 8 4.1 
a Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from the analysis of the 
distribution of histological groups (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid 
tumours were classified as type I epithelial.  c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Morphologically 
verified tumours with ICD-O-3 morphology codes 8000-8004. *100% coverage of the national population. 
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 Total
a  Type I epithelialb Type II epithelialc Germ cell Sex cord-stromal Other specificd  Non-specifice 
 N N %  N %  N %  N %  N %  N %  
Russia (Arkhangelsk)                       
1995-99 - - . - . - . - . - . - . 
2000-04 440 76 17.3 255 58.0 9 2.0 61 13.9 3 0.7 36 8.2 
2005-09 402 76 18.9 202 50.2 7 1.7 46 11.4 - . 71 17.7 
Slovakia*                           
1995-99 - - . - . - . - . - . - . 
2000-04 1,983 555 28.0 1,243 62.7 41 2.1 63 3.2 56 2.8 25 1.3 
2005-09 1,339 351 26.2 868 64.8 29 2.2 37 2.8 44 3.3 10 0.7 
Slovenia*                           
1995-99 824 194 23.5 567 68.8 15 1.8 11 1.3 33 4.0 4 0.5 
2000-04 911 236 25.9 604 66.3 18 2.0 8 0.9 39 4.3 6 0.7 
2005-09 986 256 26.0 677 68.7 8 0.8 7 0.7 37 3.8 1 0.1 
Spanish registries                         
1995-99 2,728 890 32.6 1,591 58.3 51 1.9 25 0.9 138 5.1 33 1.2 
2000-04 2,862 827 28.9 1,784 62.3 64 2.2 21 0.7 136 4.8 30 1.0 
2005-09 2,553 674 26.4 1,675 65.6 49 1.9 19 0.7 114 4.5 22 0.9 
Swiss registries                         
1995-99 1,413 325 23.0 1,002 70.9 19 1.3 18 1.3 45 3.2 4 0.3 
2000-04 1,376 285 20.7 1,013 73.6 24 1.7 14 1.0 35 2.5 5 0.4 
2005-09 1,581 297 18.8 1,172 74.1 19 1.2 7 0.4 82 5.2 4 0.3 
a Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from the analysis of the 
distribution of histological groups (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid 
tumours were classified as type I epithelial.  c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Morphologically 
verified tumours with ICD-O-3 morphology codes 8000-8004. *100% coverage of the national population. 
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 Total
a  Type I epithelialb Type II epithelialc Germ cell Sex cord-stromal Other specificd  Non-specifice 
 N N %  N %  N %  N %  N %  N %  
United Kingdom*                         
1995-99 28,070 6,541 23.3 20,273 72.2 306 1.1 311 1.1 397 1.4 242 0.9 
2000-04 29,950 6,371 21.3 22,233 74.2 330 1.1 290 1.0 460 1.5 266 0.9 
2005-09 29,700 5,783 19.5 22,506 75.8 377 1.3 288 1.0 445 1.5 301 1.0 
OCEANIA                           
Australian registries                         
1995-99 5,281 1,203 22.8 3,757 71.1 102 1.9 71 1.3 130 2.5 18 0.3 
2000-04 5,895 1,161 19.7 4,363 74.0 145 2.5 47 0.8 144 2.4 35 0.6 
New Zealand*                         
1995-99 1,251 353 28.2 789 63.1 31 2.5 18 1.4 26 2.1 34 2.7 
2000-04 1,247 305 24.5 838 67.2 35 2.8 19 1.5 38 3.0 12 1.0 
2005-09 1,432 288 20.1 1,027 71.7 40 2.8 11 0.8 38 2.7 28 2.0 
a Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from the analysis of the 
distribution of histological groups (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid 
tumours were classified as type I epithelial.  c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Morphologically 
verified tumours with ICD-O-3 morphology codes 8000-8004. *100% coverage of the national population.  
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Figure 4.5 Distribution (%) of ovarian cancer histological groups by country (Central 
and South America and North America), 2005-2009 
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Brazilian registries (n=252)
Ecuador (Quito) (n=270)
Colombia (Cali) (n=335)
Puerto Rico* (n=684)
Cuba* (n=560)
Argentinian registries (n=598)
*100% coverage of the national population. N = number of women. Continents are ranked 
by the proportion of type II epithelial tumours from highest to lowest.
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Canada* (n=12,196)
US registries (n=94,702)
*100% coverage of the national population. N = number of women. Continents are ranked 
by the proportion of type II epithelial tumours from highest to lowest.
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Figure 4.6 Distribution (%) of ovarian cancer histological groups by country (Asia and 
Oceania), 2005-2009
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Thai registries (n=549)
Taiwan* (n=5,165)
Indonesia (Jakarta) (n=182)
Japanese registries (n=3,647)
Hong Kong* (n=437)
Korea* (n=7,859)
Malaysia (Penang) (n=281)
Turkey (Izmir) (n=699)
Jordan* (n=382)
Chinese registries (n=3,150)
Cyprus* (n=225)
Israel* (n=1,957)
*100% coverage of the national population. N = number of women. Countries are ranked 
by the proportion of type II epithelial tumours from highest to lowest.
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New Zealand*
(n=1,432)
Australian registries
(n=4,954)
*100% coverage of the national population. N = number of women. Countries are ranked by
the proportion of type II epithelial tumours from highest to lowest.
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Figure 4.7 Distribution (%) of ovarian cancer histological groups by country (Europe), 
2005-2009 
Type II Type I
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Russia (Arkhangelsk) (n=402)
Finland* (n=2,485)
Malta* (n=191)
Slovakia* (n=1,339)
Spanish registries (n=2,553)
Romania (Cluj) (n=196)
French registries (n=242)
Italian registries (n=5,087)
Slovenia* (n=986)
Poland* (n=14,837)
Czech Republic* (n=5,220)
Bulgaria* (n=3,933)
Portugal* (n=1,978)
Estonia* (n=613)
Ireland* (n=1,607)
Denmark* (n=2,997)
Netherlands* (n=6,403)
Belgium* (n=4,720)
Croatia* (n=1,930)
Swiss registries (n=1,581)
Austria* (n=3,653)
Lithuania* (n=1,780)
United Kingdom* (n=29,700)
Iceland* (n=118)
Norway* (n=2,416)
German registries (n=10,566)
Latvia* (n=1,233)
*100% coverage of the national population. N = number of women. Countries are ranked by 
the proportion of type II epithelial tumours from highest to lowest.  
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The proportion of type I epithelial tumours decreased slightly over time in all continents 
except Central and South America [Table 4.5]. The largest decrease was seen in North 
America from 23.8% in 1995-99 to 19.4% in 2005-2009. Most countries saw decreases in 
the proportion of type I epithelial tumours, but the proportion increased in a few 
countries in Central and South America (Cuba and Ecuador), Asia (Japan, Taiwan and 
Thailand) and Europe (Bulgaria, Croatia, France, Italy, Latvia, Lithuania, Russia and 
Slovenia). The countries in which the proportion of type I increased often saw 
corresponding decreases in type II epithelial tumours over time as well, because the 
proportions of other histological groups remained stable.  
Germ cell tumours were uncommon everywhere; during 2005-2009 the proportion in Asia 
(4.2%) was the highest in any continent, over three times the proportion seen in Europe 
(1.3%) [Table 4.5]. The proportion of germ cell tumours was similar for all countries during 
the same period in Europe (1.3%), North America (2.0%) and Oceania (2.5%). However, 
there was wide variation between countries in Central and South America and Asia. In 
Central and South America, the lowest proportion (1.6%) was seen in Cuba and the highest 
(7.8%) in Ecuador [Table 4.6]. Among Asian countries, the variation was wider, with the 
lowest proportion in Cyprus (0.9%), and the highest in Jordan (8.1%). The proportion of 
germ cell tumours increased between 1995-1999 and 2005-2009 in Oceania, decreased 
in Central and South America and Asia and remained constant in North America and 
Europe [Table 4.5].  
Sex cord-stromal tumours were even more uncommon than germ cell tumours. The 
proportion also varied widely between countries in Asia, Central and South America and 
Europe. During 2005-2009, the proportion was similar for both countries in North America 
(1.5%) and in Oceania (0.9%) [Table 4.6]. The widest between-country variation was seen 
in Europe, with only 0.3% of tumours diagnosed as sex cord-stromal in Denmark, but 
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11.4% in Russia. In Central and South America, the proportion ranged from 1.6% in Brazil 
and Puerto Rico to 4.5% in Cuba. The lowest proportion in Asia was in Israel (0.6%), while 
the highest proportion was in Jordan (4.7%). The proportion of sex cord-stromal tumours 
remained constant over time in all continents except Oceania, where it decreased slightly 
from 1.4% in 1995-1999 to 0.9% in 2005-2009.  
The highest proportion of tumours coded to other specific non-epithelial histology was in 
Central and South America during 2005-2009 (3.4%). The proportion was generally less 
than 5% in all countries, and between-country variation within each continent was small. 
The widest variation in the proportions was seen in Asia (0.5% in Indonesia and 5.8% in 
Cyprus) and Europe (0.6% in Croatia and 5.9% in Iceland) [Table 4.6]. In all continents 
except Central and South America, the proportion of other specific non-epithelial tumours 
did not change over time. In Central and South America, however, the proportion 
decreased from 5.5% to 3.4%.  
Non-specific tumours generally accounted for 3% or less of ovarian tumours in all 
countries. During 2005-2009, the highest proportion of these tumours was seen Central 
and South America (3.1%) [Table 4.5]. At the national level, the variation was much wider. 
The highest proportion was recorded in Russia (17.7%), much higher than the next highest 
proportion (Malta, 6.3%). The lowest proportions of non-specific tumours were seen in 
the Netherlands and Slovenia (0.1%) [Table 4.6]. Tumours of non-specific morphology 
remained rare and the proportion did not change much over time in all continents, though 
there was a small decrease from 3.3% to 2.3% in Asia [Table 4.5]. 
Within the type I epithelial group, the distribution of histological subtypes varied by 
country, continent and calendar period. Histological subtypes grouped as type II epithelial 
also varied by country, continent and calendar period. Serous carcinoma was the most 
common type of epithelial tumour worldwide and in all three calendar periods [Table 4.7].  
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Table 4.7 Epithelial ovarian cancer subtypes: worldwide distribution (%) by calendar period, 1995-2009, 51 countries 
     Type I epithelial     Type II epithelial  
  Totala Clear cell Endometrioidb Mucinous Squamous 
Transitional 
cell   Serousc Mixedd  Undifferentiatede  
  N  N  %  N %   N  %  N %  N  %   N %   N  %  N %  
1995-99 192,080 7,063 3.7 19,238 10.0 17,684 9.2 1,022 0.5 763 0.4  68,980 35.9 4,600 2.4 58,123 30.3 
2000-04 240,397 9,705 4.0 23,512 9.8 18,797 7.8 1,227 0.5 1,032 0.4  94,318 39.2 7,170 3.0 66,020 27.5 
2005-09 249,282 11,057 4.4 22,151 8.9 17,029 6.8 1,297 0.5 1,297 0.5   107,836 43.3 10,342 4.1 59,072 23.7 
a Total including non-epithelial tumours. Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing 
morphology were excluded from the analysis of the distribution of histological subtypes (see text). Only microscopically verified tumours or those with a 
clinical diagnosis but specific morphology code were included. b No information on grade was available; therefore, all endometrioid tumours were classified 
as type I epithelial. c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Mixed epithelial-stromal 
tumours. e Undifferentiated and other specific epithelial carcinomas.  
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The proportion of serous tumours increased over the 15-year period from 35.9% to 43.3%. 
“Undifferentiated and other epithelial carcinoma” was the second most common 
subtype, but the proportion decreased over time from 30.3% to 23.7%. Endometrioid 
tumours were the most common subtype of type I epithelial tumours, and the proportion 
of these tumours decreased slightly from 10.0% to 8.9% over time. Mucinous tumours 
comprised 9.2% of the total distribution during 1995-1999, but only 6.8% from 2005 to 
2009. The proportion of clear cell tumours, however, increased very slightly over time 
from 3.7% to 4.4%. There was also an increase in the proportion of mixed epithelial-
stromal tumours (2.4% to 4.1%), while the proportions of squamous cell and transitional 
cell tumours were around 0.5% each and remained stable over time.  
Serous carcinoma was the most common epithelial subtype in all continents except 
Central and South America for all years and Europe during 1995-99 [Table 4.8]. The 
proportion of serous tumours increased over time, including in Central and South 
America.  
Undifferentiated carcinoma and other epithelial carcinomas decreased over time in all 
continents: this was the second most common subtype everywhere except in Central and 
South America, and in Europe from 1995-1999 where it was the most common subtype 
instead of serous.  
In North America, Europe and Oceania the distribution of the epithelial subtypes was 
similar. After serous and undifferentiated carcinoma, endometrioid and mucinous 
carcinomas were the next most common subtypes, followed by clear cell, mixed 
epithelial-stromal, squamous and transitional cell.  
The distribution in Asia was slightly different from those in other continents. Mucinous 
tumours were generally more common in Asia than in other countries and were more 
common than endometrioid tumours. Over time, the proportions of endometrioid and  
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Table 4.8 Epithelial ovarian cancer subtypes: distribution (%) by continent and calendar period, 1995-2009 
     Type I epithelial     Type II epithelial  
  Totala Clear cell Endometrioidb Mucinous Squamous Transitional   Serous
c Mixedd  Undifferentiatede  
  N  N  %  N %   N  %  N %  N  %  N %   N  %  N %  
AMERICA (CENTRAL AND SOUTH) 
1995-99 1,113 15 1.3 106 9.5 91 8.2 6 0.5 2 0.2  275 24.7 10 0.9 435 39.1 
2000-04 3,278 55 1.7 185 5.6 292 8.9 38 1.2 17 0.5  849 25.9 23 0.7 1,337 40.8 
2005-09 2,699 73 2.7 222 8.2 236 8.7 28 1.0 11 0.4  815 30.2 45 1.7 912 33.8 
AMERICA (NORTH) 
1995-99 87,459 3,416 3.9 9,673 11.1 6,931 7.9 356 0.4 407 0.5  35,210 40.3 2,669 3.1 22,554 25.8 
2000-04 101,774 4,279 4.2 10,588 10.4 6,204 6.1 452 0.4 484 0.5  44,428 43.7 4,295 4.2 23,757 23.3 
2005-09 106,898 4,632 4.3 9,590 9.0 5,473 5.1 495 0.5 520 0.5  49,290 46.1 7,003 6.6 21,782 20.4 
ASIA 
1995-99 12,920 729 5.6 1,333 10.3 1,998 15.5 185 1.4 79 0.6  4,054 31.4 157 1.2 2,564 19.8 
2000-04 19,312 1,548 8.0 2,007 10.4 2,654 13.7 224 1.2 155 0.8  6,567 34.0 305 1.6 3,370 17.5 
2005-09 24,533 2,366 9.6 2,405 9.8 2,666 10.9 259 1.1 283 1.2  9,080 37.0 543 2.2 4,152 16.9 
EUROPE 
1995-99 84,056 2,588 3.1 7,579 9.0 8,024 9.5 440 0.5 256 0.3  26,657 31.7 1,528 1.8 31,044 36.9 
2000-04 108,891 3,468 3.2 10,141 9.3 9,176 8.4 487 0.4 353 0.3  39,142 35.9 2,208 2.0 36,026 33.1 
2005-09 108,766 3,650 3.4 9,469 8.7 8,256 7.6 491 0.5 447 0.4  45,470 41.8 2,465 2.3 31,022 28.5 
OCEANIA 
1995-99 6,532 315 4.8 547 8.4 640 9.8 35 0.5 19 0.3  2,784 42.6 236 3.6 1,526 23.4 
2000-04 7,142 355 5.0 591 8.3 471 6.6 26 0.4 23 0.3  3,332 46.7 339 4.7 1,530 21.4 
2005-09 6,386 336 5.3 465 7.3 398 6.2 24 0.4 36 0.6   3,181 49.8 286 4.5 1,204 18.9 
a Total including non-epithelial tumours. Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from 
the analysis of the distribution of histological subtypes (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid tumours were 
classified as type I epithelial. c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Mixed epithelial-stromal tumours. e Undifferentiated 
and other specific epithelial carcinomas. 
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mucinous tumours generally decreased, while the proportion of clear cell and mixed 
epithelial-stromal tumours increased.  
The proportion of squamous and transitional cell tumours were relatively constant over 
time in all continents [Table 4.8].  
The distribution of epithelial subtypes varied between countries within continents [Table 
4.9]. The proportion of serous carcinoma was highest in Iceland (60.2%) and lowest in 
Indonesia (15.9%) during 2005-2009. In Cuba, undifferentiated and other epithelial 
carcinoma was the most common subtype, where the proportion was the highest 
worldwide (48.4%). The lowest proportion of undifferentiated and other epithelial 
carcinoma was seen in Turkey (Izmir) (11.4%) during the same period. The highest 
proportion of endometrioid tumours was seen in Indonesia (Jakarta) (18.1%), and was 
nearly eight times as high as the proportion in Latvia (2.4%). Mucinous tumours were 
more common in East Asian countries, and the highest proportion of these tumours was 
seen in Thailand (18.0%), while only 3.2% of tumours were of this subtype in Israel. Over 
20% of tumours were classified as clear cell carcinoma in Hong Kong, while only 0.2% were 
this subtype in Jordan. Mixed epithelial tumours were highest in the US (6.6%) and lowest 
in Latvia (0.1%). The proportions of squamous and transitional tumours were below 2% in 
all countries.  
 
Continued on page 136 
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Table 4.9 Epithelial ovarian cancer subtypes: distribution (%) by country and calendar period, 1995-2009 
    Type I epithelial   Type II epithelial 
  Totala Clear cell Endometrioidb Mucinous Squamous Transitional  Serous
c Mixedd Undifferentiatede  
  N N %  N %  N %  N %  N %    N %  N %  N %  
AMERICA (CENTRAL AND SOUTH) 
Argentinian registries                                 
1995-99 - - . - . - . - . - .  - . - . - . 
2000-04 182 2 1.1 11 6.0 24 13.2 - . 2 1.1  48 26.4 1 0.5 68 37.4 
2005-09 598 7 1.2 37 6.2 62 10.4 5 0.8 1 0.2  159 26.6 7 1.2 237 39.6 
Brazilian registries                                   
1995-99 168 4 2.4 19 11.3 24 14.3 2 1.2 - .  41 24.4 1 0.6 50 29.8 
2000-04 434 5 1.2 40 9.2 46 10.6 4 0.9 1 0.2  126 29.0 1 0.2 154 35.5 
2005-09 252 10 4.0 16 6.3 33 13.1 - . 1 0.4  92 36.5 1 0.4 67 26.6 
Colombia (Cali)                                   
1995-99 302 5 1.7 33 10.9 39 12.9 1 0.3 - .  102 33.8 3 1.0 76 25.2 
2000-04 337 11 3.3 34 10.1 37 11.0 2 0.6 2 0.6  122 36.2 2 0.6 80 23.7 
2005-09 335 14 4.2 29 8.7 36 10.7 2 0.6 - .  120 35.8 5 1.5 91 27.2 
Cuba*                                     
1995-99 455 4 0.9 47 10.3 15 3.3 3 0.7 2 0.4  65 14.3 4 0.9 251 55.2 
2000-04 1,464 10 0.7 35 2.4 109 7.4 27 1.8 6 0.4  235 16.1 7 0.5 818 55.9 
2005-09 560 6 1.1 82 14.6 28 5.0 12 2.1 2 0.4  99 17.7 1 0.2 271 48.4 
Ecuador (Quito)                                   
1995-99 188 2 1.1 7 3.7 13 6.9 - . - .  67 35.6 2 1.1 58 30.9 
2000-04 209 4 1.9 9 4.3 18 8.6 - . 1 0.5  64 30.6 1 0.5 68 32.5 
2005-09 270 6 2.2 13 4.8 24 8.9 - . - .  89 33.0 4 1.5 80 29.6 
a Total including non-epithelial tumours. Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from 
the analysis of the distribution of histological subtypes (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid tumours were 
classified as type I epithelial. c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Mixed epithelial-stromal tumours. e Undifferentiated 
and other specific epithelial carcinomas. 
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    Type I epithelial   Type II epithelial 
  Totala Clear cell Endometrioidb Mucinous Squamous Transitional  Serous
c Mixedd Undifferentiatede  
  N N %  N %  N %  N %  N %    N %  N %  N %  
Puerto Rico*                                   
1995-99 - - . - . - . - . - .  - . - . - . 
2000-04 652 23 3.5 56 8.6 58 8.9 5 0.8 5 0.8  254 39.0 11 1.7 149 22.9 
2005-09 684 30 4.4 45 6.6 53 7.7 9 1.3 7 1.0  256 37.4 27 3.9 166 24.3 
AMERICA (NORTH)                                   
Canada*                                     
1995-99 10,366 492 4.7 1,319 12.7 910 8.8 63 0.6 44 0.4  4,519 43.6 305 2.9 2,035 19.6 
2000-04 11,347 643 5.7 1,275 11.2 730 6.4 90 0.8 49 0.4  5,117 45.1 335 3.0 2,454 21.6 
2005-09 12,196 657 5.4 1,182 9.7 705 5.8 77 0.6 55 0.5  5,641 46.3 768 6.3 2,353 19.3 
US registries                                   
1995-99 77,093 2,924 3.8 8,354 10.8 6,021 7.8 293 0.4 363 0.5  30,691 39.8 2,364 3.1 20,519 26.6 
2000-04 90,427 3,636 4.0 9,313 10.3 5,474 6.1 362 0.4 435 0.5  39,311 43.5 3,960 4.4 21,303 23.6 
2005-09 94,702 3,975 4.2 8,408 8.9 4,768 5.0 418 0.4 465 0.5  43,649 46.1 6,235 6.6 19,429 20.5 
ASIA                                     
Chinese registries                                   
1995-99 131 1 0.8 1 0.8 28 21.4 1 0.8 - .  27 20.6 - . 49 37.4 
2000-04 1,139 47 4.1 62 5.4 105 9.2 13 1.1 19 1.7  324 28.4 18 1.6 327 28.7 
2005-09 3,150 235 7.5 189 6.0 182 5.8 23 0.7 58 1.8  1,084 34.4 41 1.3 906 28.8 
Cyprus*                                     
1995-99 - - . - . - . - . - .  - . - . - . 
2000-04 - - . - . - . - . - .  - . - . - . 
2005-09 225 14 6.2 13 5.8 13 5.8 1 0.4 1 0.4  103 45.8 3 1.3 57 25.3 
a Total including non-epithelial tumours. Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from 
the analysis of the distribution of histological subtypes (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid tumours were 
classified as type I epithelial. c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Mixed epithelial-stromal tumours. e Undifferentiated 
and other specific epithelial carcinomas. 
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    Type I epithelial   Type II epithelial 
  Totala Clear cell Endometrioidb Mucinous Squamous Transitional  Serous
c Mixedd Undifferentiatede  
  N N %  N %  N %  N %  N %    N %  N %  N %  
Hong Kong*                                   
1995-99 527 87 16.5 90 17.1 96 18.2 3 0.6 4 0.8  146 27.7 1 0.2 100 19.0 
2000-04 1,012 193 19.1 155 15.3 159 15.7 3 0.3 12 1.2  301 29.7 4 0.4 185 18.3 
2005-09 437 89 20.4 71 16.2 61 14.0 1 0.2 4 0.9  133 30.4 9 2.1 69 15.8 
Indian registries                                   
1995-99 391 6 1.5 10 2.6 28 7.2 2 0.5 - .  79 20.2 - . 173 44.2 
2000-04 - - . - . - . - . - .  - . - . - . 
2005-09 - - . - . - . - . - .  - . - . - . 
Indonesia (Jakarta)                                   
1995-99 - - . - . - . - . - .  - . - . - . 
2000-04 - - . - . - . - . - .  - . - . - . 
2005-09 182 14 7.7 33 18.1 23 12.6 3 1.6 - .  29 15.9 1 0.5 56 30.8 
Israel*                                     
1995-99 1,690 24 1.4 208 12.3 89 5.3 10 0.6 5 0.3  704 41.7 30 1.8 461 27.3 
2000-04 1,921 29 1.5 191 9.9 77 4.0 4 0.2 8 0.4  959 49.9 30 1.6 418 21.8 
2005-09 1,957 27 1.4 144 7.4 63 3.2 6 0.3 11 0.6  1,078 55.1 15 0.8 429 21.9 
Japanese registries                                   
1995-99 1,790 171 9.6 140 7.8 209 11.7 11 0.6 6 0.3  550 30.7 28 1.6 380 21.2 
2000-04 3,124 434 13.9 331 10.6 377 12.1 21 0.7 13 0.4  907 29.0 52 1.7 614 19.7 
2005-09 3,647 593 16.3 412 11.3 440 12.1 42 1.2 21 0.6  1,033 28.3 69 1.9 630 17.3 
a Total including non-epithelial tumours. Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from 
the analysis of the distribution of histological subtypes (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid tumours were 
classified as type I epithelial. c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Mixed epithelial-stromal tumours. e Undifferentiated 
and other specific epithelial carcinomas. 
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    Type I epithelial   Type II epithelial 
  Totala Clear cell Endometrioidb Mucinous Squamous Transitional  Serous
c Mixedd Undifferentiatede  
  N N %  N %  N %  N %  N %    N %  N %  N %  
Jordan*                                     
1995-99 - - . - . - . - . - .  - . - . - . 
2000-04 305 1 0.3 18 5.9 40 13.1 2 0.7 - .  92 30.2 12 3.9 92 30.2 
2005-09 382 2 0.5 21 5.5 29 7.6 5 1.3 1 0.3  154 40.3 9 2.4 83 21.7 
Korea*                                     
1995-99 4,526 164 3.6 419 9.3 904 20.0 116 2.6 45 1.0  1,510 33.4 70 1.5 694 15.3 
2000-04 6,036 341 5.6 549 9.1 1,055 17.5 118 2.0 69 1.1  2,273 37.7 101 1.7 788 13.1 
2005-09 7,859 574 7.3 691 8.8 997 12.7 121 1.5 129 1.6  3,476 44.2 151 1.9 923 11.7 
Malaysia (Penang)                                   
1995-99 144 18 12.5 16 11.1 17 11.8 1 0.7 - .  37 25.7 - . 38 26.4 
2000-04 220 27 12.3 21 9.5 44 20.0 1 0.5 - .  40 18.2 1 0.5 63 28.6 
2005-09 281 34 12.1 32 11.4 22 7.8 5 1.8 - .  50 17.8 3 1.1 111 39.5 
Saudi Arabia*                                   
1995-99 392 1 0.3 30 7.7 60 15.3 3 0.8 1 0.3  138 35.2 2 0.5 94 24.0 
2000-04 552 10 1.8 35 6.3 64 11.6 5 0.9 4 0.7  208 37.7 5 0.9 122 22.1 
2005-09 - - . - . - . - . - .  - . - . - . 
Taiwan*                                     
1995-99 2,768 222 8.0 359 13.0 471 17.0 28 1.0 18 0.7  668 24.1 19 0.7 490 17.7 
2000-04 3,998 386 9.7 537 13.4 579 14.5 41 1.0 25 0.6  1,108 27.7 51 1.3 624 15.6 
2005-09 5,165 690 13.4 652 12.6 676 13.1 43 0.8 51 1.0  1,495 28.9 187 3.6 718 13.9 
a Total including non-epithelial tumours. Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from 
the analysis of the distribution of histological subtypes (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid tumours were 
classified as type I epithelial. c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Mixed epithelial-stromal tumours. e Undifferentiated 
and other specific epithelial carcinomas. 
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    Type I epithelial   Type II epithelial 
  Totala Clear cell Endometrioidb Mucinous Squamous Transitional  Serous
c Mixedd Undifferentiatede  
  N N %  N %  N %  N %  N %    N %  N %  N %  
Thai registries                                   
1995-99 171 6 3.5 6 3.5 57 33.3 7 4.1 - .  28 16.4 1 0.6 41 24.0 
2000-04 478 50 10.5 48 10.0 106 22.2 12 2.5 2 0.4  120 25.1 8 1.7 72 15.1 
2005-09 549 63 11.5 79 14.4 99 18.0 6 1.1 5 0.9  117 21.3 15 2.7 90 16.4 
Turkey (Izmir)                                   
1995-99 390 29 7.4 54 13.8 39 10.0 3 0.8 - .  167 42.8 6 1.5 44 11.3 
2000-04 527 30 5.7 60 11.4 48 9.1 4 0.8 3 0.6  235 44.6 23 4.4 65 12.3 
2005-09 699 31 4.4 68 9.7 61 8.7 3 0.4 2 0.3  328 46.9 40 5.7 80 11.4 
EUROPE                                     
Austria*                                     
1995-99 4,331 50 1.2 290 6.7 295 6.8 17 0.4 22 0.5  1,161 26.8 77 1.8 2,049 47.3 
2000-04 4,180 47 1.1 293 7.0 236 5.6 19 0.5 8 0.2  1,255 30.0 69 1.7 1,844 44.1 
2005-09 3,653 57 1.6 290 7.9 176 4.8 18 0.5 11 0.3  1,254 34.3 68 1.9 1,422 38.9 
Belgium*                                     
1995-99 - - . - . - . - . - .  - . - . - . 
2000-04 948 37 3.9 91 9.6 94 9.9 3 0.3 3 0.3  444 46.8 25 2.6 184 19.4 
2005-09 4,720 155 3.3 350 7.4 430 9.1 20 0.4 25 0.5  2,539 53.8 123 2.6 782 16.6 
Bulgaria*                                     
1995-99 2,792 78 2.8 101 3.6 243 8.7 18 0.6 8 0.3  832 29.8 19 0.7 1,194 42.8 
2000-04 3,368 93 2.8 149 4.4 421 12.5 20 0.6 8 0.2  1,174 34.9 23 0.7 1,126 33.4 
2005-09 3,933 64 1.6 211 5.4 486 12.4 9 0.2 15 0.4  1,571 39.9 25 0.6 1,154 29.3 
a Total including non-epithelial tumours. Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from 
the analysis of the distribution of histological subtypes (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid tumours were 
classified as type I epithelial. c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Mixed epithelial-stromal tumours. e Undifferentiated 
and other specific epithelial carcinomas. 
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    Type I epithelial   Type II epithelial 
  Totala Clear cell Endometrioidb Mucinous Squamous Transitional  Serous
c Mixedd Undifferentiatede  
  N N %  N %  N %  N %  N %    N %  N %  N %  
Croatia*                                     
1995-99 771 2 0.3 58 7.5 71 9.2 5 0.6 2 0.3  134 17.4 1 0.1 462 59.9 
2000-04 1,998 16 0.8 227 11.4 173 8.7 10 0.5 2 0.1  558 27.9 19 1.0 914 45.7 
2005-09 1,930 51 2.6 204 10.6 162 8.4 6 0.3 5 0.3  752 39.0 24 1.2 646 33.5 
Czech Republic*                                   
1995-99 5,223 91 1.7 560 10.7 639 12.2 30 0.6 19 0.4  2,011 38.5 46 0.9 1,273 24.4 
2000-04 5,502 97 1.8 661 12.0 557 10.1 35 0.6 16 0.3  2,084 37.9 70 1.3 1,411 25.6 
2005-09 5,220 112 2.1 490 9.4 414 7.9 43 0.8 31 0.6  2,275 43.6 107 2.0 1,250 23.9 
Denmark*                                     
1995-99 3,068 123 4.0 345 11.2 300 9.8 18 0.6 10 0.3  1,238 40.4 89 2.9 753 24.5 
2000-04 2,991 137 4.6 308 10.3 279 9.3 16 0.5 10 0.3  1,310 43.8 75 2.5 665 22.2 
2005-09 2,997 107 3.6 260 8.7 235 7.8 12 0.4 19 0.6  1,577 52.6 101 3.4 483 16.1 
Estonia*                                     
1995-99 792 19 2.4 25 3.2 83 10.5 5 0.6 1 0.1  317 40.0 5 0.6 189 23.9 
2000-04 710 15 2.1 17 2.4 82 11.5 1 0.1 1 0.1  368 51.8 9 1.3 118 16.6 
2005-09 613 20 3.3 25 4.1 42 6.9 4 0.7 4 0.7  316 51.5 4 0.7 112 18.3 
Finland*                                     
1995-99 2,325 91 3.9 503 21.6 295 12.7 11 0.5 1 0.0  992 42.7 46 2.0 228 9.8 
2000-04 2,512 116 4.6 480 19.1 282 11.2 8 0.3 9 0.4  1,142 45.5 44 1.8 245 9.8 
2005-09 2,485 130 5.2 315 12.7 249 10.0 5 0.2 13 0.5  1,283 51.6 45 1.8 233 9.4 
a Total including non-epithelial tumours. Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from 
the analysis of the distribution of histological subtypes (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid tumours were 
classified as type I epithelial. c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Mixed epithelial-stromal tumours. e Undifferentiated 
and other specific epithelial carcinomas. 
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    Type I epithelial   Type II epithelial 
  Totala Clear cell Endometrioidb Mucinous Squamous Transitional  Serous
c Mixedd Undifferentiatede  
  N N %  N %  N %  N %  N %    N %  N %  N %  
French registries                                   
1995-99 2,495 80 3.2 225 9.0 264 10.6 6 0.2 5 0.2  1,112 44.6 40 1.6 572 22.9 
2000-04 2,870 80 2.8 258 9.0 253 8.8 13 0.5 17 0.6  1,351 47.1 70 2.4 614 21.4 
2005-09 242 10 4.1 35 14.5 14 5.8 1 0.4 2 0.8  109 45.0 4 1.7 50 20.7 
German registries                                   
1995-99 5,295 82 1.5 335 6.3 454 8.6 24 0.5 17 0.3  1,593 30.1 89 1.7 2,321 43.8 
2000-04 9,047 163 1.8 662 7.3 672 7.4 34 0.4 43 0.5  3,646 40.3 183 2.0 3,092 34.2 
2005-09 10,566 199 1.9 774 7.3 724 6.9 62 0.6 50 0.5  4,971 47.0 204 1.9 3,048 28.8 
Iceland*                                     
1995-99 113 3 2.7 7 6.2 9 8.0 1 0.9 1 0.9  58 51.3 1 0.9 27 23.9 
2000-04 127 9 7.1 9 7.1 6 4.7 - . - .  72 56.7 2 1.6 20 15.7 
2005-09 118 1 0.8 10 8.5 9 7.6 - . - .  71 60.2 3 2.5 16 13.6 
Ireland*                                     
1995-99 1,332 42 3.2 104 7.8 169 12.7 5 0.4 3 0.2  485 36.4 27 2.0 436 32.7 
2000-04 1,477 78 5.3 130 8.8 161 10.9 4 0.3 2 0.1  525 35.5 34 2.3 484 32.8 
2005-09 1,607 83 5.2 153 9.5 134 8.3 8 0.5 4 0.2  649 40.4 59 3.7 438 27.3 
Italian registries                                   
1995-99 6,772 153 2.3 568 8.4 596 8.8 44 0.6 23 0.3  2,215 32.7 109 1.6 2,387 35.2 
2000-04 8,394 229 2.7 763 9.1 661 7.9 45 0.5 26 0.3  3,112 37.1 215 2.6 2,484 29.6 
2005-09 5,087 152 3.0 529 10.4 364 7.2 37 0.7 22 0.4  1,942 38.2 122 2.4 1,384 27.2 
a Total including non-epithelial tumours. Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from 
the analysis of the distribution of histological subtypes (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid tumours were 
classified as type I epithelial. c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Mixed epithelial-stromal tumours. e Undifferentiated 
and other specific epithelial carcinomas. 
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    Type I epithelial   Type II epithelial 
  Totala Clear cell Endometrioidb Mucinous Squamous Transitional  Serous
c Mixedd Undifferentiatede  
  N N %  N %  N %  N %  N %    N %  N %  N %  
Latvia*                                     
1995-99 1,219 13 1.1 13 1.1 35 2.9 8 0.7 2 0.2  361 29.6 1 0.1 702 57.6 
2000-04 1,205 13 1.1 25 2.1 60 5.0 4 0.3 2 0.2  363 30.1 5 0.4 645 53.5 
2005-09 1,233 23 1.9 30 2.4 69 5.6 10 0.8 7 0.6  448 36.3 1 0.1 524 42.5 
Lithuania*                                     
1995-99 1,630 14 0.9 15 0.9 38 2.3 47 2.9 2 0.1  232 14.2 12 0.7 1,123 68.9 
2000-04 1,781 29 1.6 70 3.9 87 4.9 15 0.8 2 0.1  409 23.0 3 0.2 1,016 57.0 
2005-09 1,780 45 2.5 121 6.8 114 6.4 6 0.3 9 0.5  812 45.6 9 0.5 525 29.5 
Malta*                                     
1995-99 149 7 4.7 10 6.7 33 22.1 - . - .  40 26.8 4 2.7 41 27.5 
2000-04 197 12 6.1 22 11.2 26 13.2 - . - .  59 29.9 - . 54 27.4 
2005-09 191 7 3.7 22 11.5 18 9.4 - . - .  51 26.7 5 2.6 64 33.5 
Netherlands*                                   
1995-99 6,624 266 4.0 609 9.2 793 12.0 18 0.3 28 0.4  2,235 33.7 153 2.3 2,096 31.6 
2000-04 6,289 285 4.5 590 9.4 593 9.4 15 0.2 25 0.4  2,497 39.7 168 2.7 1,720 27.3 
2005-09 6,403 311 4.9 613 9.6 469 7.3 15 0.2 29 0.5  2,964 46.3 150 2.3 1,517 23.7 
Norway*                                     
1995-99 2,358 118 5.0 247 10.5 159 6.7 6 0.3 4 0.2  1,067 45.3 44 1.9 528 22.4 
2000-04 2,506 102 4.1 238 9.5 186 7.4 2 0.1 6 0.2  1,163 46.4 68 2.7 552 22.0 
2005-09 2,416 85 3.5 171 7.1 119 4.9 8 0.3 2 0.1  1,257 52.0 44 1.8 547 22.6 
a Total including non-epithelial tumours. Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from 
the analysis of the distribution of histological subtypes (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid tumours were 
classified as type I epithelial. c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Mixed epithelial-stromal tumours. e Undifferentiated 
and other specific epithelial carcinomas. 
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    Type I epithelial   Type II epithelial 
  Totala Clear cell Endometrioidb Mucinous Squamous Transitional  Serous
c Mixedd Undifferentiatede  
  N N %  N %  N %  N %  N %    N %  N %  N %  
Poland                                     
1995-99 3,158 64 2.0 281 8.9 304 9.6 20 0.6 14 0.4  949 30.1 63 2.0 1,165 36.9 
2000-04 13,114 219 1.7 1,561 11.9 1,118 8.5 48 0.4 71 0.5  4,668 35.6 136 1.0 4,141 31.6 
2005-09 14,837 263 1.8 1,859 12.5 1,213 8.2 42 0.3 78 0.5  5,956 40.1 215 1.4 4,035 27.2 
Portugal*                                     
1995-99 574 18 3.1 39 6.8 56 9.8 3 0.5 4 0.7   174 30.3 8 1.4 210 36.6 
2000-04 2,153 63 2.9 142 6.6 217 10.1 29 1.3 3 0.1  680 31.6 40 1.9 777 36.1 
2005-09 1,978 53 2.7 168 8.5 166 8.4 21 1.1 11 0.6  614 31.0 54 2.7 720 36.4 
Romania (Cluj)                                   
1995-99 - - . - . - . - . - .  - . - . - . 
2000-04 - - . - . - . - . - .  - . - . - . 
2005-09 196 4 2.0 21 10.7 14 7.1 4 2.0 4 2.0  102 52.0 1 0.5 26 13.3 
Russia (Arkhangelsk)                                 
1995-99 - - . - . - . - . - .  - . - . - . 
2000-04 440 12 2.7 11 2.5 41 9.3 4 0.9 8 1.8  125 28.4 1 0.2 129 29.3 
2005-09 402 7 1.7 25 6.2 33 8.2 3 0.7 8 2.0  90 22.4 3 0.7 109 27.1 
Slovakia*                                     
1995-99 - - . - . - . - . - .  - . - . - . 
2000-04 1,983 69 3.5 214 10.8 261 13.2 4 0.2 7 0.4  834 42.1 18 0.9 391 19.7 
2005-09 1,339 45 3.4 156 11.7 142 10.6 4 0.3 4 0.3  606 45.3 21 1.6 241 18.0 
a Total including non-epithelial tumours. Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from 
the analysis of the distribution of histological subtypes (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid tumours were 
classified as type I epithelial. c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Mixed epithelial-stromal tumours. e Undifferentiated 
and other specific epithelial carcinomas. 
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    Type I epithelial   Type II epithelial 
  Totala Clear cell Endometrioidb Mucinous Squamous Transitional  Serous
c Mixedd Undifferentiatede  
  N N %  N %  N %  N %  N %    N %  N %  N %  
Slovenia*                                     
1995-99 824 20 2.4 119 14.4 52 6.3 2 0.2 1 0.1  344 41.7 6 0.7 217 26.3 
2000-04 911 39 4.3 134 14.7 58 6.4 3 0.3 2 0.2  429 47.1 29 3.2 146 16.0 
2005-09 986 38 3.9 151 15.3 61 6.2 1 0.1 5 0.5  526 53.3 23 2.3 128 13.0 
Spanish registries                                   
1995-99 2,728 140 5.1 378 13.9 336 12.3 26 1.0 10 0.4  884 32.4 25 0.9 682 25.0 
2000-04 2,862 133 4.6 370 12.9 297 10.4 15 0.5 12 0.4  1,044 36.5 47 1.6 693 24.2 
2005-09 2,553 143 5.6 274 10.7 231 9.0 5 0.2 21 0.8  1,030 40.3 59 2.3 586 23.0 
Swiss registries                                   
1995-99 1,413 49 3.5 115 8.1 147 10.4 9 0.6 5 0.4  644 45.6 44 3.1 314 22.2 
2000-04 1,376 45 3.3 138 10.0 96 7.0 3 0.2 3 0.2  651 47.3 51 3.7 311 22.6 
2005-09 1,581 45 2.8 141 8.9 88 5.6 7 0.4 16 1.0  782 49.5 48 3.0 342 21.6 
United Kingdom*                                   
1995-99 28,070 1,065 3.8 2,632 9.4 2,653 9.5 117 0.4 74 0.3  7,579 27.0 619 2.2 12,075 43.0 
2000-04 29,950 1,330 4.4 2,578 8.6 2,259 7.5 137 0.5 67 0.2  9,179 30.6 804 2.7 12,250 40.9 
2005-09 29,700 1,440 4.8 2,071 7.0 2,080 7.0 140 0.5 52 0.2  10,923 36.8 943 3.2 10,640 35.8 
a Total including non-epithelial tumours. Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from 
the analysis of the distribution of histological subtypes (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid tumours were 
classified as type I epithelial. c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Mixed epithelial-stromal tumours. e Undifferentiated 
and other specific epithelial carcinomas. 
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    Type I epithelial   Type II epithelial 
  Totala Clear cell Endometrioidb Mucinous Squamous Transitional  Serous
c Mixedd Undifferentiatede  
  N N %  N %  N %  N %  N %    N %  N %  N %  
OCEANIA                                     
Australian registries                                 
1995-99 5,281 265 5.0 422 8.0 482 9.1 21 0.4 13 0.2  2,347 44.4 191 3.6 1,219 23.1 
2000-04 5,895 295 5.0 458 7.8 380 6.4 12 0.2 16 0.3  2,788 47.3 282 4.8 1,293 21.9 
2005-09 4,954 259 5.2 372 7.5 309 6.2 12 0.2 19 0.4  2,482 50.1 217 4.4 945 19.1 
New Zealand*                                   
1995-99 1,251 50 4.0 125 10.0 158 12.6 14 1.1 6 0.5  437 34.9 45 3.6 307 24.5 
2000-04 1,247 60 4.8 133 10.7 91 7.3 14 1.1 7 0.6  544 43.6 57 4.6 237 19.0 
2005-09 1,432 77 5.4 93 6.5 89 6.2 12 0.8 17 1.2   699 48.8 69 4.8 259 18.1 
a Total including non-epithelial tumours. Borderline tumours (ICD-O-3 morphology codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) and those with missing morphology were excluded from 
the analysis of the distribution of histological subtypes (see text). Only microscopically verified tumours or those with a clinical diagnosis but specific morphology code were included. African 
countries were not included because fewer than 100 women were available for each calendar period. b No information on grade was available; therefore, all endometrioid tumours were 
classified as type I epithelial. c No information on grade was available; therefore, all serous tumours were classified as type II epithelial. d Mixed epithelial-stromal tumours. e Undifferentiated 
and other specific epithelial carcinomas. 
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4.4 Discussion 
This is the largest study of the distribution of ovarian cancer histology. It is based on 
individual patient records from 218 population-based cancer registries in 51 countries. 
Data were available for 681,759 women, including 249,282 diagnosed between 2005 and 
2009. Type II epithelial tumours were the most common histological group in each 
continent, but the distribution of histological groups varied greatly worldwide, and, to a 
lesser extent, by time. The distribution was similar in Europe, North America and Oceania, 
while a much higher proportion of type I epithelial tumours was in Asia. 
Tumours of the anatomic ovary were the most common in all continents, but the 
proportion decreased over time except in Central and South America. The distribution of 
topographical sub-sites for tumours diagnosed between 2005 and 2009 was largely similar 
for most continents. The proportion of tumours of the ovary was lower in North America 
and Oceania (85-86%) than in Asia, Central and South America and Europe (90-93%). The 
decrease in the proportion of ovarian tumours over time is most likely due to the 
increasing adoption of guidelines for diagnosing primary peritoneal tumours, which were 
established in 199320,211.  
Additionally, there has been improvement in the understanding of the extra-ovarian 
nature of the development of “ovarian” tumours, including the proposal that serous tubal 
intraepithelial carcinoma may be a precursor lesion both for high-grade serous ovarian 
carcinoma and for high-grade serous peritoneal carcinoma6,12,31-33,212. Therefore, 
pathological the examination of the fallopian tubes of high-risk women during 
prophylactic bilateral salpingo-oophorectomies could explain the increase in the 
proportion in which the topography was coded to fallopian tube, because serous tubal 
intraepithelial carcinoma will be diagnosed as a fallopian tube cancer before it has spread 
to and involved the ovaries, which may require a diagnosis of ovarian cancer based on 
restrictive guidelines10,12. The decrease in the proportion of tumours diagnosed as ovarian 
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and the corresponding increase in the proportions coded to the peritoneum and fallopian 
tube may represent an improvement in the accuracy of diagnosing pelvic tumours.  
Previous studies of the histological subtypes of ovarian cancer have focused on epithelial 
tumours, and they have generally been limited to a small number of countries. One meta-
analysis included data for 98,099 women from 41 studies published between 1992 and 
2012, only 12 of which used data from population-based registries213. The results were 
similar to those found in this study, with type II epithelial tumours more common than 
type I epithelial tumours.  
Some of the variations in the distribution of ovarian cancer histology may be explained by 
ethnicity. A higher proportion of type II epithelial tumours diagnosed between 2005 and 
2009 was reported in Israel (77.8%) than in most other countries. This may be attributable 
to the fact that a high percentage of the population in Israel is of Jewish ancestry, in whom 
BRCA1 and BRCA2 gene mutations are more common than in other populations. Serous 
tumours, which are classified as type II epithelial, are the most common histological 
subtype among women with BRCA1 and BRCA2 mutations214. The proportion of serous 
carcinoma in Israel was the second highest proportion worldwide.   
The proportions of type I and type II epithelial tumours were markedly different between 
the US and Japan. In Japan, 41.3% of tumours were type I epithelial and 47.5% were type 
II epithelial, compared to 19.0% and 73.2% in the US. The lower proportion of serous 
tumours in Japan and other East Asian countries is due in part to the higher proportion of 
mucinous, clear cell and endometrioid tumours. These differences are most probably due 
to the higher incidence of endometriosis, a potential pre-cursor of clear cell and 
endometrioid tumours215, in East Asian women216.  
The proportion of mucinous tumours varied, ranging from over 10% in most Asian 
countries to 5-6% in most North American, European and Oceanian countries. The higher 
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proportion in Japan is not clearly explained. Many tumours classified as mucinous may in 
fact be metastatic to the ovary from the gastrointestinal tract, including the stomach, 
which has a high incidence in Asia23,217. The reduction in the worldwide proportion of 
mucinous ovarian cancer from 9.2% in 1995-1999 to 6.8% in 2005-2009 may be partially 
attributable to more accurate immunohistochemical and imaging assessment, which 
allows for the exclusion of primary mucinous tumours from a different primary site, 
particularly those of the gastrointestinal tract. It can otherwise be difficult to differentiate 
a true primary mucinous ovarian cancer from mucinous tumours that are metastatic to 
the ovary218. 
Germ cell tumours of the ovary should be considered separately in survival analysis, 
because they typically have higher survival than epithelial ovarian cancers. The proportion 
of germ cell tumours was less than 3% in most countries, but in some Asian and Central 
and South American countries, the proportions were much higher (5-8%). These 
differences are important, because the incidence of germ cell tumours is highest among 
young women and survival is usually very high, even when the tumour is diagnosed at an 
advanced stage, if optimal treatment is achievable219. The higher proportion of germ cell 
tumours in Asia and Central and South America may therefore be due to the younger age 
profile of populations in these regions.  
The proportion of sex cord-stromal tumours was less than 2% in most countries, but much 
higher in some European countries. These differences are also important in the 
comparison of survival from all ovarian cancers combined, because survival is much higher 
for sex cord-stromal tumours than for epithelial ovarian cancers220. While sex cord-
stromal tumours can occur at any age, incidence is highest among middle-aged women; 
thus, the higher proportion in some European countries may be due to the age structure 
of the population.  
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Variation in the distribution of histological groups of ovarian cancer may impact 
international comparisons of survival from all ovarian cancers combined if survival in 
countries with more favourable histological distributions, where more tumours are 
classified as type I epithelial, germ cell or sex cord-stromal, is compared with survival in 
countries with higher proportions of type II epithelial tumours. In the main CONCORD-2 
analysis188, age-standardised 5-year survival from all ovarian tumours combined was 
higher in some East Asian countries than in Europe, North America and Oceania. In Hong 
Kong, 5-year survival was 52.9% for women diagnosed from 2005 to 2009, much higher 
than the highest level of survival in Europe (Finland: 44.9%), North America (US: 40.9%) 
and Oceania (Australia: 37.5%)188. The proportion of type I epithelial tumours in Hong 
Kong (51.7%) was the highest among the 51 countries, and Hong Kong was one of only 
two countries where type I epithelial tumours were more common than type II epithelial 
tumours. Thus, the higher survival for all ovarian cancers combined in Hong Kong may be 
partially explained by the more favourable distribution of histology. A favourable 
distribution was also seen in Ecuador, with one of the highest proportions of germ cell 
tumours (7.8%), and age-standardised 5-year survival was 47.0% for all tumours 
combined188. Survival for each histological groups is examined in the next chapter.  
For many areas of the world, data from population-based cancer registries are still 
insufficient to allow meaningful comparisons of ovarian cancer histology. Lack of accurate 
cancer registration in many areas, and the high proportion of non-specific morphology in 
many countries, still limits worldwide comparison of survival by histology.  
During 2005-2009, the highest proportion of tumours of non-specific morphology was 
seen in Russia (17.7%), which may explain the low proportion of type II epithelial tumours 
in the country, because many non-specific tumours will be diagnosed at an advanced 
stage. In order to classify a tumour as a specific histological subtype, such as serous or 
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endometrioid, a tissue biopsy or surgical resection is required; thus, histology may not be 
correctly classified into a specific subtype if the disease is diagnosed at an advanced stage, 
because surgery may not be performed. In Central and South America, the largest registry 
(Puerto Rico) provided data only for 684 women, of which 24.3% were recorded as having 
been diagnosed with undifferentiated or other epithelial carcinoma.  
Variation between pathologists in the description of and classification of ovarian tumours 
into specific histological subtypes may affect the distribution of subtypes within a country, 
and thus, comparisons of the distributions of subtypes between countries. Various studies 
conducted from 1984 to 1994 of the reproducibility of the World Health Organization’s 
1973 histological classification of ovarian tumours221 showed only moderate levels of 
reproducibility (kappa statistics of 0.46 to 0.55)211. Lower levels of agreement between 
pathologists about the correct subtype were seen for high-grade carcinomas (serous 
versus endometrioid), undifferentiated subtypes and mixed subtypes. The WHO 
classification for ovarian tumours was updated in 1999222, 200319 and 20142. Because 
tumours diagnosed from 1995 to 2009 were included in the analysis, pathologists could 
have used either the 1973, 1999 or 2003 criteria to assign a histological subtype to a 
tumour included in the study. The definitions of the various histological subtypes do not 
change drastically over time from 1973 to 2003, so the edition used by the pathologist is 
not necessarily relevant. However, the definitions of the subtypes are general and the 
2003 criteria did not include changes or criteria that could improve reproducibility; thus, 
observer variation remains an issue211.  
Studies of immunohistochemical biomarkers and molecular genetic features for certain 
histological subtypes may allow for more reproducible diagnoses. TP53 mutations are 
found in 80% of women diagnosed with high-grade serous carcinoma, while KRAS, BRAF 
and ERBB2 mutations are more common in women with low-grade serous carcinoma. 
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Mutations of CTNNB1, PTEN, PIK3CA are common in endometrioid tumours and KRAS 
mutations can be found in 50% of mucinous tumours. For clear cell carcinoma, mutations 
or ARID1A and PIK3CA are common2,10-12. With this knowledge and the updated WHO 
classification of 2014, reproducibility of the histological typing of ovarian cancers should 
improve.   
The accuracy of histology data is also reliant upon data transmission to the cancer 
registries and recording of morphology codes, so the distribution of subtypes may be 
affected by registry procedures and the classifications in use. For example, in Sweden, 
only 324 of 12,969 (2.5%) women with ovarian cancer were reported as being diagnosed 
with a specific morphology, compared with 6,311 of 7,322 women (86.2%) in Finland. 
Previous reports on ovarian cancer in Sweden showed over 98% specific morphology 
codes120. Therefore, the higher proportion of non-specific morphology in the data 
submitted by Sweden to the CONCORD-2 study was due to a choice in data submission by 
the Swedish cancer registry, and thus not an accurate representation of the distribution 
of histological groups within the country. Additionally, the distribution for Hong Kong 
included only epithelial tumours, because other ovarian cancer subtypes were not 
submitted by the registry. While Sweden was excluded from these analyses as a result, 
Hong Kong was included because comparison of the most common groups, type I and 
type II epithelial, was still achievable.  
In order to classify serous tumours appropriately into histological groups, knowledge of 
the tumour grade is important. However, data on tumour grade are not routinely 
collected by cancer registries. For ovarian cancer, most serous carcinomas are high-grade, 
and will have been correctly classified in our analysis as type II epithelial, but a small 
proportion are low-grade, and should have been classified as type I epithelial10-12,14,35,223. 
Because the proportion of low-grade serous tumours is small2,  the effect of any 
142 
 
misclassification on the distribution of histology is expected to be minimal. The distinction 
between high-grade and low-grade serous carcinoma is important, because these 
subtypes have distinct developmental pathways and are thought to be different 
diseases10,12. Low-grade serous carcinoma is more common in younger women, and is 
thought to arise from borderline serous tumours. In contrast, high-grade serous 
carcinoma is more common in older women and is thought to arise from tubal 
disease10,12,30. Similarly, endometrioid tumours are classified as either low- or high-grade, 
and classification into type I or type II epithelial has previously depended on tumour 
grade12. Most endometrioid ovarian tumours will be low-grade2, and some pathologists 
have argued that high-grade endometrioid tumours may not exist12,14. Distinguishing 
between high-grade endometrioid and high-grade serous tumours is difficult, and when 
distinction between endometrioid and serous tumours is unclear, most high-grade 
tumours may be classified as high-grade serous, because this subtype is more common 
than high-grade endometrioid12,14. Following an update in 2016 of the original definitions 
of type I and type II epithelial tumours, all endometrioid tumours should now be 
categorised as type I, regardless of tumour grade10. Future analyses of ovarian cancer 
survival should, if possible, incorporate a distinction between high- and low-grade serous 
carcinoma, to reflect the current understanding of ovarian cancer pathogenesis and 
behaviour, and to classify serous carcinomas appropriately into type I and type II epithelial 
tumours.  
Tumours for which the morphology was coded as simply carcinoma, not otherwise 
specified (NOS) (ICD-O-3 morphology code 8010), large cell carcinoma, NOS (8012) or 
adenocarcinoma, NOS (8140) were all categorised as “undifferentiated and other 
epithelial” tumours, and grouped with type II epithelial tumours. There may be some 
misclassification of these tumours, because these morphology codes are not specific 
codes, so classification into type I or type II is difficult. However, carcinoma (NOS), large 
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cell carcinoma (NOS) and adenocarcinoma (NOS) are treated clinically as if they were high-
grade serous carcinomas, which are classified as type II. These three tumour types 
comprise 20.9% of all tumours included in the analysis.  
Only morphologically verified tumours, or those with specific morphologies that implied 
morphological verification, were included in the analysis. This restriction may affect the 
distribution of histological subtypes, because the histology of advanced-stage tumours 
that are not fully investigated may be coded as non-specific or missing. If more advanced-
stage tumours are not morphologically verified and therefore excluded from analysis, the 
distribution of histological groups may appear more favourable than it actually is.  
This worldwide study of ovarian cancer histology has identified striking variations in 
histological distribution, using individual data on 681,759 women from 218 population-
based cancer registries in 51 countries. The two main histological groups of ovarian cancer 
have different prognosis, primarily due to differences in the distribution of stage, 
sensitivity to chemotherapy and response to surgical resection. International comparisons 
of ovarian cancer survival should therefore include consideration of histology, to help 
identify the extent to which the distribution of histological groups contributes to 
international differences in ovarian cancer survival, which is typically reported for all 
histological subtypes combined. Registration of both the morphology and the grade of 
ovarian cancers is important to help categorise these tumours more accurately into 
histological groups, especially type I and type II epithelial.  
Increased support for the development of high-quality population-based cancer registries 
in low-income countries will improve international comparisons of ovarian cancer 
survival. To understand further the impact on survival for all ovarian cancers combined, 
international differences in ovarian cancer survival by histological group are examined in 
Chapter 5.
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Chapter 5: Ovarian cancer survival by histological 
group 
5.1 Introduction 
The CONCORD-2 study showed wide variation in 5-year net survival for ovarian cancer 
among 779,302 women diagnosed during 1995-2009 in 61 countries188. While age-
standardised survival from ovarian cancer was generally around 30-40% in most 
countries, there was a wide range from the lowest to the highest survival worldwide. Most 
international comparisons of ovarian cancer survival include all histological subtypes 
combined3,122,188. The different histological subtypes have unique molecular pathways and 
treatment, and survival also differs widely, especially for type I and type II epithelial 
tumours11-13,15. This chapter examines patterns of survival for each histological group, in 
order to gain a better understanding of international differences in ovarian cancer 
survival. 
Type I epithelial tumours include low-grade serous, endometrioid, clear cell, mucinous, 
squamous and transitional cell (Brenner) carcinomas, while type II epithelial tumours 
include high-grade serous, undifferentiated and mixed epithelial stromal carcinomas. 
Type II epithelial tumours account for approximately 70% of all malignant ovarian 
tumours, while only 22% of ovarian tumours are type I epithelial. Type I epithelial tumours 
often present at an early stage and have better prognosis than type II epithelial tumours, 
which typically present at an advanced stage12. Germ cell and sex cord-stromal tumours 
are rarer subtypes of ovarian cancer, but they generally have much better prognosis than 
type II epithelial tumours.  
5.2 Material and methods 
The CONCORD-2 study was based on data for over 25.7 million patients diagnosed with 
one of 10 common cancers, contributed by 279 population-based cancer registries in 67 
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countries. The data included 779,302 women diagnosed with ovarian cancer in 61 
countries during the 15-year period of 1995 to 2009. The protocol, ethical approvals, 
quality control procedures and analytic methods for CONCORD-2 have been described 
elsewhere188 and in Chapter 3a.  
Data for 793,098 women (aged 15-99 years) diagnosed from 1995 to 2009 with a cancer 
of the ovary, fallopian tube, uterine ligaments and adnexa, other specified and 
unspecified female genital organs, peritoneum and retroperitoneum were available for 
analysis [Figure 5.1]. This number is slightly larger than the number of women included in 
the analysis for the main CONCORD-2 article, because of a data submission error that was 
corrected after the analysis for the main article had been completed. Data submitted by 
Ontario for women diagnosed from 1995 to 2007 did not initially include tumours of the 
ovary, but included only tumours of the fallopian tube and peritoneum. The registry 
resubmitted data including all sub-sites for the entire 15-year period, resulting in an 
increase of 13,796 women.  
Recent evidence suggests that high-grade serous carcinoma, the most common type of 
ovarian cancer, originates in the fallopian tube. Therefore, cancers of the fallopian tube 
and other specified and unspecified female genital organs were included in a broader 
definition of ovarian cancer12. Similarly, primary peritoneal and retroperitoneal 
carcinomas are managed in the same way as advanced-stage epithelial ovarian cancer, 
and they are also included12. The term “ovarian” in this chapter refers to tumours at all 
these sub-sites, unless the context makes clear that it refers to tumours of the anatomic 
ovary.  
                                                             
a The material in Chapters 4-7 is based on examination of the distribution of and survival from 
ovarian cancer histology, stage at diagnosis and race/ethnicity. A few paragraphs of material and 
methods are repeated in each of these chapters for ease of reference and to ensure consistency 
of the descriptions. A detailed definition and description of the data and methods can be found in 
Chapter 3. 
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Figure 5.1 Data exclusion flow chart for net survival analysis by ovarian cancer 
histological group, 1995-2009 
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Follow-up until 31 December 2009 for each woman’s vital status was available. Women 
diagnosed with ovarian cancer as a second or higher-order primary tumour are included 
in the analysis, in addition to those for whom ovarian cancer was their first cancer. 
Women whose cancer registration was from a death certificate or autopsy only were 
excluded, because their true survival time was unknown.  
In ICD-O-2, ovarian cystadenomas were coded as invasive, i.e. with a behaviour code of 3. 
The behaviour code changed, however, from invasive to benign (0) or of borderline 
malignancy (1) in ICD-O-3, which was introduced in 2000. Due to this change in 
classification, some women diagnosed with borderline tumours were included in the data 
submissions. Ovarian cancer registrations were checked to select ICD-O-3 morphologies 
that are no longer considered to be invasive malignancies, and these tumours were 
excluded from analysis, even if diagnosed prior to 2000, because their inclusion would 
inflate survival estimates. Cancer registrations with a haematological morphology 
(lymphoma or leukaemia) arising in the ovary, fallopian tube, uterine ligaments or adnexa, 
peritoneum or retroperitoneum were also excluded from the analysis.   
Six “histological groups” were defined based on ICD-O-3 codes, the literature210 and 
clinical advice: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other 
specific non-epithelial, and non-specific morphology [Table 5.1]. “Histological subtypes” 
grouped as type I epithelial included clear cell, endometrioid, mucinous, squamous and 
transitional cell (Brenner) carcinomas. Serous, mixed epithelial-stromal and 
“undifferentiated or other classified epithelial carcinomas” were grouped as type II 
epithelial. Tumours with a non-specific morphology code (8000-8004), or with a code of 
9999 (specific to the CONCORD-2 protocol indicating that the morphology code was 
missing), were analysed separately. Throughout this chapter, “histological group” refers 
to the broader categories of tumours, each comprising one or more of the “histological  
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Table 5.1 Ovarian cancer histological groups and subtypes 
Histological groupa Histological subtype ICD-O-3 morphology code 
Type I epithelial Clear cell carcinoma 8005, 8310, 8443, 9110 
Endometrioid 
carcinomab 
8380, 8382-8383, 8560, 8570 
Mucinous carcinoma 8470-8471, 8480-8482, 8490 
Squamous carcinoma 8051-8084 
Transitional cell or 
Brenner carcinoma 
8120-8131, 9000 
Type II epithelial Serous carcinomac 8050, 8441, 8450, 8460-8461 
Mixed epithelial-stromal 
carcinoma 
8313, 8323, 8381, 8930-8991, 
9010-9030 
Undifferentiated or 
other epithelial 
8010-8015, 8020-8046, 8090-
8110, 8140-8231, 8246-8300, 
8311-8312, 8314-8322, 8324-
8325, 8336-8337, 8341-8375, 
8384-8440, 8452-8454, 8500-
8551, 8561-8562, 8571-8589 
Germ cell Germ cell  8240-8245, 8330-8335, 8340, 
9060-9105, 9380-9523 
Sex cord-stromal Sex cord-stromal 8590-8671, 8810  
Other specific non-
epithelial 
Other specific non-
epithelial 
8680-8806, 8811-8921, 9040-
9055, 9120-9373, 9530-9589 
Non-specific Non-specific 8000-8004 
Table presented here for ease of reference (originally presented in Chapter 4, page 81). 
a Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) were 
excluded from the analysis of survival by histological group. Tumours with missing 
morphology codes were analysed separately (see text). b No information on grade was 
available; therefore, all endometrioid tumours were classified as type I epithelial. c No 
information on grade was available; therefore, all serous tumours were classified as 
type II epithelial. 
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subtypes”. All microscopically verified tumours were included in the analysis. Tumours 
that were not reported as microscopically verified but for which a specific ICD-O-3 
morphology code was available (any valid ICD-O-3 morphology code except 8000-8004) 
were also included. 
Survival from ovarian cancer was estimated by histological group for each country. Only 
countries with at least 10 women available for any given histological group for all years 
combined were included in the analysis for that histological group. Registries for which 
net survival estimates were considered as less reliable in the main CONCORD-2 analysis188 
were also excluded. Data from countries that were included in the analysis of specific 
histological groups were included in the analysis for non-specific morphology, provided 
that there were at least 10 women with non-specific tumours available for all years 
combined. Only four countries were included in the analysis for tumours with a missing 
morphology code, because most microscopically verified tumours had a known 
morphology code. If fewer than 50 women were available for survival analysis by 
histological group in a given calendar period, the data for two or more calendar periods 
were merged. Overall, 695,932 women (87.7% of the 793,098 eligible) from 60 countries 
were included in the analysis [Figure 5.1].   
Net survival is defined as the probability of survival for cancer patients up to a given point 
in time after diagnosis (for example, 5 years) if death from cancer were to be the only 
cause of death. Net survival controls for the background mortality of competing causes of 
death in a population. Life tables of all-cause mortality rates by single year of age (0-99 
years), region, sex, calendar year and, where possible, race were used to control for 
variations in background mortality. The Pohar Perme estimator of net survival224, which 
allows for the fact that competing risks of death increase with age, was used to estimate 
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net survival. The Pohar Perme estimator was implemented using stns208 in Stata version 
14207. Standard errors were calculated using the Greenwood method209.  
Net survival is reported for each country and histological group with 95% confidence 
intervals (CI). Survival by histological group was estimated for three calendar periods of 
diagnosis: 1995-1999, 2000-2004 and 2005-2009. The cohort approach was used for 
1995-1999 and 2000-2004 because five or more years of follow-up were available for all 
women, while a period approach was used for 2005-2009a.  
Survival for specific histological subtypes was estimated for the three calendar periods for 
the United States and the United Kingdom separately. The larger number of women 
included in the data submissions from the US and the UK allowed for more detailed 
analysis of the specific type I epithelial and type II epithelial subtypes. Registrations from 
the United States and the United Kingdom comprised over 50% of the data (37.7% from 
the US and 12.6% from the UK) for all years combined.  
Survival for each histological group by topographical sub-site was estimated for each 
calendar period of diagnosis for the US and the UK separately. Tumours grouped as 
“fallopian tube” (ICD-O-3 codes C57.0-C57.4, C57.7-C57.9) include those coded to the 
uterine ligaments and adnexa and other specified and unspecified female genital organs, 
as well as fallopian tube neoplasms. Tumours grouped as “peritoneal” (ICD-O-3 codes 
C48.0-C48.2) include tumours of the peritoneum and retroperitoneum. Tumours grouped 
as “ovarian” include only tumours coded as ovarian (ICD-O-3 code C56.9). This analysis 
was conducted to determine whether survival varies by sub-site within histological 
groups.  
                                                             
a See Chapter 3 for a more detailed explanation of these methods.  
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Survival estimates for all ages combined were age-standardised, where possible, with the 
International Cancer Standard Survival (ICSS) weights for a cancer for which incidence 
increases with age206. Age at diagnosis was categorised into five age groups: 15-44, 45-54, 
55-64, 65-74 and 75-99 years. If an age-specific estimate could not be produced, or fewer 
than 10 women were available for analysis in an age group, data for adjacent age groups 
were pooled and the re-estimated survival was used for both of the original age groups. 
If two or more age-specific estimates could not be produced, or fewer than 10 women 
were available for analysis in two or more age groups, then only the unstandardised 
estimate is reported. 
5.3 Results 
5.3.1 Histological group by country and calendar period 
Data for a total of 695,932 women in 60 countries were available for analysis [Figure 5.1], 
including 98.3% with a specific morphology, 1.6% with non-specific morphology and 0.1% 
with missing morphology [Table 5.2]. Most women (488,634, 70.2%) were diagnosed with 
type II epithelial tumours. The mean age at diagnosis varied between histological groups, 
ranging from 36 years for germ cell tumours to 66 years for tumours of non-specific 
morphology.  
Type I epithelial 
Net survival for women diagnosed with type I epithelial tumours five years after diagnosis 
was fairly high, generally 40-60% [Figures 5.2 -5.4]. During 2005 to 2009, age-standardised 
5-year survival for type I epithelial tumours varied widely, with the highest survival in 
Hong Kong (82.9%, 95% CI: 72.4-93.4%) and the lowest in Argentina (30.8%, 16.3-45.2%) 
[Table 5.3].  
Age-standardised survival from type I epithelial tumours also varied within each continent 
and over time. The between-country variation in survival was widest in Central and South  
Continued on page 163 
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Table 5.2 Worldwide distribution (%) of ovarian cancer histology and mean age at 
diagnosis, 1995-2009, 60 countries 
Histological group No. % Mean age (SD)a (years)  
Type I epithelialb 152,970 22.0 58 (14) 
Type II epithelialc 488,634 70.2 64 (14) 
Germ cell 13,306 1.9 36 (18) 
Sex cord-stromal 11,430 1.6 54 (16) 
Other specific non-epithelial 17,619 2.5 61 (15) 
Non-specific tumours 11,282 1.6 66 (17) 
Missing morphology 691 0.1 64 (16) 
Total 695,932 100.0 62 (15) 
a Standard deviation. b No information on grade was available, therefore all 
endometrioid tumours were classified as type I epithelial. c No information on grade 
was available, therefore all serous tumours were classified as type II epithelial.  
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Figure 5.2 Five-year age-standardised net survival (%) for type I epithelial tumours, 
1995-1999 
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Figure 5.3 Five-year age-standardised net survival (%) for type I epithelial tumours, 
2000-2004
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Figure 5.4 Five-year age-standardised net survival (%) for type I epithelial tumours, 
2005-2009
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Table 5.3 Five-year age-standardised net survival (NS, %) (95% CI) by histological group 
(epithelial tumours), country and calendar period, 1995-2009, 60 countries 
  Type I epithelial
c Type II epitheliald 
 
No. of 
registries 
No. of 
patientse NS (%) 95% CI 
No. of 
patientse NS (%) 95% CI 
AFRICA 
Algerian registries                
1995-1999 - - . .  -  . . 
2000-2004 - - . .  -  . . 
2005-2009 2 26 41.6 16.1 - 67.2               86  37.1 24.6 - 49.5 
Libya (Benghazi)                
1995-1999 - - . .  -  . . 
2000-2004 - - . .  -  . . 
2005-2009 1 - . .               44  5.6 0.0 - 13.5 
Mauritius*                
1995-1999 - - . .  -  . . 
2000-2004 - - . .  -  . . 
2005-2009 1 - . .               25  73.9 52.9 - 94.8 
South Africa (Eastern Cape)                
1995-1999 - - . .  -  . . 
2000-2004 - - . .  -  . . 
2005-2009 1 - . .               20  100.0 86.1 - 100.0 
Tunisia (Central)                
1995-1999 - - . .  -  . . 
2000-2004 - - . .  -  . . 
2005-2009 1 - . .               21  47.3 25.0 - 69.6 
AMERICA (CENTRAL AND SOUTH) 
Argentinian registries                
1995-1999 - - . .  -  . . 
2000-2004 3 - . .             117  19.6 11.4 - 27.8 
2005-2009 3 151 30.8 16.3 - 45.2             403  30.5 21.9 - 39.2 
Brazilian registries                
1995-1999 3 - . .               92  29.1 15.7 - 42.5 
2000-2004 4 145 46.7 35.5 - 58.0             281  38.3 29.6 - 47.0 
2005-2009 4 60 40.9 24.2 - 57.5             160  29.2 17.7 - 40.7 
Chile (Los Rios)                
1995-1999 - - . .  -  . . 
2000-2004 - - . .  -  . . 
2005-2009 1 56 55.2 39.8 - 70.7               75  18.1 6.3 - 29.9 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-
standardised. Where data for two or more calendar periods of diagnosis were merged, the net survival estimates are 
underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) 
were not included in the analysis. b Only microscopically verified tumours or tumours with a clinical diagnosis and a 
specific morphology code were included. c Endometrioid tumours are defined as type I epithelial.  d Serous tumours are 
defined as type II epithelial. e Number of patients included in the analysis for a given calendar period. The number of 
women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and 
updates from some registries. The number of patients in each time period may differ from the number shown in Table 
5.5 due to merging of calendar periods.   
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  Type I epithelial
c Type II epitheliald 
 
No. of 
registries 
No. of 
patientse NS (%) 95% CI 
No. of 
patientse NS (%) 95% CI 
Colombia (Cali)                
1995-1999 1 78 44.8 29.3 - 60.2             181  29.1 18.2 - 40.0 
2000-2004 1 86 55.4 38.0 - 72.9             204  27.1 21.8 - 32.5 
2005-2009 1 81 77.1 64.7 - 89.6             216  32.0 20.5 - 43.4 
Cuba*                
1995-1999 1 71 70.6 58.3 - 82.9             320  53.4 45.1 - 61.7 
2000-2004 1 187 61.8 50.1 - 73.5          1,060  44.7 39.9 - 49.5 
2005-2009 1 130 74.6 64.7 - 84.6             371  39.2 29.3 - 49.1 
Ecuador (Quito)                
1995-1999 1 - . .             127  35.3 21.0 - 49.6 
2000-2004 1 - . .             133  35.1 21.6 - 48.7 
2005-2009 1 97 60.2 40.9 - 79.5             173  55.0 44.6 - 65.5 
Puerto Rico*                
1995-1999 - - . .  -  . . 
2000-2004 1 147 47.2 33.7 - 60.8             414  29.5 23.3 - 35.7 
2005-2009 1 144 62.2 43.7 - 80.8             449  36.2 26.9 - 45.5 
AMERICA (NORTH) 
Canada*                
1995-1999 13 2,828 58.6 55.8 - 61.4          6,859  28.0 26.6 - 29.3 
2000-2004 13 2,787 62.9 60.0 - 65.8          7,906  29.8 28.5 - 31.1 
2005-2009 13 2,676 69.4 64.7 - 74.0          8,762  33.7 30.9 - 36.6 
US registries                
1995-1999 34 17,955 58.3 57.1 - 59.5        53,574  33.4 32.9 - 33.9 
2000-2004 38 19,220 61.7 60.6 - 62.8        64,574  34.4 33.9 - 34.8 
2005-2009 38 18,034 65.9 63.9 - 67.9        69,313  36.1 34.5 - 37.6 
ASIA 
Chinese registries                
1995-1999 3 - . .               76  40.5 27.8 - 53.2 
2000-2004 18 277 66.3 58.4 - 74.3             669  41.9 34.1 - 49.6 
2005-2009 19 687 59.3 46.1 - 72.5          2,031  45.0 38.4 - 51.6 
Cyprus*                
1995-1999 - - . .  -  . . 
2000-2004 - - . .  -  . . 
2005-2009 1 45 57.5 38.5 - 76.5             195  42.0 26.9 - 57.2 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-
standardised. Where data for two or more calendar periods of diagnosis were merged, the net survival estimates are 
underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) 
were not included in the analysis. b Only microscopically verified tumours or tumours with a clinical diagnosis and a 
specific morphology code were included. c Endometrioid tumours are defined as type I epithelial.  d Serous tumours are 
defined as type II epithelial. e Number of patients included in the analysis for a given calendar period. The number of 
women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and 
updates from some registries. The number of patients in each time period may differ from the number shown in Table 
5.5 due to merging of calendar periods.   
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  Type I epithelial
c Type II epitheliald 
 
No. of 
registries 
No. of 
patientse NS (%) 95% CI 
No. of 
patientse NS (%) 95% CI 
Hong Kong*                
1995-1999 1 280 64.0 52.9 - 75.1             247  26.0 16.8 - 35.3 
2000-2004 1 522 71.3 62.5 - 80.1             490  33.0 26.9 - 39.0 
2005-2009 1 226 82.9 72.4 - 93.4             211  61.5 54.8 - 68.2 
Indian registries                
1995-1999 2 - . .             252  22.4 13.0 - 31.9 
2000-2004 - - . .  -  . . 
2005-2009 2 57 31.7 15.7 - 47.8               54  21.6 7.4 - 35.8 
Indonesia (Jakarta)                
1995-1999 - - . .  -  . . 
2000-2004 - - . .  -  . . 
2005-2009 1 73 54.2 32.4 - 76.0               86  . . 
Israel*                
1995-1999 1 336 54.6 45.7 - 63.4          1,195  35.6 31.4 - 39.8 
2000-2004 1 309 57.5 48.8 - 66.2          1,407  36.1 32.0 - 40.1 
2005-2009 1 251 53.9 31.0 - 76.8          1,522  28.4 11.3 - 45.4 
Japanese registries                
1995-1999 2 537 48.7 40.5 - 56.8             958  26.2 21.1 - 31.2 
2000-2004 6 1,176 53.4 48.2 - 58.5          1,573  30.5 26.9 - 34.1 
2005-2009 8 1,508 48.9 27.2 - 70.5          1,732  37.0 32.0 - 41.9 
Jordan*                
1995-1999 - - . .  -  . . 
2000-2004 1 61 22.2 3.1 - 41.4             196  18.3 6.4 - 30.3 
2005-2009 1 58 0.0 0.0 - 0.0             246  0.0 0.0 - 0.0 
Korea*                
1995-1999 1 1,648 65.5 59.0 - 72.1          2,274  37.9 33.3 - 42.4 
2000-2004 1 2,132 64.9 59.6 - 70.3          3,162  37.7 33.5 - 42.0 
2005-2009 1 2,512 60.8 50.7 - 70.8          4,550  39.5 33.8 - 45.1 
Malaysia (Penang)                
1995-1999 1 52 49.3 35.6 - 63.1               75  52.4 38.0 - 66.7 
2000-2004 1 93 70.5 60.6 - 80.4             104  27.5 14.3 - 40.7 
2005-2009 1 93 72.9 59.7 - 86.0             164  47.3 31.6 - 63.1 
Mongolia*                
1995-1999 - - . .  -  . . 
2000-2004 - - . .  -  . . 
2005-2009 1 - . .               52  68.3 51.2 - 85.3 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-
standardised. Where data for two or more calendar periods of diagnosis were merged, the net survival estimates are 
underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) 
were not included in the analysis. b Only microscopically verified tumours or tumours with a clinical diagnosis and a 
specific morphology code were included. c Endometrioid tumours are defined as type I epithelial.  d Serous tumours are 
defined as type II epithelial. e Number of patients included in the analysis for a given calendar period. The number of 
women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and 
updates from some registries. The number of patients in each time period may differ from the number shown in Table 
5.5 due to merging of calendar periods.   
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  Type I epithelial
c Type II epitheliald 
 
No. of 
registries 
No. of 
patientse NS (%) 95% CI 
No. of 
patientse NS (%) 95% CI 
Qatar*                
1995-1999 - - . .  -  . . 
2000-2004 - - . .  -  . . 
2005-2009 1 - . .               22  31.9 6.7 - 57.1 
Saudi Arabia*                
1995-1999 1 95 70.1 51.6 - 88.6             234  42.9 23.2 - 62.5 
2000-2004 1 118 49.7 25.3 - 74.1             336  31.9 16.9 - 46.9 
2005-2009 - - . .  -  . . 
Taiwan*                
1995-1999 1 1,098 59.5 52.4 - 66.6          1,177  35.0 29.2 - 40.7 
2000-2004 1 1,568 61.8 56.3 - 67.3          1,783  35.8 31.3 - 40.3 
2005-2009 1 2,112 61.3 53.8 - 68.7          2,400  35.3 12.3 - 58.3 
Thai registries                
1995-1999 1 76 70.3 57.8 - 82.8               70  45.1 31.3 - 59.0 
2000-2004 3 218 62.9 52.3 - 73.4             200  32.1 18.0 - 46.1 
2005-2009 3 252 71.9 60.8 - 83.0             222  44.4 35.2 - 53.6 
Turkey (Izmir)                
1995-1999 1 125 60.3 49.8 - 70.7             217  40.5 31.8 - 49.2 
2000-2004 1 145 58.4 48.0 - 68.9             323  39.3 27.8 - 50.8 
2005-2009 1 165 56.9 42.6 - 71.3             448  31.2 11.2 - 51.3 
EUROPE 
Austria*                
1995-1999 2 674 56.4 50.4 - 62.4          3,287  39.6 37.1 - 42.0 
2000-2004 2 603 61.3 55.6 - 67.1          3,168  36.7 34.5 - 39.0 
2005-2009 2 552 59.9 48.9 - 70.8          2,744  40.0 36.0 - 44.1 
Belgium*                
1995-1999 - - . .  -  . . 
2000-2004 1 228 65.2 56.3 - 74.1             653  35.8 31.1 - 40.6 
2005-2009 1 980 62.9 52.9 - 73.0          3,444  35.4 31.3 - 39.4 
Bulgaria*                
1995-1999 1 448 42.2 32.8 - 51.6          2,045  30.2 25.6 - 34.9 
2000-2004 1 691 49.1 42.7 - 55.4          2,323  33.9 30.2 - 37.7 
2005-2009 1 785 43.8 33.4 - 54.2          2,750  32.6 23.8 - 41.3 
Croatia*                
1995-1999 1 138 53.7 45.3 - 62.1             597  35.7 28.9 - 42.5 
2000-2004 1 428 55.5 47.6 - 63.4          1,491  33.4 29.3 - 37.5 
2005-2009 1 428 54.0 42.0 - 65.9          1,422  28.1 20.2 - 35.9 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-
standardised. Where data for two or more calendar periods of diagnosis were merged, the net survival estimates are 
underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) 
were not included in the analysis. b Only microscopically verified tumours or tumours with a clinical diagnosis and a 
specific morphology code were included. c Endometrioid tumours are defined as type I epithelial.  d Serous tumours are 
defined as type II epithelial. e Number of patients included in the analysis for a given calendar period. The number of 
women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and 
updates from some registries. The number of patients in each time period may differ from the number shown in Table 
5.5 due to merging of calendar periods.   
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  Type I epithelial
c Type II epitheliald 
 
No. of 
registries 
No. of 
patientse NS (%) 95% CI 
No. of 
patientse NS (%) 95% CI 
Czech Republic*                
1995-1999 1 1,339 44.3 39.1 - 49.6          3,330  30.8 28.0 - 33.5 
2000-2004 1 1,366 46.9 42.8 - 50.9          3,565  32.9 30.4 - 35.5 
2005-2009 1 1,090 53.2 45.9 - 60.5          3,632  40.4 36.7 - 44.1 
Denmark*                
1995-1999 1 796 50.8 45.8 - 55.9          2,080  23.9 21.3 - 26.5 
2000-2004 1 750 47.4 41.9 - 52.8          2,050  28.4 25.6 - 31.3 
2005-2009 1 633 69.6 62.9 - 76.3          2,161  30.1 23.2 - 37.0 
Estonia*                
1995-1999 1 133 43.0 27.5 - 58.4             511  26.0 18.6 - 33.4 
2000-2004 1 116 46.2 33.9 - 58.4             495  32.9 26.2 - 39.5 
2005-2009 1 95 75.3 61.5 - 89.0             432  31.2 22.5 - 39.8 
Finland*                
1995-1999 1 901 45.3 39.3 - 51.3          1,266  38.7 34.9 - 42.5 
2000-2004 1 895 48.2 43.2 - 53.1          1,431  40.1 36.2 - 44.0 
2005-2009 1 712 66.4 59.3 - 73.6          1,561  46.3 40.9 - 51.7 
French registries                
1995-1999 10 580 47.0 40.7 - 53.2          1,724  28.9 25.7 - 32.1 
2000-2004 10 621 53.2 46.8 - 59.6          2,035  35.8 33.2 - 38.4 
2005-2009 10 62 56.7 36.5 - 76.9             163  24.8 9.0 - 40.7 
German registries                
1995-1999 4 912 52.7 48.2 - 57.1          4,003  34.0 31.9 - 36.0 
2000-2004 8 1,574 57.6 54.3 - 60.9          6,921  36.6 35.1 - 38.1 
2005-2009 8 1,809 46.3 32.7 - 59.8          8,223  35.4 32.3 - 38.5 
Iceland*                
1995-1999 1 - . .               86  21.1 9.8 - 32.4 
2000-2004 1 - . .               94  30.6 15.5 - 45.7 
2005-2009 1 65 56.4 32.3 - 80.4               90  41.5 26.9 - 56.1 
Ireland*                
1995-1999 1 323 55.9 46.0 - 65.8             948  21.9 17.9 - 25.9 
2000-2004 1 375 53.4 44.9 - 61.9          1,043  24.7 20.8 - 28.6 
2005-2009 1 382 73.0 63.5 - 82.5          1,146  25.7 13.0 - 38.3 
Italian registries                
1995-1999 25 1,384 58.0 54.0 - 61.9          4,711  33.2 31.3 - 35.1 
2000-2004 30 1,724 56.6 53.2 - 60.1          5,811  36.1 34.3 - 37.9 
2005-2009 30 1,104 62.9 57.6 - 68.3          3,448  38.4 32.5 - 44.2 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-
standardised. Where data for two or more calendar periods of diagnosis were merged, the net survival estimates are 
underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) 
were not included in the analysis. b Only microscopically verified tumours or tumours with a clinical diagnosis and a 
specific morphology code were included. c Endometrioid tumours are defined as type I epithelial.  d Serous tumours are 
defined as type II epithelial. e Number of patients included in the analysis for a given calendar period. The number of 
women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and 
updates from some registries. The number of patients in each time period may differ from the number shown in Table 
5.5 due to merging of calendar periods.   
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  Type I epithelial
c Type II epitheliald 
 
No. of 
registries 
No. of 
patientse NS (%) 95% CI 
No. of 
patientse NS (%) 95% CI 
Latvia*                
1995-1999 1 71 57.4 44.5 - 70.4          1,064  34.8 28.9 - 40.7 
2000-2004 1 104 50.2 39.0 - 61.3          1,013  37.5 32.4 - 42.5 
2005-2009 1 139 51.2 32.8 - 69.6             973  34.8 26.6 - 43.0 
Lithuania*                
1995-1999 1 116 43.5 31.2 - 55.7          1,367  31.7 27.6 - 35.8 
2000-2004 1 203 48.2 37.6 - 58.8          1,428  29.2 25.5 - 33.0 
2005-2009 1 295 52.4 40.3 - 64.5          1,346  25.3 14.5 - 36.1 
Malta*                
1995-1999 1 50 63.1 48.5 - 77.8               85  26.0 16.4 - 35.6 
2000-2004 1 - . .             113  32.2 22.4 - 42.0 
2005-2009 1 107 58.0 48.1 - 68.0             120  29.7 18.7 - 40.7 
Netherlands*                
1995-1999 1 1,714 49.7 45.8 - 53.6          4,484  27.7 25.8 - 29.5 
2000-2004 1 1,508 57.1 53.2 - 61.0          4,385  29.1 27.4 - 30.9 
2005-2009 1 1,437 56.4 47.4 - 65.5          4,631  28.1 19.0 - 37.1 
Norway*                
1995-1999 1 534 57.2 50.4 - 64.0          1,639  29.2 26.2 - 32.3 
2000-2004 1 534 65.8 60.0 - 71.7          1,783  33.8 30.9 - 36.7 
2005-2009 1 385 61.9 52.0 - 71.9          1,848  34.2 28.4 - 40.0 
Poland*                
1995-1999 4 683 45.4 36.6 - 54.1          2,177  30.9 27.1 - 34.7 
2000-2004 5 3,017 44.4 40.8 - 48.0          8,945  31.3 29.4 - 33.1 
2005-2009 5 3,455 52.5 48.0 - 57.1        10,206  31.3 28.1 - 34.5 
Portugal*                
1995-1999 1 120 50.8 38.9 - 62.8             392  30.0 23.7 - 36.4 
2000-2004 4 454 55.8 48.6 - 63.0          1,497  35.5 31.9 - 39.1 
2005-2009 4 419 68.4 60.8 - 76.1          1,388  36.3 29.0 - 43.6 
Romania (Cluj)                
1995-1999 - - . .  -  . . 
2000-2004 - - . .  -  . . 
2005-2009 1 47 68.0 52.3 - 83.7             129  49.7 33.8 - 65.7 
Russia (Arkhangelsk)                
1995-1999 - - . .  -  . . 
2000-2004 1 76 45.2 31.8 - 58.6             255  23.7 12.4 - 34.9 
2005-2009 1 76 56.5 37.8 - 75.2             202  32.3 17.0 - 47.7 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-
standardised. Where data for two or more calendar periods of diagnosis were merged, the net survival estimates are 
underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) 
were not included in the analysis. b Only microscopically verified tumours or tumours with a clinical diagnosis and a 
specific morphology code were included. c Endometrioid tumours are defined as type I epithelial.  d Serous tumours are 
defined as type II epithelial. e Number of patients included in the analysis for a given calendar period. The number of 
women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and 
updates from some registries. The number of patients in each time period may differ from the number shown in Table 
5.5 due to merging of calendar periods.   
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  Type I epithelial
c Type II epitheliald 
 
No. of 
registries 
No. of 
patientse NS (%) 95% CI 
No. of 
patientse NS (%) 95% CI 
Slovakia*                
1995-1999 - - . .  -  . . 
2000-2004 1 555 44.5 37.5 - 51.5          1,243  30.8 26.6 - 35.1 
2005-2009 1 351 47.6 35.1 - 60.1             868  29.5 23.8 - 35.1 
Slovenia*                
1995-1999 1 194 50.9 37.4 - 64.3             567  27.8 22.6 - 33.0 
2000-2004 1 236 59.8 50.4 - 69.3             604  30.4 25.0 - 35.9 
2005-2009 1 256 53.2 36.4 - 70.0             677  30.3 21.8 - 38.8 
Spanish registries                
1995-1999 10 890 55.0 50.1 - 59.9          1,591  28.5 25.1 - 31.9 
2000-2004 10 827 59.6 54.4 - 64.8          1,784  31.9 28.8 - 35.1 
2005-2009 10 674 49.7 39.7 - 59.6          1,675  35.7 31.2 - 40.3 
Sweden*                
1995-1999 1 - . .          4,062  40.3 38.3 - 42.3 
2000-2004 1 - . .          3,950  41.1 39.0 - 43.2 
2005-2009 1 - . .          3,729  35.0 26.7 - 43.3 
Swiss registries                
1995-1999 7 325 52.7 43.5 - 61.8          1,002  28.9 24.7 - 33.0 
2000-2004 7 285 57.4 49.8 - 65.1          1,013  31.7 28.0 - 35.4 
2005-2009 8 297 63.0 51.4 - 74.5          1,172  38.0 32.3 - 43.7 
United Kingdom*                
1995-1999 12 6,541 48.6 46.8 - 50.4        20,273  21.6 20.8 - 22.3 
2000-2004 12 6,371 54.3 52.5 - 56.1        22,233  22.7 22.0 - 23.4 
2005-2009 12 5,783 59.5 55.3 - 63.8        22,506  25.0 23.6 - 26.5 
OCEANIA 
Australian registries                
1995-1999 6 1,203 58.3 53.7 - 62.8          3,757  29.3 27.3 - 31.2 
2000-2004 6 1,161 62.5 58.0 - 66.9          4,363  30.2 28.4 - 32.0 
2005-2009 6 971 64.2 57.2 - 71.2          3,644  31.2 25.5 - 36.8 
New Zealand*                
1995-1999 1 353 51.1 42.6 - 59.6             789  23.8 19.8 - 27.8 
2000-2004 1 305 69.1 60.1 - 78.1             838  23.9 20.3 - 27.6 
2005-2009 1 288 40.5 19.4 - 61.6          1,027  23.4 14.3 - 32.6 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-
standardised. Where data for two or more calendar periods of diagnosis were merged, the net survival estimates are 
underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) 
were not included in the analysis. b Only microscopically verified tumours or tumours with a clinical diagnosis and a 
specific morphology code were included. c Endometrioid tumours are defined as type I epithelial.  d Serous tumours are 
defined as type II epithelial. e Number of patients included in the analysis for a given calendar period. The number of 
women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and 
updates from some registries. The number of patients in each time period may differ from the number shown in Table 
5.5 due to merging of calendar periods.   
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America (from 30.8% (16.3-45.2%) in Argentina to 77.1% (64.7-89.6%) in Colombia) for 
women diagnosed during 2005-2009. In Central and South America and North America 
age-standardised net survival from type I tumours increased over time in all countries for 
which data were available. In Asia, Europe, and Oceania, most countries saw an 
improvement in survival from type I tumours, but survival actually fell over time for some 
countries in these regions (from 66.3% to 59.3% in China, 52.7% to 46.3% in Germany and 
51.1% to 40.5% in New Zealand) [Table 5.3]. 
Type II epithelial 
Survival from type II epithelial tumours five years after diagnosis was lower than that of 
type I epithelial tumours, around only 20-40% [Figures 5.5 – 5.7]. For women diagnosed 
between 2005 and 2009, the highest age-standardised survival was seen in Hong Kong 
(61.5%, 54.8-68.2%), compared with only 18.1% (6.3-29.9%) for women in Chile (Los Rios) 
[Table 5.3]. 
Age-standardised survival from type II epithelial tumours increased over time for most 
countries worldwide, though there were decreases in some countries. In Cuba, for 
example, survival was 53.4% (45.1-61.7%) for women diagnosed during 1995-1999, but 
only 39.2% (29.3-49.1%) during 2005-2009. Between-country variation was widest in 
Central and South America, where age-standardised 5-year survival was only 18.1% (6.3-
29.9%) in Chile (Los Rios), but 55.0% (44.6-65.5%) in Ecuador (Quito). Type II epithelial 
was the only histological group for which survival estimates could be produced for all five 
African countries, but none of these estimates were age standardised. The number of 
women available in each of the African countries was small, and thus the confidence 
intervals for the survival estimates were wide. 
Continued on page 167 
164 
 
 
 
 
Figure 5.5 Five-year age-standardised net survival (%) for type II epithelial tumours, 
1995-1999
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*Data with 100% coverage of the national population. ˠ Estimate not age-standardised. 95% CI represented by error 
bars. Ranked from highest to lowest net survival by continent for men diagnosed in the calendar period of 2005-
2009. 
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Figure 5.6 Five-year age-standardised net survival (%) from type II epithelial tumours, 
2000-2004 
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*Data with 100% coverage of the national population. ˠ Estimate not age-standardised. ˢ Data for two or more 
calendar periods of diagnosis have been merged. 95% CI represented by error bars. Ranked from highest to lowest 
net survival by continent for women diagnosed in the calendar period of 2005-2009. 
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Figure 5.7 Five-year age-standardised net survival (%) from type II epithelial tumours, 
2005-2009 
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*Data with 100% coverage of the national population. ˠ Estimate not age-standardised. ˢ Data for two or more 
calendar periods of diagnosis have been merged. 95% CI represented by error bars. Ranked from highest to lowest 
net survival by continent for women diagnosed in the calendar period of 2005-2009. 
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Germ cell 
Survival from germ cell tumours could only be presented for all women diagnosed 
between 1995 and 2009 combined instead of for each calendar period separately, 
because these tumours are so uncommon. As a result, more than half the survival 
estimates for germ cell tumours were not age standardised (27 of 46 countries). This is 
because younger women have the highest incidence of germ cell tumours and this 
histological group is extremely rare in older women36,39. Therefore, only for a few 
countries were enough women available in each age group to allow for age 
standardisation. Considering the age-standardised estimates for all 15 years combined, 
the highest was seen in Australia (76.0%, 57.6-94.5%, n=367 women) and the lowest in 
China (41.5%, 23.6-59.4%, n=169 women) [Table 5.4]. 
Sex cord-stromal 
Sex cord-stromal tumours are also rare, and survival could only be estimated in each 
calendar period separately in 11 of 46 countries for all three calendar periods [Table 5.4]. 
During 2005-2009, age-standardised net survival was over 90% at 5 years after diagnosis 
in Korea (100.0%, 96.0-100.0%, n=207 women) and Portugal (94.1%, 83.3-100.0%, n=64 
women). However, survival varied widely between countries, and the lowest survival 
during the same period was almost half that seen in Korea (Japan, 58.9%, 34.2-83.7%, 
n=63 women). Of the 11 countries for which survival could be estimated for each calendar 
period separately, survival from sex cord-stromal tumours remained stable or increased 
over time in all countries except the Netherlands, where survival decreased from 83.6% 
(72.8-94.4%) in 1995-1999 to 70.9% (55.7-86.2%) in 2005-2009. 
Other specific non-epithelial  
Survival from other specific non-epithelial tumours was generally around 30-60%, slightly 
higher than that of type II epithelial tumours. The variation in age-standardised survival 
was wide, ranging from only 0.3% (0.0-0.8%) in Bulgaria (n=133) to 60.0% (48.4-71.5%) in 
Continued on page 183 
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Table 5.4 Five-year age-standardised net survival (NS, %) (95% CI) by histological group (non-epithelial tumours), country and calendar period, 1995-2009, 60 countries 
    Germ cell  Sex cord-stromal  Other specific 
  
Period of 
diagnosis 
No. of 
registries 
No. of 
patientsc NS (%) 95% CI  
No. of 
patientsc NS (%) 95% CI  
No. of 
patientsc 
NS 
(%) 95% CI 
AFRICA                                     
 Algerian registries                            
  1995-1999 - - . .  - . .  - . . 
  2000-2004 - - . .  - . .  - . . 
  2005-2009 2 - . .  10 60.0 28.0 - 92.0  - . . 
 Libya (Benghazi)                            
  1995-1999 - - . .  - . .  - . . 
  2000-2004 - - . .  - . .  - . . 
  2005-2009 1 - . .  - . .  - . . 
 Mauritius*                             
  1995-1999 - - . .  - . .  - . . 
  2000-2004 - - . .  - . .  - . . 
  2005-2009 1 - . .  - . .  - . . 
 South Africa (Eastern Cape)                            
  1995-1999 - - . .  - . .  - . . 
  2000-2004 - - . .  - . .  - . . 
  2005-2009 1 - . .  - . .  - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. 
b Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar 
period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of 
patients in each time period may differ from the number shown in Table 5.5 due to merging of calendar periods.   
169 
 
    Germ cell  Sex cord-stromal  Other specific 
  
Period of 
diagnosis 
No. of 
registries 
No. of 
patientsc NS (%) 95% CI  
No. of 
patientsc NS (%) 95% CI  
No. of 
patientsc 
NS 
(%) 95% CI 
 Tunisia (Central)                            
  1995-1999 - - . .  - . .  - . . 
  2000-2004 - - . .  - . .  - . . 
  2005-2009 1 - . .  - . .  - . . 
AMERICA (CENTRAL AND SOUTH)                                 
 Argentinian registries                            
  1995-1999 - - . .  - . .  - . . 
  2000-2004 3 - . .  - . .  - . . 
  2005-2009 3 34 80.9 61.3 - 100.0  19 74.4 50.1 - 98.8  14 55.5 27.7 - 83.3 
 Brazilian registries                            
  1995-1999 3 - . .  - . .  - . . 
  2000-2004 4 - . .  - . .  - . . 
  2005-2009 4 31 67.9 49.5 - 86.3  13 61.0 31.3 - 90.7  55 36.1 18.5 - 53.7 
 Chile (Los Rios)                            
  1995-1999 - - . .  - . .  - . . 
  2000-2004 - - . .  - . .  - . . 
  2005-2009 1 - . .  - . .  - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. 
b Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar 
period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of 
patients in each time period may differ from the number shown in Table 5.5 due to merging of calendar periods. 
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 Colombia (Cali)                            
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 44 76.5 57.7 - 95.2  28 54.1 31.8 - 76.3  26 74.0 51.6 - 96.4 
 Cuba*                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 73 70.9 60.2 - 81.5  85 76.6 66.3 - 86.9  93 60.0 48.4 - 71.5 
 Ecuador (Quito)                            
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 49 82.9 71.6 - 94.1  25 58.3 37.8 - 78.8  39 36.3 16.7 - 55.8 
 Puerto Rico*                             
  1995-1999 - - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 49 87.5 77.2 - 97.8  24 81.3 62.3 - 100.0  57 32.0 17.5 - 46.4 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. 
b Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar 
period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of 
patients in each time period may differ from the number shown in Table 5.5 due to merging of calendar periods.   
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AMERICA (NORTH)                                   
 Canada*                             
  1995-1999 13 - . .  128 87.4 76.0 - 98.8  251 39.4 29.3 - 49.4 
  2000-2004 13 - . .  114 89.9 76.6 - 100.0  247 41.9 33.9 - 49.9 
  2005-2009 13 693 70.8 57.2 - 84.5  133 87.1 73.0 - 100.0  276 45.4 35.5 - 55.3 
 US registries                             
  1995-1999 34 - . .  1,232 79.9 75.0 - 84.9  2,162 40.3 37.6 - 43.0 
  2000-2004 38 - . .  1,340 84.0 79.3 - 88.7  2,487 42.1 39.5 - 44.8 
  2005-2009 38 4,972 70.6 66.1 - 75.0  1,523 84.9 77.7 - 92.0  2,803 46.3 41.8 - 50.8 
ASIA                                     
 Chinese registries                            
  1995-1999 3 - . .  - . .  - . . 
  2000-2004 18 - . .  - . .  - . . 
  2005-2009 19 169 41.5 23.6 - 59.4  93 83.4 71.7 - 95.0  128 26.1 14.7 - 37.5 
 Cyprus*                             
  1995-1999 - - . .  - . .  - . . 
  2000-2004 - - . .  - . .  - . . 
  2005-2009 1 - . .  - . .  14 79.0 53.8 - 100.0 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. 
b Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar 
period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of 
patients in each time period may differ from the number shown in Table 5.5 due to merging of calendar periods.    
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 Hong Kong*                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 - . .  - . .  - . . 
 Indian registries                            
  1995-1999 2 - . .  13 90.8 65.4 - 100.0  - . . 
  2000-2004 - - . .  - . .  - . . 
  2005-2009 2 34 83.4 68.8 - 98.1  - . .  - . . 
 Indonesia (Jakarta)                            
  1995-1999 - - . .  - . .  - . . 
  2000-2004 - - . .  - . .  - . . 
  2005-2009 1 14 68.1 23.7 - 100.0  - . .  - . . 
 Israel*                             
  1995-1999 1 - . .  - . .  53 42.2 28.1 - 56.4 
  2000-2004 1 - . .  - . .  78 55.6 41.8 - 69.4 
  2005-2009 1 131 92.9 88.0 - 97.9  35 78.6 60.3 - 97.0  71 38.5 17.9 - 59.1 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. 
b Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar 
period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of 
patients in each time period may differ from the number shown in Table 5.5 due to merging of calendar periods.   
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 Japanese registries                            
  1995-1999 2 - . .  - . .  72 26.1 11.8 - 40.3 
  2000-2004 6 - . .  - . .  126 28.8 20.2 - 37.3 
  2005-2009 8 280 50.6 33.9 - 67.3  63 58.9 34.2 - 83.7  119 40.4 28.9 - 51.8 
 Jordan*                             
  1995-1999 - - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 53 . .  29 0.0 0.0 - 0.0  27 . . 
 Korea*                             
  1995-1999 1 - . .  123 74.3 61.1 - 87.5  - . . 
  2000-2004 1 - . .  215 88.9 81.4 - 96.5  71 51.0 39.0 - 63.0 
  2005-2009 1 1,130 72.4 58.3 - 86.5  207 100.0 96.0 - 100.0  64 73.0 60.2 - 85.8 
 Malaysia (Penang)                            
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 36 80.4 66.8 - 94.0  19 62.0 36.7 - 87.4  - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. 
b Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar 
period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of 
patients in each time period may differ from the number shown in Table 5.5 due to merging of calendar periods.    
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 Mongolia*                             
  1995-1999 - - . .  - . .  - . . 
  2000-2004 - - . .  - . .  - . . 
  2005-2009 1 - . .  - . .  - . . 
 Qatar*                             
  1995-1999 - - . .  - . .  - . . 
  2000-2004 - - . .  - . .  - . . 
  2005-2009 1 - . .  - . .  - . . 
 Saudi Arabia*                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 90 100.0 100.0 - 100.0  33 69.3 43.4 - 95.3  24 37.0 10.8 - 63.3 
  2005-2009 - - . .  - . .  - . . 
 Taiwan*                             
  1995-1999 1 - . .  65 82.3 72.1 - 92.5  183 41.7 32.3 - 51.0 
  2000-2004 1 - . .  93 88.8 81.0 - 96.7  277 39.4 28.5 - 50.3 
  2005-2009 1 689 57.4 46.0 - 68.7  126 85.0 68.0 - 100.0  252 43.5 35.3 - 51.7 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. 
b Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar 
period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of 
patients in each time period may differ from the number shown in Table 5.5 due to merging of calendar periods. 
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 Thai registries                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 3 - . .  - . .  - . . 
  2005-2009 3 76 88.0 79.7 - 96.3  38 79.3 59.7 - 99.0  22 21.1 2.2 - 39.9 
 Turkey (Izmir)                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 55 80.8 68.3 - 93.3  25 71.9 51.6 - 92.2  51 25.1 4.3 - 45.9 
EUROPE                                     
 Austria*                             
  1995-1999 2 - . .  63 78.2 66.6 - 89.8  83 35.1 22.2 - 48.0 
  2000-2004 2 - . .  67 65.8 49.8 - 81.8  86 35.9 22.7 - 49.1 
  2005-2009 2 187 69.7 51.4 - 88.0  64 86.7 75.0 - 98.5  93 43.9 28.3 - 59.5 
 Belgium*                             
  1995-1999 - - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 76 90.4 82.0 - 98.7  53 82.4 67.8 - 96.9  178 42.1 26.9 - 57.4 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. 
b Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar 
period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of 
patients in each time period may differ from the number shown in Table 5.5 due to merging of calendar periods. 
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 Bulgaria*                             
  1995-1999 1 - . .  155 63.8 54.5 - 73.1  73 32.9 19.9 - 45.8 
  2000-2004 1 - . .  142 80.2 70.5 - 89.9  104 30.5 18.7 - 42.3 
  2005-2009 1 123 42.5 25.5 - 59.4  166 64.4 48.0 - 80.9  133 0.3 0.0 - 0.8 
 Croatia*                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 61 78.4 67.1 - 89.6  64 76.4 62.9 - 90.0  44 32.4 17.1 - 47.8 
 Czech Republic*                            
  1995-1999 1 - . .  209 67.6 55.1 - 80.0  131 33.2 16.8 - 49.6 
  2000-2004 1 - . .  172 67.5 52.6 - 82.5  160 31.8 21.9 - 41.7 
  2005-2009 1 212 46.9 29.3 - 64.4  140 81.6 68.3 - 95.0  143 43.2 24.8 - 61.6 
 Denmark*                             
  1995-1999 1 - . .  - . .  78 35.2 22.7 - 47.7 
  2000-2004 1 - . .  - . .  58 32.5 24.0 - 41.0 
  2005-2009 1 125 47.2 33.5 - 61.0  96 73.3 55.5 - 91.1  74 47.9 34.0 - 61.8 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) were not included in the 
analysis. b Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given 
calendar period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The 
number of patients in each time period may differ from the number shown in Table 5.5 due to merging of calendar periods.   
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 Estonia*                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 25 67.7 48.5 - 86.9  87 71.0 59.5 - 82.5  57 39.2 24.0 - 54.4 
 Finland*                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 92 75.1 64.9 - 85.3  58 60.8 43.8 - 77.8  101 33.7 18.2 - 49.2 
 French registries                            
  1995-1999 10 - . .  - . .  87 43.3 28.9 - 57.6 
  2000-2004 10 - . .  55 98.9 92.6 - 100.0  - . . 
  2005-2009 10 114 78.1 70.1 - 86.1  - . .  107 44.6 35.3 - 53.9 
 German registries                            
  1995-1999 4 - . .  118 74.2 61.0 - 87.5  110 38.5 27.8 - 49.3 
  2000-2004 8 - . .  160 74.6 63.7 - 85.4  172 39.8 30.6 - 49.0 
  2005-2009 8 255 43.6 23.8 - 63.4  114 77.4 67.5 - 87.2  207 30.8 10.9 - 50.7 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. 
b Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar 
period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of 
patients in each time period may differ from the number shown in Table 5.5 due to merging of calendar periods. 
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 Iceland*                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 - . .  - . .  14 40.9 15.2 - 66.7 
 Ireland*                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 63 77.0 66.4 - 87.7  39 71.6 52.5 - 90.6  54 29.4 14.8 - 44.0 
 Italian registries                            
  1995-1999 25 - . .  83 65.7 46.1 - 85.4  298 34.8 27.4 - 42.2 
  2000-2004 30 - . .  - . .  383 39.0 32.9 - 45.1 
  2005-2009 30 234 62.3 46.0 - 78.5  125 66.4 54.8 - 78.0  234 37.1 26.3 - 47.9 
 Latvia*                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  79 65.1 53.3 - 76.9  - . . 
  2005-2009 1 45 47.7 32.0 - 63.4  75 65.2 51.3 - 79.1  75 36.4 22.9 - 49.8 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. 
b Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar 
period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of 
patients in each time period may differ from the number shown in Table 5.5 due to merging of calendar periods. 
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 Lithuania*                             
  1995-1999 1 - . .  58 79.4 65.4 - 93.3  - . . 
  2000-2004 1 - . .  - . .  94 27.9 15.3 - 40.6 
  2005-2009 1 61 76.1 64.5 - 87.6  91 87.5 79.0 - 95.9  53 30.5 12.0 - 48.9 
 Malta*                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 13 100.0 100.0 - 100.0  - . .  15 35.4 8.5 - 62.4 
 Netherlands*                             
  1995-1999 1 - . .  173 83.6 72.8 - 94.4  157 35.7 26.9 - 44.5 
  2000-2004 1 - . .  101 81.5 68.2 - 94.9  177 37.0 28.0 - 46.1 
  2005-2009 1 292 66.2 54.8 - 77.6  82 70.9 55.7 - 86.2  150 54.0 43.0 - 64.9 
 Norway*                             
  1995-1999 1 - . .  61 94.4 85.9 - 100.0  69 33.4 20.0 - 46.8 
  2000-2004 1 - . .  - . .  82 30.7 19.7 - 41.7 
  2005-2009 1 133 65.9 47.0 - 84.7  55 92.9 85.5 - 100.0  73 31.5 7.2 - 55.8 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. 
b Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar 
period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of 
patients in each time period may differ from the number shown in Table 5.5 due to merging of calendar periods.   
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 Poland*                             
  1995-1999 4 - . .  136 73.3 63.4 - 83.1  - . . 
  2000-2004 5 - . .  474 80.3 69.6 - 91.0  222 32.3 27.8 - 36.8 
  2005-2009 5 552 47.2 32.8 - 61.7  463 89.1 75.0 - 100.0  191 27.6 8.1 - 47.2 
 Portugal*                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 4 - . .  - . .  127 32.4 22.8 - 42.0 
  2005-2009 4 102 85.2 77.4 - 92.9  64 94.1 83.3 - 100.0  97 52.9 39.3 - 66.5 
 Romania (Cluj)                            
  1995-1999 - - . .  - . .  - . . 
  2000-2004 - - . .  - . .  - . . 
  2005-2009 1 - . .  - . .  - . . 
 Russia (Arkhangelsk)                            
  1995-1999 - - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 16 75.4 53.8 - 97.0  107 82.4 68.1 - 96.7  - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. 
b Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar 
period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of 
patients in each time period may differ from the number shown in Table 5.5 due to merging of calendar periods.   
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 Slovakia*                             
  1995-1999 - - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 70 81.3 70.5 - 92.0  100 71.0 54.4 - 87.5  100 35.5 23.0 - 48.1 
 Slovenia*                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 41 81.4 68.5 - 94.3  26 98.0 84.3 - 100.0  109 38.8 26.0 - 51.5 
 Spanish registries                            
  1995-1999 10 - . .  - . .  138 26.5 17.0 - 36.0 
  2000-2004 10 - . .  - . .  136 33.3 8.8 - 57.9 
  2005-2009 10 164 64.5 45.5 - 83.4  65 75.5 59.4 - 91.6  114 36.9 27.6 - 46.2 
 Sweden*                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
  2005-2009 1 - . .  - . .  64 14.6 4.9 - 24.3 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. 
b Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar 
period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of 
patients in each time period may differ from the number shown in Table 5.5 due to merging of calendar periods.    
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 Swiss registries                            
  1995-1999 7 - . .  - . .  - . . 
  2000-2004 7 - . .  - . .  80 42.9 29.8 - 56.0 
  2005-2009 8 62 88.9 76.0 - 100.0  39 77.5 60.1 - 94.9  82 55.5 40.6 - 70.4 
 United Kingdom*                            
  1995-1999 12 - . .  311 76.2 67.8 - 84.6  397 30.2 23.6 - 36.7 
  2000-2004 12 - . .  290 80.0 72.0 - 88.0  460 29.0 23.3 - 34.7 
  2005-2009 12 1,013 57.1 48.0 - 66.1  288 76.8 59.5 - 94.2  445 35.4 26.6 - 44.3 
OCEANIA                                     
 Australian registries                            
  1995-1999 6 - . .  71 74.9 58.9 - 90.9  130 40.1 28.3 - 52.0 
  2000-2004 6 - . .  - . .  144 43.3 31.0 - 55.7 
  2005-2009 6 367 76.0 57.6 - 94.5  92 69.6 56.7 - 82.6  132 32.4 13.9 - 51.0 
 New Zealand*                             
  1995-1999 1 - . .  - . .  - . . 
  2000-2004 1 - . .  - . .  - . . 
    2005-2009 1 106 92.4 86.3 - 98.6   48 76.8 62.3 - 91.3   102 40.1 24.4 - 55.9 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with data for fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. 
b Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar 
period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of 
patients in each time period may differ from the number shown in Table 5.5 due to merging of calendar periods.   
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Cuba (n=93). For only 16 of 45 countries could survival be estimated for all three calendar 
periods. Age-standardised net survival increased or remained stable in most countries, 
but decreases in survival were seen in Australia, Bulgaria, Germany, and Norway. The 
most striking decrease was seen in Bulgaria, where survival fell from 32.9% (19.9-45.8%) 
in 1995-1999 to only 0.3% (0.0-0.8%) in 2005-2009.   
Non-specific morphology 
Age-standardised net survival for tumours of non-specific morphology (ICD-O-3 codes 
8000-8004) was generally lower than that for all specific morphologies combined, with a 
few notable exceptions [Table 5.5]. During 2005-2009 in Turkey, survival from tumours 
with non-specific morphology was 42.8% (27.4-58.3%) while survival from tumours with 
a specific morphology was only 36.8% (20.3-53.3%). Survival from tumours of non-specific 
morphology was 57.4% (52.8-62.0%; n=62) while survival from tumours with a specific 
morphology was 35.0% (26.7-43.3%) in Sweden. Only for 12 of the 45 countries could 
survival be estimated for all three calendar periods. Over time, age-standardised survival 
for tumours of non-specific morphology decreased over time in most countries, with the 
largest decrease seen in Korea (from 44.3%, 29.5-59.0% in 1995-1999 to 25.0% (21.5-
28.5%) in 2005-2009). The largest increase in survival was seen in Austria (from 31.6% 
(21.0-42.1%) in 1995-1999 to 45.5% (37.5-53.6%) in 2005-2009).  
Tumours with missing morphology 
Tumours that were coded as microscopically verified but with missing ICD-O-3 
morphology (coded for CONCORD-2 as 9999) were included in the data submissions from 
Ireland (n=4), Italy (n=12), Latvia (n=271), Lithuania (n=298), Mongolia (n=98) and Russia 
(n=12) [Table 5.5]. Survival was estimated for all these countries except for Ireland, 
because fewer than 10 women were available for analysis. The was a wide range in age-
standardised survival during 2005-2009, from only 17.9% (4.5-31.4%) in Latvia to 48.2% 
(30.0-66.3%) in Mongolia. In Latvia, the only country for which age-standardised survival  
Continued on page 199 
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Table 5.5 Five-year age-standardised net survival (NS, %) (95% CI) by country and calendar period for all tumours, tumours of specific morphology, tumours 
of non-specific morphology and tumours with missing morphology, 1995-2009, 60 countries 
    All tumours Specific morphology Non-specific morphology Missing morphology 
   
No. of 
registries 
NS 
(%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
No. of 
patientsc NS (%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
AFRICA                                    
 Algerian registries                              
  1995-1999 - . . - . . - . . - . . 
  2000-2004 - . . - . . - . . - . . 
  2005-2009 2 30.8 17.9 - 43.8 122 30.8 17.9 - 43.8 - . . - . . 
 Libya (Benghazi)                              
  1995-1999 - . . - . . - . . - . . 
  2000-2004 - . . - . . - . . - . . 
  2005-2009 1 5.6 0.0 - 13.5 44 5.6 0.0 - 13.5 - . . - . . 
 Mauritius*                              
  1995-1999 - . . - . . - . . - . . 
  2000-2004 - . . - . . - . . - . . 
  2005-2009 1 73.5 57.7 - 89.3 25 73.9 52.9 - 94.8 19 74.4 51.9 - 96.9 - . . 
 South Africa (Eastern Cape)                             
  1995-1999 - . . - . . - . . - . . 
  2000-2004 - . . - . . - . . - . . 
  2005-2009 1 100.0 86.1 - 100.0 20 100.0 86.1 - 100.0 - . . - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. b Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar period. 
The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of patients in 
each time period may differ from the number shown in Tables 5.3 and 5.4 due to merging of calendar periods.   
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    All tumours Specific morphology Non-specific morphology Missing morphology 
   
No. of 
registries 
NS 
(%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
No. of 
patientsc NS (%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
 Tunisia (Central)                              
  1995-1999 - . . - . . - . . - . . 
  2000-2004 - . . - . . - . . - . . 
  2005-2009 1 47.3 25.0 - 69.6 21 47.3 25.0 - 69.6 - . . - . . 
AMERICA (CENTRAL AND SOUTH)                                       
 Argentinian registries                             
  1995-1999 - . . - . . - . . - . . 
  2000-2004 3 26.7 15.5 - 37.9 172 28.4 16.6 - 40.1 - . . - . . 
  2005-2009 3 30.9 23.3 - 38.5 566 31.4 23.7 - 39.2 42 27.8 12.4 - 43.2 - . . 
 Brazilian registries                              
  1995-1999 3 34.6 24.4 - 44.8 167 34.7 24.5 - 45.0 - . . - . . 
  2000-2004 4 41.0 34.1 - 47.8 425 40.5 33.5 - 47.4 - . . - . . 
  2005-2009 4 31.7 20.5 - 42.9 245 31.3 20.2 - 42.4 17 76.4 53.1 - 99.7 - . . 
 Chile (Los Rios)                              
  1995-1999 - . . - . . - . . - . . 
  2000-2004 1 33.1 21.2 - 45.1 57 38.9 25.7 - 52.0 - . . - . . 
  2005-2009 1 41.4 24.9 - 57.8 74 37.3 20.9 - 53.7 - . . - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. b Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar period. 
The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of patients in 
each time period may differ from the number shown in Tables 5.3 and 5.4 due to merging of calendar periods.  
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    All tumours Specific morphology Non-specific morphology Missing morphology 
   
No. of 
registries 
NS 
(%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
No. of 
patientsc NS (%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
 Colombia (Cali)                              
  1995-1999 1 32.4 22.9 - 41.9 291 31.9 22.3 - 41.5 - . . - . . 
  2000-2004 1 34.0 17.5 - 50.5 326 33.9 17.4 - 50.3 - . . - . . 
  2005-2009 1 42.3 31.7 - 53.0 327 43.0 32.2 - 53.8 30 40.0 20.7 - 59.2 - . . 
 Cuba*                              
  1995-1999 1 58.1 50.7 - 65.6 442 58.8 51.2 - 66.4 - . . - . . 
  2000-2004 1 46.6 42.5 - 50.8 1,394 48.2 43.9 - 52.5 - . . - . . 
  2005-2009 1 51.8 44.6 - 59.0 554 51.0 43.7 - 58.2 89 30.8 19.4 - 42.2 - . . 
 Ecuador (Quito)                              
  1995-1999 1 34.5 21.1 - 47.9 181 35.0 21.5 - 48.6 - . . - . . 
  2000-2004 1 46.9 35.6 - 58.2 202 46.7 35.3 - 58.2 - . . - . . 
  2005-2009 1 46.6 30.2 - 63.1 260 42.5 24.0 - 61.0 24 51.7 27.3 - 76.1 - . . 
 Puerto Rico*                              
  1995-1999 - . . - . . - . . - . . 
  2000-2004 1 35.4 29.8 - 41.0 622 34.3 28.5 - 40.1 - . . - . . 
  2005-2009 1 41.2 32.8 - 49.6 662 41.9 33.4 - 50.5 52 55.6 40.7 - 70.6 - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. b Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar period. 
The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of patients in 
each time period may differ from the number shown in Tables 5.3 and 5.4 due to merging of calendar periods.   
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    All tumours Specific morphology Non-specific morphology Missing morphology 
   
No. of 
registries 
NS 
(%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
No. of 
patientsc NS (%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
AMERICA (NORTH)                                         
 Canada*                              
  1995-1999 13 37.1 35.9 - 38.4 10,292 37.1 35.9 - 38.4 74 36.3 24.1 - 48.6 - . . 
  2000-2004 13 38.1 36.9 - 39.3 11,263 38.2 37.0 - 39.5 84 22.0 12.4 - 31.5 - . . 
  2005-2009 12 41.9 39.3 - 44.5 12,105 42.0 39.4 - 44.6 91 30.1 21.7 - 38.5 - . . 
 US registries                              
  1995-1999 34 39.8 39.3 - 40.3 76,288 39.9 39.4 - 40.3 805 33.2 28.2 - 38.2 - . . 
  2000-2004 38 40.6 40.2 - 41.1 89,319 40.8 40.3 - 41.2 1,108 30.0 26.4 - 33.6 - . . 
  2005-2009 38 42.2 40.7 - 43.6 93,582 42.4 40.9 - 43.8 1,120 29.8 22.1 - 37.5 - . . 
ASIA                                           
 Chinese registries                              
  1995-1999 3 42.3 31.3 - 53.4 115 41.6 29.8 - 53.3 - . . - . . 
  2000-2004 18 48.3 42.0 - 54.6 1,024 48.7 42.1 - 55.3 115 44.6 34.7 - 54.5 - . . 
  2005-2009 19 46.8 41.2 - 52.4 2,991 47.2 40.9 - 53.5 175 35.2 21.6 - 48.7 - . . 
 Cyprus*                              
  1995-1999 - . . - . . - . . - . . 
  2000-2004 - . . - . . - . . - . . 
  2005-2009 1 44.2 28.7 - 59.7 254 44.2 28.7 - 59.7 - . . - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. b Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar period. 
The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of patients in 
each time period may differ from the number shown in Tables 5.3 and 5.4 due to merging of calendar periods.  
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    All tumours Specific morphology Non-specific morphology Missing morphology 
   
No. of 
registries 
NS 
(%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
No. of 
patientsc NS (%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
                   
 Hong Kong*                              
  1995-1999 1 41.9 34.3 - 49.4 527 41.9 34.3 - 49.4 - . . - . . 
  2000-2004 1 46.6 41.2 - 52.0 1,012 46.6 41.2 - 52.0 - . . - . . 
  2005-2009 1 66.6 59.2 - 74.1 437 66.6 59.2 - 74.1 - . . - . . 
 Indian registries                              
  1995-1999 2 22.2 14.7 - 29.7 338 24.2 15.4 - 33.0 - . . - . . 
  2000-2004 - . . - . . - . . - . . 
  2005-2009 2 17.3 10.2 - 24.4 72 20.1 11.8 - 28.4 68 14.2 3.7 - 24.7 - . . 
 Indonesia (Jakarta)                              
  1995-1999 - . . - . . - . . - . . 
  2000-2004 - . . - . . - . . - . . 
  2005-2009 1 59.9 44.3 - 75.5 173 59.9 44.3 - 75.5 - . . - . . 
 Israel*                              
  1995-1999 1 40.1 36.4 - 43.8 1,633 40.1 36.2 - 43.9 57 42.3 28.4 - 56.3 - . . 
  2000-2004 1 41.0 37.6 - 44.4 1,860 40.8 37.3 - 44.4 61 44.4 30.4 - 58.3 - . . 
  2005-2009 1 28.8 11.6 - 45.9 1,895 29.2 11.7 - 46.6 62 20.1 3.1 - 37.1 - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. b Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar period. 
The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of patients in 
each time period may differ from the number shown in Tables 5.3 and 5.4 due to merging of calendar periods.   
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    All tumours Specific morphology Non-specific morphology Missing morphology 
   
No. of 
registries 
NS 
(%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
No. of 
patientsc NS (%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
 Japanese registries                              
  1995-1999 2 30.3 26.5 - 34.1 1,641 31.9 27.8 - 36.0 149 18.2 10.7 - 25.8 - . . 
  2000-2004 6 37.0 34.3 - 39.7 2,989 38.4 35.6 - 41.2 135 16.0 7.9 - 24.2 - . . 
  2005-2009 8 42.2 35.7 - 48.7 3,514 42.9 36.2 - 49.5 133 27.2 15.4 - 39.0 - . . 
 Jordan*                              
  1995-1999 - . . - . . - . . - . . 
  2000-2004 1 17.2 6.8 - 27.6 298 17.8 7.1 - 28.6 - . . - . . 
  2005-2009 1 0.0 0.0 - 0.0 372 0.0 0.0 - 0.0 17 . . - . . 
 Korea*                              
  1995-1999 1 48.2 44.4 - 52.0 4,430 48.6 44.8 - 52.4 96 44.3 29.5 - 59.0 - . . 
  2000-2004 1 48.4 45.2 - 51.5 5,933 48.8 45.6 - 52.0 103 35.4 24.2 - 46.6 - . . 
  2005-2009 1 47.4 42.6 - 52.2 7,725 48.0 43.3 - 52.8 134 25.0 21.5 - 28.5 - . . 
 Malaysia (Penang)                              
  1995-1999 1 56.5 43.8 - 69.3 142 56.5 43.8 - 69.3 - . . - . . 
  2000-2004 1 45.4 35.0 - 55.7 216 45.4 35.0 - 55.7 - . . - . . 
  2005-2009 1 53.5 38.9 - 68.1 278 53.5 38.9 - 68.1 - . . - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. b Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar period. 
The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of patients in 
each time period may differ from the number shown in Tables 5.3 and 5.4 due to merging of calendar periods.   
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    All tumours Specific morphology Non-specific morphology Missing morphology 
   
No. of 
registries 
NS 
(%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
No. of 
patientsc NS (%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
 Mongolia*                              
  1995-1999 - . . - . . - . . - . . 
  2000-2004 - . . - . . - . . - . . 
  2005-2009 1 55.5 41.5 - 69.5 52 68.3 51.2 - 85.3 - . . 98 48.2 30.0 - 66.3 
 Qatar*                              
  1995-1999 - . . - . . - . . - . . 
  2000-2004 - . . - . . - . . - . . 
  2005-2009 1 31.9 6.7 - 57.1 22 31.9 6.7 - 57.1 - . . - . . 
 Saudi Arabia*                              
  1995-1999 1 49.7 31.2 - 68.2 384 50.9 32.1 - 69.8 - . . - . . 
  2000-2004 1 42.4 28.8 - 56.1 546 42.4 28.7 - 56.0 15 70.4 43.3 - 97.5 - . . 
  2005-2009 - . . - . . - . . - . . 
 Taiwan*                              
  1995-1999 1 45.6 41.4 - 49.8 2,738 45.6 41.3 - 49.9 - . . - . . 
  2000-2004 1 45.3 42.2 - 48.5 3,947 45.2 42.0 - 48.5 - . . - . . 
  2005-2009 1 43.4 29.3 - 57.4 5,138 43.4 29.4 - 57.4 108 42.1 28.1 - 56.2 - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. b Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar period. 
The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of patients in 
each time period may differ from the number shown in Tables 5.3 and 5.4 due to merging of calendar periods. 
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    All tumours Specific morphology Non-specific morphology Missing morphology 
   
No. of 
registries 
NS 
(%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
No. of 
patientsc NS (%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
 Thai registries                              
  1995-1999 1 46.3 31.0 - 61.6 170 46.6 31.2 - 62.1 - . . - . . 
  2000-2004 3 39.2 25.8 - 52.6 467 40.1 26.5 - 53.7 - . . - . . 
  2005-2009 3 47.3 39.0 - 55.5 537 48.5 40.1 - 56.9 24 20.2 0.2 - 40.3 - . . 
 Turkey (Izmir)                              
  1995-1999 1 41.0 23.4 - 58.6 379 41.4 23.7 - 59.2 - . . - . . 
  2000-2004 1 47.5 38.5 - 56.5 508 47.5 38.0 - 57.1 - . . - . . 
  2005-2009 1 36.6 20.2 - 52.9 667 36.8 20.3 - 53.3 62 42.8 27.4 - 58.3 - . . 
EUROPE                                         
 Austria*                              
  1995-1999 2 42.5 40.3 - 44.7 4,202 42.8 40.5 - 45.0 129 31.6 21.0 - 42.1 - . . 
  2000-2004 2 40.7 38.6 - 42.7 3,969 40.7 38.6 - 42.9 211 41.7 31.6 - 51.9 - . . 
  2005-2009 2 43.3 39.5 - 47.0 3,500 43.7 39.9 - 47.6 153 45.5 37.5 - 53.6 - . . 
 Belgium*                              
  1995-1999 - . . - . . - . . - . . 
  2000-2004 1 42.8 38.6 - 47.0 936 43.1 38.9 - 47.4 - . . - . . 
  2005-2009 1 42.5 38.6 - 46.4 4,676 42.6 38.7 - 46.5 56 17.4 4.7 - 30.1 - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. b Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar period. 
The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of patients in 
each time period may differ from the number shown in Tables 5.3 and 5.4 due to merging of calendar periods.  
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    All tumours Specific morphology Non-specific morphology Missing morphology 
   
No. of 
registries 
NS 
(%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
No. of 
patientsc NS (%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
 Bulgaria*                              
  1995-1999 1 33.3 29.4 - 37.3 2,755 34.0 30.0 - 38.0 - . . - . . 
  2000-2004 1 38.5 35.4 - 41.5 3,305 39.2 36.2 - 42.3 63 11.6 3.8 - 19.4 - . . 
  2005-2009 1 36.0 30.2 - 41.8 3,878 36.6 30.7 - 42.6 92 0.2 0.0 - 0.8 - . . 
 Croatia*                              
  1995-1999 1 38.4 32.0 - 44.8 764 38.7 32.3 - 45.1 - . . - . . 
  2000-2004 1 38.5 35.0 - 42.1 1,990 38.4 34.8 - 42.0 - . . - . . 
  2005-2009 1 33.6 26.8 - 40.4 1,919 33.5 26.6 - 40.4 26 31.4 11.7 - 51.0 - . . 
 Czech Republic*                              
  1995-1999 1 34.8 32.5 - 37.2 5,085 35.5 33.1 - 38.0 138 10.8 4.1 - 17.5 - . . 
  2000-2004 1 36.8 34.8 - 38.9 5,344 37.5 35.5 - 39.6 158 16.8 8.1 - 25.5 - . . 
  2005-2009 1 43.2 40.0 - 46.4 5,060 44.2 40.9 - 47.5 160 15.2 10.4 - 20.1 - . . 
 Denmark*                              
  1995-1999 1 31.8 29.5 - 34.1 3,045 31.9 29.6 - 34.2 - . . - . . 
  2000-2004 1 33.8 31.3 - 36.2 2,953 33.9 31.4 - 36.4 38 13.0 0.8 - 25.3 - . . 
  2005-2009 1 37.5 31.5 - 43.5 2,903 37.9 31.8 - 43.9 117 29.2 17.1 - 41.3 - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. b Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar period. 
The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of patients in 
each time period may differ from the number shown in Tables 5.3 and 5.4 due to merging of calendar periods. 
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    All tumours Specific morphology Non-specific morphology Missing morphology 
   
No. of 
registries 
NS 
(%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
No. of 
patientsc NS (%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
 Estonia*                              
  1995-1999 1 28.6 22.0 - 35.3 712 30.7 23.7 - 37.8 80 11.4 1.0 - 21.8 - . . 
  2000-2004 1 33.3 27.8 - 38.8 658 35.9 30.0 - 41.7 - . . - . . 
  2005-2009 1 36.5 28.3 - 44.6 581 37.8 29.4 - 46.3 84 10.5 1.3 - 19.8 - . . 
 Finland*                              
  1995-1999 1 40.2 37.1 - 43.4 2,242 41.4 38.2 - 44.6 83 5.5 0.4 - 10.7 - . . 
  2000-2004 1 42.3 39.3 - 45.2 2,408 43.3 40.2 - 46.3 104 12.9 5.7 - 20.2 - . . 
  2005-2009 1 51.6 47.5 - 55.7 2,367 53.4 49.1 - 57.6 118 . . - . . 
 French registries                              
  1995-1999 10 34.3 31.4 - 37.1 2,470 34.4 31.6 - 37.3 - . . - . . 
  2000-2004 10 40.4 38.0 - 42.9 2,837 40.6 38.1 - 43.1 - . . - . . 
  2005-2009 8 29.9 10.9 - 48.8 241 29.9 10.9 - 48.8 59 15.7 5.7 - 25.7 - . . 
 German registries                              
  1995-1999 4 38.0 36.2 - 39.8 5,193 38.2 36.3 - 40.0 102 29.9 20.2 - 39.6 - . . 
  2000-2004 8 40.7 39.4 - 42.1 8,922 40.9 39.6 - 42.3 125 22.6 14.8 - 30.5 - . . 
  2005-2009 8 38.3 35.3 - 41.3 10,463 38.3 35.2 - 41.4 103 25.2 14.3 - 36.2 - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. b Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar period. 
The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of patients in 
each time period may differ from the number shown in Tables 5.3 and 5.4 due to merging of calendar periods. 
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    All tumours Specific morphology Non-specific morphology Missing morphology 
   
No. of 
registries 
NS 
(%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
No. of 
patientsc NS (%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
 Iceland*                              
  1995-1999 1 25.7 12.7 - 38.8 108 25.7 12.7 - 38.8 - . . - . . 
  2000-2004 1 34.6 17.8 - 51.5 124 34.6 17.8 - 51.5 - . . - . . 
  2005-2009 1 42.9 27.9 - 58.0 117 42.9 27.9 - 58.0 - . . - . . 
 Ireland*                              
  1995-1999 1 29.4 25.6 - 33.3 1,317 29.7 25.8 - 33.6 - . . - . . 
  2000-2004 1 30.9 27.3 - 34.6 1,461 31.1 27.5 - 34.8 - . . - . . 
  2005-2009 1 32.3 17.2 - 47.5 1,595 32.5 17.3 - 47.7 43 8.5 0.0 - 17.1 - . . 
 Italian registries                              
  1995-1999 25 38.3 36.6 - 39.9 6,561 38.7 37.0 - 40.4 211 29.4 17.3 - 41.4 - . . 
  2000-2004 30 40.0 38.6 - 41.5 8,085 40.8 39.3 - 42.4 309 20.4 14.2 - 26.6 - . . 
  2005-2009 29 43.6 40.0 - 47.3 4,893 44.3 40.6 - 48.0 194 25.1 18.9 - 31.4 12 8.6 0.0 - 21.8 
 Latvia*                              
  1995-1999 1 32.8 27.7 - 37.8 1,219 36.1 30.6 - 41.6 - . . 133 9.1 6.2 - 12.0 
  2000-2004 1 36.7 31.9 - 41.4 1,196 39.1 34.2 - 44.1 - . . 81 14.6 8.3 - 20.9 
  2005-2009 1 35.9 28.9 - 42.9 1,223 37.2 29.9 - 44.5 19 27.8 7.2 - 48.4 57 17.9 4.5 - 31.4 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. b Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar period. 
The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of patients in 
each time period may differ from the number shown in Tables 5.3 and 5.4 due to merging of calendar periods. 
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    All tumours Specific morphology Non-specific morphology Missing morphology 
   
No. of 
registries 
NS 
(%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
No. of 
patientsc NS (%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
 Lithuania*                              
  1995-1999 1 31.3 27.7 - 34.8 1,593 33.7 29.8 - 37.6 - . . 204 22.9 13.1 - 32.6 
  2000-2004 1 33.0 29.7 - 36.3 1,755 33.3 29.9 - 36.7 - . . - . . 
  2005-2009 1 31.5 24.0 - 39.1 1,764 31.5 23.5 - 39.6 79 18.3 9.1 - 27.4 94 33.4 18.1 - 48.7 
 Malta*                              
  1995-1999 1 33.3 17.5 - 49.1 145 33.6 17.6 - 49.5 - . . - . . 
  2000-2004 1 38.0 28.2 - 47.9 180 41.3 30.9 - 51.8 - . . - . . 
  2005-2009 1 36.0 27.8 - 44.2 178 38.0 29.5 - 46.5 27 4.1 0.0 - 10.5 - . . 
 Netherlands*                              
  1995-1999 1 35.0 33.3 - 36.7 6,616 35.1 33.4 - 36.8 - . . - . . 
  2000-2004 1 36.7 35.0 - 38.3 6,280 36.7 35.1 - 38.3 - . . - . . 
  2005-2009 1 34.6 23.7 - 45.5 6,395 34.6 23.7 - 45.6 25 . . - . . 
 Norway*                              
  1995-1999 1 37.6 34.8 - 40.4 2,340 37.3 34.6 - 40.1 - . . - . . 
  2000-2004 1 41.3 38.8 - 43.9 2,477 41.3 38.7 - 43.9 - . . - . . 
  2005-2009 1 38.1 32.9 - 43.3 2,379 38.2 33.0 - 43.4 84 39.7 25.4 - 54.1 - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. b Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar period. 
The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of patients in 
each time period may differ from the number shown in Tables 5.3 and 5.4 due to merging of calendar periods. 
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    All tumours Specific morphology Non-specific morphology Missing morphology 
   
No. of 
registries 
NS 
(%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
No. of 
patientsc NS (%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
 Poland*                              
  1995-1999 4 35.1 31.5 - 38.7 3,094 35.5 31.8 - 39.2 64 21.9 11.4 - 32.5 - . . 
  2000-2004 5 35.5 33.8 - 37.1 12,861 35.8 34.1 - 37.4 253 21.9 14.9 - 28.9 - . . 
  2005-2009 5 36.9 34.2 - 39.5 14,566 37.2 34.5 - 39.9 271 22.9 15.8 - 30.0 - . . 
 Portugal*                              
  1995-1999 1 35.9 30.5 - 41.3 574 35.9 30.5 - 41.3 - . . - . . 
  2000-2004 4 40.4 37.3 - 43.5 2,128 40.6 37.5 - 43.7 - . . - . . 
  2005-2009 4 43.1 36.5 - 49.7 1,958 43.2 36.6 - 49.8 45 35.2 20.6 - 49.9 - . . 
 Romania (Cluj)                              
  1995-1999 - . . - . . - . . - . . 
  2000-2004 - . . - . . - . . - . . 
  2005-2009 1 . . 176 54.6 40.7 - 68.5 - . . - . . 
 Russia (Arkhangelsk)                              
  1995-1999 - . . - . . - . . - . . 
  2000-2004 1 33.2 23.0 - 43.5 401 33.9 21.8 - 46.1 - . . - . . 
  2005-2009 1 35.3 23.0 - 47.6 331 43.0 29.3 - 56.8 107 14.5 5.4 - 23.6 12 33.0 5.1 - 61.0 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. b Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar period. 
The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of patients in 
each time period may differ from the number shown in Tables 5.3 and 5.4 due to merging of calendar periods. 
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    All tumours Specific morphology Non-specific morphology Missing morphology 
   
No. of 
registries 
NS 
(%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
No. of 
patientsc NS (%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
 Slovakia*                              
  1995-1999 - . . - . . - . . - . . 
  2000-2004 1 35.8 32.4 - 39.3 1,958 36.3 32.8 - 39.8 - . . - . . 
  2005-2009 1 35.7 30.7 - 40.8 1,329 35.9 30.7 - 41.0 35 9.2 0.0 - 18.9 - . . 
 Slovenia*                              
  1995-1999 1 34.3 29.5 - 39.1 820 34.4 29.6 - 39.2 - . . - . . 
  2000-2004 1 38.9 34.3 - 43.6 905 39.2 34.5 - 43.9 - . . - . . 
  2005-2009 1 35.5 27.3 - 43.8 985 35.6 27.3 - 43.8 11 9.8 0.0 - 24.1 - . . 
 Spanish registries                              
  1995-1999 10 36.9 34.3 - 39.6 2,695 37.0 34.3 - 39.7 - . . - . . 
  2000-2004 10 39.9 37.3 - 42.6 2,832 40.1 37.4 - 42.8 - . . - . . 
  2005-2009 10 39.8 35.7 - 44.0 2,531 40.1 35.9 - 44.3 85 22.1 12.5 - 31.6 - . . 
 Sweden*                              
  1995-1999 1 40.9 39.0 - 42.8 4,096 40.1 38.1 - 42.0 373 48.9 40.1 - 57.7 - . . 
  2000-2004 1 42.8 40.9 - 44.7 3,963 41.0 39.0 - 43.1 408 59.6 52.9 - 66.2 - . . 
  2005-2009 1 38.4 31.5 - 45.3 3,746 35.0 26.7 - 43.3 380 57.4 52.8 - 62.0 - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. b Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar period. 
The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of patients in 
each time period may differ from the number shown in Tables 5.3 and 5.4 due to merging of calendar periods. 
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    All tumours Specific morphology Non-specific morphology Missing morphology 
   
No. of 
registries 
NS 
(%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
No. of 
patientsc NS (%) 95% CI 
No. of 
patientsc 
NS 
(%) 95% CI 
 Swiss registries                              
  1995-1999 7 35.7 32.0 - 39.3 1,409 35.6 31.9 - 39.3 - . . - . . 
  2000-2004 7 36.8 33.6 - 40.1 1,371 37.0 33.7 - 40.2 - . . - . . 
  2005-2009 8 43.7 38.5 - 48.9 1,577 43.8 38.5 - 49.0 13 19.3 0.0 - 40.5 - . . 
 UK*                               
  1995-1999 12 28.6 27.8 - 29.3 27,828 28.6 27.8 - 29.3 242 31.0 21.5 - 40.4 - . . 
  2000-2004 12 30.1 29.3 - 30.8 29,684 30.1 29.4 - 30.8 266 25.9 18.2 - 33.6 - . . 
  2005-2009 12 32.3 30.8 - 33.8 29,399 32.3 30.8 - 33.8 301 28.6 22.5 - 34.8 - . . 
OCEANIA                                         
 Australian registries                         - . . 
  1995-1999 6 36.5 34.7 - 38.4 5,263 36.6 34.7 - 38.4 - . . - . . 
  2000-2004 6 37.2 35.5 - 38.9 5,860 37.2 35.5 - 39.0 - . . - . . 
  2005-2009 6 39.4 35.5 - 43.2 4,912 39.5 35.7 - 43.4 95 22.4 12.4 - 32.4      
 New Zealand*                              
  1995-1999 1 32.6 28.9 - 36.4 1,217 32.4 28.5 - 36.2 - . . - . . 
  2000-2004 1 35.6 31.9 - 39.3 1,235 35.7 32.0 - 39.4 - . . - . . 
    2005-2009 1 27.8 20.1 - 35.5 1,404 28.7 20.7 - 36.7 74 34.7 22.8 - 46.6 - . . 
*Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were 
merged, the net survival estimates are underlined. a Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included in the analysis. b Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code were included. c Number of patients included in the analysis for a given calendar period. 
The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from some registries. The number of patients in 
each time period may differ from the number shown in Tables 5.3 and 5.4 due to merging of calendar periods.  
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could be estimated for all three calendar periods, survival increased over time from 9.1% 
(6.2-12.0%) to 17.9% (4.5-31.4%).  
5.3.2 Histological group by sub-site 
Tumours of the anatomic ovary were the most common sub-site (628,582, 90.3%) 
compared to peritoneal tumours (41,333, 5.9%) and fallopian tube tumours (26,017, 
3.7%). Survival for each histological group varied with the different topographical sub-
sites. Survival by histological group for each sub-site was estimated for the UK and the US 
separately. The mean age at diagnosis for women with peritoneal cancer was 66 years, 
while the mean age at diagnosis for women with a tumour of the ovary itself was 63 years, 
and 65 years for women with fallopian tube cancer. For type I and type II epithelial 
tumours, women diagnosed with peritoneal cancer had lower survival than women 
diagnosed with a tumour of the ovary or fallopian tube in both countries [Table 5.6]. 
During 2005-2009, five-year age-standardised net survival for type I epithelial tumours 
was only 38.3% (28.5-48.2%) for peritoneal cancer, but as high as 66.5% (64.3-68.6%) for 
tumours of the anatomic ovary and 70.8% (62.3-79.3%) for tumours of the fallopian tube 
in the US. In the UK, survival from type I epithelial tumours of the fallopian tube diagnosed 
during 2005-2009 was lower than that for tumours of the ovary (52.6% (31.8-73.4%) 
versus 60.1% (55.8-64.4%)). A similar pattern was seen for type II epithelial tumours in 
both countries, with survival ranging from 14.7% (10.4-19.0%) for peritoneal cancer 
during 2005-2009 to 53.3% (44.2-62.4%) for fallopian tube tumours during the same time 
period in the UK, and from 31.9% (28.8-35.1%) for peritoneal tumours to 53.6% (48.2-
59.0%) for fallopian tube tumours in the US.  
For germ cell tumours, occurrence in the fallopian tube was extremely rare and survival 
could not be age-standardised for either country. Unstandardised survival was high in 
both countries. For germ cell tumours of the peritoneum, age-standardised survival 
during 2005-2009 in the US was 73.4% (58.8-88.0%). The survival estimate for peritoneal  
Continued on page 203 
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Table 5.6 Five-year age-standardised net survival (NS, %) (95% CI) by sub-site, histological group, country and calendar period, United Kingdom and 
United States, 1995-2009 
 Fallopian tube  Peritoneum  Ovary 
 No NS (%) 95% CI  N NS (%) 95% CI  N NS (%) 95% CI 
Type I epithelial                                   
United Kingdom                            
1995-1999 97 45.0 30.8 - 59.3  - . -  6,414 48.9 47.1 - 50.7 
2000-2004 97 51.1 36.7 - 65.5  58 20.2 12.9 - 27.5  6,246 54.5 52.7 - 56.3 
2005-2009 129 52.6 31.8 - 73.4  73 40.1 23.0 - 57.2  5,581 60.1 55.8 - 64.4 
United States                            
1995-1999 387 63.4 55.7 - 71.1  164 36.6 27.0 - 46.2  17,404 58.5 57.3 - 59.7 
2000-2004 533 65.9 59.6 - 72.1  217 35.8 26.9 - 44.8  18,470 62.0 60.9 - 63.2 
2005-2009 613 70.8 62.3 - 79.3  277 38.3 28.5 - 48.2  17,144 66.5 64.3 - 68.6 
Type II epithelial                                  
United Kingdom                            
1995-1999 427 43.2 36.5 - 49.9  323 15.9 11.1 - 20.6  19,523 21.2 20.5 - 22.0 
2000-2004 450 44.3 38.6 - 50.0  842 17.6 14.1 - 21.0  20,941 22.4 21.7 - 23.2 
2005-2009 766 53.3 44.2 - 62.4  1,559 14.7 10.4 - 19.0  20,181 24.7 23.3 - 26.2 
United States                            
1995-1999 1,978 52.5 49.7 - 55.4  2,392 26.6 24.5 - 28.6  49,204 33.0 32.5 - 33.6 
2000-2004 2,430 55.3 52.6 - 58.0  4,981 28.8 27.3 - 30.3  57,163 34.0 33.5 - 34.5 
2005-2009 3,467 53.6 48.2 - 59.0  6,370 31.9 28.8 - 35.1  59,476 35.5 33.6 - 37.3 
Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were merged, the net 
survival estimates are underlined. Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included. 
Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code are included. 
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 Fallopian tube  Peritoneum  Ovary 
 No NS (%) 95% CI  N NS (%) 95% CI  N NS (%) 95% CI 
Germ cell                                   
United Kingdom                            
1995-1999 - . -  - . -  289 53.3 37.5 - 69.0 
2000-2004 - . -  - . -  306 61.2 47.5 - 75.0 
2005-2009 18 83.1 63.9 - 100.0  43 33.5 17.2 - 49.9  357 74.9 64.2 - 85.6 
United States                            
1995-1999 - . -  58 58.7 44.3 - 73.0  1,293 67.3 59.2 - 75.3 
2000-2004 - . -  75 55.7 41.0 - 70.3  1,604 73.4 66.0 - 80.8 
2005-2009 62 86.7 76.5 - 96.9  94 73.4 58.8 - 88.0  1,786 76.0 65.0 - 87.1 
Sex cord-stromal                                   
United Kingdom                            
1995-1999 - . -  - . -  304 77.2 68.9 - 85.6 
2000-2004 - . -  - . -  284 81.2 73.2 - 89.3 
2005-2009 3 . -  14 41.9 16.2 - 67.6  284 78.0 60.5 - 95.5 
United States                            
1995-1999 - . -  - . -  1,200 81.0 75.9 - 86.0 
2000-2004 - . -  - . -  1,317 84.4 79.6 - 89.2 
2005-2009 14 100.0 84.6 - 100.0  59 56.8 42.3 - 71.3  1,505 85.3 78.1 - 92.4 
Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were merged, the net 
survival estimates are underlined. Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included. 
Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code are included. 
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 Fallopian tube  Peritoneum  Ovary 
 No NS (%) 95% CI  N NS (%) 95% CI  N NS (%) 95% CI 
Other specific non-epithelial                               
United Kingdom                            
1995-1999 - . -  300 30.9 23.0 - 38.9  76 27.2 15.2 - 39.1 
2000-2004 - . -  358 30.6 24.2 - 36.9  77 22.2 5.1 - 39.3 
2005-2009 67 28.1 12.2 - 43.9  362 40.0 31.0 - 49.1  62 28.9 10.2 - 47.5 
United States                            
1995-1999 66 55.7 41.8 - 69.6  1,886 41.1 38.2 - 44.0  210 30.9 22.7 - 39.1 
2000-2004 80 44.8 28.8 - 60.7  2,196 43.2 40.3 - 46.0  211 30.3 21.5 - 39.0 
2005-2009 93 60.3 49.1 - 71.6  2,488 47.9 43.2 - 52.6  222 21.3 9.9 - 32.6 
Non-specific                                   
United Kingdom                            
1995-1999 - . -  - . -  190 28.1 18.1 - 38.1 
2000-2004 - . -  - . -  244 24.1 16.1 - 32.0 
2005-2009 55 59.6 44.9 - 74.4  56 22.5 8.8 - 36.2  264 34.5 24.8 - 44.3 
United States                            
1995-1999 - . -  73 25.2 13.4 - 36.9  695 33.6 28.3 - 39.0 
2000-2004 80 44.6 27.2 - 62.1  106 28.9 18.4 - 39.3  959 29.6 25.7 - 33.5 
2005-2009 52 35.3 10.4 - 60.1   89 36.0 21.4 - 50.7   979 28.2 18.5 - 37.9 
Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of diagnosis were merged, the net 
survival estimates are underlined. Countries with fewer than 10 women for any histological group (all calendar periods combined) were not included. 
Only microscopically verified tumours or tumours with a clinical diagnosis and a specific morphology code are included.  
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germ cell tumours could not be age-standardised for the UK. For ovarian germ cell 
tumours, age-standardised survival was similar in both countries during 2005-2009 (74.9% 
(64.2-85.6%) in the UK and 76.0% (65.0-87.1%) in the US).  
Sex cord-stromal tumours of the fallopian tube were also rare. Age-standardised survival 
was generally higher for tumours of the ovary than for tumours of the peritoneum (85.3% 
(78.1-92.4%) versus 56.8% (42.3-71.3%) in the US from 2005 to 2009).  
Survival from other specific non-epithelial tumours, which was the most common 
histological group for peritoneal tumours, was generally higher for tumours of the 
peritoneum than for tumours of the ovary (47.9% (43.2-52.6%) versus 21.3% (9.9-32.6%) 
in the US during 2005-2009).  
For peritoneal and fallopian tube cancers, tumours with non-specific morphology were 
rare. No obvious pattern in survival can been seen for these tumours. Survival for non-
specific tumours of the ovary increased over time in the UK (from 28.1% (18.1-38.1%) to 
34.5% (24.8-44.3%)), but decreased for the US (from 33.6% (28.3-39.0%) to 28.2% (18.5-
37.9%)). Survival from non-specific tumours of the peritoneum, however, increased over 
time in the US (from 25.2%, 13.4-36.9% to 36.0%, 21.4-50.7%).  
5.3.3 Survival for histological subtypes 
Within the type I and type II epithelial groups, survival for each histological subtype varied 
[Table 5.7]. Estimates for each epithelial subtype were calculated for each calendar period 
of diagnosis for the US and the UK. During 2005-2009, five-year age-standardised net 
survival was highest for endometrioid (UK: 64.8%, US: 76.2%) and transitional cell (US: 
69.6%) tumours. Survival from clear cell and mucinous tumours was moderate – 57.0-
59.1% and 51.3-55.8%, respectively. Survival from squamous tumours was moderate in 
the UK (51.9%), but poor in the US (37.2%). 
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Table 5.7 Five-year age-standardised net survival (NS, %) (95% CI) by histological 
subtype, country and calendar period, United Kingdom and United States, 1995-2009 
 United Kingdom  United States 
 N NS (%) 95% CI  N NS (%) 95% CI 
TYPE I  
Clear cell 
1995-1999 1,065 45.7 41.3 - 50.2  2,924 57.7 54.6 - 60.9 
2000-2004 1,330 52.5 48.7 - 56.4  3,636 61.4 58.5 - 64.2 
2005-2009 1,440 57.0 51.1 - 62.8  3,975 59.1 54.6 - 63.5 
Endometrioid 
1995-1999 2,632 51.4 48.5 - 54.3  8,354 65.2 63.5 - 66.9 
2000-2004 2,578 59.6 56.6 - 62.6  9,313 70.2 68.6 - 71.8 
2005-2009 2,071 64.8 58.6 - 71.1  8,408 76.2 72.8 - 79.5 
Mucinous 
1995-1999 2,653 47.5 44.8 - 50.3  6,021 50.7 48.7 - 52.6 
2000-2004 2,259 50.7 47.8 - 53.7  5,474 50.1 48.0 - 52.1 
2005-2009 2,080 51.3 34.0 - 68.6  4,768 55.8 52.6 - 59.0 
Squamous 
1995-1999 117 29.5 18.2 - 40.7  293 31.9 24.4 - 39.4 
2000-2004 137 35.6 24.7 - 46.5  362 37.8 30.8 - 44.7 
2005-2009 140 51.9 40.0 - 63.8  418 37.2 27.3 - 47.2 
Transitional cell (Brenner) 
1995-1999 74 54.9 40.5 - 69.3  363 64.6 58.0 - 71.2 
2000-2004 67 62.1 48.1 - 76.0  435 69.2 63.0 - 75.4 
2005-2009 52 53.7 38.3 - 69.1  465 69.6 60.2 - 79.1 
TYPE II 
Serous 
1995-1999 7,579 30.8 29.4 - 32.2  30,691 38.3 37.6 - 39.0 
2000-2004 9,179 31.2 29.9 - 32.5  39,311 38.6 38.0 - 39.2 
2005-2009 10,923 32.9 30.4 - 35.4  43,649 39.5 37.4 - 41.6 
Mixed epithelial-stromal carcinoma 
1995-1999 619 17.5 13.9 - 21.1  2,364 32.6 30.2 - 34.9 
2000-2004 804 24.7 20.9 - 28.4  3,960 39.1 37.1 - 41.0 
2005-2009 943 32.5 25.7 - 39.3  6,235 44.4 41.3 - 47.6 
Undifferentiated or other specific epithelial carcinoma 
1995-1999 12,075 16.4 15.5 - 17.3  20,519 26.9 26.1 - 27.6 
2000-2004 12,250 16.3 15.4 - 17.2  21,303 26.6 25.9 - 27.4 
2005-2009 10,640 16.4 14.8 - 18.1   19,429 27.3 25.7 - 28.9 
Italics denote net survival estimates that are not age-standardised. Only 
microscopically verified tumours or tumours with a clinical diagnosis and a specific 
morphology code were included.  
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For subtypes grouped as type II, survival from mixed-epithelial stromal tumours was the 
highest during 2005-2009 (44.4%) in the US, while undifferentiated carcinoma had the 
lowest (16.4%) in the UK. Survival from serous tumours was 39.5% in the US and 32.9% in 
the UK during the same time period. Survival for all type II subtypes was lower than that 
for type I subtypes, except for squamous tumours in the US, which was closer to that of 
mixed epithelial-stromal and serous carcinoma than mucinous – the second lowest 
survival for type I epithelial tumours. Survival for each subtype increased or remained 
stable over time in both countries. 
5.4 Discussion 
There are few international comparisons of survival for the various histological groups of 
ovarian cancer. The results from this large study show the importance of histology in 
comparisons of survival from ovarian cancer between countries.  
The distribution of histological groups may explain some of the wide international 
variation in ovarian cancer survival, which is most frequently reported for epithelial 
tumours for all histological groups combined. In Asia, for example, type I epithelial 
tumours are more common than in other regions, in part due to a higher percentage of 
clear cell tumours. Because survival for type I epithelial tumours is generally higher than 
that of type II epithelial tumours, survival for all histological groups combined would be 
expected to be higher in Asian countries with this larger proportion of more favourable 
tumours. As shown in the results, survival for all histological groups combined was 
generally higher in Asian countries than other regions. It is therefore important to 
examine survival from ovarian cancer for each histological group separately, at least in 
international comparisons, because survival for all histological groups combined may be 
influenced by a higher proportion of tumours with a more favourable outcome.  
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The results also confirm that survival is higher for type I epithelial, germ cell and sex cord-
stromal tumours than for the more aggressive type II epithelial tumours. Survival from 
tumours with a non-specific morphology is much lower than for tumours in any of these 
specific morphology groups, and generally decreased over time. This decrease is likely due 
to fewer tumours being coded as non-specific morphology over time and a corresponding 
increase in the number of tumours classified as type II epithelial. The decrease in the 
proportion of and survival for tumours of non-specific morphology suggests that 
improvements in the pathological examination of these tumours has led to more tumours 
being classified appropriately as type II epithelial (with slightly higher survival). Thus, the 
survival estimates for tumours coded as non-specific morphology were no longer inflated 
by the inappropriately classified type II epithelial tumours.  Survival from tumours of non-
specific morphology is expected to be even lower than that of type II tumours, because 
most women diagnosed with ovarian cancer for whom a specific morphology is not 
recorded are likely to have been too sick to undergo surgery, which is required for 
pathological examination and histological classification of the tumour. However, tumours 
recorded with missing or non-specific morphology may be recorded as such due to lack of 
or incomplete pathological information reported to registries. 
Tumours of the peritoneum and fallopian tube have, more recently, been included in 
studies of tumours of the ovary. Cancers at all three sub-sites are treated clinically in the 
same manner, and are thought to have similar aetiology17. Since 2000, peritoneal and 
fallopian tube tumours have been included in clinical trials of tumours of the ovary. The 
results for this analysis show that survival varies greatly between the three sub-sites 
within each histological group. Survival was generally higher for tumours of the fallopian 
tube, and lower for tumours of the peritoneum and the anatomical ovary. Fallopian tube 
tumours may be diagnosed at an early stage, because of the restrictive guidelines for 
assigning “fallopian tube” as the sub-site for a pelvic tumour. In order for a tumour to be 
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considered a primary fallopian tube carcinoma, the majority of the tumour has to be 
within the fallopian tube rather than the ovary, and there must be evidence of an 
intraepithelial tubal carcinoma. Additionally, there must be a clear transition from benign 
to malignant epithelium21. 
Survival for each of the eight epithelial histological subtypes was only estimated 
separately for the UK and the US, because of the relatively small numbers of women 
available for analysis in other countries for some of the rarer subtypes. Data from the UK 
and the US comprised over 50% of all the data included in the analysis. Grouping epithelial 
subtypes into “type I” and “type II” may have masked some of the differences in survival 
between histological subtypes. Survival for tumours classified as type I ranged from 37.2% 
(squamous in the US) to 76.2% (endometrioid in the US). Squamous tumours are rare and 
are not typically included in epithelial ovarian cancer clinical trials. There is a striking 
difference in survival between endometrioid (76.2% in the US) and clear cell tumours 
(59.1% in the US). Clear cell tumours are known to be chemo-resistant, women with clear 
cell tumours have been shown to have lower survival than women with serous tumours225. 
However, the results from this analysis show that women diagnosed with clear cell 
tumours have higher survival than women with serous tumours (58.1% versus 39.5% in 
the US). This contrasting result may be due to women with clear cell tumours being 
diagnosed at an earlier stage than women with serous tumours. While survival increased 
or remained stable over time for all histological subtypes, increases in survival for most of 
type II subtypes were small, while larger increases over time were seen for most type I 
subtypes. This suggests that improvements in treatment and cancer care may have more 
influence on type I epithelial subtypes than type II epithelial subtypes.    
Some cancer registries do not routinely collect data on tumour grade, and no information 
on grade was available for this study. Therefore, some serous tumours may have been 
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misclassified, because grade is required to classify these tumours appropriately. Only 
high-grade serous tumours are considered as type II epithelial, but all serous tumours 
were included in the definition of type II epithelial, because grade was not available. The 
effect on survival should be small, because only a small proportion (5%) of serous tumours 
are of low grade2.  
All endometrioid tumours were classified as type I epithelial, despite this subtype being 
previously sub-divided into type I and type II epithelial tumours12. If grade had been 
available, only low-grade endometrioid tumours would have been classified as type I 
epithelial while high-grade endometrioid tumours would have been classified as type II 
epithelial based on previous definitions of type I and type II epithelial tumours12. As with 
low-grade serous tumours, however, high-grade endometrioid tumours are rare, so the 
inclusion of these tumours in the type I epithelial group should not greatly affect the 
survival estimate by histological group2. An update in 2016 to the classification of 
endometrioid tumours into type I and type II epithelial tumours now classifies all 
endometrioid tumours as type I, regardless of tumour grade10. A sensitivity analysis was 
conducted to determine how the survival estimates varied between the two possible 
classifications for endometrioid tumours. Survival for both type I and type II epithelial 
generally increased by around 3 percentage points on average when endometrioid 
tumours were included in each group separately (appendix C). Because survival from 
endometrioid tumours was generally high when examined separately, including these 
tumours with the less-aggressive type I epithelial subtypes is preferable.  
The quality and comparability of histology data between countries may be limited for 
several reasons, including differences in diagnostic techniques, histological classification 
and transfer of data to the cancer registry, or even to the CONCORD-2 study. For example, 
almost all tumours submitted by Sweden were coded as type II epithelial subtypes, the 
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majority of which were unspecified epithelial carcinomas. Given that previous studies 
show a wider distribution of histological subtypes120, it is unlikely that almost all tumours 
from Sweden included in the analysis would have been true type II epithelial tumours. 
Additionally, Hong Kong only submitted epithelial ovarian cancers for the CONCORD-2 
study. Therefore, the survival comparison is limited to type I and type II epithelial tumours 
for Hong Kong.  
The analysis was limited to tumours that had been reported by the registry as 
morphologically verified, though tumours with specific ICD-O-3 morphology codes were 
also included even if the basis of diagnosis was clinical or missing. Morphological 
verification requires a tumour biopsy, and it may not be performed if the woman presents 
with advanced-stage disease, or is very elderly or has a high number of comorbidities. 
Additionally, morphological verification may be difficult to achieve in low resource 
settings, where survival may also be lower. Therefore, limiting the analysis to 
morphologically verified tumours may overestimate survival. However, given that 90.8% 
of tumours (before any exclusions) were reported as morphologically verified, the bias 
would be small.  
This is the largest international population-based study of survival for ovarian cancer by 
histological subtype. The large number of women included allowed for comparison of 
survival from epithelial and non-epithelial tumours: these are usually studied separately, 
complicating comparison between different populations and time periods. The difference 
in survival between the histological groups emphasises the need to focus future 
international comparisons of ovarian cancer survival on the various subtypes, rather than 
simply analysing survival from “ovarian cancer” as if it were a single homogenous group 
of tumours.  
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The results from this analysis also emphasise the need for further development of high-
quality population-based cancer registries in low-income countries, and the continued 
improvement of the quality and completeness of cancer registry data in all countries. 
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Chapter 6: Ovarian cancer survival by stage at 
diagnosis 
6.1 Introduction 
While most women with ovarian cancer are diagnosed at an advanced stage, stage-
specific survival differs widely between countries3. In a comparison of one-year net 
survival between six high-income countries, the highest percentage of women with 
advanced disease and the second lowest survival for all stages combined was seen in 
Denmark3. Thus, the international variation in ovarian cancer survival for all stages 
combined may be partially explained by the distribution of stage at diagnosis.  
The distribution of stage has also been shown to vary between histological groups. Type I 
epithelial tumours tend to be early-stage, while type II epithelial tumours tend to be more 
advanced. Among type I epithelial tumours, stage I and II are the most common stages at 
diagnosis for endometrioid, clear cell, mucinous and transitional cell tumours2,9.  Around 
60-70% of germ cell tumours are stage I or II at diagnosis, while 30-40% are stage III; stage 
IV germ cell tumours are extremely rare36. Sex cord-stromal tumours are usually unilateral 
and confined to the ovaries at diagnosis2.   
6.2 Material and methods 
The CONCORD-2 study was based on data for over 25.7 million patients diagnosed with 
one of 10 common cancers, contributed by 279 population-based cancer registries in 67 
countries. The data included 779,302 women diagnosed with ovarian cancer in 61 
countries during the 15-year period of 1995 to 2009. The CONCORD-2 protocol, ethical 
approvals, and quality control procedures have been described elsewhere188 and in  
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Chapter 3a. 
Information on stage at diagnosis was requested for only women diagnosed between 
2001 and 2009, because the quality and completeness of data on stage at diagnosis in 
most registries prior to this would be inadequate for survival analysis; therefore, the 
stage-specific analysis only includes women diagnosed between 2001 and 2009.  
Data were available for 517,586 women (aged 15-99 years) diagnosed from 2001 to 2009 
with a cancer of the ovary, fallopian tube, uterine ligaments and adnexa, other specified 
and unspecified female genital organs, peritoneum and retroperitoneum in 245 registries 
in 61 countries [Figure 6.1]. Survival was estimated for each registry for two calendar 
periods: 2001-2003 and 2004-2009, when possible. Country-level survival estimates were 
derived by pooling data for registries that were included in the registry-specific analysis 
by stage at diagnosis. Borderline tumours and those coded with haematological 
morphology were excluded from the analysis. Registries for which net survival estimates 
were considered as less reliable in the main CONCORD-2 analysis188 were excluded. 
Registries with fewer than 10 women available for analysis in each stage for any given 
time period were excluded. Registries were only included if less than 30% of tumours were 
missing stage at diagnosis during 2004-2009. The majority of the exclusions were because 
of this requirement. If fewer than 50 women were available for survival analysis by stage 
at diagnosis in a given calendar period, the data for that registry were merged for the two 
calendar periods.  
Recent evidence suggests that high-grade serous carcinoma, the most common type of 
ovarian cancer, originates in the fallopian tube. Therefore, cancers of the fallopian tube  
                                                             
a The material in Chapters 4-7 is based on examination of the distribution of and ovarian from 
cancer survival histology, stage at diagnosis and race/ethnicity. A few paragraphs of material and 
methods are repeated in each of these chapters for ease of reference and to ensure consistency 
of the descriptions. A detailed definition and description of the data and methods can be found in 
Chapter 3. 
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Figure 6.1 Data exclusion flow chart for net survival analysis by stage at diagnosis, 
2001-2009 
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and other specified and unspecified female genital organs were included in a broader 
definition of ovarian cancer12. Similarly, primary peritoneal and retroperitoneal 
carcinomas are managed in the same way as advanced-stage epithelial ovarian cancer, 
and they are also included12. The term “ovarian” in this chapter refers to tumours at all 
these sub-sites, unless the context makes clear that it refers to tumours of the anatomic 
ovary. 
Follow-up until 31 December 2009 for vital status was available. Women diagnosed with 
ovarian cancer as a second or higher-order primary tumour are included in the analysis, 
in addition to those for whom ovarian cancer was their first cancer. Women whose cancer 
registration was from a death certificate or autopsy only were excluded, because their 
true survival time was unknown. 
Stage at diagnosis was categorised as “localised” or “advanced”. Registries submitted 
stage data coded to one of several classifications: the UICC’s TNM staging system (7th 
edition), the FIGO system or SEER Summary Stage 2000. Data were received on 
pathological and/or clinical T, N and M, as well as tumour size (in millimetres) and the 
number of positive lymph nodes. These data were used to create a final stage at diagnosis 
variable, prioritising pathological TNM information, supplemented with clinical TNM 
information where missing. Information on FIGO stage and SEER Summary Stage 2000 
was used to supplement missing TNM information when both pathological and clinical 
TNM were missing, and if no data on tumour size or number of positive lymph nodes were 
available. Tumours with TNM Stage I are those confined to the ovaries at diagnosis; and 
these tumours were defined as “localised”. Stage II tumours are rare and have spread 
beyond the ovaries. Stage III tumours have spread to regional lymph nodes, and Stage IV 
tumours have metastasised to other organs. TNM Stage II, Stage III and Stage IV tumours 
were defined as “advanced”. Where there was no information available on stage, the 
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tumours were classified as missing stage at diagnosis; net survival was estimated 
separately for these tumours.  Survival was analysed by stage at diagnosis in each country, 
and where possible, for registry separately. 
Net survival is defined as the probability of survival for cancer patients up to a given point 
in time after diagnosis (for example, 5 years) if death from cancer were to be the only 
cause of death. Net survival controls for the background mortality of competing causes of 
death in a population. Life tables of all-cause mortality rates by single year of age (0-99 
years), region, sex, calendar year and, where possible, race were used to control for 
variations in background mortality. The Pohar Perme estimator of net survival224, which 
allows for the fact that competing risks of death increase with age, was used to estimate 
net survival. The Pohar Perme estimator was implemented using stns208 in Stata version 
14207. Standard errors were calculated using the Greenwood method209.  
Net survival is reported for each country and/or registry and stage at diagnosis with 95% 
confidence intervals (CI). Survival by stage at diagnosis was estimated for two calendar 
periods of diagnosis: 2001-2003 and 2004-2009. The cohort approach was used for 2001-
2003 because five or more years of follow-up were available for all patients, while the 
complete approach was used for 2004-2009a.  
Survival by stage at diagnosis for each histological group (see Chapters 4 and 5) was also 
analysed for the US only (n=169,832). Data from the US comprised over 70% of the data 
available for the analysis by stage at diagnosis. Only microscopically verified tumours or 
tumours that were clinically diagnosed but for which a specific morphology code was 
available were included in this analysis (94.5%; n=160,560). The larger number of women 
                                                             
a See Chapter 3 for a more detailed explanation of these methods. 
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from the US included in the analysis allowed for a more detailed analysis than for other 
countries.  
Survival estimates for all ages combined were age-standardised, where possible, with the 
International Cancer Standard Survival (ICSS) weights206. Age at diagnosis was categorised 
into five age groups: 15-44, 45-54, 55-64, 65-74 and 75-99 years. If an age-specific 
estimate could not be produced, or fewer than 10 women were available for analysis in 
an age group, data for adjacent age groups were pooled and the re-estimated survival 
was used for both of the original age groups. If two or more age-specific estimates could 
not be produced, or fewer than 10 women were available for analysis in two or more age 
groups, only the unstandardised estimate is reported. 
6.3 Results 
6.3.1 Stage at diagnosis 
Data for 233,659 women were available from 67 registries in 25 countries for analysis of 
survival by stage [Figure 6.1]. Only two out of 19 Central and South American registries 
provided enough information on stage at diagnosis to be included in this analysis. In North 
America, one out of 13 Canadian registries and 36 out of 37 US registries provided 
adequate stage data. In Asia and Europe, only 12 (out of 48) and 13 (out of 115) registries, 
respectively, provided adequate stage data to be included in the analysis. No data from 
African registries were available for analysis by stage at diagnosis. 
Overall, 38,033 (16.3%) of these 233,659 women were diagnosed with localised ovarian 
cancer, and 169,033 (72.3%) with advanced disease. Stage at diagnosis was missing for 
26,593 women (11.4%). Women diagnosed with localised ovarian cancer were the 
youngest (mean age 56 years), while women with a missing stage at diagnosis were the 
oldest (mean age 68 years).  The mean age at diagnosis for women diagnosed with 
advanced disease was 65 years [Table 6.1].  
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Table 6.1 Worldwide distribution (%) of stage at diagnosis and mean age at diagnosis, 
2001-2009, 25 countries 
Stage at diagnosis No.  % Mean age(SD)a (years)  
Localised 38,033 16.3 56 (16) 
Advanced 169,033 72.3 65 (14) 
Missing 26,593 11.4 68 (16) 
Total 233,659 100.0 64 (15) 
a  Standard deviation.  
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Overall, 5-year age-standardised net survival for localised ovarian cancer was much higher 
than that for advanced disease, or tumours with a missing stage at diagnosis [Figures 6.2-
6.4]. For women diagnosed with localised ovarian cancer during 2004-2009, survival in all 
registries was much higher than for women diagnosed with advanced disease. In some 
registries, 5-year age-standardised survival was over 90% for localised tumours, with the 
highest survival in Hong Kong (95.5%, 95% CI: 89.4-100.0%) [Table 6.2]. The lowest age-
standardised survival from localised tumours was seen in Mississippi (US) (68.3%, 52.3-
84.4%). This is still much higher, however, than the highest survival for advanced-stage 
tumours during the same time period.  
Over time, age-standardised survival for localised tumours increased or remained stable 
in 21 of the 37 registries for which age-standardised estimates could be produced for both 
calendar periods. The largest increase was seen in Oklahoma (US) where survival 
increased from 80.6% (68.3-92.9%) in 2001-2003 to 91.5% (83.4-99.7%) in 2004-2009. In 
Tennessee (US), survival decreased from 84.3% (71.3-97.3%) to 79.1% (70.0-88.2%), 
whereas in New South Wales (Australia) survival decreased from 76.8% (68.1-85.5%) to 
71.6% (64.0-79.3%), two of the largest decreases seen during 2001-2009.  
For advanced-stage ovarian cancer, survival was generally around 30%. Age-standardised 
survival from advanced-stage disease diagnosed during 2004-2009 was highest in Tochigi 
(Japan; 39.3%, 22.1-56.5%), while the lowest survival was in Northern Ireland (UK; 15.2%, 
10.4-20.0%). The between-registry variation in survival for advanced-stage disease was 
not as wide as that for localised disease. Survival increased or remained stable over time 
in 47 of the 62 registries for which age-standardised survival estimates could be produced 
for both time periods. The largest increase in survival was seen in Songkhla (Thailand; 
from 14.0% (4.7-23.4%) to 23.9% (15.8-32.1%)). Decreases in survival over time were
Continued on page 232 
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Figure 6.2 Five-year age-standardised net survival (%) for localised tumours, 2004-2009 
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Figure 6.3 Five-year age-standardised net survival (%) for advanced tumours, 2004-2009 
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Figure 6.4 Five-year age-standardised net survival (%) for tumours with missing stage, 2004-2009 
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Table 6.2 Five-year age-standardised net survival (NS, %) (95% CI) by country, registry, calendar period and stage at diagnosis, 1995-2009, 25 countries 
 
Calendar 
period  
Localised  Advanced  Missing 
 
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI 
AMERICA (CENTRAL AND SOUTH) 
Brazil                             
Jaú 2001-2003               -    . .                      -    . .                    -    . . 
 2004-2009               -    . .                     18  45.7 15.4 - 76.1                    -    . . 
Puerto Rico                             
Puerto Rico 2001-2003               -    . .                      -    . .                    -    . . 
 2004-2009            187  73.1 54.4 - 91.9                   535  32.0 24.4 - 39.7                122  23.8 11.5 - 36.1 
AMERICA (NORTH)                                     
Canada*                             
Manitoba 2001-2003               -    . .                      -    . .                    -    . . 
 2004-2009              88  69.3 47.5 - 91.1                   501  15.4 9.0 - 21.7                   21  9.0 0.0 - 27.5 
                             
United States 2001-2003        8,957  84.8 83.3 - 86.4             40,928  32.4 31.8 - 33.0             5,467  31.6 29.9 - 33.3 
 2004-2009      16,612  85.5 84.4 - 86.7             88,747  34.2 33.8 - 34.7             9,121  30.9 29.7 - 32.2 
                             
Alabama 2001-2003            188  69.3 54.6 - 83.9                   806  31.0 27.0 - 34.9                   82  26.3 15.7 - 36.8 
 2004-2009            326  72.2 62.9 - 81.5               1,814  31.1 28.2 - 33.9                133  27.0 17.6 - 36.4 
                             
Alaska 2001-2003               -    . .                     71  27.6 12.9 - 42.2                    -    . . 
 2004-2009              61  87.2 72.8 - 100.0                   171  32.9 17.8 - 48.0                   23  58.9 36.4 - 81.3 
 *Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of 
diagnosis were merged, the net survival estimates are underlined. a Registries with fewer than 10 women for any stage (all calendar periods combined) were not included in 
the analysis. b Number of patients included in analysis for a given calendar period. The number of women per registry may differ from the main CONCORD-2 analysis due to 
the exclusion of borderline tumours and updates from registries. The total number of women for a country in a given calendar period may not equal the sum of the number 
per registry for that period due to merging of calendar periods to produce the registry-level estimates. 
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Calendar 
period  
Localised  Advanced  Missing 
 
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI 
California 2001-2003        1,142  90.2 86.0 - 94.5               6,188  34.1 32.5 - 35.7                455  23.3 17.1 - 29.4 
 2004-2009        2,393  85.7 82.6 - 88.8             12,921  34.9 33.8 - 36.1                965  21.5 17.5 - 25.5 
                             
Colorado 2001-2003            176  94.4 85.5 - 100.0                   719  33.6 28.9 - 38.4                   75  24.8 13.5 - 36.1 
 2004-2009            328  91.5 84.7 - 98.2               1,768  35.9 32.6 - 39.3                107  29.9 20.2 - 39.6 
                             
Connecticut 2001-2003            139  87.7 76.4 - 99.0                   771  34.4 30.0 - 38.8                   54  20.8 8.8 - 32.9 
 2004-2009            266  86.2 78.2 - 94.2               1,572  36.1 32.7 - 39.4                   80  19.9 11.2 - 28.6 
                             
Delaware 2001-2003               -    . .                   153  37.1 27.5 - 46.7                    -    . . 
 2004-2009              75  84.9 67.9 - 100.0                   368  38.0 31.3 - 44.6                   45  37.4 20.5 - 54.2 
                             
Florida 2001-2003            714  84.9 80.1 - 89.6               3,615  33.5 31.6 - 35.4                560  39.9 34.6 - 45.1 
 2004-2009        1,244  86.3 82.9 - 89.7               7,613  37.7 36.3 - 39.1                909  43.0 39.2 - 46.8 
                             
Georgia 2001-2003            267  86.8 76.5 - 97.2               1,385  33.7 30.3 - 37.0                176  27.9 18.4 - 37.4 
 2004-2009            600  85.1 78.3 - 91.9               3,100  32.8 30.5 - 35.2                263  25.6 18.9 - 32.4 
                             
Hawaii 2001-2003               -    . .                   209  37.7 29.1 - 46.3                    -    . . 
 2004-2009            114  84.7 72.6 - 96.7                   467  36.9 30.8 - 43.0                   32  10.7 0.0 - 22.8 
                             
Idaho 2001-2003               -    . .                   217  33.1 23.9 - 42.2                    -    . . 
 2004-2009            128  86.8 71.7 - 100.0                   519  34.4 29.0 - 39.8                   58  12.2 3.0 - 21.5 
 *Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of 
diagnosis were merged, the net survival estimates are underlined. a Registries with fewer than 10 women for any stage (all calendar periods combined) were not included in 
the analysis. b Number of patients included in analysis for a given calendar period. The number of women per registry may differ from the main CONCORD-2 analysis due to 
the exclusion of borderline tumours and updates from registries. The total number of women for a country in a given calendar period may not equal the sum of the number 
per registry for that period due to merging of calendar periods to produce the registry-level estimates. 
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Calendar 
period  
Localised  Advanced  Missing 
 
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI 
Iowa 2001-2003            123  83.6 71.4 - 95.9                   670  33.6 29.2 - 37.9                   69  9.0 1.6 - 16.5 
 2004-2009            233  82.6 74.0 - 91.1               1,333  31.3 28.2 - 34.4                116  11.2 5.0 - 17.4 
                             
Kentucky 2001-2003            130  78.5 63.0 - 94.0                   753  32.2 27.8 - 36.7                104  28.7 18.5 - 38.9 
 2004-2009            334  76.6 66.1 - 87.0               1,597  32.0 28.8 - 35.1                160  31.6 22.6 - 40.5 
                             
Louisiana 2001-2003            122  78.9 64.9 - 92.9                   758  29.6 25.2 - 34.0                   70  25.5 12.9 - 38.0 
 2004-2009            235  78.6 69.2 - 88.0               1,416  28.9 25.7 - 32.2                   97  28.2 16.1 - 40.4 
                             
Massachusetts 2001-2003            256  87.6 79.1 - 96.2               1,456  34.8 31.3 - 38.2                124  16.4 8.6 - 24.1 
 2004-2009            526  91.1 84.6 - 97.6               2,863  37.1 34.6 - 39.7                213  12.8 7.8 - 17.8 
                             
Michigan 2001-2003            425  88.8 82.0 - 95.7               1,823  31.7 28.8 - 34.5                292  31.4 24.7 - 38.1 
 2004-2009            737  89.9 84.9 - 95.0               3,449  33.3 31.1 - 35.5                842  30.4 26.3 - 34.5 
                             
Mississippi 2001-2003               -    . .                   123  26.7 15.4 - 38.0                    -    . . 
 2004-2009            197  68.3 52.3 - 84.4                   894  33.2 27.9 - 38.5                109  43.5 29.1 - 57.9 
                             
Montana 2001-2003               -    . .                   189  33.2 24.1 - 42.4                    -    . . 
 2004-2009            101  87.6 71.1 - 100.0                   448  32.9 26.4 - 39.5                   61  23.9 11.1 - 36.7 
                             
Nebraska 2001-2003              80  85.8 70.2 - 100.0                   342  29.7 23.8 - 35.7                   51  18.1 7.6 - 28.6 
 2004-2009            121  88.0 76.7 - 99.4                   753  31.7 27.4 - 36.0                   82  19.2 11.0 - 27.4 
 *Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of 
diagnosis were merged, the net survival estimates are underlined. a Registries with fewer than 10 women for any stage (all calendar periods combined) were not included in 
the analysis. b Number of patients included in analysis for a given calendar period. The number of women per registry may differ from the main CONCORD-2 analysis due to 
the exclusion of borderline tumours and updates from registries. The total number of women for a country in a given calendar period may not equal the sum of the number 
per registry for that period due to merging of calendar periods to produce the registry-level estimates. 
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Calendar 
period  
Localised  Advanced  Missing 
 
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI 
New Hampshire 2001-2003              61  87.8 75.7 - 99.9                   213  40.1 32.0 - 48.3                    -    . . 
 2004-2009            108  85.9 71.7 - 100.0                   553  37.9 32.5 - 43.4                   94  18.7 9.2 - 28.2 
                             
New Jersey 2001-2003            407  87.4 79.8 - 94.9               1,914  31.5 28.6 - 34.5                236  35.6 26.4 - 44.9 
 2004-2009            727  87.2 82.3 - 92.1               3,648  32.7 30.6 - 34.9                399  34.4 27.9 - 40.9 
                             
New Mexico 2001-2003              51  83.9 71.8 - 96.1                   317  34.4 26.2 - 42.7                    -    . . 
 2004-2009            126  79.5 66.7 - 92.2                   636  36.0 30.5 - 41.5                128  34.3 21.8 - 46.8 
                             
New York 2001-2003            918  82.0 77.1 - 86.9               3,670  34.0 31.9 - 36.1                735  26.8 22.4 - 31.1 
 2004-2009        1,671  85.2 81.9 - 88.5               8,001  35.2 33.7 - 36.7                791  32.2 28.3 - 36.0 
                             
North Carolina 2001-2003            396  75.2 66.9 - 83.6               1,373  31.1 27.8 - 34.5                170  43.2 32.6 - 53.8 
 2004-2009            602  78.4 72.1 - 84.6               3,298  36.2 33.9 - 38.6                277  35.3 27.7 - 43.0 
                             
Ohio 2001-2003            539  86.6 80.4 - 92.8               1,804  31.6 28.8 - 34.3                440  25.1 19.9 - 30.3 
 2004-2009            851  89.1 84.8 - 93.5               4,283  34.2 32.2 - 36.2                572  19.6 15.7 - 23.4 
                             
Oklahoma 2001-2003            147  80.6 68.3 - 92.9                   663  34.7 29.9 - 39.5                103  28.6 16.9 - 40.4 
 2004-2009            224  91.5 83.4 - 99.7               1,286  35.2 31.7 - 38.7                193  34.6 24.0 - 45.2 
                             
Oregon 2001-2003            148  86.1 74.4 - 97.9                   778  34.0 29.8 - 38.3                   77  24.8 13.5 - 36.1 
 2004-2009            263  89.0 80.9 - 97.2               1,672  35.0 31.9 - 38.1                126  15.6 9.1 - 22.1 
 *Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of 
diagnosis were merged, the net survival estimates are underlined. a Registries with fewer than 10 women for any stage (all calendar periods combined) were not included in 
the analysis. b Number of patients included in analysis for a given calendar period. The number of women per registry may differ from the main CONCORD-2 analysis due to 
the exclusion of borderline tumours and updates from registries. The total number of women for a country in a given calendar period may not equal the sum of the number 
per registry for that period due to merging of calendar periods to produce the registry-level estimates. 
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Calendar 
period  
Localised  Advanced  Missing 
 
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI 
Pennsylvania 2001-2003            658  89.7 84.0 - 95.4               2,737  32.5 30.2 - 34.8                355  32.6 25.8 - 39.5 
 2004-2009        1,044  89.8 85.3 - 94.2               5,900  34.3 32.7 - 36.0                509  32.1 27.0 - 37.2 
                             
Rhode Island 2001-2003              60  87.2 75.3 - 99.0                   177  29.9 21.5 - 38.2                    -    . . 
 2004-2009            113  90.4 75.9 - 100.0                   266  33.0 25.9 - 40.0                   97  34.3 20.3 - 48.3 
                             
South Carolina 2001-2003            176  83.7 73.1 - 94.3                   695  32.8 28.5 - 37.1                119  31.8 20.7 - 42.8 
 2004-2009            307  81.9 74.0 - 89.9               1,478  35.0 31.9 - 38.0                159  24.9 17.4 - 32.4 
                             
Tennessee 2001-2003              70  84.3 71.3 - 97.3                   308  28.3 21.7 - 34.8                    -    . . 
 2004-2009            468  79.1 70.0 - 88.2               2,048  33.3 29.9 - 36.8                217  31.6 20.2 - 43.1 
                             
Texas 2001-2003            645  89.0 82.7 - 95.3               2,608  28.7 26.4 - 31.0                576  48.4 42.3 - 54.4 
 2004-2009        1,146  88.5 83.6 - 93.4               6,053  31.3 29.6 - 33.0                932  43.7 39.2 - 48.2 
                             
Utah 2001-2003              72  70.0 56.9 - 83.1                   354  31.3 24.8 - 37.7                    -    . . 
 2004-2009            137  77.2 62.6 - 91.7                   695  32.8 27.7 - 37.9                   47  8.9 0.0 - 18.7 
                             
Virginia 2001-2003            296  79.9 71.5 - 88.3               1,201  24.8 21.7 - 27.9                112  23.8 10.9 - 36.7 
 2004-2009            494  85.8 79.8 - 91.8               2,692  32.3 29.9 - 34.6                231  25.8 17.4 - 34.1 
                             
Washington 2001-2003            228  93.3 83.9 - 100.0               1,398  35.6 32.4 - 38.7                   85  17.1 7.7 - 26.4 
 2004-2009            351  92.8 86.1 - 99.6               2,245  36.3 34.0 - 38.6                190  26.3 16.5 - 36.1 
 *Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of 
diagnosis were merged, the net survival estimates are underlined. a Registries with fewer than 10 women for any stage (all calendar periods combined) were not included in 
the analysis. b Number of patients included in analysis for a given calendar period. The number of women per registry may differ from the main CONCORD-2 analysis due to 
the exclusion of borderline tumours and updates from registries. The total number of women for a country in a given calendar period may not equal the sum of the number 
per registry for that period due to merging of calendar periods to produce the registry-level estimates. 
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Calendar 
period  
Localised  Advanced  Missing 
 
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI 
West Virginia 2001-2003            104  77.3 64.1 - 90.6                   383  25.8 20.4 - 31.1                   76  16.8 7.7 - 25.9 
 2004-2009            124  79.0 69.1 - 89.0                   740  28.1 23.9 - 32.4                110  17.2 9.6 - 24.8 
                             
Wyoming 2001-2003               -    . .                     87  30.9 18.0 - 43.8                    -    . . 
 2004-2009              56  94.7 85.1 - 100.0                   187  32.9 22.2 - 43.7                   25  29.3 10.1 - 48.4 
ASIA 
Cyprus                             
Cyprus 2001-2003               -    . .                      -    . .                    -    . . 
 2004-2009              81  86.3 75.9 - 96.6                   166  21.4 7.5 - 35.2                   18  80.5 51.0 - 100.0 
Hong Kong                             
Hong Kong 2001-2003            226  93.8 85.6 - 100.0                   322  25.2 15.4 - 35.0                   67  54.7 41.9 - 67.5 
 2004-2009            239  95.5 89.4 - 100.0                   322  34.1 26.8 - 41.4                   92  39.3 25.7 - 52.9 
Indonesia                             
Jakarta 2001-2003               -    . .                      -    . .                    -    . . 
 2004-2009            144  78.3 67.1 - 89.6                     49  21.8 0.0 - 45.7                   42  53.2 26.8 - 79.5 
Israel*                             
Israel 2001-2003            110  81.6 68.2 - 95.0                   831  30.6 26.0 - 35.2                288  61.4 52.8 - 70.0 
 2004-2009            279  76.8 66.0 - 87.6               1,698  30.9 27.2 - 34.6                438  62.3 55.7 - 68.9 
                             
Japan 2001-2003            107  80.8 70.9 - 90.8                   419  30.5 22.5 - 38.5                137  44.2 29.7 - 58.7 
 2004-2009            326  80.4 69.0 - 91.8                   920  30.7 25.3 - 36.0                233  39.1 29.9 - 48.3 
 *Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of 
diagnosis were merged, the net survival estimates are underlined. a Registries with fewer than 10 women for any stage (all calendar periods combined) were not included in 
the analysis. b Number of patients included in analysis for a given calendar period. The number of women per registry may differ from the main CONCORD-2 analysis due to 
the exclusion of borderline tumours and updates from registries. The total number of women for a country in a given calendar period may not equal the sum of the number 
per registry for that period due to merging of calendar periods to produce the registry-level estimates. 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
                 
228 
 
 
Calendar 
period  
Localised  Advanced  Missing 
 
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI 
Miyagi 2001-2003               -    . .                   282  32.2 21.9 - 42.4                106  47.2 29.7 - 64.7 
 2004-2009              88  79.9 68.7 - 91.1                   171  31.4 23.3 - 39.4                   85  45.1 28.9 - 61.3 
                             
Saga 2001-2003               -    . .                      -    . .                    -    . . 
 2004-2009              14  72.7 49.9 - 95.4                     80  28.4 13.8 - 43.0                    -    . . 
                             
Tochigi 2001-2003               -    . .                      -    . .                    -    . . 
 2004-2009            126  94.5 86.8 - 100.0                   365  39.3 22.1 - 56.5                   71  21.1 8.7 - 33.5 
                             
Yamagata 2001-2003              58  87.3 77.8 - 96.8                   137  26.5 15.6 - 37.5                    -    . . 
 2004-2009            147  82.1 70.6 - 93.6                   304  29.1 21.5 - 36.8                108  32.1 18.2 - 46.0 
Saudi Arabia*                             
Saudi Arabia 2001-2003               -    . .                   211  31.4 21.4 - 41.4                    -    . . 
 2004-2009            103  95.0 82.9 - 100.0                     78  23.5 5.4 - 41.7                   65  62.4 44.0 - 80.7 
                       
Thailand 2001-2003               -    . .                     96  19.0 10.3 - 27.7                    -    . . 
 2004-2009            150  83.8 72.7 - 94.8                   260  41.1 22.0 - 60.3                126  51.7 34.4 - 69.0 
                             
Lampang 2001-2003               -    . .                      -    . .                    -    . . 
 2004-2009              73  81.5 69.8 - 93.3                   145  34.4 23.2 - 45.6                   56  82.8 69.1 - 96.5 
                             
Songkhla 2001-2003               -    . .                     55  14.0 4.7 - 23.4                    -    . . 
 2004-2009              77  84.2 73.3 - 95.0                   156  23.9 15.8 - 32.1                   70  48.8 35.9 - 61.8 
 *Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of 
diagnosis were merged, the net survival estimates are underlined. a Registries with fewer than 10 women for any stage (all calendar periods combined) were not included in 
the analysis. b Number of patients included in analysis for a given calendar period. The number of women per registry may differ from the main CONCORD-2 analysis due to 
the exclusion of borderline tumours and updates from registries. The total number of women for a country in a given calendar period may not equal the sum of the number 
per registry for that period due to merging of calendar periods to produce the registry-level estimates. 
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Calendar 
period  
Localised  Advanced  Missing 
 
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI 
Turkey                             
Izmir 2001-2003               -    . .                      -    . .                    -    . . 
 2004-2009            200  86.9 73.5 - 100.0                   559  29.7 17.2 - 42.3                137  36.8 17.2 - 56.3 
EUROPE                                     
Austria* 2001-2003            679  75.4 70.2 - 80.5               1,427  26.6 23.6 - 29.6                420  35.5 29.1 - 41.9 
 2004-2009        1,163  74.5 70.9 - 78.2               2,589  28.3 26.2 - 30.5                848  35.8 31.1 - 40.4 
                             
Austria 2001-2003            635  74.8 69.5 - 80.2               1,276  26.4 23.2 - 29.6                405  35.0 28.5 - 41.5 
 2004-2009        1,080  73.7 69.8 - 77.6               2,317  27.7 25.4 - 29.9                816  35.1 30.4 - 39.7 
                             
Tirol 2001-2003               -    . .                   151  29.0 19.9 - 38.1                    -    . . 
 2004-2009            127  85.1 72.8 - 97.3                   272  34.5 27.6 - 41.3                   47  47.4 30.8 - 64.0 
Czech Republic*                             
Czech Republic 2001-2003            683  84.0 77.9 - 90.1               1,916  22.0 19.1 - 24.8             1,011  32.0 27.9 - 36.2 
 2004-2009        1,336  85.2 80.9 - 89.4               4,426  25.2 22.9 - 27.5             1,433  28.4 25.6 - 31.2 
Denmark*                             
Denmark 2001-2003               -    . .                      -    . .                    -    . . 
 2004-2009            716  89.9 83.4 - 96.5               2,067  25.1 20.3 - 29.9                813  34.5 28.4 - 40.6 
Estonia*                             
Estonia 2001-2003              88  86.0 72.2 - 99.8                   378  22.5 16.7 - 28.2                    -    . . 
 2004-2009            176  85.2 74.8 - 95.7                   620  24.0 19.7 - 28.4                   58  53.3 38.4 - 68.1 
 *Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of 
diagnosis were merged, the net survival estimates are underlined. a Registries with fewer than 10 women for any stage (all calendar periods combined) were not included in 
the analysis. b Number of patients included in analysis for a given calendar period. The number of women per registry may differ from the main CONCORD-2 analysis due to 
the exclusion of borderline tumours and updates from registries. The total number of women for a country in a given calendar period may not equal the sum of the number 
per registry for that period due to merging of calendar periods to produce the registry-level estimates. 
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Calendar 
period  
Localised  Advanced  Missing 
 
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI 
Finland*                             
Finland 2001-2003            234  81.1 71.3 - 90.9               1,181  30.6 26.5 - 34.7                201  60.2 45.7 - 74.8 
 2004-2009            455  89.0 83.1 - 95.0               2,314  31.8 28.8 - 34.8                420  66.0 57.8 - 74.1 
Netherlands*                             
Netherlands 2001-2003               -    . .                      -    . .                    -    . . 
 2004-2009        1,340  82.4 75.6 - 89.1               4,444  26.6 24.0 - 29.2             2,152  31.2 27.3 - 35.2 
Poland*                             
Wroclaw 2001-2003            165  65.9 47.7 - 84.1                   494  20.9 15.5 - 26.3                273  45.9 35.3 - 56.5 
 2004-2009            307  70.8 61.9 - 79.7                   989  21.0 16.7 - 25.3                447  41.0 34.4 - 47.7 
Slovenia                             
Slovenia 2001-2003            140  89.1 78.3 - 99.9                   416  23.2 17.0 - 29.5                    -    . . 
 2004-2009            279  87.6 79.9 - 95.4                   904  24.2 18.7 - 29.8                   44  19.9 4.5 - 35.2 
Sweden*                             
Sweden 2001-2003               -    . .                      -    . .                    -    . . 
 2004-2009        1,026  82.3 76.1 - 88.5               2,790  29.8 26.4 - 33.2             1,160  38.8 33.8 - 43.8 
                             
Switzerland 2001-2003               -    . .                   188  34.2 25.6 - 42.9                    -    . . 
 2004-2009            111  81.0 67.2 - 94.9                   341  34.7 27.8 - 41.5                   61  36.3 22.4 - 50.2 
                             
Geneva 2001-2003               -    . .                   114  34.0 24.0 - 44.0                    -    . . 
 2004-2009              60  81.3 63.0 - 99.5                   199  32.4 24.1 - 40.6                   20  41.5 19.4 - 63.5 
 *Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of 
diagnosis were merged, the net survival estimates are underlined. a Registries with fewer than 10 women for any stage (all calendar periods combined) were not included in 
the analysis. b Number of patients included in analysis for a given calendar period. The number of women per registry may differ from the main CONCORD-2 analysis due to 
the exclusion of borderline tumours and updates from registries. The total number of women for a country in a given calendar period may not equal the sum of the number 
per registry for that period due to merging of calendar periods to produce the registry-level estimates. 
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Calendar 
period  
Localised  Advanced  Missing 
 
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI  
No. of 
patientsb 
NS 
(%) 95% CI 
Ticino 2001-2003               -    . .                     74  36.1 24.3 - 47.9                    -    . . 
 2004-2009              51  89.4 76.9 - 100.0                   142  33.9 24.0 - 43.8                   41  33.3 16.0 - 50.5 
United Kingdom*                             
Northern Ireland 2001-2003            132  85.8 71.8 - 99.9                   255  12.9 10.0 - 15.9                130  32.2 21.0 - 43.4 
 2004-2009            221  86.9 77.4 - 96.4                   592  15.2 10.4 - 20.0                235  30.2 22.5 - 37.9 
OCEANIA                                     
Australia 2001-2003            255  77.3 68.8 - 85.8                   914  27.6 24.0 - 31.1                175  37.1 24.8 - 49.5 
 2004-2009            288  72.3 64.8 - 79.8               1,078  23.0 20.2 - 25.8                154  35.8 26.2 - 45.5 
                             
Australian Capital 
Territory 2001-2003               -    . .                      -    . .                    -    . . 
 2004-2009              20  95.2 77.0 - 100.0                   107  31.9 17.0 - 46.8                    -    . . 
                             
New South Wales 2001-2003            245  76.8 68.1 - 85.5                   872  27.0 23.4 - 30.6                175  37.1 24.8 - 49.5 
 2004-2009            278  71.6 64.0 - 79.3               1,013  22.5 19.7 - 25.3                154  35.8 26.2 - 45.5 
New Zealand*                             
New Zealand 2001-2003            166  81.1 69.0 - 93.1                   584  24.0 19.7 - 28.4                   51  24.6 12.1 - 37.1 
  2004-2009            264  79.4 69.0 - 89.8                1,466  23.7 20.7 - 26.7                 133  39.2 27.5 - 50.9 
 *Data with 100% coverage of the national population. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of 
diagnosis were merged, the net survival estimates are underlined. a Registries with fewer than 10 women for any stage (all calendar periods combined) were not included in 
the analysis. b Number of patients included in analysis for a given calendar period. The number of women per registry may differ from the main CONCORD-2 analysis due to 
the exclusion of borderline tumours and updates from registries. The total number of women for a country in a given calendar period may not equal the sum of the number 
per registry for that period due to merging of calendar periods to produce the registry-level estimates. 
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small; the largest decrease (from 27.0% (23.4-30.6%) to 22.5% (19.7-25.3%)) was seen in 
New South Wales (Australia).  
Survival from tumours with a missing stage at diagnosis was similar to or lower than that 
for advanced disease in most registries in Central and South America and North America 
during 2005-2009. In North America, survival for tumours with a missing stage at diagnosis 
was 43.7% (39.2-48.2%) in Texas but only 31.3% (29.6-33.0%) for advanced-stage 
tumours. In Florida and Mississippi, survival for tumours with a missing stage was also 
higher than that of advanced-stage disease. In contrast to registries in Central and South 
America and North America, age-standardised survival from tumours with a missing stage 
at diagnosis was higher than for advanced stage disease in Asia, Europe and Oceania 
registries for which age-standardised estimates were available.  
No obvious trend in survival over time was evident for tumours with missing stage at 
diagnosis: survival increased in 12 registries and decreased in 14 registries for which age-
standardised estimates were available for both calendar periods. Changes over time were 
generally small, and the largest increase was seen in Oklahoma (US; from 28.6%, 16.9-
40.4% to 34.6%, 24.0-45.2%). The largest decrease was seeing in South Carolina (US) 
where survival decreased from 31.8% (20.7-42.8%) in 2001-2003 to 24.9% (17.4-32.4%) in 
2004-2009. 
6.3.2 Stage at diagnosis and histology 
Survival for each histological group by stage at diagnosis was estimated for the US. Data 
from registries included in the analysis for stage at diagnosis were pooled to estimate 
survival at the national level, as numbers were too small to estimate survival for each 
stage at diagnosis within each histological group for each registry.  
The distribution of stage at diagnosis varied by histological group. For type I and type II 
epithelial tumours, advanced-stage tumours were more common than localised tumours. 
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For women diagnosed from 2004 to 2009, 60.4% were diagnosed with advanced-stage 
type I epithelial tumours, while only 37.0% were diagnosed with localised type I epithelial 
tumours. Only 2.6% of type I epithelial tumours were missing stage at diagnosis. The stage 
distribution for type II epithelial tumours was even more skewed toward advanced-stage 
disease: during 2004-2009, 87.7% of women were diagnosed with advanced tumours 
versus only 7.0% diagnosed with localised-stage tumours, with 5.3% of tumours missing 
stage at diagnosis [Table 6.3].   
For non-epithelial tumours, localised tumours were more common than advanced-stage 
tumours for germ cell and sex cord-stromal tumours. For germ cell tumours, 55.2% were 
diagnosed at a localised stage and 39.7% were diagnosed at an advanced stage. Similarly, 
55.2% of sex cord-stromal tumours were localised at diagnosis and 38.2% were advanced. 
The stage distribution for other specific non-epithelial tumours favoured advanced stage 
at diagnosis (61.1% of tumours were advanced versus 30.1% localised).  
Non-specific tumours were rarely localised at diagnosis (7.7%) during 2004-2009. Most 
tumours of non-specific morphology were either advanced-stage disease at diagnosis 
(44.9%) or tumours with a missing stage (47.5%).  
For all histological groups – type I epithelial, type II epithelial, germ cell, sex cord-stromal, 
other specific non-epithelial and tumours of non-specific morphology – survival from 
tumours that were localised at diagnosis was much higher than for tumours that were 
advanced [Table 6.4, Figure 6.5].  
For type I tumours, 5-year age-standardised survival for localised tumours was 92.9% 
(91.3-94.5%) during 2004-2009, while survival from advanced tumours was only 49.1% 
(47.8-50.4%). Similarly, for type II tumours, survival was much higher for localised 
tumours (82.7%, 80.9-84.4%) than for advanced tumours (31.9%, 31.5-32.4%). Survival 
from tumours with a missing stage at diagnosis was similar to that of advanced tumours  
Continued on page 237 
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Table 6.3 Distribution (%) of stage at diagnosis by histological group and calendar 
period, United States, 2001-2009 
 Localised Advanced Missing 
 N % N % N % 
Type I 
2001-03 4,348 39.0 6,383  57.3 414 3.7 
2004-09 7,727 37.0 12,626  60.4 542 2.6 
Type II 
2001-03 3,010 8.1 31,656  84.8 2,677 7.2 
2004-09 5,487 7.0 69,301  87.7 4,198 5.3 
Germ cell 
2001-03 597 60.0 326  32.7 73 7.3 
2004-09 1,192 55.2 857  39.7 110 5.1 
Sex cord-stromal 
2001-03 429 54.8 270  34.5 84 10.7 
2004-09 930 55.2 644  38.2 111 6.6 
Other specific 
2001-03 443 29.7 846  56.7 202 13.6 
2004-09 945 30.1 1,917  61.1 274 8.7 
Non-specific 
2001-03 - - 277  47.3 309 52.7 
2004-09 104 7.7 608  44.9 643 47.5 
Registries with fewer than 10 women for any stage (both calendar periods combined) were not 
included in the distribution. Only microscopically verified tumours or tumours with a clinical 
diagnosis and a specific morphology code were included in the distribution. 
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Table 6.4 Five-year age-standardised net survival (NS, %) by histological group, stage 
at diagnosis and calendar period, United States, 2001-2009 
 
Localised Advanced Missing 
 NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI 
Type I 
2001-03 92.5 90.3 - 94.7 45.2 43.4 - 47.1 47.0 39.3 - 54.6 
2004-09 92.9 91.3 - 94.5 49.1 47.8 - 50.4 49.4 43.7 - 55.0 
Type II 
2001-03 81.0 78.6 - 83.5 30.3 29.7 - 30.9 30.4 28.2 - 32.7 
2004-09 82.7 80.9 - 84.4 31.9 31.5 - 32.4 30.0 28.3 - 31.6 
Germ cell 
2001-03 97.1 88.4 - 100.0 45.0 32.4 - 57.7 84.6 75.0 - 94.3 
2004-09 92.9 85.7 - 100.0 51.7 42.4 - 61.0 88.3 79.1 - 97.4 
Sex cord-stromal 
2001-03 90.2 82.4 - 97.9 69.0 59.5 - 78.4 92.0 81.9 - 100.0 
2004-09 92.7 87.3 - 98.1 71.3 64.4 - 78.3 86.3 72.7 - 99.9 
Other specific 
2001-03 63.7 57.2 - 70.2 33.3 28.9 - 37.7 33.7 25.2 - 42.2 
2004-09 64.7 60.0 - 69.3 34.1 31.0 - 37.2 36.7 30.3 - 43.2 
Non-specific 
2001-03 - - 14.7 9.9 - 19.6 32.8 25.9 - 39.8 
2004-09 80.9 67.4 - 94.4 17.1 13.2 - 21.0 34.1 29.3 - 38.9 
When data for the two calendar periods of diagnosis were merged, the net survival estimates 
are underlined. Registries with fewer than 10 women for any stage (both calendar periods 
combined) were not included in the analysis. Only microscopically verified tumours or tumours 
with a clinical diagnosis and a specific morphology code were included in the analysis.  
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Figure 6.5 Five-year age-standardised net survival (%) for ovarian cancer by stage at 
diagnosis and histological group, United States, 2004-2009
Localised
Advanced
0 10 20 30 40 50 60 70 80 90 100
Non-specific
Other specific
Sex cord-stromal
Germ cell
Type II
Type I
Registries with fewer than 10 women for any stage (both calendar periods combined) were 
not included in the analysis. Only microscopically verified tumours or tumours with a clinical 
diagnosis and a specific morphology code were included in the analysis. 95% CI represented 
by error bars. 
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for both epithelial histological groups. Survival remained stable over time for each stage 
for both histological groups.   
For non-epithelial tumours, survival was highest for localised germ cell tumours during 
2004-2009 (92.9%, 85.7-100.0%), though survival from localised sex cord-stromal 
tumours was only slightly lower (92.7%, 87.3-98.1%). Survival from localised germ cell and 
sex cord-stromal tumours was similar to that of localised type I epithelial tumours. 
Survival from localised other specific non-epithelial tumours was still relatively high 
(64.7%, 60.0-69.3%), though it was the lowest survival for localised tumours among the 
histological groups. Survival from localised sex cord-stromal and other specific non-
epithelial tumours increased slightly over time, while survival decreased from 97.1% 
(82.4-97.9%) to 92.9% (85.7-100.0%) for localised germ cell tumours.  
For advanced-stage non-epithelial tumours during 2004-2009, survival was highest for sex 
cord-stromal tumours (71.3%, 64.4-78.3%) and lowest for other specific non-epithelial 
tumours (34.1%, 31.0-37.2%). Survival from advanced-stage tumours increased over time 
for all non-epithelial histological groups. Survival from tumours with missing stage was 
higher than that for advanced non-epithelial tumours for each histological group, but 
lower than that for localised non-epithelial tumours.  
For tumours of non-specific morphology, survival was 80.9% (67.4-94.4%) for localised 
tumours, but only 17.1% (13.2-21.0%) for advanced tumours. Survival from non-specific 
tumours with a missing stage was 34.1% (29.3-38.9%) during 2004-2009, which was 
similar to that for type II epithelial tumours with a missing stage at diagnosis.  
6.4 Discussion  
Survival for stage at diagnosis could only be estimated for 25 of 61 eligible countries. The 
majority of the data exclusions were because more than 30% of cancer registrations were 
missing stage at diagnosis for a majority of the registries.  
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Survival for localised tumours was much higher than for either advanced tumours or 
tumours with missing stage, and this result supports previous evidence of poorer survival 
for advanced-stage tumours3. Early diagnosis of ovarian cancer is thus important for 
improved survival.  
The poorer survival for tumours of with a missing stage at diagnosis is not surprising, 
because accurate staging can only be achieved if a woman has undergone surgery. 
Women with significantly advanced disease are less likely to have surgery, and are 
therefore less likely to be staged appropriately at diagnosis. Furthermore, women with 
higher comorbidity, some of whom will also have advanced-stage disease, may not be 
healthy enough for surgery and their tumours may also not be staged appropriately.  
In some countries, however, survival from tumours of with a missing stage was higher 
than that for advanced-stage tumours. In these countries, it seems more likely that if stage 
data are reported missing, it may be due to lack of reporting stage to the registry than to 
higher survival for tumours with missing stage. Thus, stage at diagnosis is missing at 
random for these registries and missingness of stage at diagnosis is not due to the stage 
itself.  
Tumour stage is not routinely collected by cancer all registries; therefore, the analysis by 
stage at diagnosis could only include data from 25 of 61 countries. Additionally, changes 
in coding of stage at diagnosis in the US (72.7% of women included in the analysis) from 
the Summary Staging Guide 1977 to SEER Summary Stage 2000 meant that only data from 
2001 forward could be included from the US. Thus, survival was estimated for only two 
calendar periods: 2001-2003 and 2004-2009. The method in which registries in the US 
collected and reported stage changed from 2004. Prior to 1 January 2004, some US 
registries manually coded stage data, while others derived SEER Summary Stage 2000 
using the Extent of Disease classification system. From 1 January 2004, all US registries 
239 
 
derived SEER Summary Stage using the Collaborative Staging System. The calendar 
periods were chosen taking into account this change in recording of stage at diagnosis. 
The decrease in survival from 31.8% to 24.9% over time in South Carolina (US) for tumours 
with missing stage may be partly because of this change in stage coding. The cancer 
registry in South Carolina was one of the registries in the US for which stage was manually 
coded using stage data from patient records. Thus, the adoption of a standard process for 
coding stage at diagnosis may have increased the accuracy of the recorded stage at 
diagnosis for women diagnosed in South Carolina. Because stage at diagnosis may be 
missing because of the stage of the tumour – when the disease is too advanced to be 
properly surgically staged a woman may be reported as having a missing stage at diagnosis 
– accurately recording stage at diagnosis may result in a decrease in survival for tumours 
with missing stage at diagnosis.   
International variations in survival within each stage were wider for localised tumours 
than for advanced tumours, suggesting that other factors, such as access to optimal 
treatment for or histology of localised tumours, may vary between countries more than 
for advanced-stage disease.  
Survival by stage at diagnosis also varied in the US between histological groups, though 
the range was smaller for localised tumours than for advanced-stage tumours or tumours 
with a missing stage. The results from this analysis suggest that survival can be improved 
for all histological groups if the tumour is diagnosed at an early stage. However, is it clear 
that most type II epithelial tumours are diagnosed at advanced stages, which may partly 
explain the lower survival for this histological group. Thus, it appears that survival from 
ovarian cancer is affected by a combination of factors including histology and stage at 
diagnosis, along with treatment.   
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International comparisons of survival within each stage at diagnosis were limited due to 
the quality and completeness of stage data available worldwide. Only 25 of 61 eligible 
countries could be included in by stage at diagnosis, and only for one country (US) could 
survival by estimated for each stage within each histological group. International 
comparisons of survival within each stage are essential to identify inequalities in survival 
that are not because of the stage at diagnosis, but may be due to other factors such as 
access to treatment or the management of cancer services. Without the availability of 
high-quality stage data in more countries worldwide, efforts to narrow the gap in stage-
specific survival will be limited, and progress will be difficult to measure and evaluate over 
time. Improvements in the availability and quality of stage data, therefore, are needed 
crucially worldwide.   
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Chapter 7: Ovarian cancer survival by 
race/ethnicity  
7.1 Introduction 
Ovarian cancer survival has been shown to vary by race and ethnicity, particularly for black 
and white women in the US. Minority groups generally have worse health outcomes than 
the majority race or ethnicity, and this is also evident in cancer survival. It is unclear 
whether race or ethnicity influences the histology of ovarian tumours, but given the 
higher proportion of type I epithelial tumour subtypes in most East Asian countries, 
genetic factors may influence the histology of the tumour. In order to understand more 
fully the impact of race and histology on survival, survival by race for each histological 
group was estimated for blacks and whites in the US and Māori and non-Māori in New 
Zealand. Survival for all ovarian cancers combined was also estimated by race for Israel, 
New Zealand and the US.  
7.2 Material and methods 
Data from the CONCORD-2 study were used for this analysis188. Data for adult women 
(aged 15-99 years) diagnosed during the period of 1995 to 2009 with ovarian cancer were 
included. Follow-up for vital status was available until 31 December 2009. Women 
diagnosed with ovarian cancer as a second or higher-order primary tumour were included, 
in addition to those for whom ovarian cancer was their first cancer. Women whose cancer 
registration was from a death certificate or autopsy only were excluded, because their 
true survival time was unknown. The CONCORD-2 protocol, ethical approvals, and quality 
control procedures have been described elsewhere188 and in Chapter 3a. 
                                                             
a The material in Chapters 4-7 is based on examination of the distribution of and survival from 
ovarian cancer histology, stage at diagnosis and race/ethnicity. A few paragraphs of material and 
methods are repeated in each of these chapters for ease of reference and to ensure consistency 
of the descriptions. A detailed definition and description of the data and methods can be found in 
Chapter 3. 
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Recent evidence suggests that high-grade serous carcinoma, the most common type of 
ovarian cancer, originates in the fallopian tube. Therefore, cancers of the fallopian tube 
and other specified and unspecified female genital organs were included in a broader 
definition of ovarian cancer12. Similarly, primary peritoneal and retroperitoneal 
carcinomas are managed in the same way as advanced-stage epithelial ovarian cancer, 
and they are also included12. The term “ovarian” in this chapter refers to tumours at all 
these sub-sites, unless the context makes clear that it refers to tumours of the anatomic 
ovary. 
Data on race or ethnicity were reported for only four countries in the CONCORD-2 study: 
Israel, Malaysia (Penang), New Zealand and the United States. This analysis included black 
and white women from the US, Māori and non-Māori women from New Zealand and 
Jewish and non-Jewish women from Israel. Survival was not estimated for Malaysia 
(Penang) because there were not enough women in each age-race group to provide age-
standardised estimates. 
Net survival was estimated by race for all ovarian cancers combined for Israel, New 
Zealand and the US. Survival was also estimated by race for each of the six histological 
groups [Table 7.1], where possible, for the US and New Zealand. Survival by race for each 
histological group was not estimated for Israel because most of the survival estimates 
would have been unstandardised due to small numbers, and thus could not be compared 
appropriately. 
Net survival is defined as the probability of survival for cancer patients up to a given point 
in time after diagnosis (for example, 5 years) if death from cancer were to be the only 
cause of death. Net survival controls for the hazard of death from competing causes of 
death (background mortality) in a population. Life tables of all-cause mortality rates by 
single year of age (0-99 years), region, sex, calendar year and race were used to control  
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Table 7.1 Ovarian cancer histological groups and subtypes 
Histological groupa Histological subtype ICD-O-3 morphology code 
Type I epithelial Clear cell carcinoma 8005, 8310, 8443, 9110 
Endometrioid 
carcinomab 
8380, 8382-8383, 8560, 8570 
Mucinous carcinoma 8470-8471, 8480-8482, 8490 
Squamous carcinoma 8051-8084 
Transitional cell or 
Brenner carcinoma 
8120-8131, 9000 
Type II epithelial Serous carcinomac 8050, 8441, 8450, 8460-8461 
Mixed epithelial-stromal 
carcinoma 
8313, 8323, 8381, 8930-8991, 
9010-9030 
Undifferentiated or 
other epithelial 
8010-8015, 8020-8046, 8090-
8110, 8140-8231, 8246-8300, 
8311-8312, 8314-8322, 8324-
8325, 8336-8337, 8341-8375, 
8384-8440, 8452-8454, 8500-
8551, 8561-8562, 8571-8589 
Germ cell Germ cell  8240-8245, 8330-8335, 8340, 
9060-9105, 9380-9523 
Sex cord-stromal Sex cord-stromal 8590-8671, 8810  
Other specific non-
epithelial 
Other specific non-
epithelial 
8680-8806, 8811-8921, 9040-
9055, 9120-9373, 9530-9589 
Non-specific Non-specific 8000-8004 
Table presented here for ease of reference (originally presented in Chapter 4, page 81). 
a Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) were 
excluded from the analysis of survival by histological group. Tumours with missing 
morphology codes were analysed separately (see text). b No information on grade was 
available; therefore, all endometrioid tumours were classified as type I epithelial. c No 
information on grade was available; therefore, all serous tumours were classified as 
type II epithelial. 
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for variations in background mortality. The Pohar Perme estimator of net survival224, 
which allows for the fact that competing risks of death increase with age, was used to 
estimate net survival. This estimator was implemented using stns208 in Stata version 14207. 
Standard errors were calculated using the Greenwood method209.  
Net survival is reported for each country, race and histological group, with 95% confidence 
intervals (CI). Survival by race and histological group for the US was estimated for three 
calendar periods of diagnosis: 1995-1999, 2000-2004 and 2005-2009. The cohort 
approach was used for 1995-1999 and 2000-2004, because five or more years of follow- 
up were available for all patients, while the period approach was used for 2005-2009. 
Survival was estimated for all 15 years combined for Israel and New Zealand, using the 
complete approacha.  
Survival estimates for all ages combined were age-standardised with the International 
Cancer Standard Survival (ICSS) weights206. Age at diagnosis was categorised into five age 
groups: 15-44, 45-54, 55-64, 65-74 and 75-99 years. If an age-specific estimate could not 
be produced, or fewer than 10 women were available for analysis in an age group, data 
for adjacent age groups were pooled and the re-estimated survival was used for both of 
the original age groups. Only epithelial tumours were included in the analysis for New 
Zealand because there were not enough in each race-age-histological group category to 
allow for age standardisation. 
7.3 Results 
Type II epithelial tumours were the most common histological group for each race in each 
country. Jewish women had a higher proportion (74.9%) of type II epithelial tumours than 
                                                             
a See Chapter 3 for a more detailed explanation of these methods. 
245 
 
non-Jewish women (64.2%). The distribution of histological groups was similar Māori and 
non-Māori women in New Zealand and for white and black women in the US.  
Survival for all ovarian tumour histological groups combined was estimated by race for 
Israel (all years combined), New Zealand (all years combined) and in the United States (for 
each calendar period: 1995-1999, 2000-2004 and 2005-2009) [Table 7.2]. Survival from 
ovarian cancer was higher in all countries for the majority race (Jewish, non-Māori or 
white). In Israel, survival from ovarian cancer from 1995 to 2009 was 41.5% (39.1-43.9%) 
for Jewish women, but only 34.5% (18.9-50.0%) for non-Jewish women. In New Zealand, 
survival from ovarian cancer was only slightly higher for non-Māori women (34.6%) than 
for Māori women (33.5%). In the US, survival was much higher for white women than for 
black women throughout the 15-year period of 1995-2009. Survival increased slightly over 
time for both races.  
In the US, 5-year age-standardised survival for most histological groups and periods of 
diagnosis, was higher for white women than for black women [Table 7.3]. For type I 
epithelial tumours diagnosed from 2005 to 2009, five-year age-standardised survival was 
67.0% (64.9-69.1%) for white women, but only 50.9% (44.1-57.7%) for black women. 
Survival for black women for type I epithelial tumours was lower than that for white 
women in all three calendar periods. Survival from type I tumours increased steadily over 
time from 58.9% (57.7-60.1%) to 67.0% (64.9-69.1%) for white women. Though survival 
was higher during 2005-2009 than 1995-1999 for black women, survival decreased from 
1995-1999 to 2000-2004 (44.9% to 40.9%) before increasing to 50.9%. Over time, the gap 
in survival between white and black women widened.  
For type II epithelial tumours, survival was higher for white than black women during all 
three calendar periods. Survival increased over time from 33.8% to 36.6% for white  
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Table 7.2 Five-year age-standardised net survival (NS, %) by race, country and calendar 
period, 1995-2009 
Country Years of diagnosis Race NS (%) 95% CI 
Israel 1995-2009 Jews 41.5 39.1 - 43.9 
    Non-Jews 34.5 18.9 - 50.0 
New Zealand 1995-2009 Māori 33.5 21.5 - 45.6   
Non-Māori 34.6 32.1 - 37.1 
United States 1995-1999 White 40.1 39.6 - 40.6 
    Black 31.8 29.9 - 33.7 
  2000-2004 White 41.2 40.7 - 41.6 
    Black 30.6 28.9 - 32.2 
  2005-2009 White 42.7 41.2 - 44.2 
    Black 33.1 30.4 - 35.8 
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Table 7.3 Five-year age-standardised net survival (NS, %) by race, histological group 
and period of diagnosis, United States, 1995-2009 
 Whites Blacks 
 N NS (%) 95% CI N NS (%) 95% CI 
Type I                   
1995-1999 16,136 58.9 57.7 - 60.1 963 44.9 40.3 - 49.6 
2000-2004 16,932 62.8 61.6 - 64.0 1,164 40.9 36.4 - 45.5 
2005-2009 15,673 67.0 64.9 - 69.1 1,150 50.9 44.1 - 57.7 
Type II                   
1995-1999 48,565 33.8 33.2 - 34.3 3,488 26.1 24.1 - 28.2 
2000-2004 57,836 34.9 34.5 - 35.4 4,603 25.0 23.2 - 26.7 
2005-2009 61,149 36.6 34.9 - 38.2 5,353 26.6 23.7 - 29.6 
Germ cell                   
1995-1999 1,087 63.7 55.5 - 71.9 176 71.5 58.1 - 84.9 
2000-2004 1,323 71.5 64.6 - 78.4 243 61.0 46.3 - 75.7 
2005-2009 1,459 80.5 71.8 - 89.1 287 65.0 46.5 - 83.5 
Sex cord-stromal                   
1995-1999 955 79.9 74.6 - 85.3 228 71.9 56.1 - 87.6 
2000-2004 970 82.0 76.9 - 87.2 314 90.6 78.8 - 100.0 
2005-2009 1,088 86.8 79.3 - 94.2 359 77.5 58.7 - 96.4 
Other non-epithelial                   
1995-1999 1,866 40.6 37.7 - 43.5 219 35.3 26.1 - 44.6 
2000-2004 2,050 43.2 40.4 - 46.1 308 31.5 19.6 - 43.5 
2005-2009 2,290 45.9 41.0 - 50.8 369 44.9 30.5 - 59.4 
Non-specific                   
1995-1999 700 34.4 29.0 - 39.7 78 21.0 8.4 - 33.6 
2000-2004 975 30.6 26.7 - 34.4 99 25.2 14.4 - 36.1 
2005-2009 955 29.3 21.5 - 37.2 106 22.8 5.8 - 39.7 
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women, but remained relatively stable for black women (26.1% during 1995-1999 and 
26.6% during 2005-2009). 
For non-epithelial tumours, survival was highest for white women diagnosed with sex 
cord-stromal tumours (86.8%, 79.3-94.2%) during 2005-2009. Survival for this histological 
group was only 77.5% (58.7-96.4%) for black women during the same time period. Survival 
for sex cord-stromal tumours increased over time for both races. For germ cell tumours, 
survival was 80.5% (71.8-89.1%) for white women, but only 65.0% (46.5-83.5%) for black 
women. While survival increased over time for white women diagnosed with germ cell 
tumours, survival fell from 71.5% (58.1-84.9%) during 1995-1999 to 65.0% (46.5-83.5%) 
during 2005-2009 for black women. Survival from other specific non-epithelial tumours 
was similar for white and black women (45.9% vs. 44.9%) during 2005-2009, respectively. 
For tumours of non-specific morphology, survival was lower for both races than for other 
histological groups, but was still lower among black women (22.8%) than white women 
(29.3%).  Survival for white women decreased over time from 34.4% (29.0-37.2%) to 
29.3% (5.8-39.7%), while survival was relatively stable for black women (21.0%, 8.4-33.6% 
during 1995-1999 versus 22.8%, 5.8-39.7% during 2005-2009). 
In New Zealand, Māori women had higher survival (68.7%) than non-Māori women 
(58.3%) for type I epithelial tumours [Table 7.4]. Trends over time could not be assessed, 
because data were merged for the entire period 1995-2009 in order to for enough women 
to be available in each race-histological group combination to produce estimates.  Survival 
from type II tumours, however, was higher for non-Māori women (25.0%, 22.4-27.6%) 
than for Māori women (20.4%, 13.0-27.9%).  Estimates for non-epithelial histological 
groups could not be age-standardised, therefore comparison between race groups was 
not possible due to potential differences in the age structure of the cancer patient 
populations. 
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Table 7.4 Five-year age-standardised net survival (NS, %) for epithelial ovarian cancer 
by race and histological group, New Zealand, 1995-2009 
 N NS (%) 95% CI 
Type I          
Māori 92 68.7 51.9 - 85.5 
Non-Māori 208 58.3 52.3 - 64.2 
Type II          
Māori 854 20.4 13.0 - 27.9 
Non-Māori 2,446 25.0 22.4 - 27.6 
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7.4 Discussion 
Survival from ovarian cancer varied by race in the three countries included in these 
analyses. Survival was generally higher for the majority racial group, which is similar to 
results from studies of survival by race for other cancers. The minority racial groups may 
experience more barriers to accessing cancer care.   
Survival by race could only be estimated for each histological group for the US and New 
Zealand, due to the limited number of woman for each race available in each histological 
group in Israel and Malaysia. Survival from all histological groups of ovarian cancer was 
higher for white women than for black women in the US.  This suggests that the impact of 
race on survival may not vary by histological group.  The persistently lower survival for 
black women than for white women in each of the histological groups, suggests that other 
factors such as stage at diagnosis or treatment may explain variations in survival more 
than histology. Racial disparities in ovarian cancer survival among women in the US first 
appeared in the 1980s with the emergence of debulking surgery, thus suggesting a lack of 
access to optimal treatment for black women. While insurance status may influence a 
woman’s access to cancer care, black women diagnosed with advanced-stage epithelial 
ovarian cancer and enrolled in Medicare in the US were less likely to receive guideline-
adherent care than white women, suggesting that access to treatment may not be the 
only barrier to receiving optimal care for black women87. 
There is some evidence that racial inequalities in ovarian cancer survival may be 
eliminated when black and white women receive equal treatment. Results from clinical 
trial results85 and data on women treated in the same hospital88 suggest that when black 
and white women with advanced-stage epithelial ovarian cancer received similar 
treatment, inequalities in survival are non-existent. When the likelihood of receiving 
treatment is controlled for among white and black women, differences in ovarian cancer 
survival between these women are eliminated89.  
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In New Zealand, however, Māori women – the minority race – had higher survival for type 
I epithelial tumours than the majority group, non-Māori women. This is interesting, 
because minority groups usually have worse outcomes than the majority group. Survival 
for type I epithelial tumours was much higher for Māori women than for non-Māori 
women; however, the confidence interval was wide and includes the point estimate for 
non-Māori women. Thus, the more favourable survival estimate seen for Māori women 
may be due to smaller numbers rather than an actual higher survival for this tumour type.  
Estimates for other tumour types were not possible because of small numbers for Māori 
women. Age-standardisation of survival estimates by race was only possible for epithelial 
tumours because they are the most common and therefore enough women were 
available in each age-race-histological group category to include in the analysis. However, 
even with the most common groups, data for all three time periods had to be combined, 
and therefore trends over time in survival by histological group could not be satisfactorily 
examined for Māori and non-Māori in New Zealand.  
While the number of women from the US was quite large, more detailed analysis of stage-
specific survival by histological group for each race was not possible, because the number 
of women available in each age-stage-race-histological group category was not always 
large enough to produce age-specific estimates required for age-standardisation. Future 
analyses could include multivariable modelling to examine the impact of race on survival, 
when controlling for age, stage at diagnosis and histology.  
In this large study of ovarian cancer survival by race/ethnicity, minority groups generally 
had lower survival than the majority racial group. Efforts to ensure equal access to 
optimal, guideline-adherent care for minority women are needed to help minimise 
inequalities in ovarian cancer survival between racial or ethnic groups. 
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Chapter 8: Strengths and Limitations  
8.1 Strengths 
This is the largest international study examining some of the factors that influence ovarian 
cancer survival worldwide. The data included in this thesis came from over 240 
population-based cancer registries in 60 countries, which are home to over two-thirds of 
the world’s population. A common protocol and strict, centralised quality control 
measures were used to collect and clean the data to ensure the highest standard and 
completeness of data for analysis. Individual data for women diagnosed between 1995 
and 2009 were used to produce robust and comparable estimates of survival for each 
country.  
Due to the scope of the data collected, survival by various histological groups was 
estimated using the same methods, allowing for direct comparison of survival between 
the various histological groups of ovarian cancer. Previous research has focused on only a 
few countries when comparing survival from different histological groups.  
While the data quality and availability varies worldwide, it is generally high, and the 
inclusion of data from low- and middle-income countries is an essential first step to 
understanding the cancer burden in these countries. Improvements in data quality are 
needed before the quality of the data will allow more detailed analyses. 
8.2 Limitations 
The proportion of women lost to follow-up as reported by the registries was only 0.5% 
overall. The proportions were highest in Switzerland (1.8%), France (4.9%), Hong Kong 
(7.2%), Mongolia (11.5%), India (32.4%) and Jordan (57.5%). The proportion was less than 
1% in the 54 other countries. Women who were lost to follow-up were presumed still to 
be alive at the date of last known vital status or at the end of the follow-up period (31 
December 2009). Thus, if the women who are lost to follow-up are different with respect 
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to their (unknown) survival from those who were not lost to follow-up and were known 
to be alive at the end of the study, the survival estimates may be biased. If being lost to 
follow-up is associated with risk of dying from ovarian cancer, then survival may be 
overestimated because women with poor survival, who were lost to follow-up, were in 
fact presumed to be alive. While for most countries the proportion lost to follow up was 
0.0% (36 countries) or less than 1.0% (18 countries) and this bias would thus be non-
existent or extremely small, the bias would be larger for the countries where a higher 
proportion of women are lost to follow-up (India and Jordan).  
When registries use passive follow-up only, it is impossible to distinguish women who are 
lost to follow-up from those who are actually alive at the end of follow-up. Because of the 
reliance on death registration systems, deaths are ascertained only if they occur and are 
then registered. Thus, passive follow-up will capture accurately all deaths that have 
occurred and been registered, and it will also identify accurately women who are still alive 
because they were not matched to a death record, but it will not identify women who 
have been lost to follow-up, regardless of whether they are alive or dead.  Women who 
are lost to follow-up are, therefore, identical in this respect to women who are actually 
alive at the end of follow-up. Thus, those who are lost to follow-up must be presumed to 
be alive at the end of follow-up. Because it is impossible to distinguish the women lost to 
follow-up from women who are, in fact, alive at the end of follow-up, it is also impossible 
to quantify the amount of bias the presumed alive assumption may have on survival 
estimates. Thus, for some registries using passive follow-up only, survival estimates may 
be overestimated if a large proportion of women who are unknowingly lost to follow-up 
have actually died. However, if the quality of the national death index is high, then passive 
follow-up is less biased193,226. 
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The proportion of women excluded because their tumour was registered through a death 
certificate or autopsy only was 3.7% for all countries combined. This proportion was 
greater than 10% of the eligible cases for analysis for Brazil (11.3%), Argentina (11.8%), 
Japan (12.4%), Germany (18.2%) and Romania (18.7%). Survival for patients whose 
tumours are death-certificate-initiated tend to have lower survival than patients who are 
registered while alive. Therefore, if efforts to trace back death-certificate-initiated 
patients to obtain a date of diagnosis are not effective, a higher proportion of patients 
will be registered through a death certificate only. A higher proportion of DCO may result 
in an overestimation of survival because these patients must be excluded from survival 
analysis because their survival time is not known and they tend to have lower survival 
than patients who are registered while alive.  
Tumours coded as not morphologically verified but with a specific ICD-O-3 morphology 
code (any valid code except 8000-8004) were included in survival analyses by histological 
group. Registries reported the basis of diagnosis for each tumour record: clinical, 
morphologically verified or unknown whether clinical or morphologically verified. A 
specific morphology code was given priority over codes reported as clinically diagnosed, 
since it was assumed that reporting a specific morphology implied that morphological 
verification had, in fact, been conducted. Thus, the error was assumed to be in the coding 
of the basis of diagnosis rather than in the coding of morphology, since it seems 
improbable that the basis of diagnosis could correctly be coded as “clinical” if the 
morphology code was specific as, for example, mucinous cystadenocarcinoma (8470). 
This may be a limitation of the analyses by histological group if the morphology code was 
reported in error and the basis of diagnosis was, in fact, correct as reported by the registry.  
A surgical procedure is required to obtain a sample of an ovarian tumour for 
morphological verification, and women with advanced disease or comorbidity may not 
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receive surgery as part of their treatment. Survival for these women may thus be lower 
than for women with morphologically verified tumours who were healthy enough at the 
time of diagnosis to undergo surgery. Thus, survival estimates may be under-estimated 
when including the tumours that were reported as not morphologically verified but had 
been assigned a specific morphology, because survival from these tumours may be lower 
if the basis of diagnosis had in fact been solely clinical. However, given that these tumours 
represented only 2.2% of the data, the bias in survival estimation would be small. The 
proportion of these tumours was highest in Germany (4.6%), Australia (5.5%), the UK 
(11.6%) and Qatar (13.6%). The proportion was less than 2.1% in all other countries 
included in the analyses.  
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Chapter 9: Conclusion 
The aim of this thesis was to examine how and why ovarian cancer survival differs 
between and within countries. There were four objectives: (1) to determine if the 
distribution of histology varied by country or geographic region, or over time, (2) to determine 
if survival varied between histological groups, (3) to determine if survival varied by stage at 
diagnosis, and (4) to determine if survival varied by race/ethnicity. 
9.1 Distribution of histology  
Type II epithelial tumours were the most common histology worldwide (69.9%), followed 
by type I epithelial (22.4%). Germ cell, sex cord-stromal, other specific non-epithelial and 
non-specific tumours were all rare by comparison, comprising only 8% of tumours 
worldwide; the distribution of these groups remained relatively stable over the 15-year 
period 1995 to 2009. The proportion of type II epithelial tumours increased slightly from 
68.6% to 71.1%, and there was a corresponding decrease in type I epithelial tumours 
(from 23.8% to 21.2%).  
During 2005-2009, type II ovarian cancer was the most common histological group in all 
continents, although the proportion was much higher in Oceania (73.1%), North America 
(73.0%) and Europe (72.6%) than in Central and South America (65.7%) and Asia (56.1%). 
The range at the national level, however, was much wider. There was little between-
country variation in the proportion of type II tumours in Central and South America, North 
America and Oceania. However, the proportion varied widely in Asia, where the 
proportion of type II tumours was lower than that of type I epithelial tumours in Hong 
Kong and Thailand. There was also variation in the proportion of type II tumours in Europe, 
where they accounted for over 70% of tumours in 15 countries, 60% in 11 countries and 
only 50.2% in Russia.  
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9.2 Survival by histological group 
Net survival for women diagnosed with type I epithelial tumours five years after diagnosis 
was fairly high, generally 40-60%. During 2005 to 2009, age-standardised 5-year survival 
for type I epithelial tumours varied widely, with the highest survival in Hong Kong (82.9%, 
95% CI: 72.4-93.4%) and the lowest in Argentina (30.8%, 16.3-45.2%).  
Survival from type II epithelial tumours five years after diagnosis was lower than that of 
type I epithelial tumours, around only 20-40%. For women diagnosed between 2005 and 
2009, the highest age-standardised survival was again seen in Hong Kong (61.5%, 54.8-
68.2%), compared with only 18.1% (6.3-29.9%) for women in Chile (Los Rios). 
Survival from germ cell tumours was generally higher than that for type II epithelial 
tumours, though it varied widely between countries. Considering the age-standardised 
estimates for all 15 years combined, the highest survival was seen in Australia (76.0%, 
57.6-94.5%) and the lowest in China (41.5%, 23.6-59.4%). 
During 2005-2009, age-standardised net survival was over 90% at 5 years after diagnosis 
in Korea and Portugal for women diagnosed with sex cord-stromal tumours. However, 
survival varied widely between countries, and the lowest survival during the same period 
(Japan: 58.9%) was almost half that seen in Korea.  
Survival from other specific non-epithelial tumours was generally around 30-60%, slightly 
higher than that of type II epithelial tumours. The variation in age-standardised survival 
was very wide, ranging from only 0.3% (0.0-0.8%) in Bulgaria to 60.0% (48.4-71.5%) in 
Cuba.  
Age-standardised net survival for tumours of non-specific morphology (ICD-O-3 codes 
8000-8004) was generally lower than that for all specific histological groups combined, 
and generally decreased over time. This suggests pathological examination of ovarian 
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tumours is improving and that tumours previously coded as non-specific morphology are 
increasingly being pathologically examined and coded as a specific morphology.  
9.3 Survival by stage at diagnosis  
Overall, 5-year age-standardised net survival for localised ovarian cancer was much higher 
than that for advanced disease, or tumours with a missing stage at diagnosis. In some 
countries, 5-year age-standardised survival was over 90% for localised tumours, whereas 
for advanced-stage ovarian cancer, survival was generally around 30%. The highest age-
standardised five-year survival from advanced-stage disease diagnosed during 2004 to 
2009 was seen in Tochigi (Japan), but it was still only 39.3%. 
Survival from tumours with a missing stage at diagnosis was similar to or lower than that 
of advanced disease in most registries in Central and South America and North America 
during 2005-2009, but age-standardised survival was higher for missing stage at diagnosis 
than for advanced stage disease in all registries in Asia, Europe and Oceania for which age-
standardised estimates were available.  
Survival also varied by stage at diagnosis within each histological group. Survival from 
localised tumours was higher in all histological groups, and was as high as 81% in the US 
for localised type II epithelial tumours, which are thought to have a poor prognosis when 
survival is estimated for all stages combined. Survival was much lower for advanced-stage 
type II epithelial tumours (32%). Survival from localised type I epithelial tumours was 
around 90% and around 49% for advanced-stage tumours. Thus, the variation in survival 
between type I and type II epithelial tumours is not completely explained by stage at 
diagnosis.   
9.4 Survival by race/ethnicity 
Differences in survival by race could only be examined in detail for three countries. For all 
histological groups and stages combined, minority racial groups had lower survival than 
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the majority group.  In the US, survival for black women was lower than for white women 
for each histological group. Thus, the impact of race on survival does not appear to differ 
by histological group. 
9.5 Future directions 
Data on treatment were not available for these analyses. International differences in 
ovarian cancer survival may be explained in part or even largely by differences in access 
to and the quality of care. Differences in survival between racial groups have been shown 
to be eliminated when both groups receive equal treatment. Future analyses could 
examine how much variation between countries in survival for each histological group of 
ovarian cancer could be explained by differences in treatment. CONCORD-3 will include 
data on the type and date of the first course of treatment received by each patient, and 
it will examine differences in treatment between countries and their impact on variations 
in survival.  
The Pohar Perme estimator used throughout the thesis is a non-parametric approach to 
estimating net survival. Future analyses could examine excess mortality using various 
model-based methods. This would allow for more detailed analyses of the data, 
particularly when numbers are small. Modelling approaches could also explore how much 
of the variation in survival between countries can be explained by the factors that 
influence survival, such as histology, stage, race/ethnicity and treatment.  
Age-standardised 5-year net survival was the main outcome for the analyses in this thesis. 
Other approaches could examine differences in age-standardised one-year net survival or 
5-year survival conditional on surviving the first year after diagnosis. One-year net survival 
may be of particular interest to help identify the reasons for disparities in 5-year survival 
seen in this thesis.  
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One could also examine whether the international differences in short-term survival 
widen (or narrow) over time, perhaps focusing on the survival from just one histological 
group of ovarian cancer for a certain region of the world.  
The focus of most comparisons in this thesis is the between-country variation in survival. 
Survival was also compared between histological groups and over time, but examining the 
differences between countries was given priority. The data in this thesis could have been 
visualised in other ways. An emphasis on the improvements, or lack thereof, over time 
would require focusing on fewer countries at one time, but allow for a clearer picture of 
the trends in ovarian cancer survival. Additionally, the differences between histological 
groups could have also been emphasised by focusing on fewer countries and time periods. 
The analysis by stage at diagnosis also focused on the variations in survival within each 
stage between countries. The focus could have been, however, comparing survival 
between stages within a country.  
9.6 Conclusion 
Ovarian cancer survival for all histological groups and stages combined varies widely 
between countries. This variation appears to be explained in part by the variation 
between countries in the distribution of histological groups, which have varying levels of 
survival. Previous work in ovarian cancer survival has shown that the different histological 
subtypes have varying levels of survival, but such work has been limited to a few countries 
and histological groups. This is the largest ever study of the distribution of – and survival 
from – the various ovarian cancer histological groups, including rare subtypes such as sex 
cord-stromal and germ cell tumours.  
Stage at diagnosis also has a strong influence survival and thus on international 
comparisons of survival. However, more than half of the data eligible for analysis by stage 
at diagnosis was excluded because of the quality of the stage data. This lack of quality and 
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completeness of stage data in several registries worldwide severely limits the examination 
of international variations in survival by stage at diagnosis. While this is the largest ever 
study on survival from ovarian cancer by stage at diagnosis, only 25 of the eligible 61 
countries could be included.  
Race and/or ethnicity impacts ovarian cancer survival greatly. In each of the three 
countries for which survival could be estimated by race or ethnicity, the minority 
race/ethnicity had consistently lower survival than the majority race or ethnic group – 
except for Māori women in New Zealand diagnosed with type I epithelial tumours. Race 
or ethnicity is not routinely collected by cancer registries, and may even be illegal to report 
to the registry in some jurisdictions. Thus, data for race or ethnicity were only available 
for four of 61 countries, and ovarian cancer survival by race could only be estimated for 
three of the countries for which data on race were available.   
There is increasing interest in the prevention of cancer, in addition to earlier diagnosis 
and improvements in treatment, and all three are key factors in improving the healthcare 
system’s management of the cancer burden. Treatment for ovarian cancer has not 
changed greatly over the past few decades, despite numerous clinical trials and drug 
combinations for chemotherapy. 
Early diagnosis, particularly for epithelial ovarian cancer, remains elusive. Previous efforts 
to increase early diagnosis have focused on finding tumours while they are confined to 
the ovary. However, given the recent discovery of serous tubal intraepithelial carcinoma 
as a potential precursor to ovarian epithelial carcinoma, future efforts should focus on 
identifying any potential precursor lesions outside the ovary. 
Prevention of ovarian cancer is difficult, because the development of the various 
histological subtypes of ovarian cancer is still poorly understood. The primary prevention 
strategy currently in use is risk-reducing salpingo-oophorectomy for high-risk women 
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(women with either a BRCA mutation and/or a strong family history of ovarian cancer). 
While this decreases a woman’s risk of developing ovarian cancer, it does not eliminate it 
completely, and no routine prevention strategies are available for women who are not at 
a higher risk of ovarian cancer.  
International comparisons of cancer survival depend inherently on the availability and 
reliability of high-quality cancer data. Information on the cancer patient’s age at diagnosis, 
date of diagnosis, vital status and type of cancer are required for survival analysis. 
Additional variables such as stage at diagnosis, histological subtype of the tumour, the 
patient’s race or ethnicity, the patient’s socioeconomic status and the patient’s residence 
are useful in understanding why survival may vary between countries. The availability and 
quality of these data varies worldwide. In some countries with high-quality data, detailed 
analysis such as stage-specific survival for each histological group is possible.  However, in 
countries with fewer resources, collecting such information is difficult and often 
impossible. In this thesis, survival from ovarian cancer could only be estimated in five 
African countries. The comparisons for African countries were limited as none of the 
estimates could be age-standardised. Additionally, only for one country (Algeria) were the 
numbers of women large enough to produce estimates for histological groups other than 
type II epithelial tumours.  
The majority of the analyses by histology in this thesis are by histological group using a 
classification for epithelial tumours, which was introduced in 200416 and recently updated 
in 201610. The use of this classification system may mask differences in survival between 
epithelial subtypes grouped as either type I or type II. However, because most of the 
histological subtypes classified as type I epithelial are quite rare, survival by histological 
subtype could be estimated only for the US. Thus, in order to compare survival by 
histology worldwide, a grouping of histological subtypes of epithelial tumours is required. 
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International cancer survival comparisons are useful to establish benchmarks in order to 
monitor progress in the management of the cancer burden. However, without the high-
quality data needed to produce robust survival estimates, it is extremely difficult, if not 
impossible, to understand the variations in survival, in order to design strategies to reduce 
them. Efforts to increase the quality of cancer registration data in low resource settings 
are needed.  
Given the high-quality data, centralised protocol and rigorous methods used to produce 
ovarian cancer survival estimates for women diagnosed over the 15-year period of 1995 
to 2009 in 61 countries, the results presented in this thesis may be taken as a 
comprehensive overview of the trends and variations in ovarian cancer survival among 
women diagnosed up to 2009 worldwide.  The results presented in this thesis provide a 
valuable contribution to the understanding of variations in ovarian cancer survival, which 
may thus be used to inform health care policies and plans to reduce disparities in survival.  
The burden of ovarian cancer will increase for the foreseeable future, particularly in low- 
and middle-income countries with aging populations. To achieve the highest survival 
possible, women will need access to optimal ovarian cancer care. The global surveillance 
of ovarian cancer, which monitors trends and variations in survival, is thus essential, 
because unless the inequalities in survival are measured, efforts to reduce them will be 
limited, or even non-existent. 
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Appendix A: CONCORD-2 data specification  
Annex 3 Data specification                                                        29 November 2012 
 
 
1 Introduction 
 
1.1 CONCORD-2 will establish global surveillance of cancer survival. This annex to the 
main protocol provides a detailed description of the data that each registry is asked 
to provide. It has been substantially modified in the light of discussion at the 
CONCORD Working Group meeting in Cork, Ireland, 20-21 September 2012, 
attended by participants from 48 countries. 
 
1.2 Data for the CONCORD study will be sent to the Cancer Survival Group at the 
London School of Hygiene and Tropical Medicine. We expect to receive up to 2,000 
data files - 200 or more cancer registries may each supply up to 10 data files (one 
for each cancer). To manage these files efficiently, we must impose strict rules 
on data structure. This annex sets out the rules! 
 
1.3 First, we define 10 index sites - the stomach, colon, rectum, liver, lung, breast 
(women), cervix, ovary and prostate, plus leukaemia. 
 
1.4 Second, for simplicity, we will use "cancer" to refer to all invasive, primary, 
malignant neoplasms, including the haematological malignancies. 
 
1.5 Index cancers are those that: 
 occur at an index site 
 were diagnosed in persons who are normally resident in the territory covered by 
the registry 
 were diagnosed during the calendar period covered by the registry's data 
submission 
 
1.6 Most participating registries will supply data on all 10 index cancers, but that is 
not a requirement in order to participate in CONCORD. Some specialised 
registries only record certain cancers (e.g., breast, colorectal, haematological; 
childhood cancers). Some registries do not have follow-up data for patients with 
every type of cancer that they register. 
 
1.7 We will focus on analysing survival for index cancers diagnosed during the period 
1 January 1995 to 31 December 2009. You are invited to contribute data for as 
much of that period as possible, but it is not a requirement to supply data for the 
entire period 1995-2009. Some registries only began operation more recently than 
1995. 
 
1.8 When identifying the data you propose to submit, however, you should ensure that 
(a) the incidence data are considered to be complete for the years submitted and 
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(b) the follow-up of all patients for their vital status is also considered to be 
complete, at least up to 31 December of the last year of incidence, and preferably 
a later year. More recent data are admissible, if your data are complete for 2010 
or a later year. Some examples follow: 
 Example (1): incidence data 1995-2009, follow-up to 31 December 2009 
 Example (2): incidence data 1998-2007, follow-up to 31 December 2008 
 Example (3): incidence data 2000-2010, follow-up to 31 December 2011 
 
1.9 Some participating cancer registries will cover the entire national population; 
others will only cover part of a country (state, province, region, etc.). 
 
1.10 Survival analyses will focus on adults (defined as aged 15-99 years at diagnosis). 
We will also examine survival from acute lymphoid leukaemia in children (0-14 
years).  
 
1.11 If your registry collects data on tumours that are benign (behaviour code 0), 
uncertain (1) or in situ (2), such as in situ cancers of the cervix, please include 
records for all neoplasms diagnosed at an index site when submitting your data. 
This will enable comparison of the intensity of diagnostic activity between 
participating registries (see variable 22, behaviour, in Section 3). Please note, 
however, that survival analyses will be restricted to invasive, primary 
malignancies (behaviour code 3). 
 
1.12 During the period 1995-2009, most registries switched to ICD-O-31 for coding 
tumour site, morphology and behaviour, instead of ICD-92, ICD-103 or ICD-O-24. At 
the CONCORD Working Group meeting in Cork in September 2012, it was agreed 
to use ICD-O-3. If your data are not coded to ICD-O-3, please discuss this with 
us before submitting your data. 
 
1.13 Full dates (day, month and year) of birth, diagnosis and death are important in 
international survival analyses. The evidence and the rationale are explained in a 
recent paper5. This is also available on the CONCORD web-site. A brief summary 
is given with the relevant variables in Section 3 of this document. If you cannot 
send the full dates of birth, diagnosis and death, please discuss this with us 
before preparing your data for submission. We may be able to help you obtain 
ethical approval, or to find an alternative solution. 
 
1.14 All cancer data files must have the same structure. The details are set out for 
each variable in the following pages. First, please note the general points below, 
which apply to most variables: 
 
 All data files will be tested for adherence to protocol. This is the first step of 
quality control. Tables of protocol adherence will be sent to you shortly after 
data submission. Data files that do not meet the protocol cannot be used. If you 
are in doubt about how to construct your data files, please discuss this with 
us before sending them. 
 Every tumour record must contain a value for every variable, both core and 
optional variables (see page 3): 
 If you do not collect data for a particular variable, you must still include that variable 
in every tumour record, whether it is a core variable or an optional variable. Do 
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not leave the variable blank. For example, if you do not collect data on race/ethnicity 
(variable 8), you should assign the value 99 to that variable in every tumour record 
(see summary list on page 32). 
 If no data are available for a variable in a particular tumour record, you must still 
include that variable, whether it is a core variable or an optional variable. Assign 
the value 9, 99 or 999, etc., depending on how many digits are specified for that 
variable (see page 32). For example, if a tumour record contains no data for the core 
variable ‘sex’, you should assign the value 9 to that variable in every tumour record. 
Do not assign an imputed value. 
 If you choose not to supply an optional variable, you must still include that variable 
in every tumour record. Do not leave the variable blank. For example, if you choose 
not to supply the optional variables 23-37 on stage at diagnosis, you should assign 
the value 9, 99 or 999 (etc.) to these variables, depending on how many digits are 
specified for each variable (see page 32). 
 If it is routine practice in your registry to substitute an imputed value for a 
missing value (e.g. the month of the year), and some of the variables you 
submit contain imputed values please tell us: we will request a description of 
the imputation procedures. 
  If tumour records in your database include a special code (“flag”) to indicate 
when a missing value has been imputed, please discuss this with us before 
submitting your data. We will request a description of how each flag has been 
generated.  
 If you have modified a standard coding scheme (such as ICD-O-3) by adding 
special codes for local use in your registry, please recode your data to the 
standard form before submission. If you have any doubts about the appropriate 
conversion, please discuss this with us. 
 The variables on stage at diagnosis are optional, but many registries that do 
collect such data have requested survival analyses by stage. Stage data are 
only requested for cases diagnosed in 2001 or later. For cancers diagnosed 
during the period 1995-2000, therefore, the stage variables should be set to 9, 
99, etc. (see page 32). Data on stage for 2000 or earlier years will not be 
included in quality control or survival analyses.   
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2 Variable names and short descriptions 
 
 
2.1 The sequence of variables to be used in each record is as follows: 
 
 Core variables Optional variables
  
 Name Short description 
 VAR1 Country 
 VAR2 Registry 
 VAR3 Person code 
 VAR4 Tumour code 
 VAR5 IARC check flag * 
 VAR6 Sex 
 VAR7 Region * 
 VAR8 Race/ethnicity * 
 VAR9 Day of birth 
 VAR10 Month of birth 
 VAR11 Year of birth 
 VAR12 Day of diagnosis 
 VAR13 Month of diagnosis 
 VAR14 Year of diagnosis 
 VAR15 Last known vital status 
 VAR16 Day of last known vital status 
 VAR17 Month of last known vital status 
 VAR18 Year of last known vital status 
 VAR19 Basis of diagnosis 
 VAR20 ICD-O-3 Topography  
 VAR21 ICD-O-3 Morphology 
 VAR22 Behaviour 
  
 Name Short description 
VAR23 SEER Summary Stage 2000 
VAR24 Pathological T 
VAR25 Pathological N 
VAR26 Pathological M 
VAR27 Clinical T 
VAR28 Clinical N 
VAR29 Clinical M 
VAR30 Condensed T 
VAR31 Condensed N 
VAR32 Condensed M 
VAR33 Dukes’ stage 
VAR34 FIGO stage 
VAR35 Tumour size 
VAR36 No. of lymph nodes examined 
VAR37 No. of lymph nodes involved 
 
 
 
 
 
 
 
 
*  If your registry does not use these variables, see paragraph 1.14 on page 2 
 
279 
 
2.2 Details of the content and coding of each variable are given in Section 3. 
 
2.3 Abbreviations 
 AJCC American Joint Committee on Cancer  
 DCO Death-certificate-only registration 
 FIGO Fédération Internationale de Gynécologie et d’Obstétrique; International 
Federation of Gynecology and Obstetrics 
 IARC International Agency for Research on Cancer (WHO) 
 ICCC International Classification of Childhood Cancers 
 ICD International Classification of Diseases (WHO) 
 ICD-O International Classification of Diseases for Oncology (WHO) 
 LSHTM London School of Hygiene and Tropical Medicine 
 NAACCR North American Association of Central Cancer Registries  
 SEER Surveillance, Epidemiology and End Results programme (US National 
Cancer Institute) 
 TNM Tumour Nodes Metastasis (UICC) 
 UICC Union for International Cancer Control 
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3 Description of variables 
 
Variable 1 Country  
 
Numeric variable, four digits. 
 
The value for this variable is assigned centrally (see table below). It comprises a one-
digit code for the continent followed by the 3-digit UN code for each country. The 4-digit 
code for your country in the table below must be included in each tumour record. 
 
The names shown for each country in the table are mainly the English names associated 
with the UN code. We have shortened some of the names for convenience: this does not 
carry any political significance. 
 
 AFRICA Eastern Africa  North America  Northern Europe 
 2404 Kenya 1124 Canada 4208 Denmark 
 2480 Mauritius 1840 United States of America 4233 Estonia 
 2638 Réunion   4246 Finland 
 2800 Uganda ASIA Eastern Asia 4352 Iceland 
 2716 Zimbabwe 3156 China 4372 Ireland 
  Northern Africa 3344 China, Hong Kong SAR 4428 Latvia 
 2012 Algeria 3392 Japan 4440 Lithuania 
 2818 Egypt 3410 Korea 4578 Norway 
 2434 Libya 3158 Taiwan 4752 Sweden 
 2504 Morocco  Southern Asia 4826 United Kingdom 
 2788 Tunisia 3356 India  Southern Europe 
  Southern Africa 3364 Iran 4191 Croatia 
 2710 South Africa 3586 Pakistan 4292 Gibraltar 
  Western Africa  South-Eastern Asia 4380 Italy 
 2270 Gambia 3360 Indonesia 4470 Malta 
 2288 Ghana 3458 Malaysia 4620 Portugal 
 2466 Mali 3608 Philippines 4705 Slovenia 
 2566 Nigeria 3702 Singapore 4724 Spain 
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   3764 Thailand  Western Europe 
 AMERICAS Caribbean  Western Asia 4040 Austria 
 5192 Cuba 3196 Cyprus 4056 Belgium 
 5312 Guadeloupe 3368 Iraq 4250 France 
 5474 Martinique 3376 Israel 4276 Germany 
 5630 Puerto Rico 3400 Jordan 4528 Netherlands 
  Central America 3414 Kuwait 4756 Switzerland 
 5188 Costa Rica 3634 Qatar   
 5484 Mexico 3792 Turkey OCEANIA Australia and NZ 
  South America   9036 Australia 
 5032 Argentina EUROPE Eastern Europe 9554 New Zealand 
 5076 Brazil 4100 Bulgaria  Melanesia 
 5152 Chile 4203 Czech Republic 9540 New Caledonia 
 5170 Colombia 4348 Hungary  Micronesia 
 5218 Ecuador 4616 Poland 9316 Guam 
 5604 Peru 4642 Romania  Polynesia 
 5858 Uruguay 4643 Russian Federation 9258 French Polynesia 
   4703 Slovakia   
 
If your country is not listed, please contact us for advice. 
 
For reference, the country codes are at the following United Nations web-page, accessed 
31 October 2012: http://unstats.un.org/unsd/methods/m49/m49regin.htm  
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Variable 2 Registry 
 
Numeric variable; one to three digits (range 1-950). 
 
We will provide the code for your registry before you prepare your data. The code for 
your registry must be included as variable 2 in every tumour record. 
 
Together with the country code (variable 1), this variable will be used to link the data file 
with the relevant life tables during survival analysis.  
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Variable 3 Person code 
  
Numeric variable, up to 15 digits; or 
Alphanumeric variable, up to 15 characters. 
 
If the person code in your registry is numeric, you should not submit ‘leading zeros’. For 
example, if the person code has nine digits, submit it as a nine-digit number (e.g. 
123456789), and not as 000000123456789 (15 characters). 
 
This is a unique code used in your cancer registry to refer to each registered cancer 
patient.  
 
The person code can be any unique string of characters, but not the person’s name, 
national identity number, social security number or any similarly recognisable code. The 
person code must be included in each tumour record, to enable you to check the record 
in the event that we identify possible errors during quality control. 
 
The same person code must be included in any other tumour records supplied for the 
same person. Together with the tumour code (variable 4), this variable provides a 
unique identification of each tumour included in the study, for the purposes of quality 
control, but without compromising patient confidentiality. 
 
Note: A few cancer registries do not routinely use a person code. These registries will 
need to create a unique code for each person included in their data files. The code will 
be used to identify patients with more than one index cancer. It will also enable the 
registry to identify all tumours for a given person in the event that we identify possible 
errors during quality control. If you have any doubts about the appropriate procedure, 
please discuss this with us. 
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Variable 4 Tumour code 
  
Numeric variable, up to ten digits, or  
Alphanumeric variable, up to ten characters. 
 
If the tumour codes in your registry are numeric, you should not submit ‘leading zeros’. 
For example, if your tumour code has six digits, submit it as a six-digit number (e.g. 
123456), and not as 0000123456 (10 characters). 
 
This is the code used in your cancer registry to refer to each registered tumour. 
Together with the person code (variable 3), this variable will enable persons with more 
than one index cancer to be identified. 
 
The main survival analyses will include all primary, invasive, malignancies at an index 
site for patients diagnosed during the period 1995-2009 (or the calendar period for which 
your registry provides data – see paragraph 1.8 on page 1).  
 
If your registry has submitted data for all patients diagnosed during 1995-2009, a patient 
with an invasive primary cancer of the breast diagnosed in 2000, followed by a different 
invasive primary cancer of the colon diagnosed in 2005, would therefore be included in 
the survival analyses for each of those cancers.  
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Variable 5 IARC CHECK flag 
 
Numeric variable, one digit. 
 
We will use this variable to avoid sending you requests to check tumour records that you 
have already checked and, if necessary, corrected (codes 2, 3 or 4). 
 
Code Meaning 
 1 = Tumour record has not been checked with IARC CHECK 
 2 = Tumour record has been checked with IARC CHECK: no error(s) or warning(s) 
 3 = Tumour record has been checked with IARC CHECK: any error(s) or 
warning(s) have been corrected 
 4 =  Tumour record has been checked with IARC CHECK: no change was made 
because the registry has confirmed that the original record was correct 
 9 = This variable will not be provided 
 
If you choose not to supply the IARC CHECK flag, please assign the code 9 to this 
variable in every tumour record. 
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Variable 6 Sex   
 
Numeric variable, one digit. 
 
Code Meaning 
 1 = Male 
 2 = Female 
 9 = Sex is ambiguous, or sex was not known 
 
Please do not exclude any records from your data on the basis of this variable, even 
if the sex of the patient is not known.  
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Variable 7 Region 
 
Numeric variable, up to five digits. 
 
In some cases, it may be possible to estimate survival for geographic areas within the 
territory of your registry. For example, if your registry has national coverage, such 
analyses could be for regions (e.g. provinces, states, etc.) within your country. 
Alternatively, if your registry covers a province or state, such analyses could be for 
smaller regions (e.g. counties) within your territory. 
 
The categories for geographic region will be different for each registry that supplies this 
variable.  
 
If you wish us to provide such analyses, you will need to include a suitable geographic 
code in each tumour record. 
 
You will also need to identify for us the region (province, state, county, etc.) that 
corresponds to each geographic code. 
 
For example, the counties within some US states are a geographic variable of interest: 
 
 Code Meaning  
21001 = Kentucky, Adair 
21003 = Kentucky, Allen 
21005 = Kentucky, Anderson 
21007 = Kentucky, Ballard 
21009 = Kentucky, Barren 
21011 = Kentucky, Bath 
21...  = Kentucky, ... 
 
99999 = Region not known, or you will not supply this variable 
 
We will also need to be able to construct appropriate life tables for each 
geographic region (province, state, etc.) for which you wish to obtain separate 
survival estimates: see Annex 6: Life tables). 
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If you choose not to supply data for separate areas of the territory covered by your 
registry ("Region"), please assign the code 99999 to this variable in every tumour 
record. 
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Variable 8 Race/ethnicity 
 
Numeric variable, one or two digits. 
 
In some cases, it may be possible to estimate survival separately for each race/ethnicity 
within a population. Cancer registries in some countries collect information on race 
and/or ethnicity (USA), race (Australia, Israel and Singapore), ethnicity (New Zealand, 
UK) or nationality (Dubai, Kuwait).  
 
By contrast, most European registries do not record information on race or ethnicity. In 
some countries, it is illegal to do so. 
 
The categories for race/ethnicity will be different for each registry that supplies this 
variable.  
 
If you wish us to provide such analyses, you will need to include a suitable code for 
race/ethnicity in each tumour record.  
 
You will also need to identify for us the race or ethnic group that corresponds to each 
code. 
 
The example shown here is for the USA: 
 
 Code Meaning  
 1 =   White, Hispanic 
 2 =   White, Non-Hispanic 
 3 =   White, Hispanic status unknown 
 4 =   Black, Hispanic 
 5 =   Black, Non-Hispanic 
 6 =   Black, Hispanic status unknown 
 7 =   Asian or Pacific Islander, Hispanic 
 8 =   Asian or Pacific Islander, Non-Hispanic 
 9 =   Asian or Pacific Islander, Hispanic status unknown 
 10 =   American Indian/Alaska Native, Hispanic 
 11 =   American Indian/Alaska Native, Non-Hispanic 
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 12 =   American Indian/Alaska Native, Hispanic status unknown 
 13 =   Other, unspecified or unknown race, Hispanic 
 14 =   Other, unspecified or unknown race, Non-Hispanic 
 15 =   Other, unspecified or unknown race, Hispanic status unknown 
 99 = Unknown or missing, or variable not supplied 
 
Other race/ethnicity groups may be used, after discussion with the registry concerned, 
but the extent to which robust life tables can be constructed for each race or ethnic group 
may limit the scope for such analyses. 
 
If you want us to provide survival analyses by race or ethnicity, we will need to 
construct appropriate life tables for each race/ethnicity: see Annex 6 (Life tables). 
 
If your registry does not collect data on race/ethnicity, or you choose not to supply such 
data, please assign the code 99 to this variable in every tumour record. 
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Variables 9-11 Date of birth  
 
A full and accurate date of birth is important because it is used to calculate the exact 
age at diagnosis. This is used to determine the age group (at diagnosis) into which 
patients are assigned for age-specific survival estimates, and later for age-standardised 
survival. It is also used to calculate the exact age at death, and thus to select the 
appropriate background death rate from the life table for the computation of expected 
survival. 
 
A few cancer registries do not record the full date of birth. Most registries do record the 
full date, but some registries may face problems in supplying this information to external 
researchers, for a range of legal, ethical or regulatory reasons. 
 
A brief explanation of why full dates are important is given in the main protocol. We 
have published a peer-reviewed article setting out the argument in detail, supported by 
empirical evidence.5 The article shows the difficulties that arise in quality control when 
full dates cannot be obtained, and, more importantly, the biases that arise in survival 
estimation and survival comparisons. The conclusions are based on sensitivity analyses 
with a large data set. The article is accessible (with your login and password) on the 
CONCORD web-site. 
 
Data preparation and analyses will be performed at the London School of Hygiene and 
Tropical Medicine (LSHTM). The Cancer Survival Group at LSHTM has acquired both 
statutory and ethical approvals from relevant bodies in the UK to receive and analyse 
individual tumour records with full dates (day, month and year) of birth, diagnosis and 
death for the CONCORD-2 study (Annex 12.1: Statutory approval; Annex 12.2: 
Ethical approval). 
 
 
Variable 9 Day of birth  
Numeric variable, one or two digits. 
 
 1-31 = the day of birth 
 99 = the day of birth of this patient is not known 
 
Note: please tell us if the day of the date of birth cannot be provided for any of your patients. 
Note: please see comments below (variables 12-14) about the imputation of dates. 
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Variable 10 Month of birth  
Numeric variable, one or two digits. 
 
 1-12 = the month of birth 
 99 = the month of birth of this patient is not known 
 
Note: please tell us if the month of the date of birth cannot be provided for any of your patients. 
Note: please see comments below (variables 12-14) about the imputation of dates. 
 
 
Variable 11 Year of birth  
Numeric variable, four digits. 
 
 YYYY = the year of birth, from 1895 (person diagnosed in 1995 aged 99) to the 
present 
 9999 = the year of birth of this patient is not known  
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Variables 12-14 Date of diagnosis  
 
The date of diagnosis should be the date used by the registry for cancer incidence or 
survival. 
 
A full and accurate date of diagnosis is important because it is the starting point for the 
duration of survival. 
 
A few cancer registries only record the month and year of diagnosis. Other registries only 
began to record the full date of diagnosis at some point since 1995. 
 
A brief explanation of why full dates are important is given in the main protocol. We 
have published a peer-reviewed article setting out the argument in detail, supported by 
empirical evidence.5 The article shows the difficulties that arise in quality control when 
full dates cannot be obtained, and, more importantly, the biases that arise in survival 
estimation and survival comparisons. The conclusions are based on sensitivity analyses 
with a large data set. The article is accessible (with your login and password) on the 
CONCORD web-site. 
 
Some registries routinely capture more than one possible date of diagnosis (e.g. date of 
admission, date of biopsy, date of surgery, etc.). Before you supply your data for 
CONCORD, you will need to complete the cancer registry questionnaire on coding 
practices in your registry (Annex 15). This includes information about any rules that you 
use to select the date of diagnosis from two or more possible dates. 
 
We kindly request that you do not impute the missing components of any dates while 
preparing your data for submission. If, however, the day and/or the month of the date of 
diagnosis for some tumours have already been imputed: 
 
$ Please provide us with any rules used to impute the day and/or the month of any 
dates 
$ If you routinely add a “flag” to tumour records to show when the day and/or the month 
of any date has been imputed, please discuss this with us before submitting your 
data. 
 
Variable 12 Day of diagnosis  
Numeric variable, one or two digits. 
 
 1-31 = the day of the date of diagnosis 
 99 = the day of the date of diagnosis of this patient is not known 
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Note: please tell us if the day of the date of diagnosis cannot be provided for any of your 
patients. 
 
Variable 13 Month of diagnosis  
Numeric variable, one or two digits. 
 
 1-12 = the month of the date of diagnosis 
 99 = the month of the date of diagnosis of this patient is not known 
 
Note: please tell us if the month of the date of diagnosis cannot be provided for any of your 
patients. 
Variable 14 Year of diagnosis  
Numeric variable, four digits. 
 
 YYYY = the year of diagnosis, from 1995 onwards 
 9999 = the year of diagnosis of this patient is not known  
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Variable 15 Last known vital status  
 
Numeric variable, one digit. 
 
This variable encodes the patient’s last known vital status, to the extent that it is known 
to the cancer registry. The date of the patient’s last known vital status is recorded in 
variables 16-18. 
 
 Code Meaning  
 1 = Alive 
 2 = Dead  
 3 = Lost to follow-up 
 9 = Vital status is not known 
  
Information about vital status is conventionally captured using either ‘active’ or ‘passive’ 
procedures, which we discuss below. Some registries use both. Before you submit a 
data file for CONCORD, you will need to complete the cancer registry questionnaire 
(Annex 15) on routine practices in your registry. If you have any doubts about which 
procedure is used for follow-up in your registry, please contact us before preparing 
your data. 
 
‘Active’ follow-up 
Active follow-up refers to the situation in which the registry actively seeks information 
about the vital status of each cancer patient on a regular basis, e.g. from the patient's 
doctor, or hospital, or even home visits. 
 
If your registry uses this approach, then you should use code “3” for patients whose vital 
status (alive or dead) could not be ascertained at the last vital status check: these 
patients are lost to follow-up. The last date at which they were known to be alive should 
be given in variables 16-18.  
 
Code “3” should be used for patients known to have emigrated, since they are also lost 
to follow-up: the date of emigration should be given in variables 16-18. 
  
‘Passive’ follow-up 
Passive follow-up refers to the situation in which the registry routinely receives 
information from one or more reliable sources on the vital status of all registered patients. 
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These sources vary widely between registries, but may include social security or health 
insurance files, or a regional or national index of persons who have died. The information 
may be derived in various ways, such as by computer linkage with the registry database, 
manual scanning of the death index, or supply of details about all deaths in the registry's 
territory.  
 
The key features of passive follow-up for international survival comparisons are that: 
 the registry uses this approach for updating its own data for local analyses of survival, 
and  
 the registry’s procedures reliably identify all deaths of registered cancer patients, 
not just the deaths for which cancer is mentioned on the death certificate, and 
 the registry can reliably assume that registered cancer patients are alive, unless 
information about a patient’s death has been received from one or more of these 
sources. 
 
If your registry uses passive follow-up, patients who are not known to be dead would 
normally be assumed to be alive on the date of the most recent linkage between the 
registry and a death index or other vital status records. The vital status of those patients 
would be coded as “1” (alive). 
 
However, if some patients cannot be traced by any passive follow-up procedure, their 
vital status may remain undetermined: it would then be coded as “9” (unknown). 
 
When you submit your data, we will ask you to tell us the last date when you performed 
linkage or other follow-up to determine the vital status of your patients. 
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Variables 16-18 Date of the patient’s last known vital status  
 
 
This is the most recent date for which the patient’s last known vital status (variable 15) 
was available. 
 
If the patient is dead, the date of last known vital status should be the date of death. 
 
If the patient is known to be dead (variable 15 is coded as “2”), but the date of death is 
not known, the date of last known vital status should be coded to 99,99,9999 (see 
page 32). 
 
If the patient has emigrated, the date of last known vital status should be the date of 
emigration. 
 
If the patient has been lost to follow-up, the date of last known vital status should be 
the date of loss to follow-up. 
 
If the patient is considered to be alive, but not emigrated or lost to follow-up, the date of 
last known vital status should be one of the following: 
 31 December of the last year for which follow-up of all patients is believed to be 
complete 
 the date on which the registry last checked that patient’s vital status, e.g. contact with 
the patient’s doctor or a home visit (for registries that perform active follow-up), or 
linkage with a death index (for registries that perform passive follow-up) (see page 
14) 
 the date when the registry extracted the data file for this study from its database 
 
Variable 16 Day of last known vital status  
 
Numeric variable, one or two digits. 
 
 1-31 = the day of the date of last known vital status 
 99 = the day of this date is not known 
 
Note: please tell us if the day of last known vital status cannot be provided for any of your 
patients. 
Note: please see comments above (variables 12-14) about the imputation of dates. 
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Variable 17 Month of last known vital status 
 
Numeric variable, one or two digits. 
 
 1-12 = the month of the date of last known vital status 
 99 = the month of this date is not known 
 
Note: please tell us if the month of last known vital status cannot be provided for any of your 
patients. 
Note: please see comments above (variables 12-14) about the imputation of dates. 
 
 
Variable 18 Year of last known vital status  
Numeric variable, four digits. 
 
YYYY = the year of the date of last known vital status, from 1995 onwards  
 9999 = the year of this date is not known 
Variable 19 Basis of diagnosis  
 
Numeric variable, one digit. 
 
This variable indicates the degree of certainty with which a diagnosis of cancer has been 
established, in the specific context of survival analysis: 
 
 Code Meaning  
Not microscopically verified 
 1 = Clinical diagnosis only  
 2 = Clinical investigation without a tissue diagnosis (e.g. endoscopy without 
biopsy, or imaging such as X-ray, ultrasound, computed tomography [CT] or 
magnetic resonance imaging [MRI]) 
 3 = Clinical diagnosis, not otherwise specified [i.e. it is not known if code “1” or “2” 
applies] 
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Microscopically verified 
 4 = Cytologically confirmed (includes blood film examination for leukaemia) 
 5 = Histologically confirmed (includes bone marrow biopsy for leukaemia) 
 6 = Microscopically verified, not otherwise specified [i.e. not known if code “4” or 
“5” applies] 
Evidence of cancer does not include the date of diagnosis 
 7 = Death-certificate-only registration (DCO) [see note] 
 8 = Autopsy only - malignancy detected only at autopsy [see note] 
No information 
 9 = Unknown 
 
 
Note: 
Cancers registered solely on the basis of a death certificate (code 7) or autopsy (code 
8) are usually included in cancer incidence statistics for the year in which they are 
registered. 
 
For DCO and autopsy-detected cases, however, the true date of diagnosis and the 
duration of survival are unknown. Therefore, they cannot normally be included in survival 
analyses. A few cancer registries do not even record DCOs or autopsy-detected cancers.  
 
If your cancer registry did register such cases during the calendar period covered by 
your data submission, however, you must include DCO and autopsy-detected 
cancers in the data you submit for this study, to enable comparative quality control. 
  
300 
 
Variable 20 ICD-O-3 Topography   
 
Alphanumeric variable, four characters. 
 
Tumour site (topography) should be coded to the third edition of the International 
Classification of Diseases (ICD-O-3)1.  
 
Please provide the full 4-character ICD-O-3 code, but without the decimal point (“.”). 
Thus, liver cancer will be C220 or C221 and prostate cancer will be C619. With this minor 
modification, the anatomic site of the index cancers will be coded as: 
 
Stomach cancer: C160-C166; C168-C169 
 
Colon cancer: C180-C189; C199 
 
Rectal cancer: C209; C210-C212, C218 
 Note: includes anus and anal canal, C210-C218. 
 
Liver cancer: C220-C221 
 Note: includes intrahepatic bile ducts, C221. 
 
Lung cancer: C340-C343; C348-C349 
 Note: trachea (ICD-O-3 C339) will not be included in this study. 
 
Breast cancer: C500-C506; C508-C509 
 
Cervical cancer: C530-C531; C538-C539 
 
Ovarian cancer: C480-C482; C569; C570-C574; C577-C579 
 Note: includes peritoneum and retroperitoneum, C480-C482, where 
cancers of high-grade serous morphology often originate in the 
fallopian tube, C570 
 Note: includes other and unspecified female genital organs, C577-
C579. 
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Prostate cancer: C619 
 
Leukaemia: You should select leukaemias for your data file on the basis of 
their morphology code (variable 21), and not on the basis of their 
topography code. You can use any valid ICD-O-3 topography code, 
but without the decimal point (“.”), as specified above. 
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Variable 21 ICD-O-3 Morphology   
 
Numeric variable, four digits. 
 
Tumour morphology should be coded to the third edition of the International 
Classification of Diseases for Oncology (ICD-O-3)1.  
 
For microscopically confirmed tumours, the ICD-O-3 range of morphology codes is: 
 
8000-9989  
 
 
For haematological malignancies, the ICD-O-3 range of morphology codes is: 
 
9590-9989 
 
This range of morphology codes should be used to select all leukaemias and other 
haematological malignancies, including the lymphomas. This range of codes is the 
same for children and adults.  
 
Leukaemia is the only index cancer for which you should use the ICD-O-3 
morphology code to select cases for your data submission: all tumour records with an 
ICD-O-3 morphology code in the range 9590-9989 should be included. The other 
nine index cancers should be selected on the basis of the ICD-O-3 topography code 
(variable 20). 
 
Selection and grouping of the adult leukaemias for survival analyses will be based on 
the categories established by a consensus of haematologists, pathologists and 
epidemiologists in the HAEMACARE Working Group6-8. The HAEMACARE manual 
for coding and reporting haematological malignancies exists in English9 and Spanish 
(available on request). 
 
Childhood leukaemias will be grouped differently from the adult leukaemias, on the 
basis of the third revision of the International Classification of Childhood Cancers10 
(ICCC-3). The ICCC-3 groupings are based on ICD-O-3 morphology codes. 
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For solid tumours without microscopic verification, you should use:  
 
9999 This means the absence of data in the CONCORD study; it is not an ICD-O-3 
code. 
 
 Note: this code is only valid for solid tumours, not leukaemias. Leukaemias are 
defined by their morphology, so they must have a morphology code in the 
range 9590-9989.  
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Variable 22 Behaviour  
 
Numeric variable, one digit. 
 
Survival analyses will only include invasive, primary, malignant neoplasms. 
However, we will also report the distribution of tumour behaviour for each cancer. This 
will enable comparison of the intensity of diagnostic activity between contributing areas, 
e.g. the proportion of women with cervical cancer who were registered with in situ 
carcinoma. 
 
Therefore, if your registry collects data on tumours that are benign (behaviour code 0), 
of uncertain behaviour (1) or in situ (2), such as in situ carcinoma of the cervix, please 
include records for all neoplasms (behaviour codes 0-3) diagnosed at an index site 
when submitting your data.  
 
Please do not select tumours for inclusion in your data files on the basis of tumour 
behaviour. 
 
Tumour behaviour should be coded to the third edition of the International Classification 
of Diseases for Oncology (ICD-O-3). The coding of tumour behaviour has been the same 
in all revisions of ICD-O. 
 
 Code Meaning  
 0 = Benign 
 1 = Uncertain whether benign or malignant 
 2 = Carcinoma in situ 
 3 = Malignant, primary site 
 
The behaviour codes below are included in ICD-O-3, but they are not usually used by 
cancer registries. We show them for completeness.  
 
If your data do include behaviour codes 6 and 9, however, please do not recode them 
before data submission. Instead, please provide us with a description of how the 
codes have been used in your data: 
 Code Meaning  
 6 = Malignant, metastatic site 
 9 = Malignant, uncertain whether primary or metastatic site 
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STAGE OF DISEASE AT DIAGNOSIS                                                           Optional 
 
Provision of data on stage at diagnosis (variables 23-37) is optional.  
 
“Tumour stage” describes how far the cancer has spread at the time of diagnosis. It is a 
key determinant of survival (prognostic factor). Knowledge of the stage at diagnosis of 
cancer patients is increasingly important for the interpretation of international survival 
comparisons11-15. Where possible, we will perform analyses of survival in relation to stage 
at diagnosis. 
 
Among the registries that collect data on stage, information of satisfactory quality is often 
available for most of the 10 index cancers, at least for more recent years.  
 
If your registry does not collect any data on tumour stage, you should assign the 
codes 9, 99 or 999 (etc.) to all stage variables (variables 23-37) in every tumour record 
(see list on page 32). However, you must ensure that your data files meet the overall 
specification, as summarised on page 32 of this Annex! 
 
If your registry does collect data on stage, but you choose not to submit data for one 
or more stage variables, please assign the codes 9, 99 or 999 (etc.) to those variables 
in every tumour record, depending on how many digits are specified for those variables 
(see list on page 32). 
 
If you do submit data on stage, please supply stage data only for patients diagnosed 
from 1 January 2001 onwards. For patients diagnosed before 2001, please assign the 
codes 9, 99 or 999 (etc.) to all stage variables (variables 23-37) in every tumour record, 
depending on how many digits are specified for those variables (see list on page 32). 
Data on stage at diagnosis for patients diagnosed before 2001 will not be included in 
quality control or survival analyses. 
 
Many different coding schemes are being used to categorise tumour stage in registries 
around the world16. 
 
We will try to obtain data on at least one widely used categorisation of stage at 
diagnosis for each tumour (details in pages 21-31), to enable analysis of survival by 
stage at diagnosis: 
 
SEER Summary Stage 2000 TNM (both pathological and clinical) 
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Condensed TNM 
Dukes’ stage (colon and rectum) 
FIGO stage (cervix and ovary) 
Tumour size 
No. of lymph nodes examined 
No. of lymph nodes positive for 
tumour 
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If you wish to supply data on stage at diagnosis, but your data on stage are not coded 
either to TNM 7th edition or to any of the other specific classifications in this list, please 
contact us before submitting your data. 
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Variable 23 SEER Summary Stage 2000                                          Optional  
 
Numeric variable, one digit. 
 
SEER Summary Stage 2000 is a simple categorisation of stage, developed by the US 
National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) 
programme. The North American Association of Central Cancer Registries uses SEER 
Summary Stage 200017 (http://seer.cancer.gov/tools/ssm/). We borrow text from the 
introduction here. It has been in use in the US and Canada since 1 January 2001. 
  
“Summary stage” is the most basic way of categorising how far a cancer has spread from 
its point of origin. Summary staging uses all the information available in the medical 
record; it is a combination of the most precise clinical and pathological evidence 
for the extent of disease. Many population-based cancer registries report summary 
stage for their registered cases, because the staging categories are sufficiently broad to 
enable measurement of progress in cancer control. 
 
We expect that North American registries will supply SEER Summary Stage 2000 coded 
directly for cases diagnosed 2001-2003, but derived from Collaborative Stage for cases 
diagnosed in 2004 and later (http://seer.cancer.gov/tools/collabstaging). If your registry 
plans to supply SEER Summary Stage 2000 coded in any other way, we request that 
you inform us of the procedures you have used. The comparability of these staging 
schemes over time is addressed on the following SEER web-page: 
http://seer.cancer.gov/seerstat/variables/seer/yr1973_2009/lrd_stage/index.html 
 
Regional spread of disease is divided into several categories, according to the method 
of spread of the cancer: 
 
 Code Meaning 
 0 = In situ 
 1 = Localised only 
 2 = Regional spread by direct extension only 
 3 = Regional lymph nodes involved only 
 4 = Regional spread by both direct extension and lymph node involvement 
 5 = Regional, NOS (not otherwise specified) – use this code if there is regional 
spread of the cancer, but the route of spread is not known 
 7 = Distant site(s) or lymph node(s) are involved 
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 9 = Unknown if there is extension or metastasis (unstaged, unknown or 
unspecified), or 
   this is a death-certificate-only case, or 
   this is an autopsy-only case 
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TNM stage (variables 24-29)                                                                            Optional 
 
The Tumour-Nodes-Metastasis (TNM) classification of stage at diagnosis uses a 
combination of clinical and pathological evidence, like SEER Summary Stage 2000. 
 
The TNM classification is published by the Union for International Cancer Control (UICC). 
We will use the 7th edition of the TNM manual18. This is identical to the classification 
published by the American Joint Committee on Cancer (AJCC) in 200919. If you have 
stage data that are coded to earlier editions of TNM, please contact us before 
submitting your data. 
 
The three components of TNM are tumour size (T); the status of regional lymph nodes, 
i.e. the extent of lymph node invasion by tumour (N), and whether there is metastasis 
(spread of disease to an organ or organs distant from the organ of origin) (M). 
 
TNM stage data may be based on pathological evidence (“p”) or clinical evidence (“c”). 
 
 
Variable 24  Pathological T                                                                  Optional   
 
Numeric variable, one digit. 
 
This variable encodes information on the physical size of the tumour. 
 
For the nine solid index cancers (i.e. excluding leukaemia), up to 4 sub-categories (a, 
b, c, d) exist for each of the stage categories pT1, pT2, pT3 and pT4. These sub-
categories should be coded in the same way as the parent category: for example, pT1a 
should be coded to “1”, in the same way as pT1. 
 
For cervical cancer only, additional sub-categories exist: pT1a1, pT1a2, pT1b1 and 
pT1b2 should be coded to “1”, in the same way as pT1. Similarly, sub-categories pT2a1 
and pT2a2 should be coded to “2”, in the same way as pT2. 
 
The following codes will be used: 
 
 Code  Meaning 
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 0 = pT0 – no histological evidence of primary tumour  
 1 = pT1 – the content of this category varies with the cancer (see TNM manual18) 
   This code should also be used for sub-categories pT1a, pT1b and pT1c, as 
well as for sub-categories pT1a1, pT1a2, pT1b1 and pT1b2 (cervix only) 
 2 = pT2 – the content of this category varies with the cancer (see TNM manual18) 
   This code should also be used for sub-categories pT2a, pT2b and pT2c, as 
well as for sub-categories pT2a1, pT2a2 (cervix only) 
 3 = pT3 – the content of this category varies with the cancer (see TNM manual18) 
   This code should also be used for sub-categories pT3a and pT3b 
 4 = pT4 – tumour of any size, with direct extension to adjacent organs 
   This code should also be used for sub-categories pT4a, pT4b, pT4c and pT4d 
 8 = is – in situ carcinoma 
 9 = pTX – unknown: primary tumour cannot be assessed histologically 
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Variable 25  Pathological N                                                                 Optional 
 
Numeric variable, one digit. 
 
This variable encodes the extent of involvement of regional lymph nodes with tumour. 
 
For cancers of the stomach, colon, rectum and breast, several subcategories of pN1, 
pN2 and pN3 exist (a, b and c). These should be coded in the same way as the parent 
category: for example, pN2b should be coded to “2”, in the same way as pN2. 
 
The following codes will be used: 
 
 Code Meaning 
 0 = pN0 – no regional lymph nodes involved with tumour, histologically 
 1 = pN1 – the content of this category varies with the cancer (see TNM manual18) 
   For colon, rectum and breast, this code should also be used for sub-categories 
pN1a, pN1b and pN1c 
 2 = pN2 – the content of this category varies with the cancer (see TNM manual18) 
   For colon, rectum and breast, this code should also be used for sub-categories 
pN2a, pN2b and pN2c  
 3 = pN3 – the content of this category varies with the cancer (see TNM manual18) 
   For stomach, this code should also be used for sub-categories pN3a and pN3b 
   For breast, this code should also be used for sub-categories pN3a, pN3b and 
pN3c   
 9 = pNX – unknown: regional lymph nodes cannot be assessed histologically 
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Variable 26  Pathological M                                                                Optional 
 
Numeric variable, one digit. 
 
This variable encodes information on the presence or absence of distant metastases.  
 
For cancers of the colon, rectum and prostate, several subcategories of pM1 exist (a, b 
and c). These should be coded to “1”, in the same way as for pM1. 
  
The following codes will be used: 
 
 Code Meaning 
 1 = pM1 – Distant metastases have been microscopically confirmed 
   This code should also be used for sub-categories pM1a, pM1b and pM1c 
 9 = Unknown – this is not a TNM code (see below). It should be used when no 
data are available on pathological M status 
 
Note: 
The codes pM0 and pMX are not valid in TNM 7th edition18: see note on variable 29 
below. 
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Variable 27-29  Clinical TNM stage                                                            Optional 
 
 
Clinical data on tumour stage may be available from clinical examination, or from imaging 
of the tumour (X-ray, computed tomography [CT], magnetic resonance imaging [MRI], 
etc.).  
 
Clinical data may be the only available data on tumour stage, if no surgical or invasive 
diagnostic procedure has been performed. 
 
These variables are optional. If you choose not to supply them, please assign the code 
9 to these variables in every tumour record. 
 
Variable 27  Clinical T                                                                           Optional  
 
Numeric variable, one digit. 
 
This variable encodes information on the physical size of the tumour. 
 
Clinical data on the T component of stage should only be submitted if pathological data 
(variable 24) are not available.  
 
For the nine solid index cancers (i.e. excluding leukaemia), up to 4 sub-categories (a, 
b, c, d) exist for each of the stage categories cT1, cT2, cT3 and cT4. These sub-
categories should be coded in the same way as the parent category: for example, cT1a 
should be coded to “1”, in the same way as cT1. 
 
For cervical cancer only, additional sub-categories exist: cT1a1, cT1a2, cT1b1 and 
cT1b2 should all be coded to “1”, in the same way as cT1. Similarly, sub-categories 
cT2a1 and cT2a2 should both be coded to “2”, in the same way as cT2.  
 
The following codes will be used: 
 
 Code Meaning 
 0 = cT0 – no evidence of primary tumour  
 1 = cT1 – the content of this category varies with the cancer (see TNM manual18) 
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   This code should also be used for sub-categories cT1a, cT1b and cT1c, as 
well as for sub-categories cT1a1, cT1a2, cT1b1 and cT1b2 (cervix only) 
 2 = cT2 – the content of this category varies with the cancer (see TNM manual18) 
   This code should also be used for sub-categories cT2a, cT2b and cT2c, as 
well as for sub-categories cT2a1, cT2a2 (cervix only) 
 3 = cT3 – the content of this category varies with the cancer (see TNM manual18) 
   This code should also be used for sub-categories cT3a and cT3b 
 4 = cT4 – tumour of any size, with direct extension to adjacent organs 
   This code should also be used for sub-categories cT4a, cT4b, cT4c and cT4d 
 8 = is – in situ carcinoma 
 9 = cTX – unknown: primary tumour cannot be assessed 
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Variable 28  Clinical N                                                                           Optional 
 
Numeric variable, one digit. 
 
This variable encodes information on the involvement of regional lymph nodes with 
tumour. 
 
Clinical data on the N component of stage should only be submitted if pathological data 
(variable 25) are not available.  
 
For cancers of the stomach, colon, rectum and breast, several subcategories of cN1, 
cN2 and cN3 exist (a, b and c). These should be coded in the same way as the parent 
category: for example, cN2b should be coded to “2”, in the same way as cN2. 
 
The following codes will be used: 
 
 Code Meaning 
 0 = cN0 – no regional lymph nodes involved with tumour 
 1 = cN1 – the content of this category varies with the cancer (see TNM manual18) 
   For colon, rectum and breast, this code should also be used for sub-categories 
cN1a, cN1b and cN1c 
 2 = cN2 – the content of this category varies with the cancer (see TNM manual18) 
   For colon, rectum and breast, this code should also be used for sub-categories 
cN2a, cN2b and cN2c  
 3 = cN3 – the content of this category varies with the cancer (see TNM manual18) 
   For stomach, this code should also be used for sub-categories cN3a and cN3b 
   For breast, this code should also be used for sub-categories cN3a, cN3b and 
cN3c   
 9 = cNX – unknown: regional lymph nodes cannot be assessed 
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Variable 29  Clinical M                                                                        Optional 
 
Numeric variable, one digit. 
 
This variable encodes information on the presence or absence of distant metastases.  
 
For cancers of the colon, rectum and prostate, several subcategories of cM1 exist (a, b 
and c). These sub-categories should be coded to “1”, in the same way as for cM1. 
 
The following codes will be used: 
  
 Code Meaning 
 0 = cM0 – No metastases 
 1 = cM1 – Metastases 
 
 
Note:  
If the clinician does not record the presence of metastases, it is assumed under the 
TNM 7th edition that no metastases are present (cM0): such cases should be coded to 
“0”. 
 
The code “MX” was used in earlier editions of TNM to indicate that the metastatic status 
of the tumour was unknown. However, clinical assessment of metastasis can be based 
on physical examination alone, so cMX is no longer considered an appropriate code. 
 
The code cMX is not valid in TNM 7th edition.  
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Variables 30-32 Condensed TNM                                                               Optional  
 
The condensed TNM scheme for recording tumour stage was developed by the 
European Network of Cancer Registries20 for tumour records in which the individual 
values of T and/or N and/or M are not explicitly recorded. Condensed TNM is based on 
the TNM 6th edition21. 
 
Condensed TNM data are only requested if neither pathological TNM data (variables 
24-26) nor clinical TNM data (variables 27-29) are available. 
 
There is a direct correspondence with the simplified stage classification that is often 
recorded by cancer registries, in which the extent of disease is classified as localised, 
regional or distant. 
 
 
Variable 30 Condensed T                                                                     Optional 
 
Numeric variable, one digit. 
 
 Code Meaning 
 1 = L - Localised disease 
 Localised disease means: 
 T1 and T2 tumours for cancers of the stomach, colon, rectum, liver, lung, 
cervix, prostate 
 T1, T2 and T3 for breast cancer 
 T1 for cancer of the ovary (note: T2 tumours of the ovary are considered as 
advanced) 
 
 2 = A - Advanced disease 
 Advanced disease means: 
 T3 and T4 tumours for cancers of the stomach, colon, rectum, liver, lung, 
cervix, prostate 
 T4 for breast (note: T3 tumours of the breast are considered as localised) 
 T2 and T3 for ovary 
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 9 = X – Cannot be assessed: no information on tumour size category 
 
Variable 31 Condensed N                                                                    Optional 
  
Numeric variable, one digit. 
 
 Code Meaning 
 1 = N0 – No regional lymph node invasion by tumour 
 2 = N+ – Regional lymph nodes invaded by tumour 
 9 = NX – Cannot be assessed: no information on nodal status 
 
 
Variable 32 Condensed M                                                                    Optional 
 
Numeric variable, one digit. 
 
This code is based on the best available information - clinical, instrumental or 
pathological. Clinical signs and findings are sufficient to justify classifying a tumour as 
having metastasised (M+), even without pathological confirmation of metastatic deposits. 
 
 Code Meaning 
 1 = M0 – No distant metastasis 
 2 = M+ – Distant metastases present 
 9 = MX – Cannot be assessed: no information on whether metastases are present 
 
  
320 
 
Variable 33 Dukes’ stage                                                                     Optional 
 
Numeric variable, one digit. 
 
This variable is optional. If you choose not to supply it, please assign the code 9 to this 
variable in every tumour record. 
 
Dukes’ stage22 is a specialised classification of tumour stage for cancers of the colon 
and rectum only. For all other index cancers, please assign the code 9 to every 
tumour record. 
 
The TNM classification is preferable, because it is more detailed. 
 
Dukes’ stage should only be reported if TNM stage data (variables 24-29) are not 
available.  
 
Dukes’ stage was later modified23 to include a category for metastasis (group D), and 
sub-categories for direct extension in groups B and C. Modified Dukes’ stage is no longer 
recommended for clinical use, but it is still widely used. 
 
 
 Code Meaning 
 1 = Dukes’ stage A (this is equivalent to T1N0M0 or T2N0M0) 
 2 = Dukes’ stage B (this is equivalent to T3N0M0 or T4N0M0) 
 3 = Dukes’ stage C (this is equivalent to T(any)N1M0 or T(any)N2M0) 
 4 = Dukes’ stage D (this is equivalent to T(any)N(any)M1) 
 9 = Dukes’ stage missing: no information on Dukes’ stage 
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Variable 34 FIGO stage                                                                        Optional 
 
Numeric variable, one digit. 
 
This variable is optional. If you choose not to supply it, please assign the code 9 to this 
variable in every tumour record. 
 
FIGO stage24 is a specialised classification of tumour stage for cervical, ovarian and 
other gynaecological cancers. For all other index cancers, please assign the code 9 to 
this variable in every tumour record. 
 
The TNM classification is preferable, because it is more detailed. 
 
FIGO stage should only be reported if TNM stage data (variables 24-29) are not 
available.  
 
FIGO stage provides five broad categories: 
Stage 0 carcinoma in situ (common in cervical cancer) 
Stage I confined to the organ of origin 
Stage II invasion of surrounding organs or tissue 
Stage III spread to distant nodes or tissue within the pelvis 
Stage IV distant metastasis(es) 
 
Cancer of the cervix (C530, C531, C538, C539) 
 Code Meaning 
 0 = FIGO Stage 0 – carcinoma in situ 
 1 = FIGO Stage I – Tumour confined to cervix (extension to corpus uteri should be 
disregarded)  
   This code should also be used for sub-categories IA, IA1, IA2, IB, IB1 and IB2 
 2 = FIGO Stage II – Tumour invades beyond uterus but not to pelvic wall or lower 
third of vagina 
   This code should also be used for sub-categories IIA, IIA1, IIA2 and IIB 
 3 = FIGO Stage III – Tumour extends to pelvic wall or lower third of vagina, or 
causes hydronephrosis  
   This code should also be used for sub-categories IIIA and IIIB 
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 4 = FIGO Stage IVA – Tumour invades mucosa of the bladder or rectum, or 
extends beyond true pelvis 
 5 = FIGO Stage IVB – Distant metastasis 
 9 = FIGO Stage unknown 
 
Cancer of the ovary (C569) or Fallopian tube (C570) 
 Code Meaning 
 1 = FIGO Stage I – Tumour limited to one or both ovaries* 
   This code should also be used for sub-categories IA, IB and IC 
 2 = FIGO Stage II – Tumour involves one or both ovaries* with pelvic extension 
   This code should also be used for sub-categories IIA, IIB and IIC 
 3 = FIGO Stage III – Tumour involves one or both ovaries* with microscopically 
confirmed peritoneal metastasis outside the pelvis, and/or regional lymph 
node metastasis 
   This code should also be used for sub-categories IIIA, IIIB and IIIC 
 4 = FIGO Stage IV – Distant metastasis outside the peritoneal cavity 
 9 = FIGO Stage unknown 
 
* For malignancies of the Fallopian tubes (C570), replace "ovaries" with "Fallopian 
tubes". 
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Variable 35 Tumour size                                                                      Optional  
 
Numeric variable, from one to three digits. 
 
Tumour size (maximum tumour diameter) must be reported in millimetres, as an integer.  
 
For breast cancer, tumour size should be based on histological examination, if available. 
 
For lung cancer, tumour size may be available by imaging. 
 
It is difficult to be prescriptive about the maximum physical dimensions of a tumour. We 
will accept values in the range 1 - 300mm (1mm – 30cm). For example, a tumour with a 
maximum diameter of 35mm (3.5cm) would be coded as “35”. 
 
 Code Meaning 
 1-300 = maximum tumour diameter, in millimetres 
 999 = maximum tumour diameter is not known, or 
   maximum tumour diameter is not applicable (leukaemia), or 
   this variable will not be supplied 
 
Zero is not a valid tumour dimension. If no data are available for a solid tumour, please 
code this variable as 999. 
 
 
Variable 36 Number of lymph nodes examined                                 Optional 
 
Numeric variable, one or two digits. 
 
Report the exact number of lymph nodes examined, as recorded in the pathological 
record: valid range 0-98. 
 
This variable should be coded to 99 in all records if: 
 you choose not to supply this variable, or 
 the data file is for leukaemia 
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For the nine solid tumours, this variable should be coded to 99 if: 
 no information is available on the number of lymph nodes examined, or 
 no pathological examination was done 
 
 
Variable 37 Number of lymph nodes involved                                   Optional 
 
Numeric variable, one or two digits. 
 
Report the exact number of involved lymph nodes (lymph nodes containing tumour 
cells), as recorded in the pathological report: valid range 0-98. 
 
This variable should be coded to 99 in all records if: 
 you choose not to supply this variable, or 
 the data file is for leukaemia 
 
For the nine solid tumours, this variable should be coded to 99 if: 
 no information is available on the number of involved lymph nodes, or 
 lymph nodes were involved, but the number of involved lymph nodes is unknown, or 
 no pathological examination was done 
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Appendix C: Sensitivity analysis 
 
Type I epithelial 
including endometrioid 
(original analysis) 
Type I excluding 
endometrioid 
Absolute 
difference 
in NS 
Relative 
difference 
in NS 
Type II epithelial excluding 
endometrioid (original 
analysis) 
Type II epithelial including 
endometrioid 
Absolute 
difference 
in NS 
Relative 
difference 
in NS 
 NS (%) 95% CI NS (%) 95% CI   NS (%) 95% CI NS (%) 95% CI   
AFRICA                                         
Algerian registries                             
1995-1999 . . . .   . . . .   
2000-2004 . . . .   . . . .   
2005-2009 41.6 16.1 - 67.2 41.6 16.1 - 67.2 0.0 0.0 37.1 24.6 - 49.5 37.1 24.6 - 49.5 0.0 0.0 
Libya (Benghazi)                             
1995-1999 . . . .   . . . .   
2000-2004 . . . .   . . . .   
2005-2009 . . . .   5.6 0.0 - 13.5 5.2 0.0 - 12.7 0.4 7.1 
Mauritius*                             
1995-1999 . . . .   . . . .   
2000-2004 . . . .   . . . .   
2005-2009 . . . .   73.9 52.9 - 94.8 74.5 55.6 - 93.5 -0.6 -0.8 
South Africa (Eastern Cape)                             
1995-1999 . . . .   . . . .   
2000-2004 . . . .   . . . .   
2005-2009 . . . .   100.0 86.1 - 100.0 100.0 86.1 - 100.0 0.0 0.0 
Tunisia (Central)                             
1995-1999 . . . .   . . . .   
2000-2004 . . . .   . . . .   
2005-2009 . . . .   47.3 25.0 - 69.6 52.2 31.0 - 73.4 -4.9 -10.4 
AMERICA (CENTRAL AND SOUTH)                                     
Argentinian registries                             
1995-1999 . . . .   . . . .   
2000-2004 . . . .   19.6 11.4 - 27.8 22.0 13.3 - 30.7 -2.4 -12.2 
2005-2009 30.8 16.3 - 45.2 32.6 18.7 - 46.5 -1.8 -5.8 30.5 21.9 - 39.2 29.9 21.5 - 38.3 0.6 2.0 
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Type I epithelial 
including endometrioid 
(original analysis) 
Type I excluding 
endometrioid 
Absolute 
difference 
in NS 
Relative 
difference 
in NS 
Type II epithelial excluding 
endometrioid (original 
analysis) 
Type II epithelial including 
endometrioid 
Absolute 
difference 
in NS 
Relative 
difference 
in NS 
 NS (%) 95% CI NS (%) 95% CI   NS (%) 95% CI NS (%) 95% CI   
Brazilian registries                             
1995-1999 . . . .   29.1 15.7 - 42.5 32.3 20.3 - 44.3 -3.2 -11.0 
2000-2004 46.7 35.5 - 58.0 . .   38.3 29.6 - 47.0 41.5 33.4 - 49.7 -3.2 -8.4 
2005-2009 40.9 24.2 - 57.5 39.7 27.4 - 52.0 1.2 2.9 29.2 17.7 - 40.7 29.3 17.8 - 40.9 -0.1 -0.3 
Chile (Los Rios)                             
1995-1999 . . . .   . . . .   
2000-2004 . . . .   . . . .   
2005-2009 55.2 39.8 - 70.7 49.4 29.1 - 69.6 5.8 10.5 18.1 6.3 - 29.9 30.3 16.4 - 44.2 -12.2 -67.4 
Colombia (Cali)                             
1995-1999 44.8 29.3 - 60.2 . .   29.1 18.2 - 40.0 33.1 22.3 - 43.9 -4.0 -13.7 
2000-2004 55.4 38.0 - 72.9 41.0 25.5 - 56.5 14.4 26.0 27.1 21.8 - 32.5 30.2 25.3 - 35.2 -3.1 -11.4 
2005-2009 77.1 64.7 - 89.6 62.1 44.5 - 79.6 15.0 19.5 32.0 20.5 - 43.4 38.0 26.5 - 49.5 -6.0 -18.8 
Cuba*                             
1995-1999 70.6 58.3 - 82.9 . .   53.4 45.1 - 61.7 55.5 47.5 - 63.4 -2.1 -3.9 
2000-2004 61.8 50.1 - 73.5 . .   44.7 39.9 - 49.5 44.8 40.1 - 49.6 -0.1 -0.2 
2005-2009 74.6 64.7 - 84.6 68.9 58.5 - 79.3 5.7 7.6 39.2 29.3 - 49.1 46.9 38.9 - 54.9 -7.7 -19.6 
Ecuador (Quito)                             
1995-1999 . . . .   35.3 21.0 - 49.6 37.0 22.6 - 51.5 -1.7 -4.8 
2000-2004 . . . .   35.1 21.6 - 48.7 37.8 25.2 - 50.3 -2.7 -7.7 
2005-2009 60.2 40.9 - 79.5 59.2 40.2 - 78.2 1.0 1.7 55.0 44.6 - 65.5 54.7 44.4 - 64.9 0.3 0.5 
Puerto Rico*                             
1995-1999 . . . .   . . . .   
2000-2004 47.2 33.7 - 60.8 41.6 25.3 - 57.8 5.6 11.9 29.5 23.3 - 35.7 32.0 25.9 - 38.2 -2.5 -8.5 
2005-2009 62.2 43.7 - 80.8 40.5 18.5 - 62.4 21.7 34.9 36.2 26.9 - 45.5 39.4 30.2 - 48.6 -3.2 -8.8 
AMERICA (NORTH)                                         
Canada*                             
1995-1999 58.6 55.8 - 61.4 53.9 50.0 - 57.9 4.7 8.0 28.0 26.6 - 29.3 33.2 31.9 - 34.5 -5.2 -18.6 
2000-2004 62.9 60.0 - 65.8 56.4 52.5 - 60.3 6.5 10.3 29.8 28.5 - 31.1 34.8 33.5 - 36.1 -5.0 -16.8 
2005-2009 69.4 64.7 - 74.0 60.4 51.9 - 68.9 9.0 13.0 33.7 30.9 - 36.6 38.6 35.9 - 41.3 -4.9 -14.5 
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Type I epithelial 
including endometrioid 
(original analysis) 
Type I excluding 
endometrioid 
Absolute 
difference 
in NS 
Relative 
difference 
in NS 
Type II epithelial excluding 
endometrioid (original 
analysis) 
Type II epithelial including 
endometrioid 
Absolute 
difference 
in NS 
Relative 
difference 
in NS 
 NS (%) 95% CI NS (%) 95% CI   NS (%) 95% CI NS (%) 95% CI   
US registries                             
1995-1999 58.3 57.1 - 59.5 52.5 51.0 - 54.1 5.8 9.9 33.4 32.9 - 33.9 37.2 36.7 - 37.7 -3.8 -11.4 
2000-2004 61.7 60.6 - 62.8 54.0 52.5 - 55.6 7.7 12.5 34.4 33.9 - 34.8 38.3 37.8 - 38.7 -3.9 -11.3 
2005-2009 65.9 63.9 - 67.9 57.0 54.6 - 59.4 8.9 13.5 36.1 34.5 - 37.6 39.9 38.4 - 41.4 -3.8 -10.5 
ASIA                                         
Chinese registries                             
1995-1999 . . . .   40.5 27.8 - 53.2 40.9 28.1 - 53.7 -0.4 -1.0 
2000-2004 66.3 58.4 - 74.3 58.7 49.3 - 68.1 7.6 11.5 41.9 34.1 - 49.6 44.9 37.2 - 52.6 -3.0 -7.2 
2005-2009 59.3 46.1 - 72.5 56.2 40.1 - 72.2 3.1 5.2 45.0 38.4 - 51.6 46.4 40.2 - 52.7 -1.4 -3.1 
Cyprus*                             
1995-1999 . . . .   . . . .   
2000-2004 . . . .   . . . .   
2005-2009 57.5 38.5 - 76.5 60.6 39.3 - 81.9 -3.1 -5.4 42.0 26.9 - 57.2 41.6 26.6 - 56.6 0.4 1.0 
Hong Kong*                             
1995-1999 64.0 52.9 - 75.1 66.1 53.2 - 79.0 -2.1 -3.3 26.0 16.8 - 35.3 31.7 23.3 - 40.2 -5.7 -21.9 
2000-2004 71.3 62.5 - 80.1 66.3 55.4 - 77.3 5.0 7.0 33.0 26.9 - 39.0 40.2 34.2 - 46.1 -7.2 -21.8 
2005-2009 82.9 72.4 - 93.4 76.6 69.5 - 83.7 6.3 7.6 61.5 54.8 - 68.2 66.6 60.5 - 72.7 -5.1 -8.3 
Indian registries                             
1995-1999 . . . .   22.4 13.0 - 31.9 20.7 11.7 - 29.6 1.7 7.6 
2000-2004 . . . .   . . . .   
2005-2009 31.7 15.7 - 47.8 37.1 19.0 - 55.2 -5.4 -17.0 21.6 7.4 - 35.8 20.8 7.1 - 34.5 0.8 3.7 
Indonesia (Jakarta)                             
1995-1999 . . . .   . . . .   
2000-2004 . . . .   . . . .   
2005-2009 54.2 32.4 - 76.0 72.2 50.6 - 93.7 -18.0 -33.2 . . 22.3 0.4 - 44.2   
Israel*                             
1995-1999 54.6 45.7 - 63.4 51.0 38.7 - 63.3 3.6 6.6 35.6 31.4 - 39.8 38.4 34.3 - 42.5 -2.8 -7.9 
2000-2004 57.5 48.8 - 66.2 43.8 30.0 - 57.5 13.7 23.8 36.1 32.0 - 40.1 39.1 35.3 - 42.9 -3.0 -8.3 
2005-2009 53.9 31.0 - 76.8 48.3 27.2 - 69.3 5.6 10.4 28.4 11.3 - 45.4 29.2 11.6 - 46.8 -0.8 -2.8 
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Type I epithelial 
including endometrioid 
(original analysis) 
Type I excluding 
endometrioid 
Absolute 
difference 
in NS 
Relative 
difference 
in NS 
Type II epithelial excluding 
endometrioid (original 
analysis) 
Type II epithelial including 
endometrioid 
Absolute 
difference 
in NS 
Relative 
difference 
in NS 
 NS (%) 95% CI NS (%) 95% CI   NS (%) 95% CI NS (%) 95% CI   
Japanese registries                             
1995-1999 48.7 40.5 - 56.8 53.1 44.4 - 61.9 -4.4 -9.0 26.2 21.1 - 31.2 27.5 22.3 - 32.7 -1.3 -5.0 
2000-2004 53.4 48.2 - 58.5 55.9 50.0 - 61.8 -2.5 -4.7 30.5 26.9 - 34.1 33.1 29.6 - 36.6 -2.6 -8.5 
2005-2009 48.9 27.2 - 70.5 47.0 26.0 - 68.0 1.9 3.9 37.0 32.0 - 41.9 40.6 35.5 - 45.7 -3.6 -9.7 
Jordan*                             
1995-1999 . . . .   . . . .   
2000-2004 22.2 3.1 - 41.4 . .   18.3 6.4 - 30.3 21.4 8.4 - 34.3 -3.1 -16.9 
2005-2009 0.0 0.0 - 0.0 7.4 0.0 - 18.1 -7.4 0.0 0.0 0.0 - 0.0 0.0 0.0 - 0.0 0.0 0.0 
Korea*                             
1995-1999 65.5 59.0 - 72.1 67.3 60.1 - 74.5 -1.8 -2.7 37.9 33.3 - 42.4 40.4 35.9 - 44.9 -2.5 -6.6 
2000-2004 64.9 59.6 - 70.3 64.0 58.1 - 70.0 0.9 1.4 37.7 33.5 - 42.0 40.9 36.9 - 45.0 -3.2 -8.5 
2005-2009 60.8 50.7 - 70.8 64.1 56.3 - 71.9 -3.3 -5.4 39.5 33.8 - 45.1 41.2 35.2 - 47.1 -1.7 -4.3 
Malaysia (Penang)                             
1995-1999 49.3 35.6 - 63.1 . .   52.4 38.0 - 66.7 54.8 41.0 - 68.6 -2.4 -4.6 
2000-2004 70.5 60.6 - 80.4 60.6 51.0 - 70.3 9.9 14.0 27.5 14.3 - 40.7 31.3 18.8 - 43.9 -3.8 -13.8 
2005-2009 72.9 59.7 - 86.0 62.8 45.4 - 80.3 10.1 13.9 47.3 31.6 - 63.1 47.8 31.6 - 63.9 -0.5 -1.1 
Mongolia*                             
1995-1999 . . . .   . . . .   
2000-2004 . . . .   . . . .   
2005-2009 . . . .   68.3 51.2 - 85.3 69.3 52.7 - 85.8 -1.0 -1.5 
Qatar*                             
1995-1999 . . . .   . . . .   
2000-2004 . . . .   . . . .   
2005-2009 . . . .   31.9 6.7 - 57.1 35.2 8.8 - 61.5 -3.3 -10.3 
Saudi Arabia*                             
1995-1999 70.1 51.6 - 88.6 53.7 34.5 - 72.8 16.4 23.4 42.9 23.2 - 62.5 46.5 26.1 - 67.0 -3.6 -8.4 
2000-2004 49.7 25.3 - 74.1 53.6 37.5 - 69.8 -3.9 -7.8 31.9 16.9 - 46.9 33.5 17.9 - 49.2 -1.6 -5.0 
2005-2009 . . . .   . . . .   
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Type I epithelial 
including endometrioid 
(original analysis) 
Type I excluding 
endometrioid 
Absolute 
difference 
in NS 
Relative 
difference 
in NS 
Type II epithelial excluding 
endometrioid (original 
analysis) 
Type II epithelial including 
endometrioid 
Absolute 
difference 
in NS 
Relative 
difference 
in NS 
 NS (%) 95% CI NS (%) 95% CI   NS (%) 95% CI NS (%) 95% CI   
Taiwan*                             
1995-1999 59.5 52.4 - 66.6 59.4 51.3 - 67.4 0.1 0.2 35.0 29.2 - 40.7 38.8 33.3 - 44.3 -3.8 -10.9 
2000-2004 61.8 56.3 - 67.3 60.7 54.1 - 67.2 1.1 1.8 35.8 31.3 - 40.3 39.8 35.7 - 43.9 -4.0 -11.2 
2005-2009 61.3 53.8 - 68.7 61.5 53.1 - 69.9 -0.2 -0.3 35.3 12.3 - 58.3 37.4 13.1 - 61.7 -2.1 -5.9 
Thai registries                             
1995-1999 70.3 57.8 - 82.8 66.9 53.5 - 80.3 3.4 4.8 45.1 31.3 - 59.0 50.5 37.2 - 63.8 -5.4 -12.0 
2000-2004 62.9 52.3 - 73.4 57.8 49.2 - 66.4 5.1 8.1 32.1 18.0 - 46.1 32.1 17.7 - 46.4 0.0 0.0 
2005-2009 71.9 60.8 - 83.0 66.7 52.5 - 80.9 5.2 7.2 44.4 35.2 - 53.6 48.8 40.5 - 57.0 -4.4 -9.9 
Turkey (Izmir)                             
1995-1999 60.3 49.8 - 70.7 59.7 46.6 - 72.7 0.6 1.0 40.5 31.8 - 49.2 44.5 36.7 - 52.4 -4.0 -9.9 
2000-2004 58.4 48.0 - 68.9 51.4 38.4 - 64.4 7.0 12.0 39.3 27.8 - 50.8 42.5 30.6 - 54.3 -3.2 -8.1 
2005-2009 56.9 42.6 - 71.3 64.6 51.9 - 77.3 -7.7 -13.5 31.2 11.2 - 51.3 37.8 22.4 - 53.3 -6.6 -21.2 
EUROPE                                         
Austria*                             
1995-1999 56.4 50.4 - 62.4 56.8 48.9 - 64.7 -0.4 -0.7 39.6 37.1 - 42.0 40.7 38.3 - 43.1 -1.1 -2.8 
2000-2004 61.3 55.6 - 67.1 59.8 51.6 - 67.9 1.5 2.4 36.7 34.5 - 39.0 38.8 36.6 - 41.0 -2.1 -5.7 
2005-2009 59.9 48.9 - 70.8 42.9 21.3 - 64.5 17.0 28.4 40.0 36.0 - 44.1 42.6 38.7 - 46.5 -2.6 -6.5 
Belgium*                             
1995-1999 . . . .   . . . .   
2000-2004 65.2 56.3 - 74.1 59.8 48.3 - 71.4 5.4 8.3 35.8 31.1 - 40.6 39.7 35.1 - 44.3 -3.9 -10.9 
2005-2009 62.9 52.9 - 73.0 53.8 37.4 - 70.2 9.1 14.5 35.4 31.3 - 39.4 39.1 35.2 - 42.9 -3.7 -10.5 
Bulgaria*                             
1995-1999 42.2 32.8 - 51.6 39.0 28.2 - 49.8 3.2 7.6 30.2 25.6 - 34.9 31.7 27.2 - 36.1 -1.5 -5.0 
2000-2004 49.1 42.7 - 55.4 47.7 40.3 - 55.1 1.4 2.9 33.9 30.2 - 37.7 35.3 31.8 - 38.8 -1.4 -4.1 
2005-2009 43.8 33.4 - 54.2 49.2 40.9 - 57.6 -5.4 -12.3 32.6 23.8 - 41.3 32.5 23.1 - 41.9 0.1 0.3 
Croatia*                             
1995-1999 53.7 45.3 - 62.1 43.0 32.1 - 53.9 10.7 19.9 35.7 28.9 - 42.5 38.3 31.6 - 45.1 -2.6 -7.3 
2000-2004 55.5 47.6 - 63.4 47.6 37.1 - 58.1 7.9 14.2 33.4 29.3 - 37.5 36.9 32.9 - 40.8 -3.5 -10.5 
2005-2009 54.0 42.0 - 65.9 61.9 48.3 - 75.5 -7.9 -14.6 28.1 20.2 - 35.9 30.0 22.1 - 38.0 -1.9 -6.8 
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Type I epithelial 
including endometrioid 
(original analysis) 
Type I excluding 
endometrioid 
Absolute 
difference 
in NS 
Relative 
difference 
in NS 
Type II epithelial excluding 
endometrioid (original 
analysis) 
Type II epithelial including 
endometrioid 
Absolute 
difference 
in NS 
Relative 
difference 
in NS 
 NS (%) 95% CI NS (%) 95% CI   NS (%) 95% CI NS (%) 95% CI   
Czech Republic*                             
1995-1999 44.3 39.1 - 49.6 46.6 39.5 - 53.7 -2.3 -5.2 30.8 28.0 - 33.5 32.1 29.5 - 34.7 -1.3 -4.2 
2000-2004 46.9 42.8 - 50.9 46.1 40.7 - 51.4 0.8 1.7 32.9 30.4 - 35.5 35.0 32.6 - 37.3 -2.1 -6.4 
2005-2009 53.2 45.9 - 60.5 51.8 43.2 - 60.4 1.4 2.6 40.4 36.7 - 44.1 41.9 38.2 - 45.7 -1.5 -3.7 
Denmark*                             
1995-1999 50.8 45.8 - 55.9 49.0 42.5 - 55.5 1.8 3.5 23.9 21.3 - 26.5 27.7 25.2 - 30.2 -3.8 -15.9 
2000-2004 47.4 41.9 - 52.8 44.5 37.4 - 51.6 2.9 6.1 28.4 25.6 - 31.3 31.4 28.6 - 34.1 -3.0 -10.6 
2005-2009 69.6 62.9 - 76.3 67.0 58.1 - 75.9 2.6 3.7 30.1 23.2 - 37.0 34.7 28.7 - 40.6 -4.6 -15.3 
Estonia*                             
1995-1999 43.0 27.5 - 58.4 39.9 21.9 - 58.0 3.1 7.2 26.0 18.6 - 33.4 27.4 20.4 - 34.5 -1.4 -5.4 
2000-2004 46.2 33.9 - 58.4 44.2 31.1 - 57.2 2.0 4.3 32.9 26.2 - 39.5 33.5 27.0 - 39.9 -0.6 -1.8 
2005-2009 75.3 61.5 - 89.0 69.6 56.7 - 82.5 5.7 7.6 31.2 22.5 - 39.8 33.0 24.2 - 41.9 -1.8 -5.8 
Finland*                             
1995-1999 45.3 39.3 - 51.3 58.9 49.4 - 68.4 -13.6 -30.0 38.7 34.9 - 42.5 38.2 34.7 - 41.6 0.5 1.3 
2000-2004 48.2 43.2 - 53.1 58.2 50.3 - 66.1 -10.0 -20.7 40.1 36.2 - 44.0 40.2 36.9 - 43.5 -0.1 -0.2 
2005-2009 66.4 59.3 - 73.6 67.3 55.9 - 78.7 -0.9 -1.4 46.3 40.9 - 51.7 49.4 44.6 - 54.3 -3.1 -6.7 
French registries                             
1995-1999 47.0 40.7 - 53.2 46.7 39.6 - 53.8 0.3 0.6 28.9 25.7 - 32.1 30.9 27.7 - 34.2 -2.0 -6.9 
2000-2004 53.2 46.8 - 59.6 . .  0.0 35.8 33.2 - 38.4 38.5 35.9 - 41.0 -2.7 -7.5 
2005-2009 56.7 36.5 - 76.9 46.9 41.4 - 52.4 9.8 17.3 24.8 9.0 - 40.7 27.8 10.0 - 45.6 -3.0 -12.1 
German registries                             
1995-1999 52.7 48.2 - 57.1 50.6 45.1 - 56.0 2.1 4.0 34.0 31.9 - 36.0 35.7 33.7 - 37.7 -1.7 -5.0 
2000-2004 57.6 54.3 - 60.9 55.0 50.8 - 59.2 2.6 4.5 36.6 35.1 - 38.1 38.6 37.2 - 40.1 -2.0 -5.5 
2005-2009 46.3 32.7 - 59.8 48.0 41.2 - 54.9 -1.7 -3.7 35.4 32.3 - 38.5 36.5 32.8 - 40.2 -1.1 -3.1 
Iceland*                             
1995-1999 . . . .   21.1 9.8 - 32.4 24.2 11.9 - 36.5 -3.1 -14.7 
2000-2004 . . . .   30.6 15.5 - 45.7 32.2 16.2 - 48.3 -1.6 -5.2 
2005-2009 56.4 32.3 - 80.4 57.4 39.5 - 75.3 -1.0 -1.8 41.5 26.9 - 56.1 40.5 22.6 - 58.5 1.0 2.4 
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Ireland*                             
1995-1999 55.9 46.0 - 65.8 55.0 42.8 - 67.1 0.9 1.6 21.9 17.9 - 25.9 24.8 20.7 - 28.8 -2.9 -13.2 
2000-2004 53.4 44.9 - 61.9 47.7 37.0 - 58.3 5.7 10.7 24.7 20.8 - 28.6 28.2 24.3 - 32.1 -3.5 -14.2 
2005-2009 73.0 63.5 - 82.5 75.3 64.6 - 86.0 -2.3 -3.2 25.7 13.0 - 38.3 29.0 14.9 - 43.1 -3.3 -12.8 
Italian registries                             
1995-1999 58.0 54.0 - 61.9 56.2 51.3 - 61.1 1.8 3.1 33.2 31.3 - 35.1 35.9 34.0 - 37.7 -2.7 -8.1 
2000-2004 56.6 53.2 - 60.1 53.4 49.1 - 57.7 3.2 5.7 36.1 34.3 - 37.9 38.7 36.9 - 40.4 -2.6 -7.2 
2005-2009 62.9 57.6 - 68.3 57.1 50.1 - 64.1 5.8 9.2 38.4 32.5 - 44.2 41.7 35.5 - 47.9 -3.3 -8.6 
Latvia*                             
1995-1999 57.4 44.5 - 70.4 57.1 42.8 - 71.4 0.3 0.5 34.8 28.9 - 40.7 35.0 29.0 - 40.9 -0.2 -0.6 
2000-2004 50.2 39.0 - 61.3 48.9 37.0 - 60.8 1.3 2.6 37.5 32.4 - 42.5 37.8 32.8 - 42.9 -0.3 -0.8 
2005-2009 51.2 32.8 - 69.6 51.9 32.9 - 70.9 -0.7 -1.4 34.8 26.6 - 43.0 35.1 26.9 - 43.3 -0.3 -0.9 
Lithuania*                             
1995-1999 43.5 31.2 - 55.7 40.9 28.2 - 53.7 2.6 6.0 31.7 27.6 - 35.8 32.1 28.0 - 36.2 -0.4 -1.3 
2000-2004 48.2 37.6 - 58.8 42.6 30.9 - 54.3 5.6 11.6 29.2 25.5 - 33.0 30.4 26.7 - 34.2 -1.2 -4.1 
2005-2009 52.4 40.3 - 64.5 38.4 25.3 - 51.4 14.0 26.7 25.3 14.5 - 36.1 29.3 19.8 - 38.7 -4.0 -15.8 
Malta*                             
1995-1999 63.1 48.5 - 77.8 . .  0.0 26.0 16.4 - 35.6 29.1 19.7 - 38.6 -3.1 -11.9 
2000-2004 . . . .   32.2 22.4 - 42.0 37.0 26.1 - 48.0 -4.8 -14.9 
2005-2009 58.0 48.1 - 68.0 52.3 40.6 - 64.0 5.7 9.8 29.7 18.7 - 40.7 37.0 25.9 - 48.1 -7.3 -24.6 
Netherlands*                             
1995-1999 49.7 45.8 - 53.6 46.8 41.8 - 51.8 2.9 5.8 27.7 25.8 - 29.5 30.8 28.9 - 32.6 -3.1 -11.2 
2000-2004 57.1 53.2 - 61.0 53.0 48.0 - 58.0 4.1 7.2 29.1 27.4 - 30.9 33.0 31.2 - 34.7 -3.9 -13.4 
2005-2009 56.4 47.4 - 65.5 53.5 45.9 - 61.1 2.9 5.1 28.1 19.0 - 37.1 31.3 21.3 - 41.2 -3.2 -11.4 
Norway*                             
1995-1999 57.2 50.4 - 64.0 53.6 45.1 - 62.1 3.6 6.3 29.2 26.2 - 32.3 33.2 30.2 - 36.3 -4.0 -13.7 
2000-2004 65.8 60.0 - 71.7 62.4 54.9 - 69.8 3.4 5.2 33.8 30.9 - 36.7 37.7 34.8 - 40.5 -3.9 -11.5 
2005-2009 61.9 52.0 - 71.9 56.1 43.7 - 68.5 5.8 9.4 34.2 28.4 - 40.0 36.9 31.1 - 42.7 -2.7 -7.9 
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Poland*                             
1995-1999 45.4 36.6 - 54.1 45.0 34.5 - 55.5 0.4 0.9 30.9 27.1 - 34.7 32.4 28.6 - 36.1 -1.5 -4.9 
2000-2004 44.4 40.8 - 48.0 44.8 39.8 - 49.8 -0.4 -0.9 31.3 29.4 - 33.1 33.0 31.2 - 34.7 -1.7 -5.4 
2005-2009 52.5 48.0 - 57.1 49.6 43.5 - 55.7 2.9 5.5 31.3 28.1 - 34.5 34.4 31.5 - 37.3 -3.1 -9.9 
Portugal*                             
1995-1999 50.8 38.9 - 62.8 50.4 36.0 - 64.8 0.4 0.8 30.0 23.7 - 36.4 31.9 25.9 - 37.9 -1.9 -6.3 
2000-2004 55.8 48.6 - 63.0 57.0 48.8 - 65.2 -1.2 -2.2 35.5 31.9 - 39.1 36.9 33.3 - 40.5 -1.4 -3.9 
2005-2009 68.4 60.8 - 76.1 61.8 52.0 - 71.7 6.6 9.6 36.3 29.0 - 43.6 39.4 31.8 - 46.9 -3.1 -8.5 
Romania (Cluj)                             
1995-1999 . . . .   . . . .   
2000-2004 . . . .   . . . .   
2005-2009 68.0 52.3 - 83.7 58.5 37.4 - 79.6 9.5 14.0 49.7 33.8 - 65.7 53.5 38.3 - 68.7 -3.8 -7.6 
Russia (Arkhangelsk)                             
1995-1999 . . . .   . . . .   
2000-2004 45.2 31.8 - 58.6 48.4 35.4 - 61.4 -3.2 -7.1 23.7 12.4 - 34.9 24.7 13.1 - 36.3 -1.0 -4.2 
2005-2009 56.5 37.8 - 75.2 60.5 43.1 - 77.9 -4.0 -7.1 32.3 17.0 - 47.7 33.5 18.3 - 48.7 -1.2 -3.7 
Slovakia*                             
1995-1999 . . . .   . . . .   
2000-2004 44.5 37.5 - 51.5 45.1 36.4 - 53.7 -0.6 -1.3 30.8 26.6 - 35.1 32.5 28.4 - 36.5 -1.7 -5.5 
2005-2009 47.6 35.1 - 60.1 47.2 34.1 - 60.3 0.4 0.8 29.5 23.8 - 35.1 32.0 26.3 - 37.7 -2.5 -8.5 
Slovenia*                             
1995-1999 50.9 37.4 - 64.3 44.6 23.9 - 65.3 6.3 12.4 27.8 22.6 - 33.0 32.3 27.1 - 37.4 -4.5 -16.2 
2000-2004 59.8 50.4 - 69.3 57.5 44.6 - 70.4 2.3 3.8 30.4 25.0 - 35.9 35.5 30.3 - 40.8 -5.1 -16.8 
2005-2009 53.2 36.4 - 70.0 53.4 35.7 - 71.2 -0.2 -0.4 30.3 21.8 - 38.8 33.1 24.2 - 41.9 -2.8 -9.2 
Spanish registries                             
1995-1999 55.0 50.1 - 59.9 50.6 43.8 - 57.4 4.4 8.0 28.5 25.1 - 31.9 34.1 31.0 - 37.1 -5.6 -19.6 
2000-2004 59.6 54.4 - 64.8 52.5 45.6 - 59.3 7.1 11.9 31.9 28.8 - 35.1 37.4 34.5 - 40.4 -5.5 -17.2 
2005-2009 49.7 39.7 - 59.6 47.3 36.4 - 58.3 2.4 4.8 35.7 31.2 - 40.3 37.9 33.2 - 42.5 -2.2 -6.2 
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Sweden*                             
1995-1999 . . . .   40.3 38.3 - 42.3 40.3 38.3 - 42.3 0.0 0.0 
2000-2004 . . . .   41.1 39.0 - 43.2 41.1 39.0 - 43.2 0.0 0.0 
2005-2009 . . . .   35.0 26.7 - 43.3 35.0 26.7 - 43.3 0.0 0.0 
Swiss registries                             
1995-1999 52.7 43.5 - 61.8 48.6 38.1 - 59.0 4.1 7.8 28.9 24.7 - 33.0 31.9 27.7 - 36.1 -3.0 -10.4 
2000-2004 57.4 49.8 - 65.1 48.4 37.2 - 59.5 9.0 15.7 31.7 28.0 - 35.4 35.1 31.5 - 38.6 -3.4 -10.7 
2005-2009 63.0 51.4 - 74.5 56.8 33.2 - 80.3 6.2 9.8 38.0 32.3 - 43.7 41.1 35.7 - 46.5 -3.1 -8.2 
United Kingdom*                             
1995-1999 48.6 46.8 - 50.4 46.7 44.4 - 49.0 1.9 3.9 21.6 20.8 - 22.3 24.8 24.0 - 25.5 -3.2 -14.8 
2000-2004 54.3 52.5 - 56.1 50.5 48.2 - 52.7 3.8 7.0 22.7 22.0 - 23.4 26.4 25.7 - 27.1 -3.7 -16.3 
2005-2009 59.5 55.3 - 63.8 56.9 51.2 - 62.5 2.6 4.4 25.0 23.6 - 26.5 28.3 26.8 - 29.8 -3.3 -13.2 
OCEANIA                                         
Australian registries                             
1995-1999 58.3 53.7 - 62.8 54.0 48.5 - 59.6 4.3 7.4 29.3 27.3 - 31.2 32.7 30.7 - 34.6 -3.4 -11.6 
2000-2004 62.5 58.0 - 66.9 55.7 50.3 - 61.2 6.8 10.9 30.2 28.4 - 32.0 33.9 32.1 - 35.7 -3.7 -12.3 
2005-2009 64.2 57.2 - 71.2 56.2 46.7 - 65.7 8.0 12.5 31.2 25.5 - 36.8 35.2 30.0 - 40.3 -4.0 -12.8 
New Zealand*                             
1995-1999 51.1 42.6 - 59.6 52.2 41.7 - 62.7 -1.1 -2.2 23.8 19.8 - 27.8 27.2 23.2 - 31.3 -3.4 -14.3 
2000-2004 69.1 60.1 - 78.1 68.2 55.7 - 80.6 0.9 1.3 23.9 20.3 - 27.6 29.7 26.0 - 33.4 -5.8 -24.3 
2005-2009 40.5 19.4 - 61.6 35.1 14.8 - 55.4 5.4 13.3 23.4 14.3 - 32.6 24.2 15.0 - 33.3 -0.8 -3.4 
*Data with 100% coverage of the national population. NS = net survival. Italics denote net survival estimates that are not age-standardised. Where data for two or more calendar periods of 
diagnosis were merged, the net survival estimates are underlined. Registries with fewer than 10 women for any stage (all calendar periods combined) were not included in the analysis.  
 
